
<html lang="en"     class="pb-page"  data-request-id="bd5a4977-fa95-4f4a-b373-9fb39fb10f67"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.1c00079;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-7;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Novel CK2-Specific Pt(II) Compound Reverses Cisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and Suppressing DNA Damage Repair in Non-small Cell Lung Cancer Treatments" /></meta><meta name="dc.Creator" content="Yuanjiang  Wang" /></meta><meta name="dc.Creator" content="Xinyi  Wang" /></meta><meta name="dc.Creator" content="Gang  Xu" /></meta><meta name="dc.Creator" content="Shaohua  Gou" /></meta><meta name="dc.Description" content="Cancer stem cells (CSCs) have a pivotal impact in drug resistance, tumor metastasis, and progression of various cancer entities, including in non-small cell lung cancer (NSCLC). A CK2 inhibitor HY1..." /></meta><meta name="Description" content="Cancer stem cells (CSCs) have a pivotal impact in drug resistance, tumor metastasis, and progression of various cancer entities, including in non-small cell lung cancer (NSCLC). A CK2 inhibitor HY1..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 30, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00079" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00079" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00079" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00079" /></link>
        
    
    

<title>Novel CK2-Specific Pt(II) Compound Reverses Cisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and Suppressing DNA Damage Repair in Non-small Cell Lung Cancer Treatments | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00079" /></meta><meta property="og:title" content="Novel CK2-Specific Pt(II) Compound Reverses Cisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and Suppressing DNA Damage Repair in Non-small Cell Lung Cancer Treatments" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0014.jpeg" /></meta><meta property="og:description" content="Cancer stem cells (CSCs) have a pivotal impact in drug resistance, tumor metastasis, and progression of various cancer entities, including in non-small cell lung cancer (NSCLC). A CK2 inhibitor HY1 was found to show potent CSC inhibitory effects in A549 cells. By taking advantage of inherent CK2 specificity and CSC inhibition of HY1, a Pt(II) agent (HY1-Pt) was developed by conjugation of HY1 with an active Pt(II) unit to reverse cisplatin-induced resistance in A549/cDDP cell treatment. In vitro biological studies indicated that HY1-Pt can target CK2, suppress DNA damage repair, reinforce cellular accumulation of platinum, and reverse resistance apart from effectively inhibiting CSCs through Wnt/β-catenin signal pathway in A549/cDDP cells. Significantly, HY1-Pt presented an acceptable pharmacokinetic behavior and exhibited higher tumor growth inhibitory efficacy than cisplatin either in A549 or A549/cDDP xenograft models with low toxicity. Overall, HY1-Pt is a promising drug candidate for NSCLC treatment." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00079"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00079">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00079&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00079&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00079&amp;href=/doi/10.1021/acs.jmedchem.1c00079" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 4163-4178</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00044" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00117" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Novel CK2-Specific Pt(II) Compound Reverses Cisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and Suppressing DNA Damage Repair in Non-small Cell Lung Cancer Treatments</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yuanjiang Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuanjiang Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, PR China</div><div class="loa-info-affiliations-info">Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuanjiang++Wang">Yuanjiang Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xinyi Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xinyi Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, PR China</div><div class="loa-info-affiliations-info">Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xinyi++Wang">Xinyi Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gang Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gang Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, PR China</div><div class="loa-info-affiliations-info">Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gang++Xu">Gang Xu</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Shaohua Gou</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shaohua Gou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, PR China</div><div class="loa-info-affiliations-info">Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#023030333b3034373a32324273732c616d6f"><span class="__cf_email__" data-cfemail="754747444c4743404d45453504045b161a18">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shaohua++Gou">Shaohua Gou</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0284-5480" title="Orcid link">http://orcid.org/0000-0003-0284-5480</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00079&amp;href=/doi/10.1021%2Facs.jmedchem.1c00079" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 4163–4178</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 30, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 January 2021</li><li><span class="item_label"><b>Published</b> online</span>30 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 April 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00079" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00079</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4163%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYuanjiang%2BWang%252C%2BXinyi%2BWang%252C%2BGang%2BXu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D7%26contentID%3Dacs.jmedchem.1c00079%26title%3DNovel%2BCK2-Specific%2BPt%2528II%2529%2BCompound%2BReverses%2BCisplatin-Induced%2BResistance%2Bby%2BInhibiting%2BCancer%2BCell%2BStemness%2Band%2BSuppressing%2BDNA%2BDamage%2BRepair%2Bin%2BNon-small%2BCell%2BLung%2BCancer%2BTreatments%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4178%26publicationDate%3DApril%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00079"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">568</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00079" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Novel CK2-Specific Pt(II) Compound Reverses Cisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and Suppressing DNA Damage Repair in Non-small Cell Lung Cancer Treatments&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yuanjiang&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Xinyi&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Gang&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Shaohua&quot;,&quot;last_name&quot;:&quot;Gou&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;4163-4178&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00079&quot;},&quot;abstract&quot;:&quot;Cancer stem cells (CSCs) have a pivotal impact in drug resistance, tumor metastasis, and progression of various cancer entities, including in non-small cell lung cancer (NSCLC). A CK2 inhibitor HY1 was found to show potent CSC inhibitory effects in A549 cells. By taking advantage of inherent CK2 specificity and CSC inhibition of HY1, a Pt(II) agent (HY1-Pt) was developed by conjugation of HY1 with an active Pt(II) unit to reverse cisplatin-induced resistance in A549/cDDP cell treatment. In vitro biological studies indicated that HY1-Pt can target CK2, suppress DNA damage repair, reinforce cellular accumulation of platinum, and reverse resistance apart from effectively inhibiting CSCs through Wnt/β-catenin signal pathway in A549/cDDP cells. Significantly, HY1-Pt presented an acceptable pharmacokinetic behavior and exhibited higher tumor growth inhibitory efficacy than cisplatin either in A549 or A549/cDDP xenograft models with low toxicity. Overall, HY1-Pt is a promising drug candidate for NSCLC treatment.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00079&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00079" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00079&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00079" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00079&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00079" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00079&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00079&amp;href=/doi/10.1021/acs.jmedchem.1c00079" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00079" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00079" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00079%26sid%3Dliteratum%253Aachs%26pmid%3D33784109%26genre%3Darticle%26aulast%3DWang%26date%3D2021%26atitle%3DNovel%2BCK2-Specific%2BPt%2528II%2529%2BCompound%2BReverses%2BCisplatin-Induced%2BResistance%2Bby%2BInhibiting%2BCancer%2BCell%2BStemness%2Band%2BSuppressing%2BDNA%2BDamage%2BRepair%2Bin%2BNon-small%2BCell%2BLung%2BCancer%2BTreatments%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D7%26spage%3D4163%26epage%3D4178%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=290768" title="Antineoplastic agents">Antineoplastic agents</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/jmcmar.2021.64.issue-7/20210408/jmcmar.2021.64.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Cancer stem cells (CSCs) have a pivotal impact in drug resistance, tumor metastasis, and progression of various cancer entities, including in non-small cell lung cancer (NSCLC). A CK2 inhibitor <b>HY1</b> was found to show potent CSC inhibitory effects in A549 cells. By taking advantage of inherent CK2 specificity and CSC inhibition of <b>HY1</b>, a Pt(II) agent (<b>HY1-Pt</b>) was developed by conjugation of <b>HY1</b> with an active Pt(II) unit to reverse cisplatin-induced resistance in A549/cDDP cell treatment. <i>In vitro</i> biological studies indicated that <b>HY1-Pt</b> can target CK2, suppress DNA damage repair, reinforce cellular accumulation of platinum, and reverse resistance apart from effectively inhibiting CSCs through Wnt/β-catenin signal pathway in A549/cDDP cells. Significantly, <b>HY1-Pt</b> presented an acceptable pharmacokinetic behavior and exhibited higher tumor growth inhibitory efficacy than cisplatin either in A549 or A549/cDDP xenograft models with low toxicity. Overall, <b>HY1-Pt</b> is a promising drug candidate for NSCLC treatment.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22272" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22272" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Lung cancer has become a serious public health issue, and its morbidity and mortality are increasing year by year, and it has become the first cause of death of malignant tumors in urban population of China.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Non-small cell lung cancer (NSCLC) occupies almost 85% of all lung cancers. More serious, nearly 70% of all patients with NSCLC with locally advanced or metastatic disease need systemic therapy, but they have only a median survival time of about 18 months in the inoperable stage.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> There are several reasons that NSCLC is difficult to cure: (i) most of the patients are found to be in the middle or advanced-stage and those who have received front-line chemotherapy face fruitless treatments.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> (ii) Lung cancers have serious intratumoral heterogeneity. According to statistics, as many as 63% of NSCLC patients contain more than one histological subtype.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> (iii) The intrinsic and/or acquired drug resistance from traditional drugs or targeted tyrosine kinase inhibitors is still a major problem in clinic. So, new agents are urgently needed to overcome drug resistance.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">Lung cancer intratumoral heterogeneity is driven by subpopulations of tumor cells termed as cancer stem cells (CSCs).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> CSCs, a small subset of cancer cells, can differentiate into different phenotypes with the ability of continuous self-renewal, differentiation, and highly tumorigenic subpopulation.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Unlike the bulk of tumor cells, CSCs are critically involved in tumorigenesis, tumor recurrence, cancer invasion, and metastasis. Moreover, mounting evidence suggests that CSCs in the quiescent phase can lead to primary and acquired drug resistance through DNA self-repair, ABC transporters, and mutation such as point mutation, gene mutation, and gene amplification, responsible for the failure of many cancer treatments.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> Therefore, development of targeted chemotherapeutic drugs to abrogate CSCs is a key task in lung cancer research and clinical application.</div><div class="NLM_p">Multi-regimen chemotherapy for NSCLC usually involves the combination of platinum-based drugs like cisplatin and other drugs with different mechanisms of action. According to the statistics, more than half of chemotherapy regimens contain platinum-based antitumor drugs.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15">(12−15)</a> However, non-specificity and drug resistance in addition to toxicity are still major inevitable barriers for their clinical use.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The great success and drawback of cisplatin have encouraged researchers to conduct more in-depth and detailed studies on its mechanism of action, attempting to achieve novel platinum-based drugs with higher efficiency, lower toxicity, and better reversal of resistance. So far, the mechanism of cisplatin resistance is recognized as follows: (i) decreased intracellular platinum accumulation, (ii) detoxification of platinum ions by sulfhydryl molecules, and (iii) increased DNA damage repair levels.<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17−19)</a> Besides, there are also other factors that may have impacts on the mechanism of drug resistance including DNA hypermethylation, histone modification, and chromatin structure changes.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">Protein kinase CK2 plays a notable role in various essential and pathological biological processes.<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21−23)</a> It has been proven that CK2 has more than 300 phosphorylated substrates, which is one of the most pleiotropic proteins in eukaryotic systems.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> CK2 is overexpressed in multiple tumors and rated as one of the most promising targets for treating many types of cancer and some life-threatening diseases.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Much significantly, CK2 can play a pivotal regulatory role in DNA damage repair and cancer stemness by Hedge-hog/Gli1, Wnt/β-catenin, NF-κB and PI3K, and so forth.<a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27−29)</a> In addition, CK2 inhibition also causes an increased uptake of known drugs in multidrug-resistant cells.<a onclick="showRef(event, 'ref30 ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref33">(30−33)</a></div><div class="NLM_p last">Notably, there has been a report that CK2α positively regulates the population of CD44<sup>+</sup>/CD24<sup>–</sup> and the transcriptional activity of Nothch1, which is concerned in the maintenance of CSCs.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> As <b>CX-4945</b> is the sole small molecule CK2 inhibitor in phase I/II clinical trials,<a onclick="showRef(event, 'ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37">(35−37)</a> we derived a hydrazide compound (<b>HY1</b>) upon the framework of <b>CX-4945</b>, which was found to exhibit potent capability of inhibiting cancer cell stemness. By taking the advantage of inherent CK2 specificity and CSC inhibition of <b>HY1</b>, a novel Pt(II) compound was developed by conjugation of <b>HY1</b> with an active Pt(II) unit as an antitumor agent, attempting to enhance antitumor efficacy and overcome cisplatin-induced resistance by targeting CK2, suppressing DNA damage repair and inhibiting cancer cell stemness for the first time.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74537" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74537" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Preparation of <b>HY1</b> and <b>HY1-Pt</b></h3><div class="NLM_p"><b>CX-4945</b> and compound <b>7</b> were synthesized in accordance with the procedures reported previously (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Scheme S1</a>).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The synthetic route of <b>HY1</b> and <b>HY1-Pt</b> is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Treatment of compound <b>7</b> with hydrazine hydrate in refluxing methanol afforded <b>HY1</b> which precipitated from the reaction mixture upon cooling. Direct condensation between <b>HY1</b> with <b>DN604</b>, a known antitumor Pt(II) agent,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> resulted in the formation of <b>HY1-Pt</b>. The resulting compounds were confirmed by <sup>1</sup>H, <sup>13</sup>C NMR, and HR electrospray ionization-mass spectrometry (ESI-MS) spectroscopy with purity over 95% determined by RP-HPLC (see also the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Supporting Information</a>).</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>HY1</b> and <b>HY1-Pt</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.2.  Inhibitory Activity of <b>HY1</b> on CK2 and Its Effect on A549 Cells Stemness</h3><div class="NLM_p">Since <b>HY1</b> and <b>CX-4945</b> share the same scaffold of benzo[<i>c</i>][2,6]naphthyridine, we explored whether <b>HY1</b> retained the CK2 inhibitory activity of its parent compound, <b>CX-4945</b>. Thus, the human CK2 assay kit and the antibodies of the specific phosphorylation targets of CK2 were used to evaluate the activity of <b>HY1</b> with <b>CX-4945</b> as the positive control. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a, <b>HY1</b> showed dose-dependent inhibition of CK2 with a higher IC<sub>50</sub> value than <b>CX-4945</b>. Besides, <b>HY1</b> also strongly inhibited the phosphorylation of Akt1 serine 129 and Cdc37 serine 13, two specific phosphorylation targets of CK2 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b). These results indicated that <b>HY1</b> maintained the inhibitory activity of the parent compound against CK2, even exhibiting slightly stronger activity than <b>CX-4945</b>.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Inhibitory activity of <b>HY1</b> on CK2 and its effect on A549 cell stemness. (a) Inhibition rate curves of <b>HY1</b> and <b>CX-4945</b> on CK2 enzyme activity. (b) Western blot analysis on the specific CK2 phosphorylation targets: phosphorylation of the Akt1 serine 129 and Cdc37 serine 13 in A549 cells after treatment with <b>CX-4945</b> and <b>HY1</b> at 20 μM, respectively, for 24 h. (c) Inhibition rate curves of <b>HY1</b> and <b>CX-4945</b> on ALDH1A1 enzyme activity. (d) Percentage of ALDH<sup>+</sup> cells in A549 cells after treatment with <b>CX-4945</b> and <b>HY1</b> at 20 μM, respectively, for 24 h. (e) ALDH1A1 mRNA levels after treatment with <b>CX-4945</b> and <b>HY1</b> at 20 μM, respectively, for 24 h in A549 cells. (f) ALDH1A1 protein levels treated with <b>CX-4945</b> and <b>HY1</b> at 20 μM, respectively, for 24 h in A549 cells. Data were obtained via using students’ <i>T</i>-test, <i>n</i> = 3 per group, Error bars = SD, asterisk indicate statistically significant differences, **<i>P</i> < 0.01, <i>vs</i> control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As CK2α can regulate the population of CD44<sup>+</sup>/CD24<sup>–</sup> involved in stem cell maintenance,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> we studied the inhibitory effect of <b>HY1</b> on cancer cell stemness as well. Aldehyde dehydrogenases (ALDHs) are a superfamily of detoxifying enzymes that are overexpressed in various cancers.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Increasing expression of ALDHs, especially ALDH1A1, in a number of malignancies and CSCs are closely related to poor prognosis, aggressiveness, and drug resistance in cancer chemotherapy. Growing lines of evidence prove that ALDH1A1 plays a significant role in tumors and CSCs except for a biomarker of CSCs and a predictor of the prognosis.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>c, <b>HY1</b> shows the potent inhibition on ALDH1A1 (IC<sub>50</sub> = 0.09 ± 0.01 μM), which is 18.8-fold as much as that of <b>CX-4945</b> (IC<sub>50</sub> = 1.69 ± 0.14 μM). The result indicated that <b>HY1</b> had strong inhibitory activity on ALDH1A1 enzyme.</div><div class="NLM_p">ALDH1A1 has been confirmed to play a notable effect in maintaining the stemness of A549 cells and is expressed preferentially.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Therefore, in A549 cells, we hypothesize that ALDH1A1 has an important effect in facilitating the toxicological mechanism of <b>HY1</b>. First, the Aldefluor Assay was selected to determine the proportion of ALDH<sup>+</sup> subsets in A549 cells. As shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>d, the subpopulation of the ALDH<sup>+</sup> cells were strongly reduced from 13.50 to 2.65% after treatment with <b>HY1</b>, stronger than that treated with <b>CX-4945</b> (5.65%). Besides, as shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>e, the transcriptional levels of ALDH1A1 in A549 cells presented a conspicuous decrease after being treated with <b>HY1</b> at 20 μM for 24 h. Meanwhile, the effect of <b>HY1</b> on the expression of ALDH1A1 in A549 cells was also explored by western blot. As shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>f, as expected, <b>HY1</b> can also down-regulate the expression of ALDH1A1 in A549 cells, stronger than <b>CX-4945</b>.</div><div class="NLM_p">CD44<sup>+</sup> is a cell surface protein, which can interact with a variety of growth factors secreted, extracellular matrix, components, and cytokines by cells present in the tumor microenvironment.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Therefore, CD44<sup>+</sup> has also been identified as a marker for CSCs in a variety of tumors. In order to study the action of <b>HY1</b> on cancer cell stemness further, the expression of CD44<sup>+</sup> in A549 cells treated with <b>HY1</b> was determined by flow cytometry using <b>CX-4945</b> and <b>BBI608</b> as positive controls. <b>BBI608</b>, currently in phase II/III clinical trials, is a STAT3 inhibitor which can potently inhibit the expression of the stemness gene, block the formation of tumorsphere, and kill CSCs isolated from multifarious cancer types.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a (see also the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Supporting Information</a>, Figure S1), the proportion of CD44<sup>+</sup> subsets in A549 cells was 61.8%, which is in accordance with other reports.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a><b>HY1</b> showed an extremely strong inhibitory effect on CD44<sup>+</sup> with an inhibition rate of 93.17%, higher than <b>BBI608</b> (91.73%) or <b>CX-4945</b> (79.45%). In addition, the function of <b>HY1</b> on stemness phenotypes in A549 cells was also investigated. The cells were cultured in a three-dimensional microenvironment without or with <b>CX-4945</b>, <b>BBI608,</b> and <b>HY1</b> for 24 h to detect their capability of tumorsphere formation. After the following 10-day treatment, the number of multicellular tumorsphere formed was counted. A549 tumorsphere cells treated with <b>HY1</b> displayed reduced sphere sizes and numbers as compared to those treated with <b>CX-4945</b>, indicating that the inhibitory effect of <b>HY1</b> was comparable to that of <b>BBI608</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b,c). Based on the above study, we assure that <b>HY1</b> is a bifunctional molecule that inhibits both CK2 and cancer cell stemness.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Study on the effect of <b>HY1</b> on the expression of intracellular CD44<sup>+</sup> and the formation of tumorsphere in A549 cells. (a) Statistics of the experimental results in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Figure S1</a>, and the proportion of CD44<sup>+</sup> subsets in A549 cells treated with <b>CX-4945</b>, <b>BBI608,</b> and <b>HY1</b> at 20 μM, respectively, for 24 h were statistically analyzed. (b) Morphological image and (c) the number of A549 cells tumorsphere treated with <b>CX-4945</b>, <b>BBI608</b>, and <b>HY1</b> at 10 μM, respectively. Error bars = SD (<i>n</i> = 3), **<i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.3.  Stability and Physicochemical Properties of <b>HY1-Pt</b></h3><div class="NLM_p">Initially, the stability of <b>HY1-Pt</b> in Hepes buffer (0.25 M) at pH 7.40 was studied via RP-HPLC and UV–vis at 37 °C. It was observed that <b>HY1-Pt</b> maintained its integrity after 12 h under the condition (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">S2a</a>). However, <b>HY1-Pt</b> was found to disassociate slowly by the hydrazine bond-breaking to yield <b>HY1</b> under the tumor acidic microenvironment (pH = 6.0) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">S2b</a>). As the lipid-water partition coefficient and LLE of a compound directly affects the absorption <i>in vivo</i>, the log <i>P</i><sub>o/w</sub> value of <b>HY1-Pt</b> was measured as −0.031, and its LLE values were 5.301 and 5.351 in A549 and A549/cDDP cells, respectively, hinting that <b>HY1-Pt</b> may have good absorption and penetration according to Lipinski’s rules.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Stability of <b>HY1-Pt</b> in Hepes buffer at pH 7.4 and 6.0 measured by UV–vis. (a) Stability of <b>HY1-Pt</b> in Hepes buffer (pH = 7.4) containing 2% DMF was recorded via time-dependent UV–vis spectra (scan every 30 min for a total of 24 times) at 37.0 °C. (b) Stability of <b>HY1-Pt</b> in Hepes buffer (pH = 6.0) containing 2% DMF was recorded via time-dependent UV–vis spectra (scan every 10 min for 12 h) at 37.0 °C.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">2.4.  <i>In Vitro</i> Cytotoxicity</h3><div class="NLM_p">Cytotoxicity of <b>HY1</b> and <b>HY1-Pt</b> as well as a physical mixture of equimolar <b>DN604</b> and <b>HY1</b> against A549 (sensitive to cisplatin) and A549/cDDP (resistant to cisplatin) cells was evaluated via MTT assay using <b>CX-4945</b>, cisplatin, and <b>DN604</b> as the positive drugs. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, cisplatin displayed the most potent anticancer activity against A549 cells, while presented the weakest activity against cisplatin-resistant A549/cDDP cells among the measured compounds. Notably, <b>HY1-Pt</b> had cytotoxicity nearly as potent as cisplatin in A549 cells, but the cytotoxicity of <b>HY1-Pt</b> to A549/cDDP cells was 5.81-fold higher than cisplatin with a RF (resistant factor) value of 0.95. It was noticed that <b>DN604</b> and its physical mixture with <b>HY1</b> showed almost the same cytotoxicity toward A549 cells. Even though the physical mixture showed 2.57-fold stronger cytotoxicity than <b>DN604</b> against A549/cDDP cells, its activity was 3.90 times weaker than <b>HY1-Pt</b>. Based on the above results, <b>HY1-Pt</b> as well as its parent compounds <b>CX-4945</b> and <b>HY1</b> was also used to treat different cancer cells and human normal hepatocytes for comparison. As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Table S2</a>, <b>HY1-Pt</b> exhibited more potent activity than <b>HY1</b> and <b>CX-4945</b> against these cancer cells. Significantly, <b>HY1-Pt</b> had the lowest toxicity to LO2 cells among the measured compounds. These results show that <b>HY1-Pt</b> exhibits strong inhibitory activity against these cancer cells, especially cisplatin-mediated drug-resistant cancer cells.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Cytotoxicity Profiles of <b>HY1-Pt</b> and Related Samples against A549 and A549/cDDP Cells</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char="±">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell</th><th class="colsep0 rowsep0" align="center" char="±"><b>CX-4945</b></th><th class="colsep0 rowsep0" align="center" char="±"><b>HY1</b></th><th class="colsep0 rowsep0" align="center"><b>HY1-Pt</b></th><th class="colsep0 rowsep0" align="center">cisplatin</th><th class="colsep0 rowsep0" align="center"><b>DN604</b></th><th class="colsep0 rowsep0" align="center"><b>DN604</b>/<b>HY1</b></th><th class="colsep0 rowsep0" align="center" char=".">FI<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A549</td><td class="colsep0 rowsep0" align="char" char="±">22.39 ± 2.04</td><td class="colsep0 rowsep0" align="char" char="±">18.16 ± 2.21</td><td class="colsep0 rowsep0" align="left">5.10 ± 0.48</td><td class="colsep0 rowsep0" align="left">4.05 ± 0.30</td><td class="colsep0 rowsep0" align="left">16.93 ± 1.35</td><td class="colsep0 rowsep0" align="left">16.76 ± 1.32</td><td class="colsep0 rowsep0" align="char" char=".">0.79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A549/cDDP</td><td class="colsep0 rowsep0" align="char" char="±">25.08 ± 2.34</td><td class="colsep0 rowsep0" align="char" char="±">17.03 ± 1.02</td><td class="colsep0 rowsep0" align="left">4.84 ± 1.38</td><td class="colsep0 rowsep0" align="left">28.12 ± 1.71</td><td class="colsep0 rowsep0" align="left">48.56 ± 4.60</td><td class="colsep0 rowsep0" align="left">18.90 ± 1.65</td><td class="colsep0 rowsep0" align="char" char=".">5.81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RF<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="left">0.95</td><td class="colsep0 rowsep0" align="left">6.94</td><td class="colsep0 rowsep0" align="left">2.86</td><td class="colsep0 rowsep0" align="left">1.12</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">RF (resistant factor) = IC<sub>50</sub> (A549/cDDP)/IC<sub>50</sub> (A549).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">FI (fold increase) = IC<sub>50</sub> (cisplatin)/IC<sub>50</sub> (<b>HY1-Pt</b>).</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">2.5.  Cellular Responses</h3><div class="NLM_p">In view of the <i>in vitro</i> anti-proliferation behavior of <b>HY1-Pt</b> on both A549 and A549/cDDP cells, its mechanisms of action were investigated. These two cancer cells were incubated with <b>CX-4945</b>, <b>HY1</b>, cisplatin, and <b>HY1-Pt</b> at 20 μM for 24 h for studying cell arrest and apoptosis. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a,b (see also the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Supporting Information</a>, Figure S3), in either A549 or A549/cDDP cells, cisplatin arrests the cell cycle in the S phase, which is in accordance with other reports.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Notably, <b>HY1-Pt</b> arrests the cell cycle also in the S phase, similar to cisplatin. Meanwhile, both A549 and A549/cDDP cells are highly sensitive to <b>HY1-Pt</b> with apoptotic percentages from 66.9 to 85.5%, much more effectively than cisplatin from 46.1 to 19.2% (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>c and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">S4</a>). To evaluate the high cytotoxicity of <b>HY1-Pt</b>, the cellular accumulation of <b>Pt</b> in A549 and A549/cDDP cells were determined via ICP-MS after being treated with <b>HY1-Pt</b> at 20 μM for 12 h, using <b>CX-4945</b> as a positive control. Significantly, the Pt accumulation of <b>HY1-Pt</b> in A549 and A549/cDDP cells is 2.33 and 6.00 times as much as that of cisplatin, respectively (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>d). As anticipated, the Pt amount of cisplatin in resistant to cisplatin cells is less than that in sensitive to cisplatin cells, however, that of <b>HY1-Pt</b> in cisplatin resistant cells is greater than in cisplatin sensitive cells with an increasing fold of 1.34. The increased Pt content would promote DNA damage in cancer cells. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>e, <b>HY1-Pt</b> produces longer length tails than cisplatin in these two cancer cells in a comet assay, while <b>CX-4945</b> and <b>HY1</b> display weaker DNA interactions than two Pt(II) agents. Based on the above, <b>HY1-Pt</b> has been proved to be capable of effectively promoting cellular accumulation of platinum, seriously causing DNA damage and largely inducing programmed cell death, exhibiting better antitumor activity than cisplatin in the cells either sensitive or resistant to cisplatin.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cellular responses of <b>CX-4945</b>, <b>HY1</b>, cisplatin, and <b>HY1-Pt</b> in A549 and A549/cDDP cells. Statistics of the results of cell cycle arrest in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Figure S3</a>. Cell cycle arrest distributions of (a) A549 and (b) A549/cDDP cells were detected by flow cytometry after treatment with the tested compounds at 20 μM, respectively, for 24 h. (c) Statistics of the results of apoptosis in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Figure S4</a>. A549 and A549/cDDP cells were treated with the tested compound at 20 μM, respectively, for 24 h, and then, the apoptosis of the cells was detected by flow cytometry. (d) Intracellular accumulation of platinum in A549 and A549/cDDP cells was detected by ICP-MS after treatment with cisplatin and <b>HY1-Pt</b> at 20 μM, respectively, for 24 h. (e) Representative images of nuclei from comet assays. A549 and A549/cDDP cells were treated with the tested compounds at 20 μM, respectively, for 12 h. Error bars = SD (<i>n</i> = 3), *<i>P</i> < 0.05, **<i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">2.6.  Study on the Expression of γ-H2AX</h3><div class="NLM_p">There are several kinds of DNA damage, such as base modification, in chain and link-crosslinking, single-strand (SSBs) and double-strand (DSBs) breaks, among which DSBs are considered to be the most serious damage to DNA. Since the occurrence of γ-H2AX is closely related to DSBs in a one-to-one correspondence, γ-H2AX appears an important indicator to detect DSBs in cells.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> Western blot, flow cytometry, and immunofluorescence techniques were used to detect the expression of γ-H2AX in either A549 or A549/cDDP cells. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a, <b>HY1-Pt</b> can promote the phosphorylation of H2AX in two cell lines more than cisplatin, especially in A549/cDDP cells. Besides, the results showed that cisplatin caused some DSBs in A549 cells, but such a damage effect obviously decreased in A549/cDDP cells. In contrast, <b>HY1-Pt</b> caused DSBs in A549 cells at a higher degree than that of cisplatin. Assessments of the γH2AX expression by flow cytometry further verified that <b>HY1-Pt</b> could lead to severe DSBs in both A549 and A549/cDDP cells, whose effect was obviously higher than cisplatin (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Figure S5</a>). Furthermore, as shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b, <b>HY1-Pt</b> also caused more serious DSBs in A549/cDDP cells with stronger fluorescence intensity than that in A549 cells.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Analysis of the γH2AX expression in A549 and A549/cDDP cells. (a) Expression of γH2AX in two cell lines was analyzed by western blot after treatment with <b>CX-4945</b>, <b>HY1</b>, cisplatin (cis), and <b>HY1-Pt</b> at 20 μM, respectively, for 24 h. (b) γH2AX foci in two cell lines were determined via immunofluorescence staining after treatment with <b>CX-4945</b>, <b>HY1</b>, cisplatin, and <b>HY1-Pt</b> at 20 μM, respectively, for 12 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">2.7.  Investigation on the Inhibition of <b>HY1-Pt</b> on CK2α and DNA Damage Repair</h3><div class="NLM_p">Since CK2 can be used as a key director in DNA damage repair and cancer cell stemness, we explored whether <b>HY1-Pt</b> retained the CK2 inhibitory activity of <b>HY1</b>.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> As illustrated in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Figure S6</a>, <b>HY1-Pt</b> showed dose-dependent inhibition of CK2 enzyme activity, and its IC<sub>50</sub> was up to 1.14 ± 0.24 nM. In addition, in either A549 or A549/cDDP cells, <b>HY1-Pt</b> can inhibit the phosphorylation of Akt1 serine 129 and Cdc37 serine 13 in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a). The potent inhibition of <b>HY1-Pt</b> on CK2 prompted us to further explore the binding mode between <b>HY1-Pt</b> and CK2α protein through molecular docking. The template of the co-crystal structure of CK2α complexed with <b>CX-4945</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6isj">6isj</a>) was used. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b, the entire CK2α molecular structure is completely wrapped in the CK2α active cavity. In addition, the hydrogen atoms on the amino group act as hydrogen bond donors form hydrogen bonds with ASP-174 and ASP-155 residues, respectively, while the carbonyl and oxygen atoms in the ester bond act as hydrogen bond receptors to form hydrogen bonds with LYS-157 and LYS-48 residues, respectively. These four hydrogen bonds firmly rivet <b>HY1-Pt</b> in the active cavity of CK2α with the lowest binding energy of −11.21 kcal/mol. These results prove that the hybrid of <b>HY1</b> into <b>DN604</b> makes <b>HY1-Pt</b> not only maintain the cytotoxicity of the active Pt(II) unit but also keep the ability of <b>CX-4945</b> to target and inhibit CK2α.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Investigation on the inhibition of <b>HY1</b> on CK2 and DNA damage repair. (a) Western blotting assay on the expression of p-Akt1<sup>S129</sup> and p-Cdc37<sup>S13</sup> in either A549 or A549/cDDP cells after treatment with different concentrations of <b>HY1-Pt</b> for 24 h. (b) <b>HY1-Pt</b> is docked into the hydrophobic pocket of CK2α protein (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6isj">6isj</a>) utilizing Autodock. Amino acid residues that may be involved in the binding are labeled, and the yellow dashed indicate the hydrogen bond interaction. (c) The co-localization of MDC1/Aprataxin and the damaged DNA in either A549 or A549/cDDP cells were detected by immunofluorescence technique after treatment with <b>CX-4945</b>, <b>HY1</b>, cisplatin, and <b>HY1-Pt</b> at 20 μM for 24 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Mediator of DNA damage checkpoint 1 (MDC1) is an important protein involved in the DSB response pathway.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Using immunofluorescence technique, we checked MDC1 to explore whether <b>HY1-Pt</b> can inhibit DNA damage repair while promoting DNA damage. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>c, <b>HY1-Pt</b> leads to dramatic reduction in co-localization of MDC1/aprataxin and the damaged DNA compared with cisplatin in either A549 or A549/cDDP cells, demonstrating that <b>HY1-Pt</b> can suppress extensive DNA damage repair via inhibiting CK2 compared with cisplatin.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">2.8.  Investigation on the Inhibition of A549/cDDP<sup>CD44bright</sup> Cells</h3><div class="NLM_p">The expression of CSC surface antigens plays a key role in invasiveness, promoting cancer recurrence.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> In solid cancer, CSCs were defined based on CD44 expression by flow cytometry as CD44<sup>bright</sup> population.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> In order to further investigate the inhibitory activity and mechanism of <b>HY1-Pt</b> on CSCs, CD44<sup>bright</sup> population cells in A549/cDDP were sorted by a flow cytometer. First, using <b>CX-4945</b>, <b>HY1</b> and cisplatin as positive controls, the inhibition rate of <b>HY1-Pt</b> to A549/CDDP<sup>CD44bright</sup> cells was detected by MTT assay. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>a, <b>HY1-Pt</b> maintained a high sensitivity to A549/CDDP<sup>CD44bright</sup> cells with an inhibition rate of 68.36%, much higher than that of cisplatin (11.47%). In addition, the expression of CSC surface antigens CD133<sup>+</sup> in A549/cDDP<sup>CD44bright</sup> cells was 24.37%, which was 7.25 times higher than that in A549/cDDP cells (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Figure S7</a>). Notably, <b>HY1-Pt</b> also showed dose-dependent inhibition effects, and the inhibition rate reached 76.78% at 20 μM. In contrast, cisplatin had hardly significant inhibitory activity (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>b).</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Study on the inhibitory effect of the tested compounds on A549/cDDP<sup>CD44bright</sup> and its intracellular CD133. (a) Mortality rate of A549/cDDP<sup>CD44bright</sup> cells incubated with <b>CX-4945</b>, <b>HY1</b>, cisplatin, and <b>HY1-Pt</b> at 20 μM, respectively, for 24 h. (b) Expression of CD133 is analyzed in A549/cDDP<sup>CD44bright</sup> cells by flow cytometry. Error bars = SD (<i>n</i> = 3), *<i>P</i> < 0.05, **<i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The effect of <b>HY1-Pt</b> on ALDH1A1 expression in A549/cDDP<sup>CD44bright</sup> cells was also investigated. As expected, the transcriptional levels of ALDH1A1 showed a remarkable decrease in A549/cDDP<sup>CD44bright</sup> cells after being treated with <b>HY1-Pt</b> at 20 μM for 24 h. However, at the same dose, cisplatin promoted the expression of ALDH1A1 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>a). Western blot analysis confirmed this result as well. Besides, <b>HY1-Pt</b> also showed a dose-dependent inhibition effect on ALDH1A1 in A549/cDDP<sup>CD44bright</sup> cells (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>b). SOX2, OCT4, and Nanog, essential transcription factors to maintain the characteristics of stem cells, are currently recognized as the signature genes of CSCs, which have an important effect in maintaining self-renewal, proliferation, and pluripotency in malignant tumors.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> To evaluate the impact of <b>HY1-Pt</b> on cancer cell stemness, we quantitatively analyzed the transcription levels of the signature genes of CSCs in A549/cDDP<sup>CD44bright</sup> cells. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>c, the transcript levels of the transcription factors in A549/cDDP<sup>CD44bright</sup> cells treated with cisplatin and <b>HY1-Pt</b> were significantly different. The transcript levels of Nanog were obviously increased after being treated with cisplatin, showing its anti-differentiation effect on CSCs, which would lead to the enrichment of the CSC population, in accordance with earlier reports.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Importantly, Nanog was down-regulated after being treated with <b>HY1-Pt</b>, indicating a diversion of the population from stemness. Due to the synergistic effect of Nanog with SOX-2 and OCT4, there is no doubt that <b>HY1-Pt</b> significantly down-regulated the expression of SOX-2 and OCT4 as well, whereas cisplatin showed the opposite effect. This has a correlation with the capability of <b>HY1-Pt</b> to influence stem cells, but cisplatin preferentially attacks non-stem cells, promoting the CSC level in the cell population. In addition, the multicellular sphere formation of A549/cDDP<sup>CD44bright</sup> cells after treatment with cisplatin and <b>HY1-Pt</b> at different concentrations, respectively, was evaluated. Obvious phenotypic changes happened in these A549/cDDP<sup>CD44bright</sup>-derived tumorsphere in each group. Compared with the control group, the size and number of A549/cDDP<sup>CD44bright</sup>-derived tumorsphere treated with <b>HY1-Pt</b> were significantly reduced, the larger the drug concentration is, the smaller the volume and the less the number of tumorsphere are. Although cisplatin has no significant effect on the number and size of tumorsphere, it may promote the growth of tumorsphere when the concentration is high (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>d,e). These results hint that our Pt(II)-based compound may overcome cisplatin resistance by inhibiting cancer cell stemness.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Study on A549/cDDP<sup>CD44bright</sup> cells. (a) qRT-PCR patterns of the ALDH1A1 in A549/cDDP<sup>CD44bright</sup> cells treated with cisplatin and <b>HY1-Pt</b> at 20 μM. (b) Expression of the ALDH1A1 in A549/cDDP<sup>CD44bright</sup> cells was explored by western blot after treatment with 10 μM cisplatin and <b>HY1-Pt</b> at concentrations of 10, 20, and 40 μM, respectively, for 24 h. (c) qRT-PCR patterns of the stem cell genes Nanog, SOX2, and OCT4 in A549/cDDP<sup>CD44bright</sup> cells treated with cisplatin and <b>HY1-Pt</b> at 20 μM, respectively. (d) Morphological observation and (e) the number of A549/cDDP<sup>CD44bright</sup> cells tumorsphere treated with cisplatin and <b>HY1-Pt</b> at two doses (5 and 10 μM), respectively. (f) Expression of DKK1, p-GSK-3β(ser9), and β-catenin in A549/cDDP cells was explored by western blot after treatment with <b>HY1-Pt</b> at concentrations of 10, 20, and 40 μM, respectively, for 24 h. Error bars = SD (<i>n</i> = 3), *<i>P</i> < 0.05, **<i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">It is known that stem cells are primarily controlled by Wnt/β-catenin, Notch, Hedgehog/Gli1, and BMI-1 signal transduction pathway.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Therefore, we tried to learn how <b>HY1-Pt</b> affects Wnt/β-catenin CSCs signal transduction pathway in A549/cDDP cells via western blot technique. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>f, the expression of anticancer protein DKK1 was upregulated with the increasing concentrations of <b>HY1-Pt</b>, while that of the phosphorylation of GSK-3β(ser9) protein was significantly down-regulated. In addition, <b>HY1-Pt</b> significantly inhibited β-catenin in a dose-dependent manner in A549/cDDP cells. Therefore, <b>HY1-Pt</b> can inhibit the signaling pathway of Wnt/β-catenin. It has already been proved that in the nucleus, β-catenin binds to TCF/LEF transcription factor family to activate the promoter of target genes of β-catenin, thus activating the target genes of Wnt signaling pathway like CD44, CD24, CD133, ABCG2, ALDH1A1, EpCAM, MMP7, Vimentin, and Slug. As Wnt1 can increase expression of ALDH1A1, it promotes the expression of Akt and β-catenin as well.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Phosphorylated Akt has been reported to inactivate GSK-3β by the phosphorylation of GSK-3β at ser9, suppressing its capability to degrade β-catenin.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a> So, it is suggested that <b>HY1-Pt</b> might regulate the expression of ALDH1A1 and CD133 via the Akt-GSK-3β(ser9)-Wnt/β-catenin signaling pathway, thereby inhibiting cancer cell stemness.</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">2.9.  Study on Mitochondrial Apoptosis Pathways</h3><div class="NLM_p">Reactive oxygen species (ROS) are inevitable products of cell metabolism, but accumulation of ROS usually oxidizes and damages the mitochondria of cells, and metal compounds induce excess ROS accumulation by disrupting intracellular redox equilibrium.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Mitochondria has emerged as a crucial coordinator of the cell death signaling network, including stimulation of caspases and other processes related to cell death.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The mitochondrial membrane potential (MMP) change in cancer cells is also considered as a key pro-apoptotic marker for early apoptosis.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Therefore, it is interesting to investigate whether <b>HY1-Pt</b> can induce production of intracellular ROS, thereby reducing MMP and then inhibiting the caspase signaling pathway. As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>a and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">S8</a>, in A549 and A549/cDDP cells, <b>HY1-Pt</b> can induce the production of a large amount of intracellular ROS, and the proportion of ROS-positive cells is 62.4 and 65.7%, respectively. In contrast, in A549/cDDP cells, the amount of ROS induced by cisplatin is significantly lower than that of <b>HY1-Pt</b>, the proportion of ROS-positive cells induced by cisplatin is 2.32-times lower than that of <b>HY1-Pt</b>. Images of ROS in two cancer cells stained with DCFH-DA (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Figure S9</a>) also indicate that the fluorescence intensity of <b>HY1-Pt</b> is greater than that of cisplatin, confirming the result obtained by flow cytometry. In order to investigate the ROS damage to the mitochondrial membrane by <b>HY1-Pt</b>, we measured the change of MMP by fluorescent probe JC-1. As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>b and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">S10</a>, in both A549 and A549/cDDP cells, <b>HY1-Pt</b> can seriously induce JC-1 monomer, especially in A549/cDDP cells, the number of JC-1 monomers induced by <b>HY1-Pt</b> is 3.19-fold as much as that by cisplatin. Meanwhile, more JC-1 monomers were observed in cells treated with <b>HY1-Pt</b> in fluorescent images (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Figure S11</a>). As illustrated in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>c, <b>HY1-Pt</b> can significantly inhibit the caspase signaling pathway, which is manifested as the decreased expression of pro-caspase-3 and pro-caspase-9 compared to the control group. Moreover, significant up-regulation of Bax, cleaved-PARP, and down-regulation of Bcl-2 in A549/cDDP cells were observed after treatment of <b>HY1-Pt</b>, which were greater than those induced by cisplatin. Different from the dysfunction of cisplatin in A549/cDDP cells owing to drug resistance, <b>HY1-Pt</b> behaved in the same way as that in A549 cells as well. These results imply that as a potent Pt(II) antitumor agent, <b>HY1-Pt</b> can induce to produce a great deal of ROS, reduce MMP, and promote the apoptosis of cancer cells through the mitochondrial apoptosis pathway.</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Study on mitochondrial apoptosis pathway. Statistical changes of (a) ROS-positive cells and (b) MMP in A549 and A549/cDDP cell treatment with <b>CX-4945</b>, <b>HY1</b>, cisplatin, and <b>HY1-Pt</b> at 20 μM for 24 h. (c) Expression levels of Bcl-2, Bax, pro-caspase 3, pro-caspase 9, and cleaved-PARP in A549 and A549/cDDP cells were explored via western blot after treatment with cisplatin and <b>HY1-Pt</b> at 20 μM for 24 h. Error bars = SD (<i>n</i> = 3), *<i>P</i> < 0.05, **<i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">2.10.  Pharmacokinetic Study</h3><div class="NLM_p">As the main hydrolytic product of <b>HY1-Pt</b>, <b>HY1</b> generated by the hydrazine bond-breaking under a tumor acidic condition was first studied in human, rat, and mouse liver microsomes for evaluating its metabolic stability. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, the metabolism of <b>HY1</b> is not much stable in these three types of liver microsomes. In addition, the clearance rate (Cl<sub>int</sub>) of <b>HY1</b> in these liver microsomes is rather fast, especially in the mouse liver ones.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Liver Microsomal Enzyme Stability of <b>HY1</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">species</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>HY1</b></th><th class="colsep0 rowsep0" align="center" char=".">human</th><th class="colsep0 rowsep0" align="center" char=".">rat</th><th class="colsep0 rowsep0" align="center" char=".">mouse</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (min)</td><td class="colsep0 rowsep0" align="char" char=".">23.88</td><td class="colsep0 rowsep0" align="char" char=".">37.83</td><td class="colsep0 rowsep0" align="char" char=".">15.55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl<sub>int</sub><a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> (mL/min/kg)</td><td class="colsep0 rowsep0" align="char" char=".">72.80</td><td class="colsep0 rowsep0" align="char" char=".">65.66</td><td class="colsep0 rowsep0" align="char" char=".">351.00</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last"><i>T</i><sub>1/2</sub> is defined as half-life.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Cl<sub>int</sub> is defined as clearance.</p></div></div></div><div class="NLM_p">In addition, the pharmacokinetic (PK) analysis of <b>HY1-Pt</b> in Sprague-Dawley (SD) rats following a single 10 mg/kg dose administration by intravenous injection (iv) was performed. As summarized in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, <b>HY1-Pt</b> demonstrated a moderate half-life and plasma clearance. In addition, <b>HY1-Pt</b> also had a good apparent volume of distribution, a relatively larger area under the concentration–time curve, and an acceptable mean residue time. We also compared the pharmacokinetics of <b>HY1-Pt</b> with that of cisplatin reported by Tanji Takada and co-workers.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> At the same dosage (10 mg/kg) by the same administration (iv), the half-life (<i>t</i><sub>1/2</sub>) of cisplatin in rats is 5.94 h, slightly higher than that of <b>HY1-Pt</b> (5.1 h). However, cisplatin was found to be difficultly eliminated with a clearance rate (CL) of 0.06 L·h<sup>–1</sup>·kg<sup>–1</sup>, and the residence time is long (MRT = 7.0 h). In comparison, <b>HY1-Pt</b> has a higher clearance rate (CL = 3.9 L·h<sup>–1</sup>·kg<sup>–1</sup>) and shorter mean residence time (MRT = 2.7 h) in rats. These data indicated that <b>HY1-Pt</b> had an acceptable PK behavior superior to cisplatin, which encouraged us to conduct <i>in vivo</i> tests on its anti-tumor activity.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Pharmacokinetic Parameters of <b>HY1-Pt</b> and Cisplatin in SD Rats</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">dose (10 mg/kg)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center" char="±"><b>HY1-Pt</b></th><th class="colsep0 rowsep0" align="center" char="±">cisplatin<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub>/h</td><td class="colsep0 rowsep0" align="char" char="±">5.1 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">5.9 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL/L·h<sup>–1</sup>·kg<sup>–1</sup></td><td class="colsep0 rowsep0" align="char" char="±">3.9 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">0.06 ± 0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0-<i>t</i></sub>/ng h·mL<sup>–1</sup></td><td class="colsep0 rowsep0" align="char" char="±">2857 ± 374.0</td><td class="colsep0 rowsep0" align="char" char="±">26920 ± 2050</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0-∞</sub>/ng h·mL<sup>–1</sup></td><td class="colsep0 rowsep0" align="char" char="±">2611 ± 371.0</td><td class="colsep0 rowsep0" align="char" char="±">66370 ± 6360</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">V<sub>d</sub>/L·kg<sup>–1</sup></td><td class="colsep0 rowsep0" align="char" char="±">28.9 ± 7.0</td><td class="colsep0 rowsep0" align="char" char="±">0.6 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>0-<i>t</i></sub>/h</td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 0.0</td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>0-∞</sub>/h</td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">7.0 ± 0.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Data were adopted from ref <a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a>.</p></div></div></div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">2.11.  <i>In Vivo</i> Antitumor Activity</h3><div class="NLM_p">Based on the above study, <i>in vivo</i> antitumor tests of <b>HY1-Pt</b> in A549 xenograft models were undertaken, in which animals were randomly divided into five groups as vehicle, cisplatin (4 mg/kg), and <b>HY1-Pt</b> at three doses (10, 20, 40 mg/kg). Due to the severe toxicity of cisplatin, its dose was limited only to the equal molar amount of platinum in <b>HY1-Pt</b> dosed at 10 mg/kg. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>, the inhibitory rate (86.92%) of <b>HY1-Pt</b> at low dose (10 mg/kg) is even higher than that (66.51%) of cisplatin (4 mg/kg), despite two agents exhibited comparable <i>in vitro</i> cytotoxicity against A549 cells. It is noticed that <b>HY1-Pt</b> displayed a dose-dependent inhibitory effect on tumor growth with a maximum inhibitory rate of 95.03% at 40 mg/kg.</div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. <i>In vivo</i> A549 xenograft model study of <b>HY1-Pt</b> and cisplatin. (a) During the observation period, tumor volumes of animals from each group, including vehicle, cisplatin (4 mg/kg, iv, once a week for 4 weeks) and <b>HY1-Pt</b> (10, 20 and 40 mg/kg, iv, once a week for 4 weeks). (b) Weights of tumors resected from all groups of mice on the last day. (c) Influence of different samples on body weight changes of the animals. (d) Images of tumors from five groups of mice at the end of the experiment. Error bars = SD (<i>n</i> = 5), **<i>P</i> < 0.01, <sup>##</sup><i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To learn whether <b>HY1-Pt</b> can overcome cisplatin resistance <i>in vivo</i>, we also tested the antitumor activity of <b>HY1-Pt</b> at two doses (10 and 20 mg/kg) in A549/cDDP xenograft mice with cisplatin as the positive drug. The mice were administered with the formulations in the same way as that in the A549 xenograft model. As shown in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, cisplatin dosed at 4 mg/kg displays much weaker activity with an inhibitory rate of 9.09% owing to the serious resistance as predicted. However, <b>HY1-Pt</b> dosed at 10 mg/kg with an equivalent molar amount of platinum in cisplatin is able to effectively inhibit the tumor growth at a rate of 72.72%. Particularly, <b>HY1-Pt</b> dosed at 20 mg/kg has the highest inhibitory rate of 82.64%, showing the dose dependence of <b>HY1-Pt</b> treatments.</div><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. <i>In vivo</i> A549/cDDP xenograft model study of <b>HY1-Pt</b> and cisplatin. (a) During the observation period, tumor volumes of animals in each group, including vehicle, cisplatin (4 mg/kg, iv, once a week for 4 weeks), and <b>HY1-Pt</b> (10 and 20 mg/kg, iv, once a week for 4 weeks). (b) Weights of tumors resected from all groups of sacrificed mice on the last day. (c) Influence of different samples on body weight changes of the animals. (d) Images of tumors from five groups of mice at the end of the experiment. Error bars = SD (<i>n</i> = 5), **<i>P</i> < 0.01, <sup>##</sup><i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">More significantly, there is no conspicuous change in body weight in all the mice treated with <b>HY1-Pt</b>, revealing that <b>HY1-Pt</b> has low systemic toxicity and good safety (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>c and <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>c). Furthermore, the H.E. staining of slices from heart, liver, spleen, lung, and kidney of an animal randomly selected from each tested group in both A549 and A549/cDDP models demonstrates that <b>HY1-Pt</b> at the used dosages has almost no toxic effects on organ tissues compared with cisplatin (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Figures S12 and S13</a>). These results indicate that <b>HY1-Pt</b> not only effectively inhibits cisplatin-mediated resistance in NSCLC cells <i>in vitro</i> but also exhibits strong anticancer activity with low toxicity both in the A549 xenograft model or in the A549/cDDP xenograft models.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">3.  Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52522" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52522" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Our study indicates that <b>HY1-Pt</b> has potent cytotoxicity activity toward the cancer cells of the tested but with low toxicity in normal cells. Notably, cisplatin-induced resistant cancer cells are also sensitive to <b>HY1-Pt</b> as expected. Further research on the mechanism of action reveals that <b>HY1-Pt</b> can target CK2 protein, reinforce cellular accumulation of platinum, inhibit cancer cell stemness, and suppress DNA damage repair, effectively reversing cisplatin resistance through the signaling pathway of Wnt/β-catenin by inhibiting expression of the signature genes of CSCs in A549/cDDP cancer cells and CK2 overexpression. Besides, treatment of cancer cells with <b>HY1-Pt</b> can dramatically increase the level of ROS, reduce MMP, and promote apoptosis of cancer cells through the mitochondrial apoptosis pathway. More significantly, <b>HY1-Pt</b> can effectively overcome cisplatin resistance, exhibiting potent <i>in vivo</i> antitumor activity in both A549 and A549/cDDP xenograft models with low toxicity. Overall, as the first example of a CSC inhibitor used in conjugation with other bioactive species in a molecular entity for drug resistance reversal, <b>HY1-Pt</b> has a potential as a Pt(II)-based drug to treat with all kinds of solid tumors including NSCLC.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">4.  Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06007" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06007" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">4.1.  Materials and Instrument</h3><div class="NLM_p last">All chemicals in analytical purity were purchased commercially from InnoChem (Beijing) Technology Co., Ltd. and Sann Chemical Technology (Shanghai) Co., Ltd. and used without further purification. DN604 and BBI608 were synthesized according to the method reported in previous literature.<a onclick="showRef(event, 'ref38 ref62'); return false;" href="javascript:void(0);" class="ref ref38 ref62">(38,62)</a><sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker 600 MHz spectrometer. High-resolution mass spectroscopy (HR-MS) was measured by an Agilent 6224 ESI/TOF MS instrument. The purity of the compounds was detected by a reversed-phase high performance liquid chromatogram (RP-HPLC) (waters, 2545 system) on an ODS column (250 × 4.6 mm, 5 μm). Flow cytometry studies were performed on a BD FACSCalibur flow cytometer. An Olympus FV1000 confocal microscope was used to record the confocal images. Besides, all cells used in this work were purchased from Biorn Lifescience Co., Ltd. Pro-caspase 3, Pro-caspase 9, Bcl-2, Bax, Cleaved-PARP, phosphor-AKT (ser129), phosphor-Cdc37 (ser13), ALDH1A1, γ-H2AX, MDC1, DKK1, phospho-GSK-3β (ser9), β-catenin, and β-actin antibodies were all purchased from Beyotime Biotechnology.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">4.2.  Chemistry</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23">4.2.1.  Synthesis and Characterization of Compound <b>7</b> and <b>CX-4945</b></h4><div class="NLM_p last">Compound <b>7</b> and <b>CX-4945</b> were synthesized in accordance with the procedures reported previously.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Compound <b>7</b>: <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.09 (s, 1H), 9.91 (s, 1H), 8.94 (d, <i>J</i> = 5.6 Hz, 1H), 8.79 (d, <i>J</i> = 8.5 Hz, 1H), 8.77 (d, <i>J</i> = 5.6 Hz, 1H), 8.34 (t, <i>J</i> = 1.9 Hz, 1H), 8.17 (dd, <i>J</i> = 6.3, 1.4 Hz, 1H), 7.90 (dd, <i>J</i> = 8.4, 1.7 Hz, 1H), 7.42 (t, <i>J</i> = 8.1 Hz, 1H), 7.12 (dd, <i>J</i> = 7.9, 1.4 Hz, 1H), 3.92 (s, 1H) ppm. <b>CX-4945</b>: <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.04 (s, 1H), 10.30 (s, 1H), 10.16 (s, 1H),9.08 (d, <i>J</i> = 5.8 Hz, 1H), 9.00–8.97 (m, 1H), 8.94 (d, <i>J</i> = 8.5 Hz, 1H), 8.31–8.28 (m, 2H), 8.12 (d, <i>J</i> = 8.2 Hz, 1H), 8.03 (dd, <i>J</i> = 8.4, 1.5 Hz, 1H), 7.45 (t, <i>J</i> = 8.1 Hz, 1H), 7.17 (d, <i>J</i> = 7.9 Hz, 1H) ppm.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24">4.2.2.  Synthesis and Characterization of <b>HY1</b></h4><div class="NLM_p last">To a solution of compound 7 (1.09 g, 3 mmol) in MeOH (20 mL) was slowly added hydrazine hydrate (1.5 g, 30 mmol) at room temperature. The reaction mixture was heated to reflux for 72 h and monitored with thin layer chromatography (TLC). After the substrate was completely consumed, the reaction liquid was slowly poured into the ice water mixture to separate out the yellow solid, filtering the precipitate, and washed with ice methanol (3 × 10 mL) to obtain the crude product of <b>HY1</b>. The crude product was recrystallized with 1, 4-dioxane (10 mL) to get a bright yellow solid (0.989 g). Yield: 90.8%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.14 (s, 1H), 10.08 (s, 1H), 9.63 (s, 1H), 8.95 (d, <i>J</i> = 6.0 Hz, 1H), 8.80 (d, <i>J</i> = 12.0 Hz, 1H), 8.55 (d, <i>J</i> = 6.0 Hz, 1H), 8.33 (t, <i>J</i> = 1.8 Hz, 1H), 8.21 (d, <i>J</i> = 1.6 Hz, 1H), 8.07 (d, <i>J</i> = 6.0 Hz, 1H), 7.91 (dd, <i>J</i> = 12.0, 1.6 Hz, 1H), 7.42 (t, <i>J</i> = 6.0 Hz, 1H), 7.12 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H), 4.63 (s, 2H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 165.77, 150.47, 148.13, 147.69, 143.76, 142.40, 134.73, 133.35, 130.52, 127.52, 126.26, 124.17, 123.00, 122.83, 122.60, 121.47, 120.57, 119.56, 116.79 ppm. HR-MS (<i>m</i>/<i>z</i>): (ESI) calcd for C<sub>19</sub>H<sub>14</sub>ClN<sub>5</sub>O [M + H]<sup>+</sup>, 364.0965; found, 364.0967.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25">4.2.3.  Synthesis and Characterization of <b>HY1-Pt</b></h4><div class="NLM_p last"><b>HY1</b> (0.181 g, 0.5 mmol), <b>DN604</b> (0.193 g, 0.5 mmol), and 3–5 drops of acetic acid were mixed in methanol (20 mL). The mixture was stirred and heated at 60 °C for 48–72 h in the dark. The reaction was monitored by TLC. After the reaction finished, the resulting deposits were filtered and washed with methanol (3 × 10 mL) to obtain the crude product <b>HY1-Pt</b>. The crude product was recrystallized with dimethylformamide (DMF)/1, 4-dioxane (1:4, v/v) to get a bright yellow solid (0.365 g). Yield: 93.4%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.15 (s, 1H), 10.19 (s, 1H), 9.67 (s, 1H), 8.99 (d, <i>J</i> = 4.2 Hz, 1H), 8.86 (d, <i>J</i> = 7.7 Hz, 1H), 8.58 (d, <i>J</i> = 3.8 Hz, 1H), 8.26 (s, 1H), 8.23 (s, 1H), 8.14 (d, <i>J</i> = 7.2 Hz, 1H), 7.93 (d, <i>J</i> = 7.3 Hz, 1H), 7.45 (t, <i>J</i> = 7.5 Hz, 1H), 7.14 (d, <i>J</i> = 6.9 Hz, 1H), 4.26 (s, 6H), 3.74 (s, 4H) ppm. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 176.45, 176.23, 163.28, 159.72, 150.55, 148.18, 147.80, 143.63, 142.33, 135.12, 133.28, 130.62, 127.50, 126.91, 124.23, 123.84, 122.80, 122.69, 121.73, 120.64, 119.68, 116.83, 56.40, 49.60, 46.96 ppm. HR-MS (<i>m</i>/<i>z</i>): (ESI) calcd for C<sub>25</sub>H<sub>22</sub>ClN<sub>7</sub>O<sub>5</sub>Pt [M + H]<sup>+</sup>, 731.1091; found, 731.1353.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">4.3.  Purity of Final Compounds</h3><div class="NLM_p last">The purity of all final compounds was determined by RP-HPLC (waters e2695, US) equipped with an ODS column (250 × 4.6 mm, 5 μm) and a 2489 UV/vis detector. Detailed steps: <b>CX-4945</b>, <b>HY1,</b> and <b>BBI608</b> were dissolved in chromatographic pure methanol and filtered by organic syringe filters of 0.45 μM aperture. The purity of these compounds was investigated at 25 °C as the column temperature, using acetonitrile/water (55:45, v/v) as the mobile phase at the flow rate of 0.8 mL/min. The purity of <b>CX-4945</b>, <b>HY1</b>, and <b>BBI608</b> was 99.43, 95.58, and 99.70%, respectively, analyzed by the peak area percentage method. <b>HY1-Pt</b> was dissolved with a small amount of dimethyl sulfoxide (DMSO), diluted with methanol, and filtered with an organic syringe filter of 0.45 μM aperture. The purity of <b>HY1-Pt</b> was investigated at 25 °C as the column temperature, using methanol/water (60:40, v/v) as the mobile phase at the flow rate of 1.0 mL/min. The purity of <b>HY1-Pt</b> was 97.40%, analyzed by the peak area percentage method.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">4.4.  CK2 Activity Assay</h3><div class="NLM_p last">CK2 kinase (human) assay/inhibitor screening assay kit and CK2 enzyme were purchased from Shanghai Fusheng Industrial Co., Ltd. (Shanghai, China). The inhibitory activity of <b>CX-4945</b>, <b>HY1</b>, and <b>HY1-Pt</b> on CK2 enzyme was detected according to manufacturer’s instruction provided in the CK2 assay kit. Briefly, the CK2 reaction solution was added into each well of 96-well plates after thawing, and five different concentrations of <b>HY1-Pt</b> (500.00, 100.00, 20.00, 1.00, 0.80 nM) were added to each well as the “test inhibitor” and five different concentrations of <b>CX-4945</b> and <b>HY1</b> (500.00, 100.00, 20.00, 1.00, 0.80 nM) were added to the well as the “positive control”, with the same solution without the inhibitor as “blank”. After sealing the plate with a sealing film, the setup was incubated at 37 °C for 30 min. After that, conjugate reagent (50 μL) was added to each well, excepting blank holes, and incubated at 37 °C for another 30 min. The color developing reagents A (50 μL) and B (50 μL) were successively added to each hole, and the mixture was shaken gently and mixed well, avoiding light for 10 min, and then stop buffer (50 μL) was added to each hole. The reaction mixtures were incubated at room temperature for 10 min and the value of O.D. was measured via an enzyme-labeling instrument at a wavelength of 490 nm. The IC<sub>50</sub> value of each compound represented as the mean ± SD was obtained by three parallel experiments.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">4.5.  Western Blot Tests</h3><div class="NLM_p last">A549 and A549/cDDP cells were diluted into 1 × 10<sup>5</sup> cells/mL mixed liquid with the corresponding medium and spread in a six-well plate and cultured at 37 °C for 12 h and then treated with 20 μM of the tested compounds for 24 h. Two cancer cells were collected, centrifuged, and washed with phosphate buffer saline (PBS) and then lysed in lysis buffer (100 mM Tris-Cl, pH 6.8, 4% (m/v) sodium dodecyl sulfonate, 20% (v/v) glycerol, 200 mM β-mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride, and 1 g/mL aprotinin) and centrifuged at 15000 rpm for 15 min at 4 °C and collected. The concentrations of total proteins were measured with BCA protein assay reagents (Imgenex, USA). Protein (20–100 μg) prepared from the indicated cells was loaded per lane and electrophoresed in 8 or 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then transferred to poly(vinylidene difluoride) Hybond-P membrane (GE Healthcare) using a transblot apparatus (Bio-Rad, USA). The blots were blocked with 5% nonfat milk in Trisbuffered saline with Tween 20 (TBST) buffer for 1 h and co-incubated with primary antibodies (anti-p-AKT(ser129), anti-p-Cdc37(ser13), anti-ALDH1A1, anti-γ-H2AX, anti-DKK1, anti-p-GSK3β(ser9), anti-β-catenin, anti-Bcl-2, anti-Bax, anti-pro-caspase-3, anti-pro-caspase-9, anti-cleaved-PARP, and anti-β-actin and diluted in TBST overnight at 4 °C. The membrane was washed with TBST and incubated with secondary antibodies conjugated with peroxidase for 2 h at 37 °C, then washed twice with TBST buffer and PBS once, and visualized with chemiluminescence reagent (Thermo Fischer Scientifics Ltd.)</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">4.6.  ALDH1A1 Enzyme Activity Assay</h3><div class="NLM_p last">ALDH1A1 kinase (human) assay/inhibitor screening assay kit and ALDH1A1 enzyme were purchased from Shanghai Fusheng Industrial Co., Ltd. (Shanghai, China). The inhibitory activity of <b>CX-4945</b> and <b>HY1</b> on ALDH1A1 enzyme was detected according to manufacturer’s instruction provided in the ALDH1A1 assay kit. The specific test procedure is the same as the CK2 kinase (human) assay/inhibitor screening assay kit.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">4.7.  Cell Culture</h3><div class="NLM_p last">Six different cells were used in this experiment including A549 (non-small cell lung cancer), A549/cDDP (cisplatin-resistant lung cancer), PC-3 (prostate cancer), HepG2 (liver cancer), T24 (bladder cancer), and LO2 (normal live cells). All of them were originally purchased from the Cell Bank of Shanghai Institute of Cell Biology. A549, A549/cDDP, and PC-3 cells were cultured with a complete medium containing 10% fetal bovine serum (FBS) and 90% Roswell Park Memorial Institute-1640 (RPMI-1640) incomplete medium at 37 °C in 5% CO<sub>2</sub>. HepG-2, T24, and LO2 cells were cultured at 37 °C in 5% CO<sub>2</sub> with Dulbecco’s modified Eagle medium supplemented with 10% FBS. The culture medium was also supplemented with <span class="smallcaps smallerCapital">d</span>-glucose of 2 g/L, <span class="smallcaps smallerCapital">l</span>-glutamine of 0.3 g/L, sodium bicarbonate of 2 g/L, penicillin of 80 U/mL, and streptomycin of 0.08 mg/mL, kept in a constant temperature incubator containing 5% CO<sub>2</sub> at 37 °C.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">4.8.  Detection of ALDH Activity</h3><div class="NLM_p last">For the evaluation of the expression levels of ALDH1A1 in A549 cells exposed to <b>CX-4945</b> (20 μM) and <b>HY1</b> (20 μM), ALDEFLUOR (Stem cell Technologies, Vancouver BC, CA) staining was measured using the FITC channel of fluorescent activated cell sorting according to the manufacturer’s instruction.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32">4.9.  Real-Time Quantitative PCR</h3><div class="NLM_p last">Total RNA was isolated by using TRIZOL from A549 and A549/cDDP<sup>CD44bright</sup> cells treated for 24 h with equitoxic concentration of tested compounds corresponding to IC<sub>50</sub>,<sub>72h</sub>. RNA was reverse-transcribed with Luna universal one-step RT-qPCR (GeneAmp 9600, PerkinElmer), and the resulting cDNA was subsequently submitted to thermal cycling on Quantitative Real-time PCR (ABI step one plus, ABI). The thermal profile was as follows: reverse transcription for 10 min at 55 °C, initial denaturation for 1 min at 95 °C, followed by 39 thermal cycles of denaturation for 10 s at 95 °C, and extension for 30 s at 60 °C. Primer sequences are listed in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Table S2</a>. All runs included melting curve analysis and template-free negative technical controls to confirm specific single-product amplification. β-actin mRNA was used as an internal control. The relative expression of mRNA is represented as fold increase (2<sup>–ΔΔC<i>t</i></sup>).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">4.10.  Spheroid Formation Assay</h3><div class="NLM_p last">Briefly, the A549 and A549/cCDDP<sup>CD44bright</sup> cells were plated on Ultra-Low Attachment Surface 24 well-plates (3473, Corning) in serum-free 1640 medium supplemented with B27 (1:50, 17504044, Invitrogen), epidermal growth factor (EGF) (20 ng/mL, AF-100-15, Peprotech), and β-fibroblast growth factor (β-FGF) (10 ng/mL, 100–18B, Peprotech) at a density of 800 cells per well. When the number of cells in a spheroid were more than 10, it was considered to have formed a clone sphere. After treatment with different drug formulations for 10 days. The number and sizes of tumorsphere were measured on day 10.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">4.11.  Assessment of CD44 Expression</h3><div class="NLM_p last">A549 cells were seeded on 6-well plates at the density of 1 × 10<sup>5</sup> cells per well. After incubating the samples for 12 h, the cells were treated with <b>CX-4945</b> (20 μM), <b>BBI608</b> (20 μM), and <b>HY1</b> (20 μM), respectively, for 24 h. Then, the cells were stained with FITC-conjugated anti-CD44 according to the manufacturer’s respective instructions. CD44 expressions were assessed by flow cytometry. Calculation of inhibition rate was based on fluorescence intensity.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">4.12.  Stability of <b>HY1-Pt</b></h3><div class="NLM_p last"><b>HY1-Pt</b> was dissolved in pH = 6.0 and 7.4 Hepes buffer (0.25 M) containing 2% DMF and incubated at 37 °C in the dark, respectively. The solution behavior of <b>HY1-Pt</b> was detected and recorded by UV–vis (Shimadzu UV-2600) with wavelength ranging from 225 to 450 nm and scanned every 30 min for a total of 24 times. In addition, the stability of <b>HY1-Pt</b> was also detected by RP-HPLC (waters, 2545 system) on an ODS column (250 × 4.6 mm, 5 mm) at different time points with an eluent of methanol/water (60:40, v/v) at a flow rate of 1 mL/min.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36">4.13.  Measurement of Water/Octanol Partition Coefficient (log <i>P</i><sub>o/w</sub>)</h3><div class="NLM_p last">The lipophilicity (log <i>P</i><sub>O/W</sub>) of <b>HY1-Pt</b> was measured using the shake-flask method in the 1-octanol/distilled water system. Octanol was saturated with a distilled water by shaking the two-phase mixture overnight. A portion of 5 mL of pre-saturated octanol containing <b>HY1-Pt</b> was incubated with 5 mL of distilled water in a 15 mL tube. The tube was shaken at room temperature in the dark for 24 h. Centrifugation was carried out at 2500 rpm for 15 min to separate different phases, and the platinum concentrations in these two phases were determined by ICP-MS. The final result was expressed as a mean of three independent experiments. The log <i>P</i><sub>O/W</sub> was calculated using the following equation<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_m001.gif" alt="" id="_i37" /></img></span></div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38">4.14.  Cytotoxicity Measurement</h3><div class="NLM_p last">MTT assay was used to evaluate the cytotoxicity of all compounds synthesized in this work. Different cells were grown on 96-well plates at a cell density of 1 × 10<sup>5</sup> cells/mL and incubated at an atmosphere of 5% CO<sub>2</sub> and 95% air at 37 °C for 12 h. After the cells were completely attached, the complete medium was replaced, and the samples were diluted into five concentrations and added to the wells in turn. Each concentration was set up with three identical experimental groups to ensure that the volume of each well was 100 μL. The MTT (3-(4,5)-dimethylthiahiazo(-<i>z</i>-y1)-3,5-di-phenytetrazoliumromide) solution with the concentration of 5 mg/mL was added to each well after 72 h. Next, the culture medium was removed and about 100 μL of DMSO was added to each well to dissolve completely after 3–4 h. The O.D. value was read at 490 nm enzyme labeling instrument. The IC<sub>50</sub> values of each group can be calculated by SPSS software.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39">4.15.  Cell Cycle Test</h3><div class="NLM_p last">A549 and A549/cDDP cells were diluted into 1 × 10<sup>5</sup> cells/mL mixed liquid with the corresponding medium and spread in a six-well plate and cultured at 37 °C for 12 h. Two cancer cells were incubated with 20 μM of the tested compounds for 24 h. The cells were collected into different centrifugal tubes, added about 500 μL of 70% ice ethanol, and placed at −20 °C for overnight. Centrifugation was carried out at 1500 rpm for 5 min to remove the supernatant, and then 1 mg/mL PI staining solution (containing 10% RnaseA) was added to the cells and stored in the dark for 30 min. The sample was measured via flow cytometry (FAC Scan, Becton Dickenson), and the data was analyzed with FlowJo software (TreeStar, Inc.).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40">4.16.  Apoptosis Assessment</h3><div class="NLM_p last">Detection of apoptosis of A549 and A549/cDDP induced by <b>CX-4945</b>, <b>HY1</b>, cisplatin, and <b>HY1-Pt</b> was made by the Annexin V-FITC apoptosis detection kit according to the manufacturer’s protocol. The A549 and A549/cDDP cells in logarithmic growth phase were collected and suspended with the corresponding culture medium after centrifugation and plated on a six-well plate with a cell concentration of 1 × 10<sup>5</sup> cells per well. After the cells have completely adhered to the wall, the original culture medium was replaced with a fresh medium and treated with 20 μM of the tested compounds, respectively, for 24 h at 37 °C. Then, the cells were incubated with Annexin V-FITC and then PI for 10 min in the dark at room temperature; cells were analyzed by flow cytometry (FAC Scan, Becton Dickenson) and the apoptosis value was obtained using Cell-Quest software (BD Biosciences).</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41">4.17.  Cellular Accumulation of Platinum</h3><div class="NLM_p last">A549 and A549/cDDP cells with a concentration of 1 × 10<sup>5</sup> cells/mL were seeded in 6-well plates until reached about 80% confluence and then incubated with cisplatin (20 μM) and <b>HY1-Pt</b> (20 μM), respectively, at 37 °C. The cells were harvested and stored in a different centrifuge after 12 h co-incubation, washed with cold PBS (3 × 3 mL), and digested with 200 mL 65% HNO<sub>3</sub> to obtain a completely uniform solution. After diluted with pure water, intracellular platinum content was detected via ICP-MS.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42">4.18.  Comet Assay</h3><div class="NLM_p last">A549 and A549/cDDP cells were incubated with 20 μM of the tested compounds for 12 h, combined with molten LM Agarose (Trevigen) at a ratio of 1:10 (v/v), and pipetted onto Comet Slide (Trevigen) immediately. In the dark, slides were incubated at 4 °C for 10 min, and then the cells were immersed in prechilled Lysis buffer and incubated at 4 °C for 60 min. In the dark, the DNA was immersed in the alkaline solution of pH > 13 (200 mM NaOH, 1 mM EDTA) for 40 min. Single cell electrophoresis was carried out at 25 V voltage for 25 min via alkaline electrophoresis solution (200 mM NaOH, 1 mM EDTA). The slides were rinsed with Tris-HCl solution of 0.4 mM of pH = 7.5 three times, stained with PI for 30 min in the dark, and visualized by microscopy.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43">4.19.  Immunofluorescence Test</h3><div class="NLM_p last">Briefly, A549 and A549/cDDP cells were grown to confluence in sterile watchglasses for 24 h at 37 °C and then treated with 20 μM of <b>CX-4945</b>, <b>HY1</b>, cisplatin, and <b>HY1-Pt</b> for 24 h. All cells were washed with PBS, fixed in 4% paraformaladehyde/PBS for 30 min, and permeabilized with PT-5 solution [0.3% Triton X-100 in PBS] for 30 min at 4 °C. The cells were blocked by incubating with PTB-5 [0.5% BSA in PBS] for 1 h at room temperature. Dishes were then incubated with the primary antibody (1:500) overnight at 4 °C. Cells were stained with the secondary antibody conjugated with Alexa 488 (1:100, Invitrogen, Carlsbad, USA). Microscopy was performed on a Leica TCS NT confocal scanner equipped with an ArKr-Laser on the Leica DM IRBE inverted microscope (lens: HCX PlanApo 63x oil/NA1.32). Confocal images were displayed as maximum projections and assembled in Adobe Photoshop 7.0.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44">4.20.  Molecular Docking</h3><div class="NLM_p last">Molecular docking of <b>HY1-Pt</b> to CK2α (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6isj">6isj</a>) was carried out by AutoDock, in which the Iterated Local Search Globule Optimizer was applied as optimization algorithm.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Ligand <b>HY1-Pt</b> was prepared in ChemBioDraw Ultra 14.0 and minimized with the ChemBio3D Ultra 14.0. Before the docking process, the nature ligand and water molecules were removed from the crystal structure. Subsequently, all hydrogen atoms were added to each protein and ligand to be docked, and each coordinate file of protein and ligand was generated as PDBQT file using AutoDockTools-1.5.6. A grid box for the binding site covered the catalytic site of the protein or 50 Å in the three dimensions for the allosteric binding site. The coordinate of the binding site is <i>X</i> = 33.303, <i>Y</i> = 6.104, <i>Z</i> = 14.131. The box had 0.375 Å grid spacing and centered at the geometric center of the protein. When using Autodock software to simulate the binding mode between <b>HY1-Pt</b> and CK2α protein, the force field parameters added to Pt were as follows “atom_par Pt 2.75 0.080 12.000–0.00110 0.0 0.0 0 -1 -1 1 # non H-bonding”. In each docking experiment, the best binding mode was selected according to the binding affinity calculated by the scoring function in AutoDock. Docking results were analyzed and visualized with PyMOL 2.4.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45">4.21.  A549/cDDP<sup>CD44bright</sup> Cell Sorting</h3><div class="NLM_p last">In order to enrich the cells by CSCs, A549/cDDP cells were stained for its CSC-marker CD44 with FITC-conjugated antibodies and subsequently sorted with magnetic anti-FITC microbeads. The effectivity of sorting was further checked by flow cytometry (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Figure S6a,b</a>). CD44-birght A549/cDDP (A549/cDDP<sup>CD44bright</sup>) cells were selected for further experiments as CSC-like population. The A549/cDDP cells were sorted by using the magnetic separation method based on anti-fluorophore microbeads from Miltenyi Biotec, Gladbach, Germany. Briefly, A549/cDDP cells were stained with CD44-FITC for 10 min at 4 °C; then, the cells were labeled with anti-FITC microbeads for 15 min at the same temperature. Cells were magnetically sorted by using the magnetic separation method based on anti-fluorophore microbeads (MS columns).</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46">4.22.  Assessment of CD133 Expression</h3><div class="NLM_p last">The A549/cDDP<sup>CD44bright</sup> cells were seeded on 6-well plates at the density of 1 × 10<sup>5</sup> cells per well. After incubating the samples for 12 h, the cells were treated with cisplatin (10 μM) and different concentration of <b>HY1-Pt</b>, respectively, for 24 h. Then, the cells were stained with PE-conjugated anti-CD133 according to the manufacturer’s respective instructions. CD133 expressions were assessed by flow cytometry. Calculation of the inhibition rate was based on fluorescence intensity.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47">4.23.  ROS Measurement</h3><div class="NLM_p last">The A549 and A549DDP cells were diluted into 1 × 10<sup>5</sup> cells/mL mixed liquid with the corresponding medium and spread in a six-well plate and cultured at 37 °C for 12 h. Two cancer cells were treated with various compounds: vehicle (DMSO), <b>CX-4945</b> (20 μM), <b>HY1</b> (20 μM), cisplatin (20 μM), and <b>HY1-Pt</b> (20 μM) for 24 h, respectively. The cells were washed two times with PBS, and 2,7-dichlorodi-hydrofluorescein diacetate (DCFH-DA) (Molecular Probe, Beyotime, Haimen, China) was used as a probe to measure the level of ROS according to the different fluorescence intensity by Confocal photography at the same voltage. Besides, after different groups of cells were washed twice with PBS, the production of ROS was also detected by flow cytometry.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48">4.24.  Mitochondrial Membrane Potential Measurement</h3><div class="NLM_p last">The A549 and A549DDP cells were diluted into 1 × 10<sup>5</sup> cells/mL mixed liquid with the corresponding medium and spread in a six-well plate and cultured at 37 °C for 12 h and then treated with 20 μM of the tested compounds for 24 h. In the dark, the medium was replaced followed by staining with a JC-1 fluorescent probe for 30 min at 37 °C, and then the cells were washed twice with PBS, and the effects of various compounds on MMP of tumor cells were analyzed with flow cytometer and confocal photography.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49">4.25.  Metabolic Stability</h3><div class="NLM_p last">The metabolic stability of <b>HY1</b> in incubation with human, rat, and mouse liver microsomes was determined through the commercially available service provided by Shanghai ChemPartner Co., Ltd. (Shanghai, China). Liver microsomal incubations were conducted in triplicate. Incubation mixtures (0.5 mg/mL microsome protein, pH 7.4 of 100 mM phosphate buffer, 1 μM compounds in DMSO) were first shaken for pre-incubation at 37 °C. The reaction was initiated by adding NAPDH to obtain a concentration of 1 mM NAPDH in the mixture. For metabolic stability studies, aliquots of the incubation sample mixture were collected at 0, 5, 15, 30, and 45 min. After collection of samples, the reaction was terminated with DMSO containing the internal standard (200 ng/mL Tolbutamide). The mixture was then centrifuged to remove the protein, and the supernatant was subsequently applied to S47 LC-MS/MS analysis. Positive control samples were prepared as described above, except for the test compound that was replaced with the known P450 substrate (1 μM Midazolam).</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50">4.26.  Pharmacokinetic Assay</h3><div class="NLM_p">The pharmacokinetic profile of <b>HY1-Pt</b> was investigated in 12 h fasted male SD rat following a single dose given intravenous injection (iv). <b>HY1-Pt</b> was dissolved in DMF: Tween 80: 5% glucose injection = 10:2:88. Three male SD rats weighing about 250–270 g were treated with <b>HY1-Pt</b> (10 mg/kg). Blood samples (0.3 mL) of each rat were collected from the rat’s posterior orbital vein at 0.0833, 0.25, 0.50, 0.75, 1, 2, 3, 4, 6, 8, 12, and 24 h following iv dosing. Samples were centrifuged at 4000 rpm for 10 min, and the plasma was collected and stored at −40 °C until analysis. Samples were analyzed by LC-MS/MS technique. The data of blood concentration (<i>c</i>)–time (<i>T</i>) measured after iv administration were processed by Das 2.0 software. The appropriate mathematical model was selected to fit, and the pharmacokinetic parameters were calculated.</div><div class="NLM_p last">Preparation of standard curves: 100 μL of blank plasma was added to 10 μL of the standard solution of <b>HY1-Pt</b> at different concentrations (30, 60, 150, 300, 600, 1500, 3000, 6000, 15000, and 30000 ng/mL), respectively, to prepare plasma samples equivalent to ropivacaine with plasma mass concentrations of 3, 6, 15, 30, 60, 150, 300, 600, 1500, and 3000 ng/mL. The samples with different concentrations (5 μL) were analyzed by the LC-MS/MS technique, the ratio <i>Y</i> of the peak area of each component to the internal standard peak area was used to perform linear regression operation on the plasma mass concentration <i>X</i>, and the regression equation obtained was the standard curve. The regression equation of <b>HY1-Pt</b> is <i>Y</i> = 0.6962<i>X</i> – 0.0137 (<i>r</i> = 0.9998), and the minimum quantitative limit all is 3 ng/mL.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51">4.27.  <i>In Vivo</i> Antitumor Efficacy of <b>HY1-Pt</b></h3><div class="NLM_p">(a) A549 xenograft model: 5 × 10<sup>7</sup> A549 cells in 0.1 mL of sterile PBS were injected subcutaneously into the flank of five-week-old, weighing about 16–18 g, male BALB/c athymic nude mice; they were all purchased from Shanghai Sipo-Bikai laboratory animal co. Ltd. (China). When the tumors reached a volume of 100–120 mm<sup>3</sup> in all mice, 25 mice were randomly divided into five groups with five mice per group and treated via intravenous injection through the tail vein with 0.1 mL 5% glucose injection (once a week for 4 weeks), cisplatin (4 mg/kg, once a week for 4 weeks), and <b>HY1-Pt</b> (10, 20 and 40 mg/kg, once a week for 4 weeks). Cisplatin was dissolved in normal saline, <b>HY1-Pt</b> was dissolved in DMF: Tween 80: 5% glucose injection = 10:2:88. Tumor volumes and body weights were recorded twice for a week. The calculation formula of tumor volume (TV, mm<sup>3</sup>) is TV = 0.5 × length × width<sup>2</sup>. Growth curves were plotted using the average tumor volume within each experimental group at the set time points via origin 9.0. 25 mice were sacrificed after the last treatment; then tumor weight was evaluated as the antitumor activity of the corresponding groups, and the heart, liver, spleen, lung, kidney, and tumor tissues were excised for H.E. staining. The body weight and physical state of the mice were measured simultaneously as an indicator of systemic toxicity.</div><div class="NLM_p last">(b) A549/cDDP xenograft model: the procedure was the same as that of the A549 xenograft model except that A549/cDDP cells were used and <b>HY1-Pt</b> was given in two groups at doses of 10 and 20 mg/kg, respectively.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52">4.28.  Statistical Analysis</h3><div class="NLM_p last">The data shown in this manuscript were expressed as means ± SD from at least three independent experiments, each in triplicate samples for individual treatment or dosage. Statistical analyses were performed using an unpaired, two-tailed Student’s <i>t</i>-test, and significance of difference is indicated as *<i>P</i> < 0.05 and **<i>P</i> < 0.01.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00079" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61642" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61642" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00079?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00079</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">The synthetic route of <b>CX-4945</b>; the proportion of CD44<sup>+</sup> subsets induced by <b>CX-4945</b>, <b>BBI608,</b> and <b>HY1</b>; RP-HPLC analysis on the stability of <b>HY1-Pt</b>; flow cytometry analysis on the cell cycles, apoptosis, and the expression of γH2AX in A549 and A549/cDDP cells induced by <b>HY1-Pt</b> and related sample; the inhibitory rate curves of <b>HY1-Pt</b> on CK2 enzyme activity; flow cytometry analysis on the expression of CD133<sup>+</sup> in A549/cDDP and A549/cDDP<sup>CD44bright</sup> cells induced by cisplatin and <b>HY1-Pt</b>; the production of ROS, changes of JC-1 and MMP in A549 and A549/cDDP cells induced by the <b>HY1-Pt</b> and related sample were detected by the flow cytometer and confocal laser scanning microscope; H.E. staining of tissues in the nude mice xenograft model of A549 and A549/cDDP; tables of the stability of <b>HY1</b> in incubation with human, rat, and mouse liver microsomes; tables of the data of the plasma concentrations at different time points after intravenous injection of <b>HY1-Pt</b> in rats; tables of the inhibitory effects of measured samples on the A549 cancer cell xenograft mice model; tables of the inhibitory effects of measured samples on the A549/cDDP cancer cell xenograft mice model; and figures of <sup>1</sup>H NMR, <sup>13</sup>C NMR, HR-MS spectra, and RP-HPLC chromatograms (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Atomic coordinates of <b>HY1-Pt</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_003.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf">jm1c00079_si_001.pdf (2.38 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_002.csv">jm1c00079_si_002.csv (0.9 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_003.pdb">jm1c00079_si_003.pdb (429.22 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00079" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68108" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68108" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shaohua Gou</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, PR China</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0284-5480" title="Orcid link">http://orcid.org/0000-0003-0284-5480</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#eddfdfdcd4dfdbd8d5ddddad9c9cc38e8280"><span class="__cf_email__" data-cfemail="7c4e4e4d454e4a49444c4c3c0d0d521f1311">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuanjiang Wang</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, PR China</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xinyi Wang</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, PR China</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gang Xu</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, PR China</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmaceutical
Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.W. and X.W. contribute equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26638" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26638" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank National Natural Science Foundation of China (Project no. 22077015), Fundamental Research Funds for the Central Universities (Project 2242020K30059), and Graduate Research and Innovation Fund of Jiangsu Province, China (Grant KYCX19_0102) for financial aid to this work. Nanjing Biorn Life Science Co. Ltd is acknowledged for the <i>in vivo</i> tests.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase</p></td></tr><tr><td class="NLM_term">ALDH1A1</td><td class="NLM_def"><p class="first last">aldehyde dehydrogenase 1A1</p></td></tr><tr><td class="NLM_term">A549</td><td class="NLM_def"><p class="first last">human NSCLC cell</p></td></tr><tr><td class="NLM_term">A459/cDDP</td><td class="NLM_def"><p class="first last">resistant to cisplatin A549 cells</p></td></tr><tr><td class="NLM_term">Bax</td><td class="NLM_def"><p class="first last">Bcl-2 associated X protein</p></td></tr><tr><td class="NLM_term">Bcl-2</td><td class="NLM_def"><p class="first last">B-cell lymphoma-2 protein</p></td></tr><tr><td class="NLM_term">cDDP</td><td class="NLM_def"><p class="first last">cisplatin</p></td></tr><tr><td class="NLM_term">CK2</td><td class="NLM_def"><p class="first last">casein kinase 2</p></td></tr><tr><td class="NLM_term">Clk2</td><td class="NLM_def"><p class="first last">cell division cycle-like kinase 2</p></td></tr><tr><td class="NLM_term">CSC</td><td class="NLM_def"><p class="first last">cancer stem cell</p></td></tr><tr><td class="NLM_term">DCHF-DA</td><td class="NLM_def"><p class="first last">2,7-dichlorodi-hydrofluorescein diacetate</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s modified Eagle medium</p></td></tr><tr><td class="NLM_term">EGF</td><td class="NLM_def"><p class="first last">epidermal growth factor</p></td></tr><tr><td class="NLM_term">β-FGF</td><td class="NLM_def"><p class="first last">β-fibroblast growth factor</p></td></tr><tr><td class="NLM_term">FITC</td><td class="NLM_def"><p class="first last">fluorescein isothiocyanate isomer</p></td></tr><tr><td class="NLM_term">GSK-3β</td><td class="NLM_def"><p class="first last">glycogen synthase kinase-3β</p></td></tr><tr><td class="NLM_term">HepG2</td><td class="NLM_def"><p class="first last">human liver hepatocellular cancer cell</p></td></tr><tr><td class="NLM_term">HR-MS</td><td class="NLM_def"><p class="first last">high resolution mass spectrometry</p></td></tr><tr><td class="NLM_term">ICP–MS</td><td class="NLM_def"><p class="first last">inductively coupled plasma–mass spectrometry</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">the half maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term">LO2</td><td class="NLM_def"><p class="first last">human normal hepatocytes cell</p></td></tr><tr><td class="NLM_term">MMP</td><td class="NLM_def"><p class="first last">mitochondrial membrane potential</p></td></tr><tr><td class="NLM_term">MMP-7</td><td class="NLM_def"><p class="first last">matrix metalloproteinase 7</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly ADP-ribose polymerase</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate buffer saline</p></td></tr><tr><td class="NLM_term">PC-3</td><td class="NLM_def"><p class="first last">human prostate cancer cell</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">propidium iodide</p></td></tr><tr><td class="NLM_term">qRT-PCR</td><td class="NLM_def"><p class="first last">quantitative real-time PCR</p></td></tr><tr><td class="NLM_term">RF</td><td class="NLM_def"><p class="first last">resistant factor</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">γH2AX</td><td class="NLM_def"><p class="first last">phosphorylation of H2AX</p></td></tr><tr><td class="NLM_term">RP-HPLC</td><td class="NLM_def"><p class="first last">reversed-phase high performance liquid chromatography</p></td></tr><tr><td class="NLM_term">TMS</td><td class="NLM_def"><p class="first last">tetramethylsilane</p></td></tr><tr><td class="NLM_term">T24</td><td class="NLM_def"><p class="first last">human bladder cancer cell</p></td></tr><tr><td class="NLM_term">UV–vis</td><td class="NLM_def"><p class="first last">ultraviolet and visible spectrophotometry</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61313" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61313" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 64 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgensztern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, C.</span></span> <span> </span><span class="NLM_article-title">The Biology and Management of Non-Small Cell Lung Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>553</i></span>,  <span class="NLM_fpage">446</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1038/nature25183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fnature25183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=29364287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12itbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=553&publication_year=2018&pages=446-454&author=R.+S.+Herbstauthor=D.+Morgenszternauthor=C.+Boshoff&title=The+Biology+and+Management+of+Non-Small+Cell+Lung+Cancer&doi=10.1038%2Fnature25183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The biology and management of non-small cell lung cancer</span></div><div class="casAuthors">Herbst, Roy S.; Morgensztern, Daniel; Boshoff, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">553</span>
        (<span class="NLM_cas:issue">7689</span>),
    <span class="NLM_cas:pages">446-454</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing the understanding of the disease biol. and mechanisms of tumor progression, and advancing early detection and multimodal care.  The use of small mol. tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients.  However, the overall cure and survival rates for NSCLC remain low, particularly in metastatic disease.  Therefore, continued research into new drugs and combination therapies is required to expand the clin. benefit to a broader patient population and to improve outcomes in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4LzsacpsnpLVg90H21EOLACvtfcHk0lj_WvhKa5a38g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12itbo%253D&md5=9e7e092850f8707b96b6828e9a0d9585</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnature25183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25183%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DMorgensztern%26aufirst%3DD.%26aulast%3DBoshoff%26aufirst%3DC.%26atitle%3DThe%2520Biology%2520and%2520Management%2520of%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DNature%26date%3D2018%26volume%3D553%26spage%3D446%26epage%3D454%26doi%3D10.1038%2Fnature25183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span> <span> </span><span class="NLM_article-title">Cost-Effectiveness Analysis of Ceritinib and Alectinib Versus Crizotinib in the Treatment of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer</span>. <i>Cancer Manage. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">9195</span>– <span class="NLM_lpage">9202</span>, <span class="refDoi"> DOI: 10.2147/cmar.s223441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.2147%2FCMAR.S223441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=31749634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BB3cXns1Gmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=9195-9202&author=M.+Liuauthor=L.+Zhangauthor=Q.+Huangauthor=N.+Liauthor=B.+Zhengauthor=H.+Cai&title=Cost-Effectiveness+Analysis+of+Ceritinib+and+Alectinib+Versus+Crizotinib+in+the+Treatment+of+Anaplastic+Lymphoma+Kinase-Positive+Advanced+Non-Small+Cell+Lung+Cancer&doi=10.2147%2Fcmar.s223441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cost-effectiveness analysis of ceritinib and alectinib versus crizotinib in the treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer</span></div><div class="casAuthors">Liu, Maobai; Zhang, Longfeng; Huang, Qishu; Li, Na; Zheng, Bin; Cai, Hongfu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Management and Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9195-9202</span>CODEN:
                <span class="NLM_cas:coden">CMRACP</span>;
        ISSN:<span class="NLM_cas:issn">1179-1322</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: This study aimed to analyze the cost-effectiveness of crizotinib vs. ceritinib or alectinib as first-line-targeted drug therapy for anaplastic lymphoma kinasepos. advanced non-small cell lung cancer in China.  Methods: The Markov model was used to simulate the medical cost and quality-adjusted life years (QALYs) of patients using crizotinib, ceritinib, or alectinib over a 10-yr period by establishing three health states: progression-free, post-progression, and death.  Randomized controlled clin. data were collected from the open-label, randomized phase 3 trials ALEX and ASCEND-4.  Cost and utility values were derived from local charges and literature.  Sensitivity analyses included one-way and probabilistic sensitivity analyses.  Results: Compared with patients who used crizotinib as first-line treatment, patients in the ceritinib and alectinib groups yielded an addnl. 1.32 and 3.30 QALYs with an incremental cost of $84,728.20 and $339,114.36, resp.  Thus, the incremental cost-effectiveness ratio (ICER) was $64,398.83 and $102,675.74 per QALY in the ceritinib and alectinib groups, resp.  Alectinib was estd. to be more effective (4.68 QALY) and more costly ($432,063.06) with an ICER of $128,019.42 per QALY compared with ceritinib (2.69 QALY and $177,676.90).  Results were robust to deterministic and probabilistic sensitivity analyses.  Conclusion: As a first-line treatment regimen, ceritinib and alectinib can extend the survival time of patients compared with crizotinib, but the medical cost also increases accordingly.  According to the World Health Organization's three-percent GDP measurement, first-line treatment with Crizotinib is the most cost-effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSVZ1aHUJ-x7Vg90H21EOLACvtfcHk0lj_WvhKa5a38g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXns1Gmt7c%253D&md5=09a0d1078417b2e55fac1d0fe6184a66</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2147%2FCMAR.S223441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCMAR.S223441%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DCai%26aufirst%3DH.%26atitle%3DCost-Effectiveness%2520Analysis%2520of%2520Ceritinib%2520and%2520Alectinib%2520Versus%2520Crizotinib%2520in%2520the%2520Treatment%2520of%2520Anaplastic%2520Lymphoma%2520Kinase-Positive%2520Advanced%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DCancer%2520Manage.%2520Res.%26date%3D2019%26volume%3D11%26spage%3D9195%26epage%3D9202%26doi%3D10.2147%2Fcmar.s223441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer Statistics, 2016</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.3322/caac.21332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.3322%2Fcaac.21332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=26742998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2016&pages=7-30&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=A.+Jemal&title=Cancer+Statistics%2C+2016&doi=10.3322%2Fcaac.21332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2016</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.  Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Cancer Registries.  Mortality data were collected by the National Center for Health Statistics.  In 2016, 1,685,210 new cancer cases and 595,690 cancer deaths are projected to occur in the United States.  Overall cancer incidence trends (13 oldest SEER registries) are stable in women, but declining by 3.1% per year in men (from 2009-2012), much of which is because of recent rapid declines in prostate cancer diagnoses.  The cancer death rate has dropped by 23% since 1991, translating to more than 1.7 million deaths averted through 2012.  Despite this progress, death rates are increasing for cancers of the liver, pancreas, and uterine corpus, and cancer is now the leading cause of death in 21 states, primarily due to exceptionally large reductions in death from heart disease.  Among children and adolescents (aged birth-19 years), brain cancer has surpassed leukemia as the leading cause of cancer death because of the dramatic therapeutic advances against leukemia.  Accelerating progress against cancer requires both increased national investment in cancer research and the application of existing cancer control knowledge across all segments of the population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKAn5ROFAaRS86Js-BCLiifW6udTcc2eYCwct2rqQL37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D&md5=2d4030a531945c5ebaaab181bfd80457</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21332%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520Statistics%252C%25202016%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2016%26volume%3D66%26spage%3D7%26epage%3D30%26doi%3D10.3322%2Fcaac.21332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzoli, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sause, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker Jr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strawn, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turrisi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somerfield, M. R.</span></span> <span> </span><span class="NLM_article-title">American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1200/jco.2004.09.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1200%2FJCO.2004.09.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=14691125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FitlektA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2004&pages=330-353&author=D.+G.+Pfisterauthor=D.+H.+Johnsonauthor=C.+G.+Azzoliauthor=W.+Sauseauthor=T.+J.+Smithauthor=S.+Baker+Jrauthor=J.+Olakauthor=D.+Stoverauthor=J.+R.+Strawnauthor=A.+T.+Turrisiauthor=M.+R.+Somerfield&title=American+Society+of+Clinical+Oncology+Treatment+of+Unresectable+Non-Small-Cell+Lung+Cancer+Guideline%3A+Update+2003&doi=10.1200%2Fjco.2004.09.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003</span></div><div class="casAuthors">Pfister David G; Johnson David H; Azzoli Christopher G; Sause William; Smith Thomas J; Baker Sherman Jr; Olak Jemi; Stover Diane; Strawn John R; Turrisi Andrew T; Somerfield Mark R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">330-53</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1oqRk11s5o75oR8RchjrrfW6udTcc2eYCwct2rqQL37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FitlektA%253D%253D&md5=fb8675053cacd502ae505270f479c6d7</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1200%2FJCO.2004.09.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2004.09.053%26sid%3Dliteratum%253Aachs%26aulast%3DPfister%26aufirst%3DD.%2BG.%26aulast%3DJohnson%26aufirst%3DD.%2BH.%26aulast%3DAzzoli%26aufirst%3DC.%2BG.%26aulast%3DSause%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DT.%2BJ.%26aulast%3DBaker%2BJr%26aufirst%3DS.%26aulast%3DOlak%26aufirst%3DJ.%26aulast%3DStover%26aufirst%3DD.%26aulast%3DStrawn%26aufirst%3DJ.%2BR.%26aulast%3DTurrisi%26aufirst%3DA.%2BT.%26aulast%3DSomerfield%26aufirst%3DM.%2BR.%26atitle%3DAmerican%2520Society%2520of%2520Clinical%2520Oncology%2520Treatment%2520of%2520Unresectable%2520Non-Small-Cell%2520Lung%2520Cancer%2520Guideline%253A%2520Update%25202003%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2004%26volume%3D22%26spage%3D330%26epage%3D353%26doi%3D10.1200%2Fjco.2004.09.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, S.</span></span> <span> </span><span class="NLM_article-title">Tumor Metabolism and Prognostic Role of EZH2 in Non-Small Cell Lung Cancer</span>. <i>Transl. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">S982</span>– <span class="NLM_lpage">S988</span>, <span class="refDoi"> DOI: 10.21037/tcr.2017.06.42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.21037%2Ftcr.2017.06.42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVKqsLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=S982-S988&author=E.+Lopciauthor=S.+Rossi&title=Tumor+Metabolism+and+Prognostic+Role+of+EZH2+in+Non-Small+Cell+Lung+Cancer&doi=10.21037%2Ftcr.2017.06.42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor metabolism and prognostic role of EZH2 in non-small cell lung cancer</span></div><div class="casAuthors">Lopci, Egesta; Rossi, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">Translational Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Suppl.6</span>),
    <span class="NLM_cas:pages">S982-S988</span>CODEN:
                <span class="NLM_cas:coden">TCRRCN</span>;
        ISSN:<span class="NLM_cas:issn">2219-6803</span>.
    
            (<span class="NLM_cas:orgname">AME Publishing Co.</span>)
        </div><div class="casAbstract">A review discussing the tumor metab. and prognostic role of EZH2 in non-small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4ve3OuQaf8bVg90H21EOLACvtfcHk0lggUKDOV7nI8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVKqsLbN&md5=9b6bdfe6c3c896a0e6d43fef846f7d3f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.21037%2Ftcr.2017.06.42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Ftcr.2017.06.42%26sid%3Dliteratum%253Aachs%26aulast%3DLopci%26aufirst%3DE.%26aulast%3DRossi%26aufirst%3DS.%26atitle%3DTumor%2520Metabolism%2520and%2520Prognostic%2520Role%2520of%2520EZH2%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DTransl.%2520Cancer%2520Res.%26date%3D2017%26volume%3D6%26spage%3DS982%26epage%3DS988%26doi%3D10.21037%2Ftcr.2017.06.42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagasaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M.</span></span> <span> </span><span class="NLM_article-title">Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1080/14737140.2018.1409624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1080%2F14737140.2018.1409624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=29168933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOhs77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=63-70&author=M.+Nagasakaauthor=S.+M.+Gadgeel&title=Role+of+Chemotherapy+and+Targeted+Therapy+in+Early-Stage+Non-Small+Cell+Lung+Cancer&doi=10.1080%2F14737140.2018.1409624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer</span></div><div class="casAuthors">Nagasaka, Misako; Gadgeel, Shirish M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-70</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Adjuvant platinum based chemotherapy is accepted as std. of care in stage II and III non-small cell lung cancer (NSCLC) patients and is often considered in patients with stage IB disease who have tumors ≥ 4 cm.  The survival advantage is modest with approx. 5% at 5 years.: This review article presents relevant data regarding chemotherapy use in the perioperative setting for early stage NSCLC.  A literature search was performed utilizing PubMed as well as clin. trial.gov.  Randomized phase III studies in this setting including adjuvant and neoadjuvant use of chemotherapy as well as ongoing trials on targeted therapy and immunotherapy are also discussed.: With increasing utilization of screening computed tomog. scans, it is possible that the percentage of early stage NSCLC patients will increase in the coming years.  Benefits of adjuvant chemotherapy in early stage NSCLC patients remain modest.  There is a need to better define patients most likely to derive survival benefit from adjuvant therapy and spare patients who do not need adjuvant chemotherapy due to the toxicity of such therapy.  Trials for adjuvant targeted therapy, including adjuvant EGFR-TKI trials and trials of immunotherapy drugs are ongoing and will define the role of these agents as adjuvant therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Z5tZ5uITYLVg90H21EOLACvtfcHk0lggUKDOV7nI8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOhs77I&md5=7eba1acf84c1d9cb9a0db63c02329d0d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1080%2F14737140.2018.1409624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737140.2018.1409624%26sid%3Dliteratum%253Aachs%26aulast%3DNagasaka%26aufirst%3DM.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26atitle%3DRole%2520of%2520Chemotherapy%2520and%2520Targeted%2520Therapy%2520in%2520Early-Stage%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2018%26volume%3D18%26spage%3D63%26epage%3D70%26doi%3D10.1080%2F14737140.2018.1409624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A. T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, P. M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiou, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.-Y. F.</span></span> <span> </span><span class="NLM_article-title">Trifluoperazine, an Antipsychotic Agent, Inhibits Cancer Stem Cell Growth and Overcomes Drug Resistance of Lung Cancer</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">1180</span>– <span class="NLM_lpage">1188</span>, <span class="refDoi"> DOI: 10.1164/rccm.201207-1180oc</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1164%2Frccm.201207-1180OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=23024022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2012&pages=1180-1188&author=C.-T.+Yehauthor=A.+T.+H.+Wuauthor=P.+M.-H.+Changauthor=K.-Y.+Chenauthor=C.-N.+Yangauthor=S.-C.+Yangauthor=C.-C.+Hoauthor=C.-C.+Chenauthor=Y.-L.+Kuoauthor=P.-Y.+Leeauthor=Y.-W.+Liuauthor=C.-C.+Yenauthor=M.+Hsiaoauthor=P.-J.+Luauthor=J.-M.+Laiauthor=L.-S.+Wangauthor=C.-H.+Wuauthor=J.-F.+Chiouauthor=P.-C.+Yangauthor=C.-Y.+F.+Huang&title=Trifluoperazine%2C+an+Antipsychotic+Agent%2C+Inhibits+Cancer+Stem+Cell+Growth+and+Overcomes+Drug+Resistance+of+Lung+Cancer&doi=10.1164%2Frccm.201207-1180oc"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer</span></div><div class="casAuthors">Yeh, Chi-Tai; Wu, Alexander T. H.; Chang, Peter M.-H.; Chen, Kuan-Yu; Yang, Chia-Ning; Yang, Shuenn-Chen; Ho, Chao-Chi; Chen, Chun-Chi; Kuo, Yu-Lun; Lee, Pei-Ying; Liu, Yu-Wen; Yen, Chueh-Chuan; Hsiao, Michael; Lu, Pei-Jung; Lai, Jin-Mei; Wang, Liang-Shun; Wu, Chih-Hsiung; Chiou, Jeng-Fong; Yang, Pan-Chyr; Huang, Chi-Ying F.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1180-1188</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Cancer stem cell (CSC) theory has drawn much attention, with evidence supporting the contribution of stem cells to tumor initiation, relapse, and therapy resistance.  Objectives: To screen drugs that target CSCs to improve the current treatment outcome and overcome drug resistance in patients with lung cancer.  Methods: We used publicly available embryonic stem cell and CSC-assocd. gene signatures to query the Connectivity Map for potential drugs that can, at least in part, reverse the gene expression profile of CSCs.  High scores were noted for several phenothiazine-like antipsychotic drugs, including trifluoperazine.  We then treated lung CSCs with different EGFR mutation status with trifluoperazine to examine its anti-CSC properties.  Lung CSCs resistant to epidermal growth factor receptor-tyrosine kinase inhibitor or cisplatin were treated with trifluoperazine plus gefitinib or trifluoperazine plus cisplatin.  Animal models were used for in vivo validation of the anti-CSC effect and synergistic effect of trifluoperazine with gefitinib.  Measurements and Main Results: We demonstrated that trifluoperazine inhibited CSC tumor spheroid formation and down-regulated the expression of CSC markers (CD44/CD133).  Trifluoperazine inhibited Wnt/β-catenin signaling in gefitinib-resistant lung cancer spheroids.  The combination of trifluoperazine with either gefitinib or cisplatin overcame drug resistance in lung CSCs.  Trifluoperazine inhibited the tumor growth and enhanced the inhibitory activity of gefitinib in lung cancer metastatic and orthotopic CSC animal models.  Conclusions: Using in silico drug screening by Connectivity Map followed by empirical validations, we repurposed an existing phenothiazine-like antipsychotic drug, trifluoperazine, as a potential anti-CSC agent that could overcome epidermal growth factor receptor-tyrosine kinase inhibitor and chemotherapy resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPf24lWeMWQbVg90H21EOLACvtfcHk0ljEPY2Gx2W1VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOjtro%253D&md5=0bc2a899c88f4f891170194d22a32de9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1164%2Frccm.201207-1180OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201207-1180OC%26sid%3Dliteratum%253Aachs%26aulast%3DYeh%26aufirst%3DC.-T.%26aulast%3DWu%26aufirst%3DA.%2BT.%2BH.%26aulast%3DChang%26aufirst%3DP.%2BM.-H.%26aulast%3DChen%26aufirst%3DK.-Y.%26aulast%3DYang%26aufirst%3DC.-N.%26aulast%3DYang%26aufirst%3DS.-C.%26aulast%3DHo%26aufirst%3DC.-C.%26aulast%3DChen%26aufirst%3DC.-C.%26aulast%3DKuo%26aufirst%3DY.-L.%26aulast%3DLee%26aufirst%3DP.-Y.%26aulast%3DLiu%26aufirst%3DY.-W.%26aulast%3DYen%26aufirst%3DC.-C.%26aulast%3DHsiao%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DP.-J.%26aulast%3DLai%26aufirst%3DJ.-M.%26aulast%3DWang%26aufirst%3DL.-S.%26aulast%3DWu%26aufirst%3DC.-H.%26aulast%3DChiou%26aufirst%3DJ.-F.%26aulast%3DYang%26aufirst%3DP.-C.%26aulast%3DHuang%26aufirst%3DC.-Y.%2BF.%26atitle%3DTrifluoperazine%252C%2520an%2520Antipsychotic%2520Agent%252C%2520Inhibits%2520Cancer%2520Stem%2520Cell%2520Growth%2520and%2520Overcomes%2520Drug%2520Resistance%2520of%2520Lung%2520Cancer%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2012%26volume%3D186%26spage%3D1180%26epage%3D1188%26doi%3D10.1164%2Frccm.201207-1180oc" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prasetyanti, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medema, J. P.</span></span> <span> </span><span class="NLM_article-title">Intra-Tumor Heterogeneity from a Cancer Stem Cell Perspective</span>. <i>Mol. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">41</span>, <span class="refDoi"> DOI: 10.1186/s12943-017-0600-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1186%2Fs12943-017-0600-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=28209166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1CrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=41&author=P.+R.+Prasetyantiauthor=J.+P.+Medema&title=Intra-Tumor+Heterogeneity+from+a+Cancer+Stem+Cell+Perspective&doi=10.1186%2Fs12943-017-0600-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Intra-tumor heterogeneity from a cancer stem cell perspective</span></div><div class="casAuthors">Prasetyanti, Pramudita R.; Medema, Jan Paul.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41/1-41/9</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Tumor heterogeneity represents an ongoing challenge in the field of cancer therapy.  Heterogeneity is evident between cancers from different patients (inter-tumor heterogeneity) and within a single tumor (intra-tumor heterogeneity).  The latter includes phenotypic diversity such as cell surface markers, (epi)genetic abnormality, growth rate, apoptosis and other hallmarks of cancer that eventually drive disease progression and treatment failure.  Cancer stem cells (CSCs) have been put forward to be one of the detg. factors that contribute to intra-tumor heterogeneity.  However, recent findings have shown that the stem-like state in a given tumor cell is a plastic quality.  A corollary to this view is that stemness traits can be acquired via (epi)genetic modification and/or interaction with the tumor microenvironment (TME).  Here we discuss factors contributing to this CSC heterogeneity and the potential implications for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUKLdoGrUZEbVg90H21EOLACvtfcHk0ljEPY2Gx2W1VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1CrsLo%253D&md5=c407c6d6c1ecaaebaa6f4f333757dbe2</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1186%2Fs12943-017-0600-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-017-0600-4%26sid%3Dliteratum%253Aachs%26aulast%3DPrasetyanti%26aufirst%3DP.%2BR.%26aulast%3DMedema%26aufirst%3DJ.%2BP.%26atitle%3DIntra-Tumor%2520Heterogeneity%2520from%2520a%2520Cancer%2520Stem%2520Cell%2520Perspective%26jtitle%3DMol.%2520Canc.%26date%3D2017%26volume%3D16%26spage%3D41%26doi%3D10.1186%2Fs12943-017-0600-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pattabiraman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Tackling the cancer stem cells - what challenges do they pose?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1038/nrd4253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fnrd4253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=24981363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOisbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=497-512&author=D.+R.+Pattabiramanauthor=R.+A.+Weinberg&title=Tackling+the+cancer+stem+cells+-+what+challenges+do+they+pose%3F&doi=10.1038%2Fnrd4253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Tackling the cancer stem cells - what challenges do they pose?</span></div><div class="casAuthors">Pattabiraman, Diwakar R.; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">497-512</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since their identification in 1994, cancer stem cells (CSCs) have been objects of intensive study.  Their properties and mechanisms of formation have become a major focus of current cancer research, in part because of their enhanced ability to initiate and drive tumor growth and their intrinsic resistance to conventional therapeutics.  The discovery that activation of the epithelial-to-mesenchymal transition (EMT) program in carcinoma cells can give rise to cells with stem-like properties has provided one possible mechanism explaining how CSCs arise and presents a possible avenue for their therapeutic manipulation.  Here we address recent developments in CSC research, focusing on carcinomas that are able to undergo EMT.  We discuss the signalling pathways that create these cells, cell-intrinsic mechanisms that could be exploited for selective elimination or induction of their differentiation, and the role of the tumor microenvironment in sustaining them.  Finally, we propose ways to use our current knowledge of the complex biol. of CSCs to design novel therapies to eliminate them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHXcwOZJN_67Vg90H21EOLACvtfcHk0lglYqfoQql1ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOisbzI&md5=db211f41b19198981cb37487b7a9abc3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrd4253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4253%26sid%3Dliteratum%253Aachs%26aulast%3DPattabiraman%26aufirst%3DD.%2BR.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DTackling%2520the%2520cancer%2520stem%2520cells%2520-%2520what%2520challenges%2520do%2520they%2520pose%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D497%26epage%3D512%26doi%3D10.1038%2Fnrd4253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martins-Neves, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleton-Jansen, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, C. M. F.</span></span> <span> </span><span class="NLM_article-title">Therapy-Induced Enrichment of Cancer Stem-Like Cells in Solid Human Tumors: Where do We Stand?</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2018.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2Fj.phrs.2018.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=30316903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKksLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2018&pages=193-204&author=S.+R.+Martins-Nevesauthor=A.-M.+Cleton-Jansenauthor=C.+M.+F.+Gomes&title=Therapy-Induced+Enrichment+of+Cancer+Stem-Like+Cells+in+Solid+Human+Tumors%3A+Where+do+We+Stand%3F&doi=10.1016%2Fj.phrs.2018.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Therapy-induced enrichment of cancer stem-like cells in solid human tumors: Where do we stand</span></div><div class="casAuthors">Martins-Neves, Sara R.; Cleton-Jansen, Anne-Marie; Gomes, Celia M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">193-204</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of local recurrence and metastatic disease, most probably attributable to the intrinsic or acquired resistance of tumor cells to std. therapy, still constitute the major clin. problem preventing the cure of cancer patients.  Despite progress in the research of new therapeutic targets and compds., resistant cells displaying stem-like properties seem to play a leading role in therapeutic failures and to be the culprit cells responsible for assocd. tumor recurrence.  A whole new plethora of research studies suggest that drug-tolerant cancer stem cells may be induced by conventional cancer chemotherapeutics such as doxorubicin, cisplatinum and ionizing radiation.  This phenotypic plasticity and transition from a differentiated to stem-like cell state assocs. with the activation of diverse stem cell self-renewal (e.g. Notch, Hedgehog, Wnt), drug efflux (e.g. ABC transporters) and survival-related pathways (e.g. TGF-β, ERK, AKT), which may confer resistance and treatment failures in solid tumors.  Therefore, combined therapeutic strategies aiming to simultaneously target drug-sensitive tumor cells and their capacity of phenotypic switching may lead to survival benefits and meaningful disease remissions.  This knowledge can be applicable to the clinic and contribute to better therapeutic outcomes and prevent tumor recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDE6ThuyN1AbVg90H21EOLACvtfcHk0lglYqfoQql1ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKksLfJ&md5=f68fae306b461bdd2c3b4496dc89cfe1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2018.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2018.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DMartins-Neves%26aufirst%3DS.%2BR.%26aulast%3DCleton-Jansen%26aufirst%3DA.-M.%26aulast%3DGomes%26aufirst%3DC.%2BM.%2BF.%26atitle%3DTherapy-Induced%2520Enrichment%2520of%2520Cancer%2520Stem-Like%2520Cells%2520in%2520Solid%2520Human%2520Tumors%253A%2520Where%2520do%2520We%2520Stand%253F%26jtitle%3DPharmacol.%2520Res.%26date%3D2018%26volume%3D137%26spage%3D193%26epage%3D204%26doi%3D10.1016%2Fj.phrs.2018.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tirino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desiderio, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rosa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaccio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Noce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaccio, G.</span></span> <span> </span><span class="NLM_article-title">Cancer Stem Cells in Solid Tumors: An Overview and New Approaches for Their Isolation and Characterization</span>. <i>Faseb. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1096/fj.12-218222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1096%2Ffj.12-218222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=23024375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Gqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=13-24&author=V.+Tirinoauthor=V.+Desiderioauthor=F.+Painoauthor=A.+De+Rosaauthor=F.+Papaccioauthor=M.+La+Noceauthor=L.+Lainoauthor=F.+De+Francescoauthor=G.+Papaccio&title=Cancer+Stem+Cells+in+Solid+Tumors%3A+An+Overview+and+New+Approaches+for+Their+Isolation+and+Characterization&doi=10.1096%2Ffj.12-218222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization</span></div><div class="casAuthors">Tirino, Virginia; Desiderio, Vincenzo; Paino, Francesca; De Rosa, Alfredo; Papaccio, Federica; La Noce, Marcella; Laino, Luigi; De Francesco, Francesco; Papaccio, Gianpaolo</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-24, 10.1096/fj.12-218222</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review.  Primary tumors are responsible for 10% of cancer deaths.  In most cases, the main cause of mortality is the formation of metastases.  Accumulating evidence suggests that a subpopulation of tumor cells with distinct stem-like properties is responsible for tumor initiation, invasive growth, and metastasis formation.  This population is defined as cancer stem cells (CSCs).  Existing therapies have enhanced the length of survival after diagnosis of cancer but have completely failed in terms of recovery.  CSCs appear to be resistant to chemotherapy, may remain quiescent for extended periods, and have affinity for hypoxic environments.  The CSCs can be identified and isolated by different methodologies, including isolation by CSC-specific cell surface marker expression, detection of side population phenotype by Hoechst 33342 exclusion, assessment of their ability to grow as floating spheres, and aldehyde dehydrogenase (ALDH) activity assay.  None of the methods mentioned are exclusively used to isolate the solid tumor CSCs, highlighting the imperative to delineate more specific markers or to use combinatorial markers and methodologies.  This review provides an overview of the main characteristics and approaches used to identify, isolate, and characterize CSCs from solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKHEZT73U6-bVg90H21EOLACvtfcHk0lglYqfoQql1ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Gqtw%253D%253D&md5=de33a9ff83242808595b3772fac12f5d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1096%2Ffj.12-218222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.12-218222%26sid%3Dliteratum%253Aachs%26aulast%3DTirino%26aufirst%3DV.%26aulast%3DDesiderio%26aufirst%3DV.%26aulast%3DPaino%26aufirst%3DF.%26aulast%3DDe%2BRosa%26aufirst%3DA.%26aulast%3DPapaccio%26aufirst%3DF.%26aulast%3DLa%2BNoce%26aufirst%3DM.%26aulast%3DLaino%26aufirst%3DL.%26aulast%3DDe%2BFrancesco%26aufirst%3DF.%26aulast%3DPapaccio%26aufirst%3DG.%26atitle%3DCancer%2520Stem%2520Cells%2520in%2520Solid%2520Tumors%253A%2520An%2520Overview%2520and%2520New%2520Approaches%2520for%2520Their%2520Isolation%2520and%2520Characterization%26jtitle%3DFaseb.%2520J.%26date%3D2013%26volume%3D27%26spage%3D13%26epage%3D24%26doi%3D10.1096%2Ffj.12-218222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Cellular Processing of Platinum Anticancer Drugs</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1038/nrd1691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fnrd1691" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=307-320&author=D.+Wangauthor=S.+J.+Lippard&title=Cellular+Processing+of+Platinum+Anticancer+Drugs&doi=10.1038%2Fnrd1691"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd1691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1691%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DCellular%2520Processing%2520of%2520Platinum%2520Anticancer%2520Drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D4%26spage%3D307%26epage%3D320%26doi%3D10.1038%2Fnrd1691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2536</span>– <span class="NLM_lpage">2544</span>, <span class="refDoi"> DOI: 10.1039/c8dt03923b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1039%2FC8DT03923B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=30633263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktF2isQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2019&pages=2536-2544&author=Z.+Wangauthor=Z.+Dengauthor=G.+Zhu&title=Emerging+platinum%28iv%29+prodrugs+to+combat+cisplatin+resistance%3A+from+isolated+cancer+cells+to+tumor+microenvironment&doi=10.1039%2Fc8dt03923b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging platinum(IV) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment</span></div><div class="casAuthors">Wang, Zhigang; Deng, Zhiqin; Zhu, Guangyu</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2536-2544</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Cisplatin plays a pivotal role in the treatment of various malignant tumors, but its therapeutic effects are hampered by drug resistance.  Pt(IV) prodrugs represent a promising class of "non-conventional" platinum-based anticancer agents to circumvent drug resistance, which can be easily functionalized with other bioactive ligands.  One strategy is to build "dual-action" and "multi-action" Pt(IV) prodrugs that not only damage DNA but also perturb other pathways related to cisplatin resistance to achieve combinatorial therapeutic effects.  Another way to overcome the shortcomings of cisplatin is to deliver Pt(IV) prodrugs via nanocarriers.  Most studies in this area have focused on designing prodrugs based on the mechanism of cisplatin resistance within isolated cancer cells.  Recent findings, however, reveal that the tumor microenvironment also plays important roles in the development of cisplatin resistance.  This perspective focuses on various types of novel cisplatin-based Pt(IV) complexes, including Pt-loaded nanostructures, to overcome cisplatin resistance.  Special attention will be devoted to complexes that target the tumor microenvironment, which is a new area for the development of effective Pt(IV) prodrugs.  Our summary and outlook may have a hope to help researchers in the field generate new ideas and strategies to develop more potent Pt(IV) prodrugs to combat cisplatin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocJ9QZUedvprVg90H21EOLACvtfcHk0lgQp_5EUu39xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktF2isQ%253D%253D&md5=1ce9e12e6df323a99b90cbbf951f65c3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1039%2FC8DT03923B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8DT03923B%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DEmerging%2520platinum%2528iv%2529%2520prodrugs%2520to%2520combat%2520cisplatin%2520resistance%253A%2520from%2520isolated%2520cancer%2520cells%2520to%2520tumor%2520microenvironment%26jtitle%3DDalton%2520Trans.%26date%3D2019%26volume%3D48%26spage%3D2536%26epage%3D2544%26doi%3D10.1039%2Fc8dt03923b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Apps, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, E. H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheate, N. J.</span></span> <span> </span><span class="NLM_article-title">The State-of-Play and Future of Platinum Drugs</span>. <i>Endocr. Relat. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1530/erc-15-0237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1530%2FERC-15-0237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvVClsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=219-233&author=M.+G.+Appsauthor=E.+H.+Y.+Choiauthor=N.+J.+Wheate&title=The+State-of-Play+and+Future+of+Platinum+Drugs&doi=10.1530%2Ferc-15-0237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The state-of-play and future of platinum drugs</span></div><div class="casAuthors">Apps, Michael G.; Choi, Eugene H. Y.; Wheate, Nial J.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">R219-R233</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">The year 2015 marks the 50th anniversary since the discovery of the anticancer potential of cisplatin and it remains just as useful now as it did back then, esp. for the treatment of some endocrine-related cancers like ovarian and testicular carcinomas.  Since its discovery, five other platin drugs have received approval in various countries.  While several new platin drugs are in preclin. development, in the last decade only two new platin drugs have entered clin. trials, LA-12 and dicycloplatin, reflecting a shift in research focus from new drug design to improved formulations of already approved platin drugs.  These formulations include their encapsulation with macrocycles to slow and prevent their degrdn. by proteins and peptides; their attachment to nanoparticles to passively target solid tumors through the enhanced permeability and retention effect and their coordination to important nutrients, proteins, antibodies and aptamers for active tumor targeting.  These formulation methods have all shown potential but none have yet yielded a new marketable medicine contg. a platin drug.  The reasons for this are problems of consistent drug loading, controlling the location and timing of drug release and the inherent toxicity of some of the drug delivery vehicles.  In addn. to drug delivery, functional genomics is now playing an increasing role in predicting patients' responses to platin chemotherapy and their likelihood of experiencing severe side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkV12nqK95QLVg90H21EOLACvtfcHk0lgQp_5EUu39xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvVClsbs%253D&md5=221eda4371079fc14147e2192b977ee8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1530%2FERC-15-0237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FERC-15-0237%26sid%3Dliteratum%253Aachs%26aulast%3DApps%26aufirst%3DM.%2BG.%26aulast%3DChoi%26aufirst%3DE.%2BH.%2BY.%26aulast%3DWheate%26aufirst%3DN.%2BJ.%26atitle%3DThe%2520State-of-Play%2520and%2520Future%2520of%2520Platinum%2520Drugs%26jtitle%3DEndocr.%2520Relat.%2520Canc.%26date%3D2015%26volume%3D22%26spage%3D219%26epage%3D233%26doi%3D10.1530%2Ferc-15-0237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galanski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakupec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, B.</span></span> <span> </span><span class="NLM_article-title">Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2075</span>– <span class="NLM_lpage">2094</span>, <span class="refDoi"> DOI: 10.2174/0929867054637626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.2174%2F0929867054637626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=16101495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFCls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=2075-2094&author=M.+Galanskiauthor=M.+Jakupecauthor=B.+Keppler&title=Update+of+the+Preclinical+Situation+of+Anticancer+Platinum+Complexes%3A+Novel+Design+Strategies+and+Innovative+Analytical+Approaches&doi=10.2174%2F0929867054637626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches</span></div><div class="casAuthors">Galanski, Markus; Jakupec, Michael A.; Keppler, Bernhard K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2075-2094</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Research in the field of bioinorg. chem. has been stimulated by the worldwide success of the anticancer drug cisplatin.  40 Years after the first report about its biol. activity, carboplatin and oxaliplatin are in routine clin. use today, whereas nedaplatin, lobaplatin, and heptaplatin (SKI2053R) are only approved in Japan, China, and South Korea, resp.  Up to now, about 35 platinum complexes entered clin. trials to circumvent the side-effects and the problem of tumor resistance to cisplatin.  Addnl., improvement of tumor selectivity as well as the need for a broader spectrum of indications are the motivations for tremendous efforts in the development of novel anticancer platinum-based drugs.  New synthetic strategies and innovative anal. approaches provide a basis for a deeper understanding of the pharmacol. profile of cisplatin and analogs (biodistribution, clearance, detoxification, side-effects, tumor specificity, cellular uptake, acquired or intrinsic resistance, platinum-DNA adduct removal by the cellular machinery) and give rise to a rational design of promising anticancer platinum coordination compds.  This article reviews the recent development of preclin. platinum complexes with interesting in vitro and in vivo tumor inhibiting properties.  It focuses also on innovative synthetic strategies leading to novel classes of platinum complexes.  A small part of the review is dedicated to new anal. approaches which have been supplied to or emerged in this field of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeeK9fKeT-F7Vg90H21EOLACvtfcHk0lgQp_5EUu39xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFCls7o%253D&md5=14606280f6c1db32323926741138fb73</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F0929867054637626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867054637626%26sid%3Dliteratum%253Aachs%26aulast%3DGalanski%26aufirst%3DM.%26aulast%3DJakupec%26aufirst%3DM.%26aulast%3DKeppler%26aufirst%3DB.%26atitle%3DUpdate%2520of%2520the%2520Preclinical%2520Situation%2520of%2520Anticancer%2520Platinum%2520Complexes%253A%2520Novel%2520Design%2520Strategies%2520and%2520Innovative%2520Analytical%2520Approaches%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2005%26volume%3D12%26spage%3D2075%26epage%3D2094%26doi%3D10.2174%2F0929867054637626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayub, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zia-ur-Rehman, I.</span></span> <span> </span><span class="NLM_article-title">Photoactivated Platinum-Based Anticancer Drugs</span>. <i>Coord. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">429</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2018.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2Fj.ccr.2018.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1entbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2018&pages=405-429&author=M.+Imranauthor=W.+Ayubauthor=I.+S.+Butlerauthor=I.+Zia-ur-Rehman&title=Photoactivated+Platinum-Based+Anticancer+Drugs&doi=10.1016%2Fj.ccr.2018.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Photoactivated platinum-based anticancer drugs</span></div><div class="casAuthors">Imran, Muhammad; Ayub, Wagma; Butler, Ian S.; Zia-ur-Rehman</div><div class="citationInfo"><span class="NLM_cas:title">Coordination Chemistry Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">405-429</span>CODEN:
                <span class="NLM_cas:coden">CCHRAM</span>;
        ISSN:<span class="NLM_cas:issn">0010-8545</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Following the serendipitous discovery of the anticancer drug, cisplatin, numerous platinum(II) complexes have been synthesized and some of them, such as carboplatin, oxaliplatin, nedaplatin, heptaplatin and lobaplatin, have been clin. approved either locally or worldwide.  Since these drugs are structurally related to cisplatin, the unfortunate problems that are assocd. with cisplatin are more or less the same for them.  To overcome these problems, octahedral, low-spin d6 and coordinatively satd. Pt(IV) complexes have been examd. because of their substitution inertness towards off-target biomols.  Owing to the availability of bio-reducing agents, mainly proteins, in all cell types, Pt(IV) prodrugs can be reduced to their cytotoxic active Pt(II) analogs in both cancer and normal cells.  However, prolonged hydrolysis and less stability against bio-reducing agents are problems still to be overcome.  To address the passive activation of Pt(IV) prodrugs, the choice of photoactivated Pt(IV) prodrugs seems to be a promising chemotherapeutic strategy.  Therefore, iodo-based photolabile Pt(IV) complexes which, upon light exposure, undergo photolytic reactions to give active Pt(II) species have been developed.  Unfortunately, these complexes had to be later discarded because of their low stability in the dark.  Eventually, azido-based complexes with enhanced stability in the dark were developed.  The selective photoactivation of these photolabile azido-based Pt(IV) prodrugs has dramatically opened up new avenues of research aimed at overcoming the problems assocd. with chemotherapeutic drug delivery by incorporating different polymers, biol. target mols., permeation enhancers or nanoparticles.  These photolabile complexes are the focus of the present review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA-BWgK4qkqLVg90H21EOLACvtfcHk0lgQp_5EUu39xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1entbrN&md5=61d0e5f94e6b70aa7f3145573dd833a0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2018.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2018.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DImran%26aufirst%3DM.%26aulast%3DAyub%26aufirst%3DW.%26aulast%3DButler%26aufirst%3DI.%2BS.%26aulast%3DZia-ur-Rehman%26aufirst%3DI.%26atitle%3DPhotoactivated%2520Platinum-Based%2520Anticancer%2520Drugs%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2018%26volume%3D376%26spage%3D405%26epage%3D429%26doi%3D10.1016%2Fj.ccr.2018.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Czarnomysy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surażyński, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muszynska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gornowicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawski, K.</span></span> <span> </span><span class="NLM_article-title">A Novel Series of Pyrazole-Platinum(II) Complexes as Potential Anti-Cancer Agents that Induce Cell Cycle Arrest and Apoptosis in Breast Cancer Cells</span>. <i>J. Enzym. Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1006</span>– <span class="NLM_lpage">1023</span>, <span class="refDoi"> DOI: 10.1080/14756366.2018.1471687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1080%2F14756366.2018.1471687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=29862867" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=1006-1023&author=R.+Czarnomysyauthor=A.+Sura%C5%BCy%C5%84skiauthor=A.+Muszynskaauthor=A.+Gornowiczauthor=A.+Bielawskaauthor=K.+Bielawski&title=A+Novel+Series+of+Pyrazole-Platinum%28II%29+Complexes+as+Potential+Anti-Cancer+Agents+that+Induce+Cell+Cycle+Arrest+and+Apoptosis+in+Breast+Cancer+Cells&doi=10.1080%2F14756366.2018.1471687"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1080%2F14756366.2018.1471687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2018.1471687%26sid%3Dliteratum%253Aachs%26aulast%3DCzarnomysy%26aufirst%3DR.%26aulast%3DSura%25C5%25BCy%25C5%2584ski%26aufirst%3DA.%26aulast%3DMuszynska%26aufirst%3DA.%26aulast%3DGornowicz%26aufirst%3DA.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DBielawski%26aufirst%3DK.%26atitle%3DA%2520Novel%2520Series%2520of%2520Pyrazole-Platinum%2528II%2529%2520Complexes%2520as%2520Potential%2520Anti-Cancer%2520Agents%2520that%2520Induce%2520Cell%2520Cycle%2520Arrest%2520and%2520Apoptosis%2520in%2520Breast%2520Cancer%2520Cells%26jtitle%3DJ.%2520Enzym.%2520Inhib.%2520Med.%2520Chem.%26date%3D2018%26volume%3D33%26spage%3D1006%26epage%3D1023%26doi%3D10.1080%2F14756366.2018.1471687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senovilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kepp, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castedo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms of Cisplatin Resistance</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1869</span>– <span class="NLM_lpage">1883</span>, <span class="refDoi"> DOI: 10.1038/onc.2011.384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fonc.2011.384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=21892204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWrsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=1869-1883&author=L.+Galluzziauthor=L.+Senovillaauthor=I.+Vitaleauthor=J.+Michelsauthor=I.+Martinsauthor=O.+Keppauthor=M.+Castedoauthor=G.+Kroemer&title=Molecular+Mechanisms+of+Cisplatin+Resistance&doi=10.1038%2Fonc.2011.384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of cisplatin resistance</span></div><div class="casAuthors">Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1869-1883</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers.  Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent (and best understood) mode of action involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of mitochondrial apoptosis.  Despite a consistent rate of initial responses, cisplatin treatment often results in the development of chemoresistance, leading to therapeutic failure.  An intense research has been conducted during the past 30 years and several mechanisms that account for the cisplatin-resistant phenotype of tumor cells have been described.  Here, we provide a systematic discussion of these mechanism by classifying them in alterations (1) that involve steps preceding the binding of cisplatin to DNA (pre-target resistance), (2) that directly relate to DNA-cisplatin adducts (on-target resistance), (3) concerning the lethal signaling pathway(s) elicited by cisplatin-mediated DNA damage (post-target resistance) and (4) affecting mol. circuitries that do not present obvious links with cisplatin-elicited signals (off-target resistance).  As in some clin. settings cisplatin constitutes the major therapeutic option, the development of chemosensitization strategies constitute a goal with important clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxTrgUhh4V17Vg90H21EOLACvtfcHk0lh7FjgZQVkLJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWrsr7E&md5=4f947e6d5b834673b819e88b06309a53</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fonc.2011.384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2011.384%26sid%3Dliteratum%253Aachs%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DSenovilla%26aufirst%3DL.%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DMichels%26aufirst%3DJ.%26aulast%3DMartins%26aufirst%3DI.%26aulast%3DKepp%26aufirst%3DO.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DMolecular%2520Mechanisms%2520of%2520Cisplatin%2520Resistance%26jtitle%3DOncogene%26date%3D2012%26volume%3D31%26spage%3D1869%26epage%3D1883%26doi%3D10.1038%2Fonc.2011.384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelland, L.</span></span> <span> </span><span class="NLM_article-title">The Resurgence of Platinum-Based Cancer Chemotherapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">584</span>, <span class="refDoi"> DOI: 10.1038/nrc2167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fnrc2167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=17625587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotVKru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=573-584&author=L.+Kelland&title=The+Resurgence+of+Platinum-Based+Cancer+Chemotherapy&doi=10.1038%2Fnrc2167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of platinum-based cancer chemotherapy</span></div><div class="casAuthors">Kelland, Lloyd</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">573-584</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The accidental discovery of the anticancer properties of cisplatin and its clin. introduction in the 1970s represent a major landmark in the history of successful anticancer drugs.  Although carboplatin - a second-generation analog that is safer but shows a similar spectrum of activity to cisplatin - was introduced in the 1980s, the pace of further improvements slowed for many years.  However, in the past several years interest in platinum drugs has increased.  Key developments include the elucidation of mechanisms of tumor resistance to these drugs, the introduction of new platinum-based agents (oxaliplatin, satraplatin and picoplatin), and clin. combination studies using platinum drugs with resistance modulators or new molecularly targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTEI4HRCjxQrVg90H21EOLACvtfcHk0lh7FjgZQVkLJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotVKru7c%253D&md5=9d55f600a83a19d7836a2524de20efbf</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrc2167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2167%26sid%3Dliteratum%253Aachs%26aulast%3DKelland%26aufirst%3DL.%26atitle%3DThe%2520Resurgence%2520of%2520Platinum-Based%2520Cancer%2520Chemotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D573%26epage%3D584%26doi%3D10.1038%2Fnrc2167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Black, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santin, A.</span></span> <span> </span><span class="NLM_article-title">Clostridium Perfringens Enterotoxin (CPE) and CPE-Binding Domain (<i>c</i>-CPE) for the Detection and Treatment of Gynecologic Cancers</span>. <i>Toxins</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1116</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.3390/toxins7041116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.3390%2Ftoxins7041116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=25835384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFKms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=1116-1125&author=J.+Blackauthor=S.+Lopezauthor=E.+Coccoauthor=C.+Schwabauthor=D.+Englishauthor=A.+Santin&title=Clostridium+Perfringens+Enterotoxin+%28CPE%29+and+CPE-Binding+Domain+%28c-CPE%29+for+the+Detection+and+Treatment+of+Gynecologic+Cancers&doi=10.3390%2Ftoxins7041116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Clostridium Perfringens enterotoxin (CPE) and CPE-binding domain (c-CPE) for the detection and treatment of gynecologic cancers</span></div><div class="casAuthors">Black, Jonathan D.; Lopez, Salvatore; Cocco, Emiliano; Schwab, Carlton L.; English, Diana P.; Santin, Alessandro D.</div><div class="citationInfo"><span class="NLM_cas:title">Toxins</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1116-1125</span>CODEN:
                <span class="NLM_cas:coden">TOXIB7</span>;
        ISSN:<span class="NLM_cas:issn">2072-6651</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Clostridium perfringens enterotoxin (CPE) is a three-domain polypeptide, which binds to Claudin-3 and Claudin-4 with high affinity.  Because these receptors are highly differentially expressed in many human tumors, claudin-3 and claudin-4 may provide an efficient mol. tool to specifically identify and target biol. aggressive human cancer cells for CPE-specific binding and cytolysis.  In this review we will discuss these surface proteins as targets for the detection and treatment of chemotherapy-resistant gynecol. malignancies overexpressing claudin-3 and -4 using CPE-based theranostic agents.  We will also discuss the use of fluorescent c-CPE peptide in the operative setting for real time detection of micro-metastatic tumors during surgery and review the potential role of CPE in other medical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKmEaM_wWnZrVg90H21EOLACvtfcHk0lh7FjgZQVkLJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFKms74%253D&md5=06a1e34150b702c44466970558e00e8d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3390%2Ftoxins7041116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Ftoxins7041116%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DLopez%26aufirst%3DS.%26aulast%3DCocco%26aufirst%3DE.%26aulast%3DSchwab%26aufirst%3DC.%26aulast%3DEnglish%26aufirst%3DD.%26aulast%3DSantin%26aufirst%3DA.%26atitle%3DClostridium%2520Perfringens%2520Enterotoxin%2520%2528CPE%2529%2520and%2520CPE-Binding%2520Domain%2520%2528c-CPE%2529%2520for%2520the%2520Detection%2520and%2520Treatment%2520of%2520Gynecologic%2520Cancers%26jtitle%3DToxins%26date%3D2015%26volume%3D7%26spage%3D1116%26epage%3D1125%26doi%3D10.3390%2Ftoxins7041116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalathur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revandkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danzer-Baltzer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guccini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alajati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Mitri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Escudero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarditi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malusa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalathur, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzzene, A. P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaleu, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catapano, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frew, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimonti, A.</span></span> <span> </span><span class="NLM_article-title">A Chemogenomic Screening Identifies CK2 as a Target for Pro-Senescence Therapy in PTEN-Deficient Tumours</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">7227</span>, <span class="refDoi"> DOI: 10.1038/ncomms8227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fncomms8227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=26085373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2kt7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=7227&author=M.+Kalathurauthor=A.+Tosoauthor=J.+Chenauthor=A.+Revandkarauthor=C.+Danzer-Baltzerauthor=I.+Gucciniauthor=A.+Alajatiauthor=M.+Sartiauthor=S.+Pintonauthor=L.+Brambillaauthor=D.+Di+Mitriauthor=G.+Carboneauthor=R.+Garcia-Escuderoauthor=A.+Padovaauthor=L.+Magnoniauthor=A.+Tarditiauthor=L.+Maccariauthor=F.+Malusaauthor=R.+K.+Kalathurauthor=L.+Cozzaauthor=A.+P.+G.+Ruzzeneauthor=M.+N.+Delaleuauthor=C.+V.+Catapanoauthor=I.+J.+Frewauthor=A.+Alimonti&title=A+Chemogenomic+Screening+Identifies+CK2+as+a+Target+for+Pro-Senescence+Therapy+in+PTEN-Deficient+Tumours&doi=10.1038%2Fncomms8227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours</span></div><div class="casAuthors">Kalathur, Madhuri; Toso, Alberto; Chen, Jingjing; Revandkar, Ajinkya; Danzer-Baltzer, Claudia; Guccini, Ilaria; Alajati, Abdullah; Sarti, Manuela; Pinton, Sandra; Brambilla, Lara; Di Mitri, Diletta; Carbone, Giuseppina; Garcia-Escudero, R.; Padova, Alessandro; Magnoni, Letizia; Tarditi, Alessia; Maccari, Laura; Malusa, Federico; Kalathur, Ravi Kiran Reddy; Pinna, Lorenzo A.; Cozza, Giorgio; Ruzzene, Maria; Delaleu, Nicolas; Catapano, Carlo V.; Frew, Ian J.; Alimonti, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7227</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Enhancement of cellular senescence in tumors triggers a stable cell growth arrest and activation of an antitumor immune response that can be exploited for cancer therapy.  Currently, there are only a limited no. of targeted therapies that act by increasing senescence in cancers, but the majority of them are not selective and also target healthy cells.  Here we developed a chemogenomic screening to identify compds. that enhance senescence in PTEN-deficient cells without affecting normal cells.  By using this approach, we identified casein kinase 2 (CK2) as a pro-senescent target.  Mechanistically, we show that Pten loss increases CK2 levels by activating STAT3.  CK2 upregulation in Pten null tumors affects the stability of Pml, an essential regulator of senescence.  However, CK2 inhibition stabilizes Pml levels enhancing senescence in Pten null tumors.  Taken together, our screening strategy has identified a novel STAT3-CK2-PML network that can be targeted for pro-senescence therapy for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpepPKZTNMFMbVg90H21EOLACvtfcHk0lj6j6KSVNBvVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2kt7%252FP&md5=c9407799e111aa8387b164701226ca86</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fncomms8227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms8227%26sid%3Dliteratum%253Aachs%26aulast%3DKalathur%26aufirst%3DM.%26aulast%3DToso%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DRevandkar%26aufirst%3DA.%26aulast%3DDanzer-Baltzer%26aufirst%3DC.%26aulast%3DGuccini%26aufirst%3DI.%26aulast%3DAlajati%26aufirst%3DA.%26aulast%3DSarti%26aufirst%3DM.%26aulast%3DPinton%26aufirst%3DS.%26aulast%3DBrambilla%26aufirst%3DL.%26aulast%3DDi%2BMitri%26aufirst%3DD.%26aulast%3DCarbone%26aufirst%3DG.%26aulast%3DGarcia-Escudero%26aufirst%3DR.%26aulast%3DPadova%26aufirst%3DA.%26aulast%3DMagnoni%26aufirst%3DL.%26aulast%3DTarditi%26aufirst%3DA.%26aulast%3DMaccari%26aufirst%3DL.%26aulast%3DMalusa%26aufirst%3DF.%26aulast%3DKalathur%26aufirst%3DR.%2BK.%26aulast%3DCozza%26aufirst%3DL.%26aulast%3DRuzzene%26aufirst%3DA.%2BP.%2BG.%26aulast%3DDelaleu%26aufirst%3DM.%2BN.%26aulast%3DCatapano%26aufirst%3DC.%2BV.%26aulast%3DFrew%26aufirst%3DI.%2BJ.%26aulast%3DAlimonti%26aufirst%3DA.%26atitle%3DA%2520Chemogenomic%2520Screening%2520Identifies%2520CK2%2520as%2520a%2520Target%2520for%2520Pro-Senescence%2520Therapy%2520in%2520PTEN-Deficient%2520Tumours%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D7227%26doi%3D10.1038%2Fncomms8227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purwin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández-Toribio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coderch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchuk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skorokhyd, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipiak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Pascual-Teresa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, A.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Novel Dual-Target Agents for HDAC1 and CK2 Inhibition</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">66595</span>– <span class="NLM_lpage">66608</span>, <span class="refDoi"> DOI: 10.1039/c6ra09717k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1039%2FC6RA09717K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFantbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=66595-66608&author=M.+Purwinauthor=J.+Hern%C3%A1ndez-Toribioauthor=C.+Coderchauthor=R.+Panchukauthor=N.+Skorokhydauthor=K.+Filipiakauthor=B.+de+Pascual-Teresaauthor=A.+Ramos&title=Design+and+Synthesis+of+Novel+Dual-Target+Agents+for+HDAC1+and+CK2+Inhibition&doi=10.1039%2Fc6ra09717k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel dual-target agents for HDAC1 and CK2 inhibition</span></div><div class="casAuthors">Purwin, M.; Hernandez-Toribio, J.; Coderch, C.; Panchuk, R.; Skorokhyd, N.; Filipiak, K.; de Pascual-Teresa, B.; Ramos, A.</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">71</span>),
    <span class="NLM_cas:pages">66595-66608</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Drug entities able to address multiple targets can be more effective than those directed to just one biol. target.  We disclose herein a series of novel dual inhibitors to target histone deacetylase 1 (HDAC 1) and protein kinase CK2.  Our bifunctional compds. combine two complementary chemo-active prototypical scaffolds: a hydroxamate essential for the chelation of the zinc ion present in the active site of HDAC (Zinc Binding Group), and a 4,5,6,7-tetrabromobenzotriazole (TBB) moiety introduced to interact with the ATP binding site in CK2 and to act simultaneously as the cap group in the interaction with HDAC1.  The synthesized dual-acting agents exhibited promising inhibitory activities towards HDAC1 and CK2.  The best result was obtained for 5c with an IC50 of 5 μM for both enzymes.  However, its N-2 substituted isomer 5e presented the best profile in cell-based assays, with cytotoxic activity in the low micromolar LC50 in two mammalian cancer cell lines and 4-fold less activity towards a pseudonormal mammalian cell line.  Furthermore, this hybrid mol. induced apoptosis in leukemia cells in a concn.-dependent manner.  All together this makes 5e a promising lead compd. for future in vivo assays in animal tumor models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0Ospcx3QT9bVg90H21EOLACvtfcHk0lj6j6KSVNBvVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFantbfO&md5=fbaa200377d08409ca85524df9e1686c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1039%2FC6RA09717K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6RA09717K%26sid%3Dliteratum%253Aachs%26aulast%3DPurwin%26aufirst%3DM.%26aulast%3DHern%25C3%25A1ndez-Toribio%26aufirst%3DJ.%26aulast%3DCoderch%26aufirst%3DC.%26aulast%3DPanchuk%26aufirst%3DR.%26aulast%3DSkorokhyd%26aufirst%3DN.%26aulast%3DFilipiak%26aufirst%3DK.%26aulast%3Dde%2BPascual-Teresa%26aufirst%3DB.%26aulast%3DRamos%26aufirst%3DA.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%2520Dual-Target%2520Agents%2520for%2520HDAC1%2520and%2520CK2%2520Inhibition%26jtitle%3DRSC%2520Adv.%26date%3D2016%26volume%3D6%26spage%3D66595%26epage%3D66608%26doi%3D10.1039%2Fc6ra09717k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossenkov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purandare, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desilva, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jure-Kunkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrilovich, D. I.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">5644</span>– <span class="NLM_lpage">5655</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-18-1229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1158%2F0008-5472.CAN-18-1229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=30139814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlSju7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=5644-5655&author=A.+Hashimotoauthor=C.+Gaoauthor=J.+Mastioauthor=A.+Kossenkovauthor=S.+I.+Abramsauthor=A.+V.+Purandareauthor=H.+Desilvaauthor=S.+Weeauthor=J.+Huntauthor=M.+Jure-Kunkelauthor=D.+I.+Gabrilovich&title=Inhibition+of+Casein+Kinase+2+Disrupts+Differentiation+of+Myeloid+Cells+in+Cancer+and+Enhances+the+Efficacy+of+Immunotherapy+in+Mice&doi=10.1158%2F0008-5472.can-18-1229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of casein kinase 2 disrupts differentiation of myeloid cells in cancer and enhances the efficacy of immunotherapy in mice</span></div><div class="casAuthors">Hashimoto, Ayumi; Gao, Chan; Mastio, Jerome; Kossenkov, Andrew; Abrams, Scott I.; Purandare, Ashok V.; Desilva, Heshani; Wee, Susan; Hunt, John; Jure-Kunkel, Maria; Gabrilovich, Dmitry I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5644-5655</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The role of myeloid cells as regulators of tumor progression that significantly impact the efficacy of cancer immunotherapies makes them an attractive target for inhibition.  Here we explore the effect of a novel, potent, and selective inhibitor of serine/threonine protein kinase casein kinase 2 (CK2) on modulating myeloid cells in the tumor microenvironment.  Although inhibition of CK2 caused only a modest effect on dendritic cells in tumor-bearing mice, it substantially reduced the amt. of polymorphonuclear myeloid-derived suppressor cells and tumor-assocd. macrophages.  This effect was not caused by the induction of apoptosis, but rather by a block of differentiation.  Our results implicated downregulation of CCAAT-enhancer binding protein-α in this effect.  Although CK2 inhibition did not directly affect tumor cells, it dramatically enhanced the antitumor activity of immune checkpoint receptor blockade using anti-CTLA-4 antibody.  These results suggest a potential role of CK2 inhibitors in combination therapies against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBY1mwFqvLhLVg90H21EOLACvtfcHk0lj6j6KSVNBvVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlSju7rO&md5=bc9ead05597f71437fbf55e6832cc2b8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-1229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-1229%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DMastio%26aufirst%3DJ.%26aulast%3DKossenkov%26aufirst%3DA.%26aulast%3DAbrams%26aufirst%3DS.%2BI.%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26aulast%3DDesilva%26aufirst%3DH.%26aulast%3DWee%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DJ.%26aulast%3DJure-Kunkel%26aufirst%3DM.%26aulast%3DGabrilovich%26aufirst%3DD.%2BI.%26atitle%3DInhibition%2520of%2520Casein%2520Kinase%25202%2520Disrupts%2520Differentiation%2520of%2520Myeloid%2520Cells%2520in%2520Cancer%2520and%2520Enhances%2520the%2520Efficacy%2520of%2520Immunotherapy%2520in%2520Mice%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D5644%26epage%3D5655%26doi%3D10.1158%2F0008-5472.can-18-1229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nitta, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gholamin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feroze, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheshier, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span> <span> </span><span class="NLM_article-title">Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">3688</span>– <span class="NLM_lpage">3699</span>, <span class="refDoi"> DOI: 10.1038/onc.2014.299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fonc.2014.299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=25241897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyhtL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=3688-3699&author=R.+T.+Nittaauthor=S.+Gholaminauthor=A.+H.+Ferozeauthor=M.+Agarwalauthor=S.+H.+Cheshierauthor=S.+S.+Mitraauthor=G.+Li&title=Casein+kinase+2%CE%B1+regulates+glioblastoma+brain+tumor-initiating+cell+growth+through+the+%CE%B2-catenin+pathway&doi=10.1038%2Fonc.2014.299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway</span></div><div class="casAuthors">Nitta, R. T.; Gholamin, S.; Feroze, A. H.; Agarwal, M.; Cheshier, S. H.; Mitra, S. S.; Li, G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3688-3699</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glioblastoma (GBM) is the most common and fatal primary brain tumor in humans, and it is essential that new and better therapies are developed to treat this disease.  Previous research suggests that casein kinase 2 (CK2) may be a promising therapeutic target for GBMs.  CK2 has enhanced expression or activity in numerous cancers, including GBM, and it has been demonstrated that inhibitors of CK2 regressed tumor growth in GBM xenograft mouse models.  Our studies demonstrate that the CK2 subunit, CK2α, is overexpressed in and has an important role in regulating brain tumor-initiating cells (BTIC) in GBM.  Initial studies showed that two GBM cell lines (U87-MG and U138) transduced with CK2α had enhanced proliferation and anchorage-independent growth.  Inhibition of CKα using siRNA or small-mol. inhibitors (TBBz, CX-4945) reduced cell growth, decreased tumor size, and increased survival rates in GBM xenograft mouse models.  We also verified that inhibition of CK2α decreased the activity of a well-known GBM-initiating cell regulator, β-catenin.  Loss of CK2α decreased two β-catenin-regulated genes that are involved in GBM-initiating cell growth, OCT4 and NANOG.  To det. the importance of CK2α in GBM stem cell maintenance, we reduced CK2α activity in primary GBM samples and tumor spheres derived from GBM patients.  We discovered that loss of CK2α activity reduced the sphere-forming capacity of BTIC and decreased numerous GBM stem cell markers, including CD133, CD90, CD49f and A2B5.  Our study suggests that CK2α is involved in GBM tumorigenesis by maintaining BTIC through the regulation of β-catenin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcrw3mE50HGLVg90H21EOLACvtfcHk0lglW_gaXtAzcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyhtL7L&md5=892bcf619d64a1a0752beb8cd720814a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fonc.2014.299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2014.299%26sid%3Dliteratum%253Aachs%26aulast%3DNitta%26aufirst%3DR.%2BT.%26aulast%3DGholamin%26aufirst%3DS.%26aulast%3DFeroze%26aufirst%3DA.%2BH.%26aulast%3DAgarwal%26aufirst%3DM.%26aulast%3DCheshier%26aufirst%3DS.%2BH.%26aulast%3DMitra%26aufirst%3DS.%2BS.%26aulast%3DLi%26aufirst%3DG.%26atitle%3DCasein%2520kinase%25202%25CE%25B1%2520regulates%2520glioblastoma%2520brain%2520tumor-initiating%2520cell%2520growth%2520through%2520the%2520%25CE%25B2-catenin%2520pathway%26jtitle%3DOncogene%26date%3D2015%26volume%3D34%26spage%3D3688%26epage%3D3699%26doi%3D10.1038%2Fonc.2014.299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui-Jain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaebe, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vialettes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darjania, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stansfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliesath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drygin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proffitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streiner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trent, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckman, D. M.</span></span> <span> </span><span class="NLM_article-title">Discovery and SAR of 5-(3-chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylic Acid (<b>CX-4945</b>), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">635</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1021/jm101251q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101251q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2kurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=635-654&author=F.+Pierreauthor=P.+C.+Chuaauthor=S.+E.+O%E2%80%99Brienauthor=A.+Siddiqui-Jainauthor=P.+Bourbonauthor=M.+Haddachauthor=J.+Michauxauthor=J.+Nagasawaauthor=M.+K.+Schwaebeauthor=E.+Stefanauthor=A.+Vialettesauthor=J.+P.+Whittenauthor=T.+K.+Chenauthor=L.+Darjaniaauthor=R.+Stansfieldauthor=K.+Anderesauthor=J.+Bliesathauthor=D.+Dryginauthor=C.+Hoauthor=M.+Omoriauthor=C.+Proffittauthor=N.+Streinerauthor=K.+Trentauthor=W.+G.+Riceauthor=D.+M.+Ryckman&title=Discovery+and+SAR+of+5-%283-chlorophenylamino%29benzo%5Bc%5D%5B2%2C6%5Dnaphthyridine-8-carboxylic+Acid+%28CX-4945%29%2C+the+First+Clinical+Stage+Inhibitor+of+Protein+Kinase+CK2+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm101251q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer</span></div><div class="casAuthors">Pierre, Fabrice; Chua, Peter C.; O'Brien, Sean E.; Siddiqui-Jain, Adam; Bourbon, Pauline; Haddach, Mustapha; Michaux, Jerome; Nagasawa, Johnny; Schwaebe, Michael K.; Stefan, Eric; Vialettes, Anne; Whitten, Jeffrey P.; Chen, Ta Kung; Darjania, Levan; Stansfield, Ryan; Anderes, Kenna; Bliesath, Josh; Drygin, Denis; Ho, Caroline; Omori, May; Proffitt, Chris; Streiner, Nicole; Trent, Katy; Rice, William G.; Ryckman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">635-654</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we chronicle the discovery of CX-4945 (I), a first-in-class, orally bioavailable ATP-competitive inhibitor of protein kinase CK2 in clin. trials for cancer.  CK2 has long been considered a prime cancer drug target because of the roles of deregulated and overexpressed CK2 in cancer-promoting pro-survival and antiapoptotic pathways.  These biol. properties as well as the suitability of CK2's small ATP binding site for the design of selective inhibitors, led us to fashion novel therapeutic agents for cancer.  The optimization leading to I (Ki = 0.38 nM) was guided by mol. modeling, suggesting a strong binding of I resulting from a combination of hydrophobic interactions, an ionic bridge with Lys68, and hydrogen bonding with the hinge region. I was highly selective, orally bioavailable across species (20-51%) and efficacious in xenograft models.  The discovery of I will allow the therapeutic targeting of CK2 in humans for the first time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoONQeRuenlPrVg90H21EOLACvtfcHk0limfc9QsjfUQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2kurjL&md5=9b0f371ee1a2182b84877743c42dfda1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm101251q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101251q%26sid%3Dliteratum%253Aachs%26aulast%3DPierre%26aufirst%3DF.%26aulast%3DChua%26aufirst%3DP.%2BC.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BE.%26aulast%3DSiddiqui-Jain%26aufirst%3DA.%26aulast%3DBourbon%26aufirst%3DP.%26aulast%3DHaddach%26aufirst%3DM.%26aulast%3DMichaux%26aufirst%3DJ.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DSchwaebe%26aufirst%3DM.%2BK.%26aulast%3DStefan%26aufirst%3DE.%26aulast%3DVialettes%26aufirst%3DA.%26aulast%3DWhitten%26aufirst%3DJ.%2BP.%26aulast%3DChen%26aufirst%3DT.%2BK.%26aulast%3DDarjania%26aufirst%3DL.%26aulast%3DStansfield%26aufirst%3DR.%26aulast%3DAnderes%26aufirst%3DK.%26aulast%3DBliesath%26aufirst%3DJ.%26aulast%3DDrygin%26aufirst%3DD.%26aulast%3DHo%26aufirst%3DC.%26aulast%3DOmori%26aufirst%3DM.%26aulast%3DProffitt%26aufirst%3DC.%26aulast%3DStreiner%26aufirst%3DN.%26aulast%3DTrent%26aufirst%3DK.%26aulast%3DRice%26aufirst%3DW.%2BG.%26aulast%3DRyckman%26aufirst%3DD.%2BM.%26atitle%3DDiscovery%2520and%2520SAR%2520of%25205-%25283-chlorophenylamino%2529benzo%255Bc%255D%255B2%252C6%255Dnaphthyridine-8-carboxylic%2520Acid%2520%2528CX-4945%2529%252C%2520the%2520First%2520Clinical%2520Stage%2520Inhibitor%2520of%2520Protein%2520Kinase%2520CK2%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D635%26epage%3D654%26doi%3D10.1021%2Fjm101251q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting Cancer with Small Molecule Kinase Inhibitors</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1038/nrc2559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+Cancer+with+Small+Molecule+Kinase+Inhibitors&doi=10.1038%2Fnrc2559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0limfc9QsjfUQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Cancer%2520with%2520Small%2520Molecule%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39%26doi%3D10.1038%2Fnrc2559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katoh, M.</span></span> <span> </span><span class="NLM_article-title">Networking of WNT, FGF, Notch, BMP, and Hedgehog Signaling Pathways During Carcinogenesis</span>. <i>Stem Cell Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1007/s12015-007-0006-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1007%2Fs12015-007-0006-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=17873379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVent7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=30-38&author=M.+Katoh&title=Networking+of+WNT%2C+FGF%2C+Notch%2C+BMP%2C+and+Hedgehog+Signaling+Pathways+During+Carcinogenesis&doi=10.1007%2Fs12015-007-0006-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis</span></div><div class="casAuthors">Katoh, Masaru</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cell Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-38</span>CODEN:
                <span class="NLM_cas:coden">SCRTCI</span>;
        ISSN:<span class="NLM_cas:issn">1550-8943</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review.  The biol. functions of some orthologs within the human genome and model-animal genomes are evolutionarily conserved, but those of others are divergent due to protein evolution and promoter evolution.  Because WNT signaling mols. play key roles during embryogenesis, tissue regeneration and carcinogenesis, the author's group has carried out a human WNT-ome project for the comprehensive characterization of human genes encoding WNT signaling mols.  From 1996 to 2002, we cloned and characterized WNT2B/WNT13, WNT3, WNT3A, WNT5B, WNT6, WNT7B, WNT8A, WNT8B, WNT9A/WNT14, WNT9B/WNT14B, WNT10A, WNT10B, WNT11, FZD1, FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, FZD10, FRAT1, FRAT2, NKD1, NKD2, VANGL1, RHOU/ARHU, RHOV/ARHV, GIPC2, GIPC3, FBXW11/βTRCP2, SOX17, TCF7L1/TCF3, and established a cDNA-PCR system for snap-shot and dynamic analyses on the WNT-transcriptome.  In 2003, we identified and characterized PRICKLE1, PRICKLE2, DACT1/DAPPER1, DACT2/DAPPER2, DAAM2, and BCL9L.  After completion of the human WNT-ome project, we have been working on the stem cell signaling network.  WNT signals are transduced to β-catenin, NLK, NFAT, PKC, JNK and RhoA signaling cascades.  FGF20, JAG1 and DKK1 are target genes of the WNT-β-catenin signaling cascade.  Cross-talk of WNT and FGF signaling pathways potentiates β-catenin and NFAT signaling cascades.  BMP signals induce IHH upregulation in co-operation with RUNX.  Hedgehog signals induce upregulation of SFRP1, JAG2 and FOXL1, and then FOXL1 induces BMP4 upregulation.  The balance between WNT-FGF-Notch and BMP-Hedgehog signaling networks is important for the maintenance of homeostasis among stem and progenitor cells.  Disruption of the stem cell signaling network results in pathol. conditions, such as congenital diseases and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov8zIO_8Bm6LVg90H21EOLACvtfcHk0limfc9QsjfUQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVent7nI&md5=8a4ac4dee7c0e49ec125a717a6904eaa</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs12015-007-0006-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12015-007-0006-6%26sid%3Dliteratum%253Aachs%26aulast%3DKatoh%26aufirst%3DM.%26atitle%3DNetworking%2520of%2520WNT%252C%2520FGF%252C%2520Notch%252C%2520BMP%252C%2520and%2520Hedgehog%2520Signaling%2520Pathways%2520During%2520Carcinogenesis%26jtitle%3DStem%2520Cell%2520Rev.%26date%3D2007%26volume%3D3%26spage%3D30%26epage%3D38%26doi%3D10.1007%2Fs12015-007-0006-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwind, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schetting, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montenarh, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Protein Kinase CK2 Prevents Adipogenic Differentiation of Mesenchymal Stem Cells Like C3H/10T1/2 Cells</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">22/1</span>– <span class="NLM_lpage">22/12</span>, <span class="refDoi"> DOI: 10.3390/ph10010022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.3390%2Fph10010022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=22%2F1-22%2F12&author=L.+Schwindauthor=S.+Schettingauthor=M.+Montenarh&title=Inhibition+of+Protein+Kinase+CK2+Prevents+Adipogenic+Differentiation+of+Mesenchymal+Stem+Cells+Like+C3H%2F10T1%2F2+Cells&doi=10.3390%2Fph10010022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.3390%2Fph10010022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph10010022%26sid%3Dliteratum%253Aachs%26aulast%3DSchwind%26aufirst%3DL.%26aulast%3DSchetting%26aufirst%3DS.%26aulast%3DMontenarh%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520Protein%2520Kinase%2520CK2%2520Prevents%2520Adipogenic%2520Differentiation%2520of%2520Mesenchymal%2520Stem%2520Cells%2520Like%2520C3H%252F10T1%252F2%2520Cells%26jtitle%3DPharmaceuticals%26date%3D2017%26volume%3D10%26spage%3D22%252F1%26epage%3D22%252F12%26doi%3D10.3390%2Fph10010022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsumoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamagata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitabayashi, I.</span></span> <span> </span><span class="NLM_article-title">Dual Inhibition of Enhancer of Zeste Homolog 1/2 Overactivates WNT Signaling to Deplete Cancer Stem Cells in Multiple Myeloma</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1111/cas.13840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1111%2Fcas.13840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=30343511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1eitrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2019&pages=194-208&author=M.+Nakagawaauthor=S.+Fujitaauthor=T.+Katsumotoauthor=K.+Yamagataauthor=Y.+Ogawaraauthor=A.+Hattoriauthor=Y.+Kagiyamaauthor=D.+Honmaauthor=K.+Arakiauthor=T.+Inoueauthor=A.+Katoauthor=K.+Inakiauthor=C.+Wadaauthor=Y.+Onoauthor=M.+Yamamotoauthor=O.+Miuraauthor=Y.+Nakashimaauthor=I.+Kitabayashi&title=Dual+Inhibition+of+Enhancer+of+Zeste+Homolog+1%2F2+Overactivates+WNT+Signaling+to+Deplete+Cancer+Stem+Cells+in+Multiple+Myeloma&doi=10.1111%2Fcas.13840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma</span></div><div class="casAuthors">Nakagawa, Makoto; Fujita, Shuhei; Katsumoto, Takuo; Yamagata, Kazutsune; Ogawara, Yoko; Hattori, Ayuna; Kagiyama, Yuki; Honma, Daisuke; Araki, Kazushi; Inoue, Tatsuya; Kato, Ayako; Inaki, Koichiro; Wada, Chisa; Ono, Yoshimasa; Yamamoto, Masahide; Miura, Osamu; Nakashima, Yasuharu; Kitabayashi, Issay</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">194-208</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is an incurable hematol. malignancy caused by accumulation of abnormal clonal plasma cells.  Despite the recent development of novel therapies, relapse of MM eventually occurs as a result of a remaining population of drug-resistant myeloma stem cells.  Side population (SP) cells show cancer stem cell-like characteristics in MM; thus, targeting these cells is a promising strategy to completely cure this malignancy.  Herein, we showed that SP cells expressed higher levels of enhancer of zeste homolog (EZH) 1 and EZH2, which encode the catalytic subunits of Polycomb repressive complex 2 (PRC2), than non-SP cells, suggesting that EZH1 as well as EZH2 contributes to the stemness maintenance of the MM cells and that targeting both EZH1/2 is potentially a significant therapeutic approach for eradicating myeloma stem cells.  Moreover, long-term continuous dosing of OR-S1 completely cured mice bearing orthotopic xenografts.  Addnl., PRC2 directly regulated WNT signaling in MM, and overactivation of this signaling induced by dual inhibition of EZH1/2 eradicated myeloma stem cells and neg. affected tumorigenesis, suggesting that repression of WNT signaling by PRC2 plays an important role in stemness maintenance of MM cells.  Our results show the role of EZH1/2 in the maintenance of myeloma stem cells and provide a preclin. rationale for therapeutic application of OR-S1, leading to significant advances in the treatment of MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5tCzftcXKF7Vg90H21EOLACvtfcHk0lhsthaDMTMvwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1eitrbJ&md5=baa39f9d47398cc1fcfebb86821c7f04</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fcas.13840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13840%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DFujita%26aufirst%3DS.%26aulast%3DKatsumoto%26aufirst%3DT.%26aulast%3DYamagata%26aufirst%3DK.%26aulast%3DOgawara%26aufirst%3DY.%26aulast%3DHattori%26aufirst%3DA.%26aulast%3DKagiyama%26aufirst%3DY.%26aulast%3DHonma%26aufirst%3DD.%26aulast%3DAraki%26aufirst%3DK.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DA.%26aulast%3DInaki%26aufirst%3DK.%26aulast%3DWada%26aufirst%3DC.%26aulast%3DOno%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DMiura%26aufirst%3DO.%26aulast%3DNakashima%26aufirst%3DY.%26aulast%3DKitabayashi%26aufirst%3DI.%26atitle%3DDual%2520Inhibition%2520of%2520Enhancer%2520of%2520Zeste%2520Homolog%25201%252F2%2520Overactivates%2520WNT%2520Signaling%2520to%2520Deplete%2520Cancer%2520Stem%2520Cells%2520in%2520Multiple%2520Myeloma%26jtitle%3DCancer%2520Sci.%26date%3D2019%26volume%3D110%26spage%3D194%26epage%3D208%26doi%3D10.1111%2Fcas.13840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becherel, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakob, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherry, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gueven, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kijas, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katyal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinnon, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smerdon, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taucher-Scholz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavin, M. F.</span></span> <span> </span><span class="NLM_article-title">CK2 Phosphorylation-Dependent Interaction Between Aprataxin and MDC1 in the DNA Damage Response</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1489</span>– <span class="NLM_lpage">1503</span>, <span class="refDoi"> DOI: 10.1093/nar/gkp1149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1093%2Fnar%2Fgkp1149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=20008512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjt1KnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1489-1503&author=O.+J.+Becherelauthor=B.+Jakobauthor=A.+L.+Cherryauthor=N.+Guevenauthor=M.+Fusserauthor=A.+W.+Kijasauthor=C.+Pengauthor=S.+Katyalauthor=P.+J.+McKinnonauthor=J.+Chenauthor=B.+Epeauthor=S.+J.+Smerdonauthor=G.+Taucher-Scholzauthor=M.+F.+Lavin&title=CK2+Phosphorylation-Dependent+Interaction+Between+Aprataxin+and+MDC1+in+the+DNA+Damage+Response&doi=10.1093%2Fnar%2Fgkp1149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response</span></div><div class="casAuthors">Becherel, Olivier J.; Jakob, Burkhard; Cherry, Amy L.; Gueven, Nuri; Fusser, Markus; Kijas, Amanda W.; Peng, Cheng; Katyal, Sachin; McKinnon, Peter J.; Chen, Junjie; Epe, Bernd; Smerdon, Stephen J.; Taucher-Scholz, Gisela; Lavin, Martin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1489-1503</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aprataxin, defective in the neurodegenerative disorder ataxia oculomotor apraxia type 1, resolves abortive DNA ligation intermediates during DNA repair.  Here, we demonstrate that aprataxin localizes at sites of DNA damage induced by high LET radiation and binds to mediator of DNA-damage checkpoint protein 1 (MDC1/NFBD1) through a phosphorylation-dependent interaction.  This interaction is mediated via the aprataxin FHA domain and multiple casein kinase 2 di-phosphorylated S-D-T-D motifs in MDC1.  X-ray structural and mutagenic anal. of aprataxin FHA domain, combined with modeling of the pSDpTD peptide interaction suggest an unusual FHA binding mechanism mediated by a cluster of basic residues at and around the canonical pT-docking site.  Mutation of aprataxin FHA Arg29 prevented its interaction with MDC1 and recruitment to sites of DNA damage.  These results indicate that aprataxin is involved not only in single strand break repair but also in the processing of a subset of double strand breaks presumably through its interaction with MDC1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreTittaIuM9LVg90H21EOLACvtfcHk0lhsthaDMTMvwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjt1KnsL8%253D&md5=7399dddc6f60329d390de63075e0cea7</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkp1149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkp1149%26sid%3Dliteratum%253Aachs%26aulast%3DBecherel%26aufirst%3DO.%2BJ.%26aulast%3DJakob%26aufirst%3DB.%26aulast%3DCherry%26aufirst%3DA.%2BL.%26aulast%3DGueven%26aufirst%3DN.%26aulast%3DFusser%26aufirst%3DM.%26aulast%3DKijas%26aufirst%3DA.%2BW.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DKatyal%26aufirst%3DS.%26aulast%3DMcKinnon%26aufirst%3DP.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DEpe%26aufirst%3DB.%26aulast%3DSmerdon%26aufirst%3DS.%2BJ.%26aulast%3DTaucher-Scholz%26aufirst%3DG.%26aulast%3DLavin%26aufirst%3DM.%2BF.%26atitle%3DCK2%2520Phosphorylation-Dependent%2520Interaction%2520Between%2520Aprataxin%2520and%2520MDC1%2520in%2520the%2520DNA%2520Damage%2520Response%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2010%26volume%3D38%26spage%3D1489%26epage%3D1503%26doi%3D10.1093%2Fnar%2Fgkp1149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Maira, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brustolon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertacchini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosoni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmiroli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzzene, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Inhibition of Protein Kinase CK2 Reverts the Multidrug Resistance Phenotype of a CEM Cell Line Characterized by High CK2 Level</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">6915</span>– <span class="NLM_lpage">6926</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fsj.onc.1210495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=17486073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOksbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=6915-6926&author=G.+Di%0AMairaauthor=F.+Brustolonauthor=J.+Bertacchiniauthor=K.+Tosoniauthor=S.+Marmiroliauthor=L.+A.+Pinnaauthor=M.+Ruzzene&title=Pharmacological+Inhibition+of+Protein+Kinase+CK2+Reverts+the+Multidrug+Resistance+Phenotype+of+a+CEM+Cell+Line+Characterized+by+High+CK2+Level&doi=10.1038%2Fsj.onc.1210495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level</span></div><div class="casAuthors">Di Maira, G.; Brustolon, F.; Bertacchini, J.; Tosoni, K.; Marmiroli, S.; Pinna, L. A.; Ruzzene, M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">6915-6926</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein kinase CK2 is an ubiquitous and constitutively active kinase, which phosphorylates many cellular proteins and is implicated in the regulation of cell survival, proliferation and transformation.  We investigated its possible involvement in the multidrug resistance phenotype (MDR) by analyzing its level in two variants of CEM cells, namely S-CEM and R-CEM, normally sensitive or resistant to chem. apoptosis, resp.  We found that, while the CK2 regulatory subunit β was equally expressed in the two cell variants, CK2α catalytic subunit was higher in R-CEM and this was accompanied by a higher phosphorylation of endogenous protein substrates.  Pharmacol. downregulation of CK2 activity by a panel of specific inhibitors, or knockdown of CK2α expression by RNA interference, were able to induce cell death in R-CEM.  CK2 inhibitors could promote an increased uptake of chemotherapeutic drugs inside the cells and sensitize them to drug-induced apoptosis in a co-operative manner.  CK2 blockade was also effective in inducing cell death of a different MDR line (U2OS).  We therefore conclude that inhibition of CK2 can be considered as a promising tool to revert the MDR phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcrgFDa7ybUrVg90H21EOLACvtfcHk0lhsthaDMTMvwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOksbrL&md5=242d0abbdbcc41d818d304df8dbd5d5c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210495%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMaira%26aufirst%3DG.%26aulast%3DBrustolon%26aufirst%3DF.%26aulast%3DBertacchini%26aufirst%3DJ.%26aulast%3DTosoni%26aufirst%3DK.%26aulast%3DMarmiroli%26aufirst%3DS.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26aulast%3DRuzzene%26aufirst%3DM.%26atitle%3DPharmacological%2520Inhibition%2520of%2520Protein%2520Kinase%2520CK2%2520Reverts%2520the%2520Multidrug%2520Resistance%2520Phenotype%2520of%2520a%2520CEM%2520Cell%2520Line%2520Characterized%2520by%2520High%2520CK2%2520Level%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D6915%26epage%3D6926%26doi%3D10.1038%2Fsj.onc.1210495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritt, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. D.</span></span> <span> </span><span class="NLM_article-title">Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">17804</span>– <span class="NLM_lpage">17815</span>, <span class="refDoi"> DOI: 10.1074/jbc.m115.712885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1074%2Fjbc.M115.712885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=27226552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyjt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=17804-17815&author=B.+Zhouauthor=D.+A.+Rittauthor=D.+K.+Morrisonauthor=C.+J.+Derauthor=A.+D.+Cox&title=Protein+Kinase+CK2%CE%B1+Maintains+Extracellular+Signal-regulated+Kinase+%28ERK%29+Activity+in+a+CK2%CE%B1+Kinase-independent+Manner+to+Promote+Resistance+to+Inhibitors+of+RAF+and+MEK+but+Not+ERK+in+BRAF+Mutant+Melanoma&doi=10.1074%2Fjbc.m115.712885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma</span></div><div class="casAuthors">Zhou, Bingying; Ritt, Daniel A.; Morrison, Deborah K.; Der, Channing J.; Cox, Adrienne D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">17804-17815</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The protein kinase casein kinase 2 (CK2) is a pleiotropic and constitutively active kinase that plays crucial roles in cellular proliferation and survival.  Overexpression of CK2, particularly the α catalytic subunit (CK2α, CSNK2A1), has been implicated in a wide variety of cancers and is assocd. with poorer survival and resistance to both conventional and targeted anticancer therapies.  Here, the authors found that CK2α protein is elevated in melanoma cell lines compared with normal human melanocytes.  The authors then tested the involvement of CK2α in drug resistance to Food and Drug Administration-approved single agent targeted therapies for melanoma.  In BRAF mutant melanoma cells, ectopic CK2α decreased sensitivity to vemurafenib (BRAF inhibitor), dabrafenib (BRAF inhibitor), and trametinib (MEK inhibitor) by a mechanism distinct from that of mutant NRAS.  Conversely, knockdown of CK2α sensitized cells to inhibitor treatment.  CK2α-mediated RAF-MEK kinase inhibitor resistance was tightly linked to its maintenance of ERK phosphorylation.  The authors found that CK2α post-translationally regulates the ERK-specific phosphatase dual specificity phosphatase 6 (DUSP6) in a kinase dependent-manner, decreasing its abundance.  However, the authors unexpectedly showed, by using a kinase-inactive mutant of CK2α, that RAF-MEK inhibitor resistance did not rely on CK2α kinase catalytic function, and both wild-type and kinase-inactive CK2α maintained ERK phosphorylation upon inhibition of BRAF or MEK.  That both wild-type and kinase-inactive CK2α bound equally well to the RAF-MEK-ERK scaffold kinase suppressor of Ras 1 (KSR1) suggested that CK2α increases KSR facilitation of ERK phosphorylation.  Accordingly, CK2α did not cause resistance to direct inhibition of ERK by the ERK1/2-selective inhibitor SCH772984.  The authors' findings support a kinase-independent scaffolding function of CK2α that promotes resistance to RAF- and MEK-targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEQDy70PYNPbVg90H21EOLACvtfcHk0lhawbUiscOB0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyjt7rJ&md5=b7ec61a6e142f9480f980898de72b000</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.712885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.712885%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DRitt%26aufirst%3DD.%2BA.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26aulast%3DCox%26aufirst%3DA.%2BD.%26atitle%3DProtein%2520Kinase%2520CK2%25CE%25B1%2520Maintains%2520Extracellular%2520Signal-regulated%2520Kinase%2520%2528ERK%2529%2520Activity%2520in%2520a%2520CK2%25CE%25B1%2520Kinase-independent%2520Manner%2520to%2520Promote%2520Resistance%2520to%2520Inhibitors%2520of%2520RAF%2520and%2520MEK%2520but%2520Not%2520ERK%2520in%2520BRAF%2520Mutant%2520Melanoma%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D17804%26epage%3D17815%26doi%3D10.1074%2Fjbc.m115.712885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loizou, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Khamisy, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatanou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meggio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldecott, K. W.</span></span> <span> </span><span class="NLM_article-title">The Protein Kinase CK2 Facilitates Repair of Chromosomal DNA Single-Strand Breaks</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1016/s0092-8674(04)00206-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2FS0092-8674%2804%2900206-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=15066279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFWqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2004&pages=17-28&author=J.+I.+Loizouauthor=S.+F.+El-Khamisyauthor=A.+Zlatanouauthor=D.+J.+Mooreauthor=D.+W.+Chanauthor=J.+Qinauthor=S.+Sarnoauthor=F.+Meggioauthor=L.+A.+Pinnaauthor=K.+W.+Caldecott&title=The+Protein+Kinase+CK2+Facilitates+Repair+of+Chromosomal+DNA+Single-Strand+Breaks&doi=10.1016%2Fs0092-8674%2804%2900206-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks</span></div><div class="casAuthors">Loizou, Joanna I.; El-Khamisy, Sherif F.; Zlatanou, Anastasia; Moore, David J.; Chan, Douglas W.; Qin, Jun; Sarno, Stefania; Meggio, Flavio; Pinna, Lorenzo A.; Caldecott, Keith W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-28</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">CK2 was the first protein kinase identified and is required for the proliferation and survival of mammalian cells.  Here, we have identified an unanticipated role for CK2.  We show that this essential protein kinase phosphorylates the scaffold protein XRCC1 and thereby enables the assembly and activity of DNA single-strand break repair protein complexes in vitro and at sites of chromosomal breakage.  Moreover, we show that inhibiting XRCC1 phosphorylation by mutation of the CK2 phosphorylation sites or preventing CK2 activity using a highly specific inhibitor ablates the rapid repair of cellular DNA single-strand breaks by XRCC1.  These data identify a direct role for CK2 in the repair of chromosomal DNA strand breaks and in maintaining genetic integrity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqiQqOcdOwurVg90H21EOLACvtfcHk0lhawbUiscOB0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFWqsbc%253D&md5=494c5eb7c11f74d080dc07ebc17eda77</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900206-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900206-5%26sid%3Dliteratum%253Aachs%26aulast%3DLoizou%26aufirst%3DJ.%2BI.%26aulast%3DEl-Khamisy%26aufirst%3DS.%2BF.%26aulast%3DZlatanou%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DD.%2BJ.%26aulast%3DChan%26aufirst%3DD.%2BW.%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DSarno%26aufirst%3DS.%26aulast%3DMeggio%26aufirst%3DF.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26aulast%3DCaldecott%26aufirst%3DK.%2BW.%26atitle%3DThe%2520Protein%2520Kinase%2520CK2%2520Facilitates%2520Repair%2520of%2520Chromosomal%2520DNA%2520Single-Strand%2520Breaks%26jtitle%3DCell%26date%3D2004%26volume%3D117%26spage%3D17%26epage%3D28%26doi%3D10.1016%2Fs0092-8674%2804%2900206-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Au, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoppler, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jablons, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of CK 2α down-regulates Notch1 signalling in lung cancer cells</span>. <i>J. Cell Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">854</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1111/jcmm.12068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1111%2Fjcmm.12068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=23651443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlCrt77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=854-862&author=S.+Zhangauthor=H.+Longauthor=Y.+L.+Yangauthor=Y.+Wangauthor=D.+Hsiehauthor=W.+Liauthor=A.+Auauthor=H.+J.+Stopplerauthor=Z.+Xuauthor=D.+M.+Jablonsauthor=L.+You&title=Inhibition+of+CK+2%CE%B1+down-regulates+Notch1+signalling+in+lung+cancer+cells&doi=10.1111%2Fjcmm.12068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells</span></div><div class="casAuthors">Zhang, Shulin; Long, Hao; Yang, Yi-Lin; Wang, Yucheng; Hsieh, David; Li, Weiming; Au, Alfred; Stoppler, Hubert J.; Xu, Zhidong; Jablons, David M.; You, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">854-862</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Protein kinase CK2 is frequently elevated in a variety of human cancers.  The Notch1 signalling pathway has been implicated in stem cell maintenance and its aberrant activation has been shown in several types of cancer including lung cancer.  Here, we show, for the first time, that CK2α is a pos. regulator of Notch1 signalling in lung cancer cell lines A549 and H1299.  We found that Notch1 protein level was reduced after CK2α silencing.  Down-regulation of Notch1 transcriptional activity was demonstrated after the silencing of CK2α in lung cancer cells.  Furthermore, small-mol. CK2α inhibitor CX-4945 led to a dose-dependent inhibition of Notch1 transcriptional activity.  Conversely, forced overexpression of CK2α resulted in an increase in Notch1 transcriptional activity.  Finally, the inhibition of CK2α led to a reduced proportion of stem-like CD44+ /CD24- cell population.  Thus, we report that the inhibition of CK2α down-regulates Notch1 signalling and subsequently reduces a cancer stem-like cell population in human lung cancer cells.  Our data suggest that CK2α inhibitors may be beneficial to the lung cancer patients with activated Notch1 signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS2z_d0QXEmrVg90H21EOLACvtfcHk0lhawbUiscOB0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlCrt77P&md5=64b28baced76a2a254fc4d99ed30bb4d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12068%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%2BL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHsieh%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DAu%26aufirst%3DA.%26aulast%3DStoppler%26aufirst%3DH.%2BJ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DJablons%26aufirst%3DD.%2BM.%26aulast%3DYou%26aufirst%3DL.%26atitle%3DInhibition%2520of%2520CK%25202%25CE%25B1%2520down-regulates%2520Notch1%2520signalling%2520in%2520lung%2520cancer%2520cells%26jtitle%3DJ.%2520Cell%2520Mol.%2520Med.%26date%3D2013%26volume%3D17%26spage%3D854%26epage%3D862%26doi%3D10.1111%2Fjcmm.12068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iegre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brear, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Fusco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sore, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyvönen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Second-generation CK2α inhibitors targeting the αD pocket</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3041</span>– <span class="NLM_lpage">3049</span>, <span class="refDoi"> DOI: 10.1039/c7sc05122k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1039%2FC7SC05122K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=29732088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFGls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3041-3049&author=J.+Iegreauthor=P.+Brearauthor=C.+De+Fuscoauthor=M.+Yoshidaauthor=S.+L.+Mitchellauthor=M.+Rossmannauthor=L.+Carroauthor=H.+F.+Soreauthor=M.+Hyv%C3%B6nenauthor=D.+R.+Spring&title=Second-generation+CK2%CE%B1+inhibitors+targeting+the+%CE%B1D+pocket&doi=10.1039%2Fc7sc05122k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation CK2α inhibitors targeting the αD pocket</span></div><div class="casAuthors">Iegre, Jessica; Brear, Paul; De Fusco, Claudia; Yoshida, Masao; Mitchell, Sophie L.; Rossmann, Maxim; Carro, Laura; Sore, Hannah F.; Hyvonen, Marko; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3041-3049</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">CK2 is a crit. cell cycle regulator that also promotes various anti-apoptotic mechanisms.  Development of ATP-non-competitive inhibitors of CK2 is a very attractive strategy considering that the ATP binding site is highly conserved among other kinases.  We have previously utilized a pocket outside the active site to develop a novel CK2 inhibitor, CAM4066.  While CAM4066 bound to this new pocket it was also interacting with the ATP site: herein, we describe an example of a CK2α inhibitor that binds completely outside the active site.  This second generation αD-site binding inhibitor, compd. CAM4712 (IC50 = 7μM, GI50 = 10.0 ± 3.6μM), has numerous advantages over the previously reported CAM4066, including a redn. in the no. of rotatable bonds, the absence of amide groups susceptible to the action of proteases and improved cellular permeability.  Unlike with CAM4066, there was no need to facilitate cellular uptake by making a prodrug.  Moreover, CAM4712 displayed no drop off between its ability to inhibit the kinase in vitro (IC50) and the ability to inhibit cell proliferation (GI50).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprPLu-nG6dLLVg90H21EOLACvtfcHk0lidZLXoZF3c6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFGls7w%253D&md5=4d57e89546e1c7bcac4868e3a02ba2f8</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1039%2FC7SC05122K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7SC05122K%26sid%3Dliteratum%253Aachs%26aulast%3DIegre%26aufirst%3DJ.%26aulast%3DBrear%26aufirst%3DP.%26aulast%3DDe%2BFusco%26aufirst%3DC.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DMitchell%26aufirst%3DS.%2BL.%26aulast%3DRossmann%26aufirst%3DM.%26aulast%3DCarro%26aufirst%3DL.%26aulast%3DSore%26aufirst%3DH.%2BF.%26aulast%3DHyv%25C3%25B6nen%26aufirst%3DM.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DSecond-generation%2520CK2%25CE%25B1%2520inhibitors%2520targeting%2520the%2520%25CE%25B1D%2520pocket%26jtitle%3DChem.%2520Sci.%26date%3D2018%26volume%3D9%26spage%3D3041%26epage%3D3049%26doi%3D10.1039%2Fc7sc05122k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S.</span></span> <span> </span><span class="NLM_article-title">Identification of a Novel Function of <b>CX-4945</b> as a Splicing Regulator</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e94978</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0094978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1371%2Fjournal.pone.0094978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=24743259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFemurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=H.+Kimauthor=K.+Choiauthor=H.+Kangauthor=S.-Y.+Leeauthor=S.-W.+Chiauthor=M.-S.+Leeauthor=J.+Songauthor=D.+Imauthor=Y.+Choiauthor=S.+Cho&title=Identification+of+a+Novel+Function+of+CX-4945+as+a+Splicing+Regulator&doi=10.1371%2Fjournal.pone.0094978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel function of CX-4945 as a splicing regulator</span></div><div class="casAuthors">Kim, Hyeongki; Choi, Kwangman; Kang, Hyunju; Lee, So-Young; Chi, Seung-wook; Lee, Min-sung; Song, Jaehyoung; Im, Donghwa; Choi, Yura; Cho, Sungchan</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e94978/1-e94978/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Alternative splicing is a nearly ubiquitous versatile process that controls gene expression and creates numerous protein isoforms with different functions from a single gene.  The significance of alternative splicing has been confirmed by the increasing no. of human diseases that are caused by misregulation of splicing events.  Very few compds., however, have been reported to act as inhibitors of alternative splicing, and their potential clin. use needs to be evaluated.  Here, we report that CX-4945, a previously well-characterized inhibitor of casein kinase 2 (CK2) and a mol. currently in clin. trials (Phase II) for cancer treatment, regulates splicing in mammalian cells in a CK2-independent manner.  Transcriptome-wide anal. using exon array also showed a widespread alteration in alternative splicing of numerous genes.  We found that CX-4945 potently inhibits the Cdc2-like kinases (Clks) in vitro and in turn, leads to suppression of the phosphorylation of serine/arginine-rich (SR) proteins in mammalian cells.  Surprisingly, the overall efficacy of CX-4945 on Clks (IC50 = 3-90 nM) was stronger than that of TG-003, the strongest inhibitor reported to date.  Of the Clks, Clk2 was most strongly inhibited by CX-4945 in an ATP-competitive manner.  Our research revealed an unexpected activity of the drug candidate CX-4945 as a potent splicing modulator and also suggested a potential application for therapy of diseases caused by abnormal splicing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEmZdGtUZUe7Vg90H21EOLACvtfcHk0lidZLXoZF3c6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFemurzL&md5=5edb2338401d950cddbcba7d35e57c04</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0094978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0094978%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%26aulast%3DChoi%26aufirst%3DK.%26aulast%3DKang%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DChi%26aufirst%3DS.-W.%26aulast%3DLee%26aufirst%3DM.-S.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DIm%26aufirst%3DD.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520a%2520Novel%2520Function%2520of%2520CX-4945%2520as%2520a%2520Splicing%2520Regulator%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0094978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazimierczuk, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzzene, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Maira, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orzeszko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meggio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, L. A.</span></span> <span> </span><span class="NLM_article-title">The Selectivity of Inhibitors of Protein Kinase CK2: an Update</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>415</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1042/bj20080309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1042%2FBJ20080309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=18588507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1CmsrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=415&publication_year=2008&pages=353-365&author=M.+A.+Paganoauthor=J.+Bainauthor=Z.+Kazimierczukauthor=S.+Sarnoauthor=M.+Ruzzeneauthor=G.+Di+Mairaauthor=M.+Elliottauthor=A.+Orzeszkoauthor=G.+Cozzaauthor=F.+Meggioauthor=L.+A.+Pinna&title=The+Selectivity+of+Inhibitors+of+Protein+Kinase+CK2%3A+an+Update&doi=10.1042%2Fbj20080309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The selectivity of inhibitors of protein kinase CK2: an update</span></div><div class="casAuthors">Pagano, Mario A.; Bain, Jenny; Kazimierczuk, Zygmunt; Sarno, Stefania; Ruzzene, Maria; Di maira, Giovanni; Elliott, Matthew; Orzeszko, Andrzej; Cozza, Giorgio; Meggio, Flavio; Pinna, Lorenzo A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">415</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">353-365</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">CK2 (casein kinase 2) is a very pleiotropic serine/threonine protein kinase whose abnormally high constitutive activity has often been correlated to pathol. conditions with special ref. to neoplasia.  The two most widely used cell permeable CK2 inhibitors, TBB (4,5,6,7-tetrabromo-1H-benzotriazole) and DMAT (2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole), are marketed as quite specific CK2 blockers.  In the present study the authors show, by using a panel of approx. 80 protein kinases, that DMAT and its parent compd. TBI (or TBBz; 4,5,6,7-tetrabromo-1H-benzimidazole) are potent inhibitors of several other kinases, with special ref. to PIM (provirus integration site for Moloney murine leukemia virus)1, PIM2, PIM3, PKD1 (protein kinase D1), HIPK2 (homeodomain-interacting protein kinase 2) and DYRK1a (dual-specificity tyrosine-phosphorylated and -regulated kinase 1a).  In contrast, TBB is significantly more selective toward CK2, although it also inhibits PIM1 and PIM3.  To improve selectivity towards CK2 a library of 68 TBB/TBI-related compds. have been tested for their ability to discriminate between CK2, PIM1, HIPK2 and DYRK1a, ending up with seven compds. whose efficacy toward CK2 is markedly higher than that toward the second most inhibited kinase.  Two of these, K64 (3,4,5,6,7-pentabromo-1H-indazole) and K66 (1-carboxymethyl-2-dimethylamino-4,5,6,7-tetrabromo-benzimidazole), display an overall selectivity much higher than TBB and DMAT when tested on a panel of 80 kinases and display similar efficacy as inducers of apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6m0pQ0Dz7b7Vg90H21EOLACvtfcHk0lidZLXoZF3c6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1CmsrnJ&md5=2a7bee7f29c2a500458240fd92fd2e3a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1042%2FBJ20080309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20080309%26sid%3Dliteratum%253Aachs%26aulast%3DPagano%26aufirst%3DM.%2BA.%26aulast%3DBain%26aufirst%3DJ.%26aulast%3DKazimierczuk%26aufirst%3DZ.%26aulast%3DSarno%26aufirst%3DS.%26aulast%3DRuzzene%26aufirst%3DM.%26aulast%3DDi%2BMaira%26aufirst%3DG.%26aulast%3DElliott%26aufirst%3DM.%26aulast%3DOrzeszko%26aufirst%3DA.%26aulast%3DCozza%26aufirst%3DG.%26aulast%3DMeggio%26aufirst%3DF.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26atitle%3DThe%2520Selectivity%2520of%2520Inhibitors%2520of%2520Protein%2520Kinase%2520CK2%253A%2520an%2520Update%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D415%26spage%3D353%26epage%3D365%26doi%3D10.1042%2Fbj20080309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span> <span> </span><span class="NLM_article-title">Potent Anticancer Activity and Possible Low Toxicity of Platinum(II) Complexes with Functionalized 1,1-Cyclobutanedicarboxylate as a Leaving Ligand</span>. <i>Chem.—Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">15216</span>– <span class="NLM_lpage">15225</span>, <span class="refDoi"> DOI: 10.1002/chem.201404090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1002%2Fchem.201404090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=25256173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVert77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=15216-15225&author=J.+Zhaoauthor=S.+Gouauthor=F.+Liu&title=Potent+Anticancer+Activity+and+Possible+Low+Toxicity+of+Platinum%28II%29+Complexes+with+Functionalized+1%2C1-Cyclobutanedicarboxylate+as+a+Leaving+Ligand&doi=10.1002%2Fchem.201404090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Anticancer Activity and Possible Low Toxicity of Platinum(II) Complexes with Functionalized 1,1-Cyclobutanedicarboxylate as a Leaving Ligand</span></div><div class="casAuthors">Zhao, Jian; Gou, Shaohua; Liu, Fengfan</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">15216-15225</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Two platinum(II) complexes, DN603 and DN604, were designed and prepd. by using 3-oxocyclobutane-1,1-dicarboxylate as a ligand.  The compds. were prepd. according to the concept that incorporation of a functionalized moiety in the leaving ligand that did not affect its coordination bonding to the metal atom would play a key role in the anticancer activity of the resulting platinum complex.  The newly prepd. compds. were found to show potent in vitro anticancer activity comparable to cisplatin and oxaliplatin; esp. DN604, which exhibited low acute toxicity similar to carboplatin, and presented acceptable soly. and stability in water.  Chem. and biol. results indicated that the functionalized moiety, uncoordinated, led to potent anticancer activity and low apparent toxicity of the platinum complexes by affecting the kinetic properties of the compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFM7XdNXKbZ7Vg90H21EOLACvtfcHk0lgsPIW2xKg8kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVert77I&md5=4d1e67325d2bbb37d7ec277ab7d8340f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fchem.201404090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201404090%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DF.%26atitle%3DPotent%2520Anticancer%2520Activity%2520and%2520Possible%2520Low%2520Toxicity%2520of%2520Platinum%2528II%2529%2520Complexes%2520with%2520Functionalized%25201%252C1-Cyclobutanedicarboxylate%2520as%2520a%2520Leaving%2520Ligand%26jtitle%3DChem.%25E2%2580%2594Eur.%2520J.%26date%3D2014%26volume%3D20%26spage%3D15216%26epage%3D15225%26doi%3D10.1002%2Fchem.201404090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khoury, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ademuyiwa, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandraseekhar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLeo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Aldehyde Dehydrogenase 1A1 Expression in Breast Cancer is Associated with Stage, Triple Negativity, and Outcome to Neoadjuvant Chemotherapy</span>. <i>Mod. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1038/modpathol.2011.172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fmodpathol.2011.172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=22080062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=388-397&author=T.+Khouryauthor=F.+O.+Ademuyiwaauthor=R.+Chandraseekharauthor=M.+Jabbourauthor=A.+DeLeoauthor=S.+Ferroneauthor=Y.+Wangauthor=X.+Wang&title=Aldehyde+Dehydrogenase+1A1+Expression+in+Breast+Cancer+is+Associated+with+Stage%2C+Triple+Negativity%2C+and+Outcome+to+Neoadjuvant+Chemotherapy&doi=10.1038%2Fmodpathol.2011.172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy</span></div><div class="casAuthors">Khoury, Thaer; Ademuyiwa, Foluso O.; Chandraseekhar, Rameela; Jabbour, Marah; DeLeo, Albert; Ferrone, Soldano; Wang, Yangyang; Wang, Xinhui</div><div class="citationInfo"><span class="NLM_cas:title">Modern Pathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">388-397</span>CODEN:
                <span class="NLM_cas:coden">MODPEO</span>;
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Studies have shown that ALDH1A1 expression in the breast is assocd. with worse clin. outcome.  ALDH1A1 inactivates cyclophosphamide, which is an integral agent in breast cancer chemotherapy regimens.  The purposes of this study were to verify these results, to correlate ALDH1A1 expression with clin. outcome in patients treated with cyclophosphamide as part of the chemotherapy (adjuvant or neoadjuvant), and to evaluate ALDH1A1 as a useful marker to predict the clin. outcome of breast cancer subsets.  A total of 513 primary breast cancers were studied.  Tissue microarrays of the studied cases were stained with ALDH1A1.  Key clinicopathol. information was obtained.  Disease-free survival and overall survival were calcd.  Patients with neoadjuvant therapy who had substantial residual cancer burden (RCB) were included in the study.  Fisher's exact test and Kaplan-Meier methods were used for statistical anal.  ALDH1A1 was expressed in 53 (10%) patients, with a higher frequency in triple neg., followed by HER2+, and finally hormonal receptor+/HER2- (P<0.0001).  Tumors with advanced stage, node-pos., or larger tumor size were correlated with ALDH1A1 expression (P=0.006, P<0.0001, and P=0.05, resp.).  ALDH1A1 expression was also correlated with worse disease-free survival (P<0.006) and overall survival (P<0.01) in patients who were treated with neoadjuvant chemotherapy.  In all, 8 of 22 (36%) received neoadjuvant chemotherapy and died of disease-expressed ALDH1A1 (P=0.008).  Similarly, 8 of 23 (35%) who received neoadjuvant chemotherapy and had tumor recurrence expressed this marker (P=0.002).  The risk of recurrence was fivefold greater than neg. ALDH1A1 tumors.  The risk of recurrence became 11-fold greater when cyclophosphamide but not trastuzumab was part of the regimen.  Our results are consistent with previous studies.  Moreover, we found that ALDH1A1 could be a useful marker to predict worse clin. outcome after chemotherapy in the neoadjuvant setting with substantial RCB.  However, a larger cohort is required to verify our results.  Modern Pathol. (2012) 25, 388-397; doi:10.1038/modpathol.2011.172; published online 11 Nov. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHXWjqIR_zu7Vg90H21EOLACvtfcHk0lgsPIW2xKg8kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wqtb0%253D&md5=369209539865a6da59c38be8c54beeb5</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fmodpathol.2011.172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmodpathol.2011.172%26sid%3Dliteratum%253Aachs%26aulast%3DKhoury%26aufirst%3DT.%26aulast%3DAdemuyiwa%26aufirst%3DF.%2BO.%26aulast%3DChandraseekhar%26aufirst%3DR.%26aulast%3DJabbour%26aufirst%3DM.%26aulast%3DDeLeo%26aufirst%3DA.%26aulast%3DFerrone%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DAldehyde%2520Dehydrogenase%25201A1%2520Expression%2520in%2520Breast%2520Cancer%2520is%2520Associated%2520with%2520Stage%252C%2520Triple%2520Negativity%252C%2520and%2520Outcome%2520to%2520Neoadjuvant%2520Chemotherapy%26jtitle%3DMod.%2520Pathol.%26date%3D2012%26volume%3D25%26spage%3D388%26epage%3D397%26doi%3D10.1038%2Fmodpathol.2011.172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaipio, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roering, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huhtinen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkonen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Östling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehtinen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansuri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korpela, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potdar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynninen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auranen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grénman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hautaniemi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpén, O.</span></span> <span> </span><span class="NLM_article-title">ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>250</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1002/path.5356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1002%2Fpath.5356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=31595974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsF2lsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=250&publication_year=2020&pages=159-169&author=K.+Kaipioauthor=P.+Chenauthor=P.+Roeringauthor=K.+Huhtinenauthor=P.+Mikkonenauthor=P.+%C3%96stlingauthor=L.+Lehtinenauthor=N.+Mansuriauthor=T.+Korpelaauthor=S.+Potdarauthor=J.+Hynninenauthor=A.+Auranenauthor=S.+Gr%C3%A9nmanauthor=K.+Wennerbergauthor=S.+Hautaniemiauthor=O.+Carp%C3%A9n&title=ALDH1A1-related+stemness+in+high-grade+serous+ovarian+cancer+is+a+negative+prognostic+indicator+but+potentially+targetable+by+EGFR%2FmTOR-PI3K%2Faurora+kinase+inhibitors&doi=10.1002%2Fpath.5356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors</span></div><div class="casAuthors">Kaipio, Katja; Chen, Ping; Roering, Pia; Huhtinen, Kaisa; Mikkonen, Piia; Oestling, Paeivi; Lehtinen, Laura; Mansuri, Naziha; Korpela, Taina; Potdar, Swapnil; Hynninen, Johanna; Auranen, Annika; Grenman, Seija; Wennerberg, Krister; Hautaniemi, Sampsa; Carpen, Olli</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">250</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-169</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Poor chemotherapy response remains a major treatment challenge for high-grade serous ovarian cancer (HGSC).  Cancer stem cells are the major contributors to relapse and treatment failure as they can survive conventional therapy.  Our objectives were to characterize stemness features in primary patient-derived cell lines, correlate stemness markers with clin. outcome and test the response of our cells to both conventional and exploratory drugs.  Tissue and ascites samples, treatment-naive and/or after neoadjuvant chemotherapy, were prospectively collected.  Primary cancer cells, cultured under conditions favoring either adherent or spheroid growth, were tested for stemness markers; the same markers were analyzed in tissue and correlated with chemotherapy response and survival.  Drug sensitivity and resistance testing was performed with 306 oncol. compds.  Spheroid growth condition HGSC cells showed increased stemness marker expression (including aldehyde dehydrogenase isoform I; ALDH1A1) as compared with adherent growth condition cells, and increased resistance to platinum and taxane.  A set of eight stemness markers sepd. treatment-naive tumors into two clusters and identified a distinct subgroup of HGSC with enriched stemness features.  Expression of ALDH1A1, but not most other stemness markers, was increased after neoadjuvant chemotherapy and its expression in treatment-naive tumors correlated with chemoresistance and reduced survival.  In drug sensitivity and resistance testing, five compds., including two PI3K-mTOR inhibitors, demonstrated significant activity in both cell culture conditions.  Thirteen compds., including EGFR, PI3K-mTOR and aurora kinase inhibitors, were more toxic to spheroid cells than adherent cells.  Our results identify stemness markers in HGSC that are assocd. with a decreased response to conventional chemotherapy and reduced survival if expressed by treatment-naive tumors.  EGFR, mTOR-PI3K and aurora kinase inhibitors are candidates for targeting this cell population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpyFDLnreWCbVg90H21EOLACvtfcHk0lgsPIW2xKg8kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsF2lsbk%253D&md5=df803ac48a19ddb99a7bbdab45c15c19</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fpath.5356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.5356%26sid%3Dliteratum%253Aachs%26aulast%3DKaipio%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DRoering%26aufirst%3DP.%26aulast%3DHuhtinen%26aufirst%3DK.%26aulast%3DMikkonen%26aufirst%3DP.%26aulast%3D%25C3%2596stling%26aufirst%3DP.%26aulast%3DLehtinen%26aufirst%3DL.%26aulast%3DMansuri%26aufirst%3DN.%26aulast%3DKorpela%26aufirst%3DT.%26aulast%3DPotdar%26aufirst%3DS.%26aulast%3DHynninen%26aufirst%3DJ.%26aulast%3DAuranen%26aufirst%3DA.%26aulast%3DGr%25C3%25A9nman%26aufirst%3DS.%26aulast%3DWennerberg%26aufirst%3DK.%26aulast%3DHautaniemi%26aufirst%3DS.%26aulast%3DCarp%25C3%25A9n%26aufirst%3DO.%26atitle%3DALDH1A1-related%2520stemness%2520in%2520high-grade%2520serous%2520ovarian%2520cancer%2520is%2520a%2520negative%2520prognostic%2520indicator%2520but%2520potentially%2520targetable%2520by%2520EGFR%252FmTOR-PI3K%252Faurora%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Pathol.%26date%3D2020%26volume%3D250%26spage%3D159%26epage%3D169%26doi%3D10.1002%2Fpath.5356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span> <span> </span><span class="NLM_article-title">Garcinol From Garcinia Indica Downregulates Cancer Stem-Like Cell Biomarker ALDH1A1 in Nonsmall Cell Lung Cancer A549 Cells through DDIT3 Activation</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">3675</span>– <span class="NLM_lpage">3683</span>, <span class="refDoi"> DOI: 10.1021/acs.jafc.7b00346</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jafc.7b00346" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFCnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2017&pages=3675-3683&author=J.+Wangauthor=L.+Wangauthor=C.-T.+Hoauthor=K.+Zhangauthor=Q.+Liuauthor=H.+Zhao&title=Garcinol+From+Garcinia+Indica+Downregulates+Cancer+Stem-Like+Cell+Biomarker+ALDH1A1+in+Nonsmall+Cell+Lung+Cancer+A549+Cells+through+DDIT3+Activation&doi=10.1021%2Facs.jafc.7b00346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinol from Garcinia indica Downregulates Cancer Stem-like Cell Biomarker ALDH1A1 in Nonsmall Cell Lung Cancer A549 Cells through DDIT3 Activation</span></div><div class="casAuthors">Wang, Jinhan; Wang, Liwen; Ho, Chi-Tang; Zhang, Kunsheng; Liu, Qiang; Zhao, Hui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3675-3683</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonsmall cell lung cancer (NSCLC) is the predominant type of lung cancer.  Patients with NSCLC show high mortality rates because of failure to clean up cancer stem cells (CSCs).  The anticancer activity of phytochem. garcinol has been identified in various cancer cell models.  However, the effect of garcinol on NSCLC cell lines is still lacking.  Of the NSCLC cell lines we tested, A549 cells were the most sensitive to garcinol.  Interestingly, Aldehyde Dehydrogenase 1 Family Member A1 (ALDH1A1) was preferentially expressed in A549 cells and downregulated by the addn. of garcinol.  We also found that garcinol enriched DNA damage-inducible transcript 3 (DDIT3) and then altered DDIT3-CCAAT-enhancer-binding proteins beta (C/EBPβ) interaction resulting in a decreased binding of C/EBPβ to the endogenous ALDH1A1 promoter.  Furthermore, garcinol's inhibition of ALDH1A1 was identified in a xenograft mice model.  Garcinol repressed ALDH1A1 transcription in A549 cells through alterations in the interaction between DDIT3 and C/EBPβ.  Garcinol could be a potential dietary phytochem. candidate for NSCLCs patients whose tumors harbored high ALDH1A1 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEfTvmCNrY67Vg90H21EOLACvtfcHk0lgdtjUuIdRvaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFCnsbs%253D&md5=d38e7b2919e0bd0c4327af678c6e1b86</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jafc.7b00346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jafc.7b00346%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHo%26aufirst%3DC.-T.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DH.%26atitle%3DGarcinol%2520From%2520Garcinia%2520Indica%2520Downregulates%2520Cancer%2520Stem-Like%2520Cell%2520Biomarker%2520ALDH1A1%2520in%2520Nonsmall%2520Cell%2520Lung%2520Cancer%2520A549%2520Cells%2520through%2520DDIT3%2520Activation%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2017%26volume%3D65%26spage%3D3675%26epage%3D3683%26doi%3D10.1021%2Facs.jafc.7b00346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morath, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmannb, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orian-Rousseau, V.</span></span> <span> </span><span class="NLM_article-title">CD44: More than a Mere Stem Cell Marker</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">166</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2016.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2Fj.biocel.2016.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=27640754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFeqsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2016&pages=166-173&author=I.+Morathauthor=T.+N.+Hartmannbauthor=V.+Orian-Rousseau&title=CD44%3A+More+than+a+Mere+Stem+Cell+Marker&doi=10.1016%2Fj.biocel.2016.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">CD44: More than a mere stem cell marker</span></div><div class="casAuthors">Morath, I.; Hartmann, T. N.; Orian-Rousseau, V.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">Part_A</span>),
    <span class="NLM_cas:pages">166-173</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">CD44 is a cell adhesion mol. that plays an important role in tumor progression and metastasis.  The role of CD44 in tumorigenesis is due to its binding to extracellular matrix components, including hyaluronan (HA) and osteopontin (OPN), and to messenger mols., such as growth factors present in the tumor microenvironment.  HA and OPN are highly abundant in the leukemic stem cell niche and in solid tumors of various cancer types, where they contribute to the maintenance of the stemness of malignant cells.  CD44 has consequently been recognized as a cancer stem cell marker in several types of cancers, which has been a topic of much recent research.  In this review we have addressed the question of how CD44 might promote cancer cell stemness by interacting with extracellular matrix components, growth factors and cytokines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruQQatjbujhrVg90H21EOLACvtfcHk0lgdtjUuIdRvaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFeqsrzJ&md5=bf58758d3734700d35bbd6c5550bb82b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2016.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2016.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DMorath%26aufirst%3DI.%26aulast%3DHartmannb%26aufirst%3DT.%2BN.%26aulast%3DOrian-Rousseau%26aufirst%3DV.%26atitle%3DCD44%253A%2520More%2520than%2520a%2520Mere%2520Stem%2520Cell%2520Marker%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2016%26volume%3D81%26spage%3D166%26epage%3D173%26doi%3D10.1016%2Fj.biocel.2016.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogoff, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keates, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murikipudi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikule, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggett, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardee, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. J.</span></span> <span> </span><span class="NLM_article-title">Suppression of Cancer Relapse and Metastasis by Inhibiting Cancer Stemness</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">1839</span>– <span class="NLM_lpage">1844</span>, <span class="refDoi"> DOI: 10.1073/pnas.1424171112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1073%2Fpnas.1424171112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=25605917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=1839-1844&author=Y.+Liauthor=H.+A.+Rogoffauthor=S.+Keatesauthor=Y.+Gaoauthor=S.+Murikipudiauthor=K.+Mikuleauthor=D.+Leggettauthor=W.+Liauthor=A.+B.+Pardeeauthor=C.+J.+Li&title=Suppression+of+Cancer+Relapse+and+Metastasis+by+Inhibiting+Cancer+Stemness&doi=10.1073%2Fpnas.1424171112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of cancer relapse and metastasis by inhibiting cancer stemness</span></div><div class="casAuthors">Li, Youzhi; Rogoff, Harry A.; Keates, Sarah; Gao, Yuan; Murikipudi, Sylaja; Mikule, Keith; Leggett, David; Li, Wei; Pardee, Arthur B.; Li, Chiang J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1839-1844</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Partial or even complete cancer regression can be achieved in some patients with current cancer treatments.  However, such initial responses are almost always followed by relapse, with the recurrent cancer being resistant to further treatments.  The discovery of therapeutic approaches that counteract relapse is, therefore, essential for advancing cancer medicine.  Cancer cells are extremely heterogeneous, even in each individual patient, in terms of their malignant potential, drug sensitivity, and their potential to metastasize and cause relapse.  Indeed, hypermalignant cancer cells, termed cancer stem cells or stemness-high cancer cells, that are highly tumorigenic and metastatic have been isolated from cancer patients with a variety of tumor types.  Moreover, such stemness-high cancer cells are resistant to conventional chemotherapy and radiation.  Here we show that BBI608, a small mol. identified by its ability to inhibit gene transcription driven by Stat3 and cancer stemness properties, can inhibit stemness gene expression and block spherogenesis of or kill stemness-high cancer cells isolated from a variety of cancer types.  Moreover, cancer relapse and metastasis were effectively blocked by BBI608 in mice.  These data demonstrate targeting cancer stemness as a novel approach to develop the next generation of cancer therapeutics to suppress cancer relapse and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBRIs4CUCKMrVg90H21EOLACvtfcHk0lgdtjUuIdRvaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKht7k%253D&md5=7f77ee7a484e6f161a0d958743a5fa12</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1424171112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1424171112%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DRogoff%26aufirst%3DH.%2BA.%26aulast%3DKeates%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DMurikipudi%26aufirst%3DS.%26aulast%3DMikule%26aufirst%3DK.%26aulast%3DLeggett%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DPardee%26aufirst%3DA.%2BB.%26aulast%3DLi%26aufirst%3DC.%2BJ.%26atitle%3DSuppression%2520of%2520Cancer%2520Relapse%2520and%2520Metastasis%2520by%2520Inhibiting%2520Cancer%2520Stemness%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2015%26volume%3D112%26spage%3D1839%26epage%3D1844%26doi%3D10.1073%2Fpnas.1424171112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, D.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span> <span> </span><span class="NLM_article-title">The Neuroleptic Drug Pimozide Inhibits Stem-Like Cell Maintenance and Tumorigenicity in Hepatocellular Carcinoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">17593</span>– <span class="NLM_lpage">17609</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.4307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.18632%2Foncotarget.4307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=26061710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A280%3ADC%252BC2MbitVyrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=17593-17609&author=J.-J.+Chenauthor=N.+Caiauthor=G.-Z.+Chenauthor=C.-C.+Jiaauthor=D.-B.+Qiuauthor=C.+Duauthor=W.+Liuauthor=Y.+Yangauthor=Z.-J.+Longauthor=Q.+Zhang&title=The+Neuroleptic+Drug+Pimozide+Inhibits+Stem-Like+Cell+Maintenance+and+Tumorigenicity+in+Hepatocellular+Carcinoma&doi=10.18632%2Foncotarget.4307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma</span></div><div class="casAuthors">Chen Jia-Jie; Cai Nan; Chen Guan-Zhong; Jia Chang-Chang; Liu Wei; Yang Yang; Zhang Qi; Chen Jia-Jie; Cai Nan; Jia Chang-Chang; Qiu Dong-Bo; Du Cong; Zhang Qi; Chen Jia-Jie; Long Zi-Jie; Chen Guan-Zhong; Qiu Dong-Bo; Du Cong; Liu Wei; Zhang Qi</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">17593-17609</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug repurposing is currently an important approach for accelerating drug discovery and development for clinical use.  Hepatocellular carcinoma (HCC) presents drug resistance to chemotherapy, and the prognosis is poor due to the existence of liver cancer stem-like cells.  In this study, we investigated the effect of the neuroleptic agent pimozide to inhibit stem-like cell maintenance and tumorigenicity in HCC.  Our results showed that pimozide functioned as an anti-cancer drug in HCC cells or stem-like cells.  Pimozide inhibited cell proliferation and sphere formation capacities in HCC cells by inducing G0/G1 phase cell cycle arrest, as well as inhibited HCC cell migration.  Surprisingly, pimozide inhibited the maintenance and tumorigenicity of HCC stem-like cells, particularly the side population (SP) or CD133-positive cells, as evaluated by colony formation, sphere formation and transwell migration assays.  Furthermore, pimozide was found to suppress STAT3 activity in HCC cells by attenuating STAT3-dependent luciferase activity and down-regulating the transcription levels of downstream genes of STAT3 signaling.  Moreover, pimozide reversed the stem-like cell tumorigenic phenotypes induced by IL-6 treatment in HCC cells.  Further, the antitumor effect of pimozide was also proved in the nude mice HCC xenograft model.  In short, the anti-psychotic agent pimozide may act as a novel potential anti-tumor agent in treating advanced HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJREZ8s_IGh7HHuJhbyicZfW6udTcc2eaoh0Wie2h5jLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbitVyrtg%253D%253D&md5=bea228d4f6fd873b07b1a1fd6b44bd39</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4307%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.-J.%26aulast%3DCai%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DG.-Z.%26aulast%3DJia%26aufirst%3DC.-C.%26aulast%3DQiu%26aufirst%3DD.-B.%26aulast%3DDu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DZ.-J.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DThe%2520Neuroleptic%2520Drug%2520Pimozide%2520Inhibits%2520Stem-Like%2520Cell%2520Maintenance%2520and%2520Tumorigenicity%2520in%2520Hepatocellular%2520Carcinoma%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D17593%26epage%3D17609%26doi%3D10.18632%2Foncotarget.4307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hooshmand, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asoodeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behnam-Rassouli, F.</span></span> <span> </span><span class="NLM_article-title">GL-9 peptide regulates gene expression of CD44 cancer marker and pro-inflammatory cytokine TNF-α in human lung epithelial adenocarcinoma cell line (A549)</span>. <i>Mol. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1007/s11010-016-2832-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1007%2Fs11010-016-2832-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=27704464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Wnur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2016&pages=141-149&author=K.+Hooshmandauthor=A.+Asoodehauthor=F.+Behnam-Rassouli&title=GL-9+peptide+regulates+gene+expression+of+CD44+cancer+marker+and+pro-inflammatory+cytokine+TNF-%CE%B1+in+human+lung+epithelial+adenocarcinoma+cell+line+%28A549%29&doi=10.1007%2Fs11010-016-2832-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">GL-9 peptide regulates gene expression of CD44 cancer marker and pro-inflammatory cytokine TNF-α in human lung epithelial adenocarcinoma cell line (A549)</span></div><div class="casAuthors">Hooshmand, Kosar; Asoodeh, Ahmad; Behnam-Rassouli, Fatemeh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">141-149</span>CODEN:
                <span class="NLM_cas:coden">MCBIB8</span>;
        ISSN:<span class="NLM_cas:issn">0300-8177</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In this study, we examd. cytotoxic effect of GL-9 peptide on A459 cell line through studying the changes in TNF-α and CD44 gene expression and ROS prodn.  Real-time PCR anal. showed that the treated A549 cells highly over expressed TNF-α, which was assocd. with a significant redn. of CD44 gene expression levels (p < 0.05).  ROS prodn. rate was measured through the usage of DCFH-DA primer.  Results demonstrated that GL-9 peptide could also induce cell death via ROS prodn.  The effect of GL-9 peptide on human erythrocytes and leukocytes was analyzed.  GL-9 peptide showed no significant toxic effect on human blood cells.  Our results suggested that the GL-9 peptide as a potent natural agent could modulate gene expression of cancer cell markers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEkCqbhy4T9rVg90H21EOLACvtfcHk0lh51m0EuoDbGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Wnur%252FJ&md5=386a059268e600bef455524dc860c308</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs11010-016-2832-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11010-016-2832-9%26sid%3Dliteratum%253Aachs%26aulast%3DHooshmand%26aufirst%3DK.%26aulast%3DAsoodeh%26aufirst%3DA.%26aulast%3DBehnam-Rassouli%26aufirst%3DF.%26atitle%3DGL-9%2520peptide%2520regulates%2520gene%2520expression%2520of%2520CD44%2520cancer%2520marker%2520and%2520pro-inflammatory%2520cytokine%2520TNF-%25CE%25B1%2520in%2520human%2520lung%2520epithelial%2520adenocarcinoma%2520cell%2520line%2520%2528A549%2529%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D2016%26volume%3D423%26spage%3D141%26epage%3D149%26doi%3D10.1007%2Fs11010-016-2832-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span> <span> </span><span class="NLM_article-title">Lead- and Drug-Like Compounds: the Rule-of-Five Revolution</span>. <i>Drug Discov. Today Technol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2004.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2Fj.ddtec.2004.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=24981612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=337-341&author=C.+A.+Lipinski&title=Lead-+and+Drug-Like+Compounds%3A+the+Rule-of-Five+Revolution&doi=10.1016%2Fj.ddtec.2004.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Lead- and drug-like compounds: the rule-of-five revolution</span></div><div class="casAuthors">Lipinski, Christopher A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today: Technologies</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-341</span>CODEN:
                <span class="NLM_cas:coden">DDTTB5</span>;
        ISSN:<span class="NLM_cas:issn">1740-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Citations in CAS SciFinder to the rule-of-five (RO5) publication will exceed 1000 by year-end 2004.  Trends in the RO5 literature explosion that can be discerned are the further definitions of drug-like.  This topic is explored in terms of drug-like physicochem. features, drug-like structural features, a comparison of drug-like and non-drug-like in drug discovery and a discussion of how drug-like features relate to clin. success.  Physicochem. features of CNS drugs and features related to CNS blood-brain transporter affinity are briefly reviewed.  Recent literature on features of non-oral drugs is reviewed and how features of lead-like compds. differ from those of drug-like compds. is discussed.  Most recently, partly driven by NIH roadmap initiatives, considerations have arisen as to what tool-like means in the search for chem. tools to probe biol. space.  All these topics frame the scope of this short review/perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnjiyP3CY7lLVg90H21EOLACvtfcHk0lh51m0EuoDbGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSqsrg%253D&md5=952c29b47003b884116d790ae9e4721f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2004.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2004.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26atitle%3DLead-%2520and%2520Drug-Like%2520Compounds%253A%2520the%2520Rule-of-Five%2520Revolution%26jtitle%3DDrug%2520Discov.%2520Today%2520Technol.%26date%3D2004%26volume%3D1%26spage%3D337%26epage%3D341%26doi%3D10.1016%2Fj.ddtec.2004.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair to Overcome Cisplatin Resistance</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">15564</span>– <span class="NLM_lpage">15568</span>, <span class="refDoi"> DOI: 10.1002/anie.201608936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1002%2Fanie.201608936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yju7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=15564-15568&author=Z.+Wangauthor=Z.+Xuauthor=G.+Zhu&title=A+Platinum%28IV%29+Anticancer+Prodrug+Targeting+Nucleotide+Excision+Repair+to+Overcome+Cisplatin+Resistance&doi=10.1002%2Fanie.201608936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance</span></div><div class="casAuthors">Wang, Zhigang; Xu, Zoufeng; Zhu, Guangyu</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">15564-15568</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">DNA damage response plays a key role not only in maintaining genome integrity but also in mediating the antitumor efficacy of DNA-damaging antineoplastic drugs.  Herein, we report the rational design and evaluation of a PtIV anticancer prodrug inhibiting nucleotide excision repair (NER), one of the most pivotal processes after the formation of cisplatin-induced DNA damage that deactivates the drug and leads to drug resistance in the clinic.  This dual-action prodrug enters cells efficiently and causes DNA damage while simultaneously inhibiting NER to promote apoptotic response.  The prodrug is strongly active against the proliferation of cisplatin-resistant human cancer cells with an up to 88-fold increase in growth inhibition compared with cisplatin, and the prodrug is much more active than a mixt. of cisplatin and an NER inhibitor.  Our study highlights the importance of targeting downstream pathways after the formation of Pt-induced DNA damage as a novel strategy to conquer cisplatin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5lc5oE4qMXrVg90H21EOLACvtfcHk0lh51m0EuoDbGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yju7fK&md5=551b6004833ce071b79c923cdf9483ca</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fanie.201608936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201608936%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DA%2520Platinum%2528IV%2529%2520Anticancer%2520Prodrug%2520Targeting%2520Nucleotide%2520Excision%2520Repair%2520to%2520Overcome%2520Cisplatin%2520Resistance%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D15564%26epage%3D15568%26doi%3D10.1002%2Fanie.201608936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luczak, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhitkovich, A.</span></span> <span> </span><span class="NLM_article-title">Monoubiquitinated γ-H2AX: Abundant product and specific biomarker for non-apoptotic DNA double-strand breaks</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2018.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2Fj.taap.2018.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=30006243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlentLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2018&pages=238-246&author=M.+W.+Luczakauthor=A.+Zhitkovich&title=Monoubiquitinated+%CE%B3-H2AX%3A+Abundant+product+and+specific+biomarker+for+non-apoptotic+DNA+double-strand+breaks&doi=10.1016%2Fj.taap.2018.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Monoubiquitinated γ-H2AX: Abundant product and specific biomarker for non-apoptotic DNA double-strand breaks</span></div><div class="casAuthors">Luczak, Michal W.; Zhitkovich, Anatoly</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">238-246</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">DNA double-strand breaks (DSBs) are a highly toxic form of DNA damage produced by a no. of carcinogens, drugs, and metabolic abnormalities.  Involvement of DSBs in many pathologies has led to frequent measurements of these lesions, primarily via biodosimetry of S139-phosphorylated histone H2AX (γ-H2AX).  However, γ-H2AX is also induced by some non-DSB conditions and abundantly formed in apoptosis, raising concerns about the overestimation of potential genotoxic agents and accuracy of DSB assessments.  DSB-triggered γ-H2AX undergoes RNF168-mediated K13/K15 monoubiquitination, which is rarely analyzed in DSB/genotoxicity studies.  Here we identified crit. methodol. factors that are necessary for the efficient detection of mono- (ub1) and diubiquitinated (ub2) γ-H2AX.  Using optimized tech. conditions, we found that γ-H2AX-ub1 was a predominant form of γ-H2AX in three primary human cell lines contg. mechanistically distinct types of DSBs.  Replication stress-assocd. DSBs also triggered extensive formation of γ-H2AX-ub1.  For DSBs induced by oxidative damage or topoisomerase II, both γ-H2AX and γ-H2AX-ub1 showed dose-dependent increases whereas γ-H2AX-ub2 plateaued at low levels of breaks.  Despite abundance of γ-H2AX, γ-H2AX-ub1,2 formation was blocked in apoptosis, which was assocd. with proteolytic cleavage of RNF168.  Chromatin damage also caused only the prodn. of γ-H2AX but not its ub1,2 forms.  Our results revealed a major contribution of ubiquitinated forms to the overall γ-H2AX response and demonstrated the specificity of monoubiquitinated γ-H2AX as a biodosimeter of non-apoptotic DSBs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolMYVFTOBCn7Vg90H21EOLACvtfcHk0lgYenbsL2GlKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlentLvM&md5=f608cd88906e963551c3952acdb7f64f</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2018.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2018.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DLuczak%26aufirst%3DM.%2BW.%26aulast%3DZhitkovich%26aufirst%3DA.%26atitle%3DMonoubiquitinated%2520%25CE%25B3-H2AX%253A%2520Abundant%2520product%2520and%2520specific%2520biomarker%2520for%2520non-apoptotic%2520DNA%2520double-strand%2520breaks%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2018%26volume%3D355%26spage%3D238%26epage%3D246%26doi%3D10.1016%2Fj.taap.2018.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedelnikova, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">γH2AX and cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">957</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.1038/nrc2523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fnrc2523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=19005492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=957-967&author=W.+M.+Bonnerauthor=C.+E.+Redonauthor=J.+S.+Dickeyauthor=A.+J.+Nakamuraauthor=O.+A.+Sedelnikovaauthor=S.+Solierauthor=Y.+Pommier&title=%CE%B3H2AX+and+cancer&doi=10.1038%2Fnrc2523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">γH2AX and cancer</span></div><div class="casAuthors">Bonner, William M.; Redon, Christophe E.; Dickey, Jennifer S.; Nakamura, Asako J.; Sedelnikova, Olga A.; Solier, Stephanie; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">957-967</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone H2AX phosphorylation on a serine four residues from the carboxyl terminus (producing γH2AX) is a sensitive marker for DNA double-strand breaks (DSBs).  DSBs may lead to cancer but, paradoxically, are also used to kill cancer cells.  Using γH2AX detection to det. the extent of DSB induction may help to detect precancerous cells, to stage cancers, to monitor the effectiveness of cancer therapies and to develop novel anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDvJ8vnkfC0bVg90H21EOLACvtfcHk0lgYenbsL2GlKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rK&md5=b0a83efe87f2823e79146ba8a2edf808</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnrc2523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2523%26sid%3Dliteratum%253Aachs%26aulast%3DBonner%26aufirst%3DW.%2BM.%26aulast%3DRedon%26aufirst%3DC.%2BE.%26aulast%3DDickey%26aufirst%3DJ.%2BS.%26aulast%3DNakamura%26aufirst%3DA.%2BJ.%26aulast%3DSedelnikova%26aufirst%3DO.%2BA.%26aulast%3DSolier%26aufirst%3DS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3D%25CE%25B3H2AX%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D957%26epage%3D967%26doi%3D10.1038%2Fnrc2523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. P.</span></span> <span> </span><span class="NLM_article-title">Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at sites of DNA damage</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">795</span>– <span class="NLM_lpage">801</span>, <span class="refDoi"> DOI: 10.1038/embor.2008.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fembor.2008.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=18583988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1Snt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=795-801&author=J.+R.+Chapmanauthor=S.+P.+Jackson&title=Phospho-dependent+interactions+between+NBS1+and+MDC1+mediate+chromatin+retention+of+the+MRN+complex+at+sites+of+DNA+damage&doi=10.1038%2Fembor.2008.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at sites of DNA damage</span></div><div class="casAuthors">Chapman, J. Ross; Jackson, Stephen P.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">795-801</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mammalian cells respond to DNA double-strand breaks (DSBs) by recruiting DNA repair and cell-cycle checkpoint proteins to such sites.  Central to these DNA damage response (DDR) events is the DNA damage mediator protein MDC1.  MDC1 interacts with several DDR proteins, including the MRE11-RAD50-NBS1 (MRN) complex.  Here, we show that MDC1 is phosphorylated on a cluster of conserved repeat motifs by casein kinase 2 (CK2).  Moreover, we establish that this phosphorylation of MDC1 promotes direct, phosphorylation-dependent interactions with NBS1 in a manner that requires the closely apposed FHA and twin BRCT domains in the amino terminus of NBS1.  Finally, we show that these CK2-targeted motifs in MDC1 are required to mediate NBS1 assocn. with chromatin-flanking sites of unrepaired DSBs.  These findings provide a mol. explanation for the MDC1-MRN interaction and yield insights into how MDC1 coordinates the focal assembly and activation of several DDR factors in response to DNA damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfw8E0hJOLwrVg90H21EOLACvtfcHk0lgYenbsL2GlKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1Snt7s%253D&md5=a6571abbd0da104e0b88c531d2804e96</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fembor.2008.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fembor.2008.103%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DJ.%2BR.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26atitle%3DPhospho-dependent%2520interactions%2520between%2520NBS1%2520and%2520MDC1%2520mediate%2520chromatin%2520retention%2520of%2520the%2520MRN%2520complex%2520at%2520sites%2520of%2520DNA%2520damage%26jtitle%3DEMBO%2520Rep.%26date%3D2008%26volume%3D9%26spage%3D795%26epage%3D801%26doi%3D10.1038%2Fembor.2008.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tirino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desiderio, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rosa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaccio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Noce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaccio, G.</span></span> <span> </span><span class="NLM_article-title">Cancer Stem Cells in Solid Tumors: an Overview and New Approaches for Their Isolation and Characterization</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1096/fj.12-218222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1096%2Ffj.12-218222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=23024375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Gqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=13-24&author=V.+Tirinoauthor=V.+Desiderioauthor=F.+Painoauthor=A.+De+Rosaauthor=F.+Papaccioauthor=M.+La+Noceauthor=L.+Lainoauthor=F.+De+Francescoauthor=G.+Papaccio&title=Cancer+Stem+Cells+in+Solid+Tumors%3A+an+Overview+and+New+Approaches+for+Their+Isolation+and+Characterization&doi=10.1096%2Ffj.12-218222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization</span></div><div class="casAuthors">Tirino, Virginia; Desiderio, Vincenzo; Paino, Francesca; De Rosa, Alfredo; Papaccio, Federica; La Noce, Marcella; Laino, Luigi; De Francesco, Francesco; Papaccio, Gianpaolo</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-24, 10.1096/fj.12-218222</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review.  Primary tumors are responsible for 10% of cancer deaths.  In most cases, the main cause of mortality is the formation of metastases.  Accumulating evidence suggests that a subpopulation of tumor cells with distinct stem-like properties is responsible for tumor initiation, invasive growth, and metastasis formation.  This population is defined as cancer stem cells (CSCs).  Existing therapies have enhanced the length of survival after diagnosis of cancer but have completely failed in terms of recovery.  CSCs appear to be resistant to chemotherapy, may remain quiescent for extended periods, and have affinity for hypoxic environments.  The CSCs can be identified and isolated by different methodologies, including isolation by CSC-specific cell surface marker expression, detection of side population phenotype by Hoechst 33342 exclusion, assessment of their ability to grow as floating spheres, and aldehyde dehydrogenase (ALDH) activity assay.  None of the methods mentioned are exclusively used to isolate the solid tumor CSCs, highlighting the imperative to delineate more specific markers or to use combinatorial markers and methodologies.  This review provides an overview of the main characteristics and approaches used to identify, isolate, and characterize CSCs from solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKHEZT73U6-bVg90H21EOLACvtfcHk0lgYenbsL2GlKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Gqtw%253D%253D&md5=de33a9ff83242808595b3772fac12f5d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1096%2Ffj.12-218222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.12-218222%26sid%3Dliteratum%253Aachs%26aulast%3DTirino%26aufirst%3DV.%26aulast%3DDesiderio%26aufirst%3DV.%26aulast%3DPaino%26aufirst%3DF.%26aulast%3DDe%2BRosa%26aufirst%3DA.%26aulast%3DPapaccio%26aufirst%3DF.%26aulast%3DLa%2BNoce%26aufirst%3DM.%26aulast%3DLaino%26aufirst%3DL.%26aulast%3DDe%2BFrancesco%26aufirst%3DF.%26aulast%3DPapaccio%26aufirst%3DG.%26atitle%3DCancer%2520Stem%2520Cells%2520in%2520Solid%2520Tumors%253A%2520an%2520Overview%2520and%2520New%2520Approaches%2520for%2520Their%2520Isolation%2520and%2520Characterization%26jtitle%3DFASEB%2520J.%26date%3D2013%26volume%3D27%26spage%3D13%26epage%3D24%26doi%3D10.1096%2Ffj.12-218222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G. D.</span></span> <span> </span><span class="NLM_article-title">The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer</span>. <i>Stem Cell. Int.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1155/2016/2087204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1155%2F2016%2F2087204" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=1-15&author=R.+Thapaauthor=G.+D.+Wilson&title=The+Importance+of+CD44+as+a+Stem+Cell+Biomarker+and+Therapeutic+Target+in+Cancer&doi=10.1155%2F2016%2F2087204"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1155%2F2016%2F2087204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F2087204%26sid%3Dliteratum%253Aachs%26aulast%3DThapa%26aufirst%3DR.%26aulast%3DWilson%26aufirst%3DG.%2BD.%26atitle%3DThe%2520Importance%2520of%2520CD44%2520as%2520a%2520Stem%2520Cell%2520Biomarker%2520and%2520Therapeutic%2520Target%2520in%2520Cancer%26jtitle%3DStem%2520Cell.%2520Int.%26date%3D2016%26volume%3D2016%26spage%3D1%26epage%3D15%26doi%3D10.1155%2F2016%2F2087204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Knockdown of Oct4 and Nanog Expression Inhibits the Stemness of Pancreatic Cancer Cells</span>. <i>Canc. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>340</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2013.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2Fj.canlet.2013.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=23872274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1WrtbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2013&pages=113-123&author=Y.+Luauthor=H.+Zhuauthor=H.+Shanauthor=J.+Luauthor=X.+Changauthor=X.+Liauthor=J.+Luauthor=X.+Fanauthor=S.+Zhuauthor=Y.+Wangauthor=Q.+Guoauthor=L.+Wangauthor=Y.+Huangauthor=M.+Zhuauthor=Z.+Wang&title=Knockdown+of+Oct4+and+Nanog+Expression+Inhibits+the+Stemness+of+Pancreatic+Cancer+Cells&doi=10.1016%2Fj.canlet.2013.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells</span></div><div class="casAuthors">Lu, Yuhua; Zhu, Hui; Shan, Haiyan; Lu, Junjie; Chang, Xu; Li, Xiaohong; Lu, Jingjing; Fan, Xiangjun; Zhu, Shajun; Wang, Yao; Guo, Qingsong; Wang, Lei; Huang, Yan; Zhu, Mingyan; Wang, Zhiwei</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-123</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Pancreatic cancer is notorious for its difficult diagnosis at early stage and poor recurrence-free prognosis.  This study aimed to investigate the possible involvement of Oct4 and Nanog in pancreatic cancer.  The high expressions of Oct4 and Nanog in human pancreatic cancer tissues were found to indicate a worse prognostic value of patients.  The pancreatic cancer stem cells (PCSCs) that isolated from PANC-1 cell line by flow cytometry exhibited high expressions of Oct4 and Nanog.  To investigate whether Oct4 and Nanog play crucial role in maintaining the stemness of PCSCs, double knockdown of Oct4 and Nanog demonstrated that Oct4 and Nanog significantly reduced proliferation, migration, invasion, chemoresistance, and tumorigenesis of PCSCs in vitro and in vivo.  The altered expression of the genes related to pancreatic carcinogenesis, metastasis, drug resistance and epithelial-mesenchymal transdifferentiation (EMT) might affect the biol. characteristics of PCSCs.  Our results suggest that Oct4 and Nanog may serve as a potential marker of prognosis and a novel target of therapy for pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokcOYM0eHQFLVg90H21EOLACvtfcHk0lg8gYDZCBwpAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1WrtbzL&md5=db8be55f62a426df2ac1d6beda29d331</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2013.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2013.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DShan%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DKnockdown%2520of%2520Oct4%2520and%2520Nanog%2520Expression%2520Inhibits%2520the%2520Stemness%2520of%2520Pancreatic%2520Cancer%2520Cells%26jtitle%3DCanc.%2520Lett.%26date%3D2013%26volume%3D340%26spage%3D113%26epage%3D123%26doi%3D10.1016%2Fj.canlet.2013.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asadzadeh, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansoori, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haji-Asgarzadeh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safarzadeh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhtarzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duijf, P. H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baradaran, B.</span></span> <span> </span><span class="NLM_article-title">microRNAs in Cancer Stem Cells: Biology, Pathways, and Therapeutic Opportunities</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">10002</span>– <span class="NLM_lpage">10017</span>, <span class="refDoi"> DOI: 10.1002/jcp.27885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1002%2Fjcp.27885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=30537109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVGmsbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2019&pages=10002-10017&author=Z.+Asadzadehauthor=B.+Mansooriauthor=A.+Mohammadiauthor=M.+Aghajaniauthor=K.+Haji-Asgarzadehauthor=E.+Safarzadehauthor=A.+Mokhtarzadehauthor=P.+H.+G.+Duijfauthor=B.+Baradaran&title=microRNAs+in+Cancer+Stem+Cells%3A+Biology%2C+Pathways%2C+and+Therapeutic+Opportunities&doi=10.1002%2Fjcp.27885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">microRNAs in cancer stem cells: Biology, pathways, and therapeutic opportunities</span></div><div class="casAuthors">Asadzadeh, Zahra; Mansoori, Behzad; Mohammadi, Ali; Aghajani, Marjan; Haji-Asgarzadeh, Khalil; Safarzadeh, Elham; Mokhtarzadeh, Ahad; Duijf, Pascal H. G.; Baradaran, Behzad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">10002-10017</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are a small subpopulation of tumor cells that have been identified in most types of cancer.  Features that distinguish them from the bulk of tumor cells include their pluripotency, self-renewal capacity, low proliferation rate, and tumor-initiating ability.  CSCs are highly malignant, as they confer drug resistance and facilitate tumor progression, relapse, and metastasis.  The mol. mechanisms underlying CSC biol. are now beginning to be understood.  In this context, microRNAs (miRNAs) occupy a prominent place.  These endogenous, small noncoding RNA mols. control gene expression at the posttranscriptional level.  This study reviews our current understanding of how the misexpression of tumor suppressor and oncogenic miRNAs in CSCs sustain their abundance and malignant properties.  We discuss how they partly do so by acting on major CSC signaling pathways, including the Wnt, Notch, Hedgehog, and BMI-1 pathways.  Our current knowledge of miRNA functions in CSCs may now be used for cancer diagnostic and prognostic purposes.  In addn., when combined with recent tech. advances in the in vivo delivery of miRNAs, we are now in an excellent position to develop strategies that harness miRNA interference and replacement technologies for the therapeutic targeting of CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsTNiKoa2uTrVg90H21EOLACvtfcHk0lg8gYDZCBwpAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVGmsbrL&md5=efbc05e5989b766a310155f1d39cc763</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fjcp.27885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.27885%26sid%3Dliteratum%253Aachs%26aulast%3DAsadzadeh%26aufirst%3DZ.%26aulast%3DMansoori%26aufirst%3DB.%26aulast%3DMohammadi%26aufirst%3DA.%26aulast%3DAghajani%26aufirst%3DM.%26aulast%3DHaji-Asgarzadeh%26aufirst%3DK.%26aulast%3DSafarzadeh%26aufirst%3DE.%26aulast%3DMokhtarzadeh%26aufirst%3DA.%26aulast%3DDuijf%26aufirst%3DP.%2BH.%2BG.%26aulast%3DBaradaran%26aufirst%3DB.%26atitle%3DmicroRNAs%2520in%2520Cancer%2520Stem%2520Cells%253A%2520Biology%252C%2520Pathways%252C%2520and%2520Therapeutic%2520Opportunities%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D234%26spage%3D10002%26epage%3D10017%26doi%3D10.1002%2Fjcp.27885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, B.</span></span> <span> </span><span class="NLM_article-title">NOR1 Suppresses Cancer Stem-Like Cells Properties of Tumor Cells via the Inhibition of the AKT-GSK-3β-Wnt/β-catenin-ALDH1A1 Signal Circuit</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>232</i></span>,  <span class="NLM_fpage">2829</span>– <span class="NLM_lpage">2840</span>, <span class="refDoi"> DOI: 10.1002/jcp.25706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1002%2Fjcp.25706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=27891591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFahsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2017&pages=2829-2840&author=W.+Wangauthor=M.+Yiauthor=S.+Chenauthor=J.+Liauthor=H.+Zhangauthor=W.+Xiongauthor=G.+Liauthor=X.+Liauthor=B.+Xiang&title=NOR1+Suppresses+Cancer+Stem-Like+Cells+Properties+of+Tumor+Cells+via+the+Inhibition+of+the+AKT-GSK-3%CE%B2-Wnt%2F%CE%B2-catenin-ALDH1A1+Signal+Circuit&doi=10.1002%2Fjcp.25706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">NOR1 Suppresses Cancer Stem-Like Cells Properties of Tumor Cells via the Inhibition of the AKT-GSK-3β-Wnt/β-catenin-ALDH1A1 Signal Circuit</span></div><div class="casAuthors">Wang, Wei; Yi, Mei; Chen, Shengnan; Li, Junjun; Zhang, Haijing; Xiong, Wei; Li, Guiyuan; Li, Xiaoling; Xiang, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2829-2840</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) play a key role in tumor radiotherapy and chemotherapy resistance, relapse, and metastasis, and are primarily maintained in a resting state in vivo.  The failure of conventional therapies to target CSCs is the main cause of treatment failure.  The discovery of CSCs in nasopharyngeal carcinoma (NPC) tumors is becoming more prevalent; however, the understanding of the mechanisms underlying the maintenance of tumor stemness is still limited.  We previously cloned NOR1, a tumor suppressor gene downregulated in NPC cell lines and tissues.  In this study, we demonstrate that Wnt/β-catenin and ALDH1A1 form a signal circuit and that NOR1 antagonizes the tumor stem cell-like phenotype in NPC cell lines: the ectopic overexpression of NOR1 reduced β-catenin and ALDH1A1 expression; β-catenin/TCF4 targeted the regulation of ALDH1A1 transcription in NPC cells; silencing ALDH1A1 reduced AKT (total and phosphorylated) and GSK-3β (phosphorylated) expression; and eventually feedback decreased β-catenin expression levels.  We also found that NOR1 expression decreased cancer stem-like cell properties of NPC cells, reduced their ability to form tumor spheroids in vitro, reduced tumorigenicity in nude mice in vivo, and increased sensitivity to chemotherapy agents.  Taken together, our findings illustrated a new function of NOR1 that suppresses cancer stem-like cell properties in tumor cells by inhibiting the AKT-GSK-3β-Wnt/β-catenin-ALDH1A1 signal circuit.  The study suggests that NOR1 deletion expression in NPC cells may be a potential mol. target for cancer stem cell therapy.  J. Cell. Physiol. 9999: 1-12, 2016. © 2016 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjQREwi8U08bVg90H21EOLACvtfcHk0li7MTHyNMiixQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFahsr0%253D&md5=49109830d2714cadee604a7fff74c3a3</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fjcp.25706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.25706%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYi%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DB.%26atitle%3DNOR1%2520Suppresses%2520Cancer%2520Stem-Like%2520Cells%2520Properties%2520of%2520Tumor%2520Cells%2520via%2520the%2520Inhibition%2520of%2520the%2520AKT-GSK-3%25CE%25B2-Wnt%252F%25CE%25B2-catenin-ALDH1A1%2520Signal%2520Circuit%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2017%26volume%3D232%26spage%3D2829%26epage%3D2840%26doi%3D10.1002%2Fjcp.25706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedert, M.</span></span> <span> </span><span class="NLM_article-title">GSK3 Inhibitors: Development and Therapeutic Potential</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1038/nrd1415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fnrd1415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=15173837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVaqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=479-487&author=P.+Cohenauthor=M.+Goedert&title=GSK3+Inhibitors%3A+Development+and+Therapeutic+Potential&doi=10.1038%2Fnrd1415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 inhibitors: development and therapeutic potential</span></div><div class="casAuthors">Cohen, Philip; Goedert, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">479-487</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metab.  In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics.  Here, we describe the biol. of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL3ua5xi0_qrVg90H21EOLACvtfcHk0li7MTHyNMiixQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVaqsrs%253D&md5=165d1354bf11faa6021ac4dba797fda2</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnrd1415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1415%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DGoedert%26aufirst%3DM.%26atitle%3DGSK3%2520Inhibitors%253A%2520Development%2520and%2520Therapeutic%2520Potential%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D479%26epage%3D487%26doi%3D10.1038%2Fnrd1415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mills, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowsheen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. S.</span></span> <span> </span><span class="NLM_article-title">Emerging Roles of Glycogen Synthase Kinase 3 in the Treatment of Brain Tumors</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">47</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2011.00047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.3389%2Ffnmol.2011.00047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=22275880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC38XovV2j" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=47&author=C.+N.+Millsauthor=S.+Nowsheenauthor=J.+A.+Bonnerauthor=E.+S.+Yang&title=Emerging+Roles+of+Glycogen+Synthase+Kinase+3+in+the+Treatment+of+Brain+Tumors&doi=10.3389%2Ffnmol.2011.00047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors</span></div><div class="casAuthors">Mills, Caroline N.; Nowsheen, Somaira; Bonner, James A.; Yang, Eddy S.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Nov.</span>),
    <span class="NLM_cas:pages">47</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The constitutively active protein glycogen synthase kinase 3 (GSK3), a serine/threonine kinase, acts paradoxically as a tumor suppressor in some cancers while potentiates growth in others.  Deciphering what governs its actions is vital for understanding many pathol. conditions, including brain cancer.  What are seemingly disparate roles of GSK3 stems from the complex regulation of many cellular functions by GSK3.  This review focuses on the regulation of GSK3, its role in survival, apoptosis and DNA damage, and finally its potential therapeutic impact in brain cancer.  A thorough understanding of this versatile protein is crit. for improving the outcome of various diseases, esp. cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDHgnEU2CYbVg90H21EOLACvtfcHk0li7MTHyNMiixQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovV2j&md5=a91f52a6292ec3ed914020d19393a989</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2011.00047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2011.00047%26sid%3Dliteratum%253Aachs%26aulast%3DMills%26aufirst%3DC.%2BN.%26aulast%3DNowsheen%26aufirst%3DS.%26aulast%3DBonner%26aufirst%3DJ.%2BA.%26aulast%3DYang%26aufirst%3DE.%2BS.%26atitle%3DEmerging%2520Roles%2520of%2520Glycogen%2520Synthase%2520Kinase%25203%2520in%2520the%2520Treatment%2520of%2520Brain%2520Tumors%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2011%26volume%3D4%26spage%3D47%26doi%3D10.3389%2Ffnmol.2011.00047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Combretastatin A-4 analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2132</span>– <span class="NLM_lpage">2148</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.6b00353</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.6b00353" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1yrsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=2132-2148&author=X.+Huangauthor=R.+Huangauthor=S.+Gouauthor=Z.+Wangauthor=Z.+Liaoauthor=H.+Wang&title=Combretastatin+A-4+analogue%3A+A+Dual-Targeting+and+Tubulin+Inhibitor+Containing+Antitumor+Pt%28IV%29+Moiety+with+a+Unique+Mode+of+Action&doi=10.1021%2Facs.bioconjchem.6b00353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action</span></div><div class="casAuthors">Huang, Xiaochao; Huang, Rizhen; Gou, Shaohua; Wang, Zhimei; Liao, Zhixin; Wang, Hengshan</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2132-2148</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abstr.: Three new Pt(IV) complexes comprising a combretastatin A-4 analog were designed and synthesized.  The resulting antitumor Pt(IV) complexes could significantly improve the antiproliferative activity and overcome the drug resistance of cisplatin in vitro.  Interestingly, these novel compds. can not only carry the DNA binding Pt(II) warhead into the cancer cells but also have a small mol. fragment that can inhibit tubulin polymn.  Among them, complex 13, which was attached to an inhibitor of tubulin at one axial position of Pt(IV) octahedral coordination sphere, could effectively enter cancer cells, arrest the cell cycle in HepG-2 cancer cells at G2/M phases, and induce activation of caspases triggering apoptotic signaling via the mitochondrial-dependent apoptosis pathways.  Moreover, complex 13 has the ability of effectively inhibiting the tumor growth in the HepG-2 xenograft model without causing significant loss of animal body wt. in comparison with cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_P-MRBiNaU7Vg90H21EOLACvtfcHk0li7MTHyNMiixQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1yrsbfO&md5=a86ac2b4f6898e01dc0910d4112ddf03</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.6b00353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.6b00353%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DCombretastatin%2520A-4%2520analogue%253A%2520A%2520Dual-Targeting%2520and%2520Tubulin%2520Inhibitor%2520Containing%2520Antitumor%2520Pt%2528IV%2529%2520Moiety%2520with%2520a%2520Unique%2520Mode%2520of%2520Action%26jtitle%3DBioconjugate%2520Chem.%26date%3D2016%26volume%3D27%26spage%3D2132%26epage%3D2148%26doi%3D10.1021%2Facs.bioconjchem.6b00353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breckenridge, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, D.</span></span> <span> </span><span class="NLM_article-title">Regulation of Mitochondrial Membrane Permeabilization by BCL-2 Family Proteins and Caspases</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">652</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2004.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2Fj.ceb.2004.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=15530776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVOrtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2004&pages=647-652&author=D.+G.+Breckenridgeauthor=D.+Xue&title=Regulation+of+Mitochondrial+Membrane+Permeabilization+by+BCL-2+Family+Proteins+and+Caspases&doi=10.1016%2Fj.ceb.2004.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases</span></div><div class="casAuthors">Breckenridge, David G.; Xue, Ding</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">647-652</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Mitochondria play an important role in the integration and transmission of cell death signals, activating caspases and other cell death execution events by releasing apoptogenic proteins from the intermembrane space.  The BCL-2 family of proteins localize (or can be targeted) to mitochondria and regulate the permeability of the mitochondrial outer membrane to these apoptotic factors.  Recent evidence suggests that multiple mechanisms may regulate the release of mitochondrial factors, some of which depend on the action of caspases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgc06hGcSXVbVg90H21EOLACvtfcHk0lgwd3adSirmdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVOrtbs%253D&md5=9e6fd14a4644e232f99dfc8183eab331</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2004.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2004.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DBreckenridge%26aufirst%3DD.%2BG.%26aulast%3DXue%26aufirst%3DD.%26atitle%3DRegulation%2520of%2520Mitochondrial%2520Membrane%2520Permeabilization%2520by%2520BCL-2%2520Family%2520Proteins%2520and%2520Caspases%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2004%26volume%3D16%26spage%3D647%26epage%3D652%26doi%3D10.1016%2Fj.ceb.2004.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6507</span>– <span class="NLM_lpage">6516</span>, <span class="refDoi"> DOI: 10.1021/acs.inorgchem.9b00708</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.inorgchem.9b00708" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFSju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=6507-6516&author=S.+Jinauthor=Y.+Guoauthor=D.+Songauthor=Z.+Zhuauthor=Z.+Zhangauthor=Y.+Sunauthor=T.+Yangauthor=Z.+Guoauthor=X.+Wang&title=Targeting+Energy+Metabolism+by+a+Platinum%28IV%29+Prodrug+as+an+Alternative+Pathway+for+Cancer+Suppression&doi=10.1021%2Facs.inorgchem.9b00708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression</span></div><div class="casAuthors">Jin, Suxing; Guo, Yan; Song, Dongfan; Zhu, Zhenzhu; Zhang, Zhenqin; Sun, Yuewen; Yang, Tao; Guo, Zijian; Wang, Xiaoyong</div><div class="citationInfo"><span class="NLM_cas:title">Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">6507-6516</span>CODEN:
                <span class="NLM_cas:coden">INOCAJ</span>;
        ISSN:<span class="NLM_cas:issn">0020-1669</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer is characterized by abnormal cellular energy metab., which preferentially switches to aerobic glycolysis rather than oxidative phosphorylation as a means of glucose metab.  Many key enzymes involved in the abnormal glycolysis are potential targets of anticancer drugs.  Platinum(IV) complexes are potential anticancer prodrugs and kinetically more inert than the platinum(II) counterparts, which offer an opportunity to be modified by functional ligands for activation or targeted delivery.  A novel platinum(IV) complex, c,c,t-[Pt(NH3)2Cl2(C10H15N2O3S)(C2HO2Cl2)] (DPB), was designed to explore the effects of axial ligands on the reactivity and bioactivity of the complex as well as on tumor energy metab.  The complex was characterized by electrospray ionization mass spectrometry and multinuclear (1H, 13C, and 195Pt) NMR spectroscopy.  The introduction of dichloroacetate (DCA) markedly increases the lipophilicity, reactivity, and cytotoxicity of the complex and blocks the growth of cancer cells having active glycolysis, and the introduction of biotin (C10H16N2O3S) enhances the tumor-targeting potential of the complex.  The cytotoxicity of DPB is increased dramatically in a variety of cancer cell lines as compared with the platinum(IV) complex PB without the DCA group.  DPB alters the mitochondrial membrane potential and disrupts the mitochondrial morphol.  The levels of mitochondrial and cellular reactive oxygen species are also decreased.  Furthermore, the mitochondrial function of tumor cells was impaired by DPB, leading to the inhibition of both glycolysis and glucose oxidn. and finally to the death of cancer cells via a mitochondria-mediated apoptotic pathway.  These findings demonstrate that DPB suppresses cancer cells mainly through altering metabolic pathways and highlight the importance of dual-targeting for the efficacy of anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVgfN85UEHMbVg90H21EOLACvtfcHk0lgwd3adSirmdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFSju78%253D&md5=e9c4433bd6e253f5be6e3e672c5276ea</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.inorgchem.9b00708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.inorgchem.9b00708%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DTargeting%2520Energy%2520Metabolism%2520by%2520a%2520Platinum%2528IV%2529%2520Prodrug%2520as%2520an%2520Alternative%2520Pathway%2520for%2520Cancer%2520Suppression%26jtitle%3DInorg.%2520Chem.%26date%3D2019%26volume%3D58%26spage%3D6507%26epage%3D6516%26doi%3D10.1021%2Facs.inorgchem.9b00708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ike, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitomi, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of Cisplatin in Analbuminemic Rats</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">428</span>, <span class="refDoi"> DOI: 10.1002/1099-081x(199912)20:9<421::aid-bdd206>3.0.co;2-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1002%2F1099-081X%28199912%2920%3A9%3C421%3A%3AAID-BDD206%3E3.0.CO%3B2-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10951431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1ymsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=421-428&author=K.+Takadaauthor=T.+Kawamuraauthor=M.+Inaiauthor=S.+Masudaauthor=T.+Okaauthor=Y.+Yoshikawaauthor=N.+Shibataauthor=H.+Yoshikawaauthor=O.+Ikeauthor=H.+Wadaauthor=S.+Hitomi&title=Pharmacokinetics+of+Cisplatin+in+Analbuminemic+Rats&doi=10.1002%2F1099-081x%28199912%2920%3A9%3C421%3A%3Aaid-bdd206%3E3.0.co%3B2-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of cisplatin in analbuminemic rats</span></div><div class="casAuthors">Takada, Kanji; Kawamura, Tomonori; Inai, Maya; Masuda, Satoru; Oka, Takashi; Yoshikawa, Yukako; Shibata, Nobuhito; Yoshikawa, Hiroshi; Ike, Osamu; Wada, Hiromi; Hitomi, Shigeki</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">421-428</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The effect of protein binding on the pharmacokinetics of cisplatin (cis-diamminedichloro-platinum (II); CDDP) has been studied in analbuminemic rats, which genetically lack albumins, in comparison with normal rats.  CDDP was reported to highly bind to serum components, and the major binder was thought to be an albumin.  However, there were no significant differences in the serum disappearance profiles of platinum after i.v. bolus injection of CDDP to analbuminemic rats as compared with normal rats.  The total body clearance, Cltot, of platinum in normal rats was 48.7±22.0 mL h-1 (5 mg kg-1), 55.9±4.04 mL h-1 (10 mg kg-1) and 49.0±3.57 mL h-1 (20 mg kg-1), whereas Cltot in analbuminemic rats was 52.0±8.48 mL h-1 (5 mg kg-1), 62.9±10.8 mL h-1 (10 mg kg-1) and 62.8±6.81 mL h-1 (20 mg kg-1).  The serum blood urea nitrogen (BUN) and creatinine levels at 6 h after iv injection were higher in both groups of rats who received CDDP than those of pre-dose level.  However, there were no significant differences in the renal function tests between analbuminemic rats and normal rats.  The binding of CDDP to the serum samples obtained from analbuminemic rats and normal rats was measured by a centrifuging filtration method.  The binding percentages were 68.0±5.9% (2.0 μg mL-1), 56.8±4.1% (5.0 μg mL-1) and 64.6±4.4% (10.0 μg mL-1) in analbuminemic rats and 52.9±3.5% (2.0 μg mL-1), 52.2±3.4% (5.0 μg mL-1), 56.9±1.9% (10.0 μg mL-1) in normal rats.  Higher binding percentages were obtained in analbuminemic rats than in normal rats.  In vitro binding studies under the two incubation conditions (5 min and 2 h) showed that the binding percentages of CDDP to serum proteins were 59.2±3.2% (5 min) and 72.3±6.5% (2 h) for albumin, 42.3±1.9% (5 min) and 39.5±2.5% (2 h) for α1-acid glycoprotein (AAG) and 51.7±5.3% (5 min) and 49.2±1.9% (2 h) for γ-globulin.  From these studies, it was elucidated that albumin is not the major ligand in the rat serum and that other proteins also have important roles in the pharmacokinetics of CDDP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkhfZ_S9M0nLVg90H21EOLACvtfcHk0lgwd3adSirmdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1ymsrY%253D&md5=0d512a6919d4959230e7667b9e529aea</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2F1099-081X%28199912%2920%3A9%3C421%3A%3AAID-BDD206%3E3.0.CO%3B2-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1099-081X%2528199912%252920%253A9%253C421%253A%253AAID-BDD206%253E3.0.CO%253B2-9%26sid%3Dliteratum%253Aachs%26aulast%3DTakada%26aufirst%3DK.%26aulast%3DKawamura%26aufirst%3DT.%26aulast%3DInai%26aufirst%3DM.%26aulast%3DMasuda%26aufirst%3DS.%26aulast%3DOka%26aufirst%3DT.%26aulast%3DYoshikawa%26aufirst%3DY.%26aulast%3DShibata%26aufirst%3DN.%26aulast%3DYoshikawa%26aufirst%3DH.%26aulast%3DIke%26aufirst%3DO.%26aulast%3DWada%26aufirst%3DH.%26aulast%3DHitomi%26aufirst%3DS.%26atitle%3DPharmacokinetics%2520of%2520Cisplatin%2520in%2520Analbuminemic%2520Rats%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D1999%26volume%3D20%26spage%3D421%26epage%3D428%26doi%3D10.1002%2F1099-081x%28199912%2920%3A9%3C421%3A%3Aaid-bdd206%3E3.0.co%3B2-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Activity of BBI608 Derivatives Targeting on Stem Cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2Fj.ejmech.2018.03.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=29604543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslKgtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=39-50&author=Q.+Zhouauthor=C.+Pengauthor=F.+Duauthor=L.+Zhouauthor=Y.+Shiauthor=Y.+Duauthor=D.+Liuauthor=W.+Sunauthor=M.+Zhangauthor=G.+Chen&title=Design%2C+Synthesis+and+Activity+of+BBI608+Derivatives+Targeting+on+Stem+Cells&doi=10.1016%2Fj.ejmech.2018.03.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and activity of BBI608 derivatives targeting on stem cells</span></div><div class="casAuthors">Zhou, Qifan; Peng, Chen; Du, Fangyu; Zhou, Linbo; Shi, Yajie; Du, Yang; Liu, Dongdong; Sun, Wenjiao; Zhang, Meixia; Chen, Guoliang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">39-50</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">STAT3 plays a vital role in maintaining the self-renewal of tumor stem cells.  BBI608, a small mol. identified by its ability to inhibit gene transcription driven by STAT3 and cancer stemness properties, can inhibit stemness gene expression and kill stemness-high cancer cells isolated from a variety of cancer types.  In order to improve the pharmacokinetic properties of BBI608 and the antitumor activity, a series of BBI608 derivs. were designed and synthesized here.  Most of these compds. were more potent than BBI608 on HepG2 cells, compd. I had the most potent inhibitory activity among them and was 5.4-fold more potent than BBI608 (IC50=11.2μM), but had considerable activity on normal liver cells L-02.  Compds. II (IC50=3.5μM) and III (IC50=2.9μM) were found to possess significant inhibitory activities and good selectivity.  The results showed that compd. LD-19 was worthy to investigate further as a lead compd. according to its potent inhibitory activity, ideal ClogP value and better water soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlEGtqRVLqrVg90H21EOLACvtfcHk0liyOdwNSSWhyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslKgtbc%253D&md5=3bd9949d032ee24e433b2e34b3ca9369</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.054%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DG.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Activity%2520of%2520BBI608%2520Derivatives%2520Targeting%2520on%2520Stem%2520Cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D39%26epage%3D50%26doi%3D10.1016%2Fj.ejmech.2018.03.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Livak, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmittgen, T. D.</span></span> <span> </span><span class="NLM_article-title">Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method</span>. <i>Methods</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1006/meth.2001.1262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1006%2Fmeth.2001.1262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=11846609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtFelt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2001&pages=402-408&author=K.+J.+Livakauthor=T.+D.+Schmittgen&title=Analysis+of+Relative+Gene+Expression+Data+Using+Real-Time+Quantitative+PCR+and+the+2%E2%88%92%CE%94%CE%94CT+Method&doi=10.1006%2Fmeth.2001.1262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method</span></div><div class="casAuthors">Livak, Kenneth J.; Schmittgen, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Methods (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">402-408</span>CODEN:
                <span class="NLM_cas:coden">MTHDE9</span>;
        ISSN:<span class="NLM_cas:issn">1046-2023</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The two most commonly used methods to analyze data from real-time, quant. PCR expts. are abs. quantification and relative quantification.  Abs. quantification dets. the input copy no., usually by relating the PCR signal to a std. curve.  Relative quantification relates the PCR signal of the target transcript in a treatment group to that of another sample such as an untreated control.  The 2-ΔΔCT method is a convenient way to analyze the relative changes in gene expression from real-time quant. PCR expts.  The purpose of this report is to present the derivation, assumptions, and applications of the 2-ΔΔCT method.  In addn., we present the derivation and applications of two variations of the 2-ΔΔCT method that may be useful in the anal. of real-time, quant. PCR data.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXNe1s-mDpprVg90H21EOLACvtfcHk0liyOdwNSSWhyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtFelt7s%253D&md5=f849383250ea43f7380ed540db8a64b1</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1006%2Fmeth.2001.1262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fmeth.2001.1262%26sid%3Dliteratum%253Aachs%26aulast%3DLivak%26aufirst%3DK.%2BJ.%26aulast%3DSchmittgen%26aufirst%3DT.%2BD.%26atitle%3DAnalysis%2520of%2520Relative%2520Gene%2520Expression%2520Data%2520Using%2520Real-Time%2520Quantitative%2520PCR%2520and%2520the%25202%25E2%2588%2592%25CE%2594%25CE%2594CT%2520Method%26jtitle%3DMethods%26date%3D2001%26volume%3D25%26spage%3D402%26epage%3D408%26doi%3D10.1006%2Fmeth.2001.1262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trott, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/jcc.21334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1002%2Fjcc.21334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=19499576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=455-61&author=O.+Trottauthor=A.+J.+Olson&title=AutoDock+Vina%3A+Improving+the+Speed+and+Accuracy+of+Docking+with+a+New+Scoring+Function%2C+Efficient+Optimization%2C+and+Multithreading&doi=10.1002%2Fjcc.21334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span></div><div class="casAuthors">Trott, Oleg; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">455-461</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">AutoDock Vina, a new program for mol. docking and virtual screening, is presented.  AutoDock Vina achieves an approx. 2 orders of magnitude speed-up compared with the mol. docking software previously developed in the authors' lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by the authors' tests on the training set used in AutoDock 4 development.  Further speed-up is achieved from parallelism, by using multithreading on multicore machines.  AutoDock Vina automatically calcs. the grid maps and clusters the results in a way transparent to the user.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLecOIkUxIlrVg90H21EOLACvtfcHk0liyOdwNSSWhyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O&md5=c6974af8a1235f7aa09918d3e6f70dc4</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21334%26sid%3Dliteratum%253Aachs%26aulast%3DTrott%26aufirst%3DO.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock%2520Vina%253A%2520Improving%2520the%2520Speed%2520and%2520Accuracy%2520of%2520Docking%2520with%2520a%2520New%2520Scoring%2520Function%252C%2520Efficient%2520Optimization%252C%2520and%2520Multithreading%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D455%26epage%3D61%26doi%3D10.1002%2Fjcc.21334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>HY1</b> and <b>HY1-Pt</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Inhibitory activity of <b>HY1</b> on CK2 and its effect on A549 cell stemness. (a) Inhibition rate curves of <b>HY1</b> and <b>CX-4945</b> on CK2 enzyme activity. (b) Western blot analysis on the specific CK2 phosphorylation targets: phosphorylation of the Akt1 serine 129 and Cdc37 serine 13 in A549 cells after treatment with <b>CX-4945</b> and <b>HY1</b> at 20 μM, respectively, for 24 h. (c) Inhibition rate curves of <b>HY1</b> and <b>CX-4945</b> on ALDH1A1 enzyme activity. (d) Percentage of ALDH<sup>+</sup> cells in A549 cells after treatment with <b>CX-4945</b> and <b>HY1</b> at 20 μM, respectively, for 24 h. (e) ALDH1A1 mRNA levels after treatment with <b>CX-4945</b> and <b>HY1</b> at 20 μM, respectively, for 24 h in A549 cells. (f) ALDH1A1 protein levels treated with <b>CX-4945</b> and <b>HY1</b> at 20 μM, respectively, for 24 h in A549 cells. Data were obtained via using students’ <i>T</i>-test, <i>n</i> = 3 per group, Error bars = SD, asterisk indicate statistically significant differences, **<i>P</i> < 0.01, <i>vs</i> control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Study on the effect of <b>HY1</b> on the expression of intracellular CD44<sup>+</sup> and the formation of tumorsphere in A549 cells. (a) Statistics of the experimental results in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Figure S1</a>, and the proportion of CD44<sup>+</sup> subsets in A549 cells treated with <b>CX-4945</b>, <b>BBI608,</b> and <b>HY1</b> at 20 μM, respectively, for 24 h were statistically analyzed. (b) Morphological image and (c) the number of A549 cells tumorsphere treated with <b>CX-4945</b>, <b>BBI608</b>, and <b>HY1</b> at 10 μM, respectively. Error bars = SD (<i>n</i> = 3), **<i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Stability of <b>HY1-Pt</b> in Hepes buffer at pH 7.4 and 6.0 measured by UV–vis. (a) Stability of <b>HY1-Pt</b> in Hepes buffer (pH = 7.4) containing 2% DMF was recorded via time-dependent UV–vis spectra (scan every 30 min for a total of 24 times) at 37.0 °C. (b) Stability of <b>HY1-Pt</b> in Hepes buffer (pH = 6.0) containing 2% DMF was recorded via time-dependent UV–vis spectra (scan every 10 min for 12 h) at 37.0 °C.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cellular responses of <b>CX-4945</b>, <b>HY1</b>, cisplatin, and <b>HY1-Pt</b> in A549 and A549/cDDP cells. Statistics of the results of cell cycle arrest in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Figure S3</a>. Cell cycle arrest distributions of (a) A549 and (b) A549/cDDP cells were detected by flow cytometry after treatment with the tested compounds at 20 μM, respectively, for 24 h. (c) Statistics of the results of apoptosis in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf" class="ext-link">Figure S4</a>. A549 and A549/cDDP cells were treated with the tested compound at 20 μM, respectively, for 24 h, and then, the apoptosis of the cells was detected by flow cytometry. (d) Intracellular accumulation of platinum in A549 and A549/cDDP cells was detected by ICP-MS after treatment with cisplatin and <b>HY1-Pt</b> at 20 μM, respectively, for 24 h. (e) Representative images of nuclei from comet assays. A549 and A549/cDDP cells were treated with the tested compounds at 20 μM, respectively, for 12 h. Error bars = SD (<i>n</i> = 3), *<i>P</i> < 0.05, **<i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Analysis of the γH2AX expression in A549 and A549/cDDP cells. (a) Expression of γH2AX in two cell lines was analyzed by western blot after treatment with <b>CX-4945</b>, <b>HY1</b>, cisplatin (cis), and <b>HY1-Pt</b> at 20 μM, respectively, for 24 h. (b) γH2AX foci in two cell lines were determined via immunofluorescence staining after treatment with <b>CX-4945</b>, <b>HY1</b>, cisplatin, and <b>HY1-Pt</b> at 20 μM, respectively, for 12 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Investigation on the inhibition of <b>HY1</b> on CK2 and DNA damage repair. (a) Western blotting assay on the expression of p-Akt1<sup>S129</sup> and p-Cdc37<sup>S13</sup> in either A549 or A549/cDDP cells after treatment with different concentrations of <b>HY1-Pt</b> for 24 h. (b) <b>HY1-Pt</b> is docked into the hydrophobic pocket of CK2α protein (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6isj">6isj</a>) utilizing Autodock. Amino acid residues that may be involved in the binding are labeled, and the yellow dashed indicate the hydrogen bond interaction. (c) The co-localization of MDC1/Aprataxin and the damaged DNA in either A549 or A549/cDDP cells were detected by immunofluorescence technique after treatment with <b>CX-4945</b>, <b>HY1</b>, cisplatin, and <b>HY1-Pt</b> at 20 μM for 24 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Study on the inhibitory effect of the tested compounds on A549/cDDP<sup>CD44bright</sup> and its intracellular CD133. (a) Mortality rate of A549/cDDP<sup>CD44bright</sup> cells incubated with <b>CX-4945</b>, <b>HY1</b>, cisplatin, and <b>HY1-Pt</b> at 20 μM, respectively, for 24 h. (b) Expression of CD133 is analyzed in A549/cDDP<sup>CD44bright</sup> cells by flow cytometry. Error bars = SD (<i>n</i> = 3), *<i>P</i> < 0.05, **<i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Study on A549/cDDP<sup>CD44bright</sup> cells. (a) qRT-PCR patterns of the ALDH1A1 in A549/cDDP<sup>CD44bright</sup> cells treated with cisplatin and <b>HY1-Pt</b> at 20 μM. (b) Expression of the ALDH1A1 in A549/cDDP<sup>CD44bright</sup> cells was explored by western blot after treatment with 10 μM cisplatin and <b>HY1-Pt</b> at concentrations of 10, 20, and 40 μM, respectively, for 24 h. (c) qRT-PCR patterns of the stem cell genes Nanog, SOX2, and OCT4 in A549/cDDP<sup>CD44bright</sup> cells treated with cisplatin and <b>HY1-Pt</b> at 20 μM, respectively. (d) Morphological observation and (e) the number of A549/cDDP<sup>CD44bright</sup> cells tumorsphere treated with cisplatin and <b>HY1-Pt</b> at two doses (5 and 10 μM), respectively. (f) Expression of DKK1, p-GSK-3β(ser9), and β-catenin in A549/cDDP cells was explored by western blot after treatment with <b>HY1-Pt</b> at concentrations of 10, 20, and 40 μM, respectively, for 24 h. Error bars = SD (<i>n</i> = 3), *<i>P</i> < 0.05, **<i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Study on mitochondrial apoptosis pathway. Statistical changes of (a) ROS-positive cells and (b) MMP in A549 and A549/cDDP cell treatment with <b>CX-4945</b>, <b>HY1</b>, cisplatin, and <b>HY1-Pt</b> at 20 μM for 24 h. (c) Expression levels of Bcl-2, Bax, pro-caspase 3, pro-caspase 9, and cleaved-PARP in A549 and A549/cDDP cells were explored via western blot after treatment with cisplatin and <b>HY1-Pt</b> at 20 μM for 24 h. Error bars = SD (<i>n</i> = 3), *<i>P</i> < 0.05, **<i>P</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. <i>In vivo</i> A549 xenograft model study of <b>HY1-Pt</b> and cisplatin. (a) During the observation period, tumor volumes of animals from each group, including vehicle, cisplatin (4 mg/kg, iv, once a week for 4 weeks) and <b>HY1-Pt</b> (10, 20 and 40 mg/kg, iv, once a week for 4 weeks). (b) Weights of tumors resected from all groups of mice on the last day. (c) Influence of different samples on body weight changes of the animals. (d) Images of tumors from five groups of mice at the end of the experiment. Error bars = SD (<i>n</i> = 5), **<i>P</i> < 0.01, <sup>##</sup><i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/medium/jm1c00079_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. <i>In vivo</i> A549/cDDP xenograft model study of <b>HY1-Pt</b> and cisplatin. (a) During the observation period, tumor volumes of animals in each group, including vehicle, cisplatin (4 mg/kg, iv, once a week for 4 weeks), and <b>HY1-Pt</b> (10 and 20 mg/kg, iv, once a week for 4 weeks). (b) Weights of tumors resected from all groups of sacrificed mice on the last day. (c) Influence of different samples on body weight changes of the animals. (d) Images of tumors from five groups of mice at the end of the experiment. Error bars = SD (<i>n</i> = 5), **<i>P</i> < 0.01, <sup>##</sup><i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00079/20210331/images/large/jm1c00079_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00079&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16363" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16363" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 64 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgensztern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, C.</span></span> <span> </span><span class="NLM_article-title">The Biology and Management of Non-Small Cell Lung Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>553</i></span>,  <span class="NLM_fpage">446</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1038/nature25183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fnature25183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=29364287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12itbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=553&publication_year=2018&pages=446-454&author=R.+S.+Herbstauthor=D.+Morgenszternauthor=C.+Boshoff&title=The+Biology+and+Management+of+Non-Small+Cell+Lung+Cancer&doi=10.1038%2Fnature25183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The biology and management of non-small cell lung cancer</span></div><div class="casAuthors">Herbst, Roy S.; Morgensztern, Daniel; Boshoff, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">553</span>
        (<span class="NLM_cas:issue">7689</span>),
    <span class="NLM_cas:pages">446-454</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing the understanding of the disease biol. and mechanisms of tumor progression, and advancing early detection and multimodal care.  The use of small mol. tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients.  However, the overall cure and survival rates for NSCLC remain low, particularly in metastatic disease.  Therefore, continued research into new drugs and combination therapies is required to expand the clin. benefit to a broader patient population and to improve outcomes in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4LzsacpsnpLVg90H21EOLACvtfcHk0lhBxfI7f4vg4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12itbo%253D&md5=9e7e092850f8707b96b6828e9a0d9585</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnature25183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25183%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DMorgensztern%26aufirst%3DD.%26aulast%3DBoshoff%26aufirst%3DC.%26atitle%3DThe%2520Biology%2520and%2520Management%2520of%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DNature%26date%3D2018%26volume%3D553%26spage%3D446%26epage%3D454%26doi%3D10.1038%2Fnature25183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, H.</span></span> <span> </span><span class="NLM_article-title">Cost-Effectiveness Analysis of Ceritinib and Alectinib Versus Crizotinib in the Treatment of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer</span>. <i>Cancer Manage. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">9195</span>– <span class="NLM_lpage">9202</span>, <span class="refDoi"> DOI: 10.2147/cmar.s223441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.2147%2FCMAR.S223441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=31749634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BB3cXns1Gmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=9195-9202&author=M.+Liuauthor=L.+Zhangauthor=Q.+Huangauthor=N.+Liauthor=B.+Zhengauthor=H.+Cai&title=Cost-Effectiveness+Analysis+of+Ceritinib+and+Alectinib+Versus+Crizotinib+in+the+Treatment+of+Anaplastic+Lymphoma+Kinase-Positive+Advanced+Non-Small+Cell+Lung+Cancer&doi=10.2147%2Fcmar.s223441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cost-effectiveness analysis of ceritinib and alectinib versus crizotinib in the treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer</span></div><div class="casAuthors">Liu, Maobai; Zhang, Longfeng; Huang, Qishu; Li, Na; Zheng, Bin; Cai, Hongfu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Management and Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9195-9202</span>CODEN:
                <span class="NLM_cas:coden">CMRACP</span>;
        ISSN:<span class="NLM_cas:issn">1179-1322</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: This study aimed to analyze the cost-effectiveness of crizotinib vs. ceritinib or alectinib as first-line-targeted drug therapy for anaplastic lymphoma kinasepos. advanced non-small cell lung cancer in China.  Methods: The Markov model was used to simulate the medical cost and quality-adjusted life years (QALYs) of patients using crizotinib, ceritinib, or alectinib over a 10-yr period by establishing three health states: progression-free, post-progression, and death.  Randomized controlled clin. data were collected from the open-label, randomized phase 3 trials ALEX and ASCEND-4.  Cost and utility values were derived from local charges and literature.  Sensitivity analyses included one-way and probabilistic sensitivity analyses.  Results: Compared with patients who used crizotinib as first-line treatment, patients in the ceritinib and alectinib groups yielded an addnl. 1.32 and 3.30 QALYs with an incremental cost of $84,728.20 and $339,114.36, resp.  Thus, the incremental cost-effectiveness ratio (ICER) was $64,398.83 and $102,675.74 per QALY in the ceritinib and alectinib groups, resp.  Alectinib was estd. to be more effective (4.68 QALY) and more costly ($432,063.06) with an ICER of $128,019.42 per QALY compared with ceritinib (2.69 QALY and $177,676.90).  Results were robust to deterministic and probabilistic sensitivity analyses.  Conclusion: As a first-line treatment regimen, ceritinib and alectinib can extend the survival time of patients compared with crizotinib, but the medical cost also increases accordingly.  According to the World Health Organization's three-percent GDP measurement, first-line treatment with Crizotinib is the most cost-effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSVZ1aHUJ-x7Vg90H21EOLACvtfcHk0lhBxfI7f4vg4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXns1Gmt7c%253D&md5=09a0d1078417b2e55fac1d0fe6184a66</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2147%2FCMAR.S223441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCMAR.S223441%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DCai%26aufirst%3DH.%26atitle%3DCost-Effectiveness%2520Analysis%2520of%2520Ceritinib%2520and%2520Alectinib%2520Versus%2520Crizotinib%2520in%2520the%2520Treatment%2520of%2520Anaplastic%2520Lymphoma%2520Kinase-Positive%2520Advanced%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DCancer%2520Manage.%2520Res.%26date%3D2019%26volume%3D11%26spage%3D9195%26epage%3D9202%26doi%3D10.2147%2Fcmar.s223441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer Statistics, 2016</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.3322/caac.21332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.3322%2Fcaac.21332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=26742998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2016&pages=7-30&author=R.+L.+Siegelauthor=K.+D.+Millerauthor=A.+Jemal&title=Cancer+Statistics%2C+2016&doi=10.3322%2Fcaac.21332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2016</span></div><div class="casAuthors">Siegel Rebecca L; Miller Kimberly D; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.  Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Cancer Registries.  Mortality data were collected by the National Center for Health Statistics.  In 2016, 1,685,210 new cancer cases and 595,690 cancer deaths are projected to occur in the United States.  Overall cancer incidence trends (13 oldest SEER registries) are stable in women, but declining by 3.1% per year in men (from 2009-2012), much of which is because of recent rapid declines in prostate cancer diagnoses.  The cancer death rate has dropped by 23% since 1991, translating to more than 1.7 million deaths averted through 2012.  Despite this progress, death rates are increasing for cancers of the liver, pancreas, and uterine corpus, and cancer is now the leading cause of death in 21 states, primarily due to exceptionally large reductions in death from heart disease.  Among children and adolescents (aged birth-19 years), brain cancer has surpassed leukemia as the leading cause of cancer death because of the dramatic therapeutic advances against leukemia.  Accelerating progress against cancer requires both increased national investment in cancer research and the application of existing cancer control knowledge across all segments of the population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKAn5ROFAaRS86Js-BCLiifW6udTcc2eamL8pfSiYCnLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rot1Kjug%253D%253D&md5=2d4030a531945c5ebaaab181bfd80457</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21332%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DK.%2BD.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520Statistics%252C%25202016%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2016%26volume%3D66%26spage%3D7%26epage%3D30%26doi%3D10.3322%2Fcaac.21332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzoli, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sause, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker Jr, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strawn, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turrisi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somerfield, M. R.</span></span> <span> </span><span class="NLM_article-title">American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1200/jco.2004.09.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1200%2FJCO.2004.09.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=14691125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FitlektA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2004&pages=330-353&author=D.+G.+Pfisterauthor=D.+H.+Johnsonauthor=C.+G.+Azzoliauthor=W.+Sauseauthor=T.+J.+Smithauthor=S.+Baker+Jrauthor=J.+Olakauthor=D.+Stoverauthor=J.+R.+Strawnauthor=A.+T.+Turrisiauthor=M.+R.+Somerfield&title=American+Society+of+Clinical+Oncology+Treatment+of+Unresectable+Non-Small-Cell+Lung+Cancer+Guideline%3A+Update+2003&doi=10.1200%2Fjco.2004.09.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003</span></div><div class="casAuthors">Pfister David G; Johnson David H; Azzoli Christopher G; Sause William; Smith Thomas J; Baker Sherman Jr; Olak Jemi; Stover Diane; Strawn John R; Turrisi Andrew T; Somerfield Mark R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">330-53</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS1oqRk11s5o75oR8RchjrrfW6udTcc2eYmQ5Qs2BkLPLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FitlektA%253D%253D&md5=fb8675053cacd502ae505270f479c6d7</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1200%2FJCO.2004.09.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2004.09.053%26sid%3Dliteratum%253Aachs%26aulast%3DPfister%26aufirst%3DD.%2BG.%26aulast%3DJohnson%26aufirst%3DD.%2BH.%26aulast%3DAzzoli%26aufirst%3DC.%2BG.%26aulast%3DSause%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DT.%2BJ.%26aulast%3DBaker%2BJr%26aufirst%3DS.%26aulast%3DOlak%26aufirst%3DJ.%26aulast%3DStover%26aufirst%3DD.%26aulast%3DStrawn%26aufirst%3DJ.%2BR.%26aulast%3DTurrisi%26aufirst%3DA.%2BT.%26aulast%3DSomerfield%26aufirst%3DM.%2BR.%26atitle%3DAmerican%2520Society%2520of%2520Clinical%2520Oncology%2520Treatment%2520of%2520Unresectable%2520Non-Small-Cell%2520Lung%2520Cancer%2520Guideline%253A%2520Update%25202003%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2004%26volume%3D22%26spage%3D330%26epage%3D353%26doi%3D10.1200%2Fjco.2004.09.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopci, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, S.</span></span> <span> </span><span class="NLM_article-title">Tumor Metabolism and Prognostic Role of EZH2 in Non-Small Cell Lung Cancer</span>. <i>Transl. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">S982</span>– <span class="NLM_lpage">S988</span>, <span class="refDoi"> DOI: 10.21037/tcr.2017.06.42</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.21037%2Ftcr.2017.06.42" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVKqsLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=S982-S988&author=E.+Lopciauthor=S.+Rossi&title=Tumor+Metabolism+and+Prognostic+Role+of+EZH2+in+Non-Small+Cell+Lung+Cancer&doi=10.21037%2Ftcr.2017.06.42"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor metabolism and prognostic role of EZH2 in non-small cell lung cancer</span></div><div class="casAuthors">Lopci, Egesta; Rossi, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">Translational Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Suppl.6</span>),
    <span class="NLM_cas:pages">S982-S988</span>CODEN:
                <span class="NLM_cas:coden">TCRRCN</span>;
        ISSN:<span class="NLM_cas:issn">2219-6803</span>.
    
            (<span class="NLM_cas:orgname">AME Publishing Co.</span>)
        </div><div class="casAbstract">A review discussing the tumor metab. and prognostic role of EZH2 in non-small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4ve3OuQaf8bVg90H21EOLACvtfcHk0liLgL1PUDSVTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVKqsLbN&md5=9b6bdfe6c3c896a0e6d43fef846f7d3f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.21037%2Ftcr.2017.06.42&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21037%252Ftcr.2017.06.42%26sid%3Dliteratum%253Aachs%26aulast%3DLopci%26aufirst%3DE.%26aulast%3DRossi%26aufirst%3DS.%26atitle%3DTumor%2520Metabolism%2520and%2520Prognostic%2520Role%2520of%2520EZH2%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DTransl.%2520Cancer%2520Res.%26date%3D2017%26volume%3D6%26spage%3DS982%26epage%3DS988%26doi%3D10.21037%2Ftcr.2017.06.42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagasaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M.</span></span> <span> </span><span class="NLM_article-title">Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1080/14737140.2018.1409624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1080%2F14737140.2018.1409624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=29168933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOhs77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=63-70&author=M.+Nagasakaauthor=S.+M.+Gadgeel&title=Role+of+Chemotherapy+and+Targeted+Therapy+in+Early-Stage+Non-Small+Cell+Lung+Cancer&doi=10.1080%2F14737140.2018.1409624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer</span></div><div class="casAuthors">Nagasaka, Misako; Gadgeel, Shirish M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-70</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Adjuvant platinum based chemotherapy is accepted as std. of care in stage II and III non-small cell lung cancer (NSCLC) patients and is often considered in patients with stage IB disease who have tumors ≥ 4 cm.  The survival advantage is modest with approx. 5% at 5 years.: This review article presents relevant data regarding chemotherapy use in the perioperative setting for early stage NSCLC.  A literature search was performed utilizing PubMed as well as clin. trial.gov.  Randomized phase III studies in this setting including adjuvant and neoadjuvant use of chemotherapy as well as ongoing trials on targeted therapy and immunotherapy are also discussed.: With increasing utilization of screening computed tomog. scans, it is possible that the percentage of early stage NSCLC patients will increase in the coming years.  Benefits of adjuvant chemotherapy in early stage NSCLC patients remain modest.  There is a need to better define patients most likely to derive survival benefit from adjuvant therapy and spare patients who do not need adjuvant chemotherapy due to the toxicity of such therapy.  Trials for adjuvant targeted therapy, including adjuvant EGFR-TKI trials and trials of immunotherapy drugs are ongoing and will define the role of these agents as adjuvant therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Z5tZ5uITYLVg90H21EOLACvtfcHk0liLgL1PUDSVTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOhs77I&md5=7eba1acf84c1d9cb9a0db63c02329d0d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1080%2F14737140.2018.1409624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737140.2018.1409624%26sid%3Dliteratum%253Aachs%26aulast%3DNagasaka%26aufirst%3DM.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26atitle%3DRole%2520of%2520Chemotherapy%2520and%2520Targeted%2520Therapy%2520in%2520Early-Stage%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2018%26volume%3D18%26spage%3D63%26epage%3D70%26doi%3D10.1080%2F14737140.2018.1409624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A. T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, P. M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiou, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.-Y. F.</span></span> <span> </span><span class="NLM_article-title">Trifluoperazine, an Antipsychotic Agent, Inhibits Cancer Stem Cell Growth and Overcomes Drug Resistance of Lung Cancer</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">1180</span>– <span class="NLM_lpage">1188</span>, <span class="refDoi"> DOI: 10.1164/rccm.201207-1180oc</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1164%2Frccm.201207-1180OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=23024022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2012&pages=1180-1188&author=C.-T.+Yehauthor=A.+T.+H.+Wuauthor=P.+M.-H.+Changauthor=K.-Y.+Chenauthor=C.-N.+Yangauthor=S.-C.+Yangauthor=C.-C.+Hoauthor=C.-C.+Chenauthor=Y.-L.+Kuoauthor=P.-Y.+Leeauthor=Y.-W.+Liuauthor=C.-C.+Yenauthor=M.+Hsiaoauthor=P.-J.+Luauthor=J.-M.+Laiauthor=L.-S.+Wangauthor=C.-H.+Wuauthor=J.-F.+Chiouauthor=P.-C.+Yangauthor=C.-Y.+F.+Huang&title=Trifluoperazine%2C+an+Antipsychotic+Agent%2C+Inhibits+Cancer+Stem+Cell+Growth+and+Overcomes+Drug+Resistance+of+Lung+Cancer&doi=10.1164%2Frccm.201207-1180oc"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer</span></div><div class="casAuthors">Yeh, Chi-Tai; Wu, Alexander T. H.; Chang, Peter M.-H.; Chen, Kuan-Yu; Yang, Chia-Ning; Yang, Shuenn-Chen; Ho, Chao-Chi; Chen, Chun-Chi; Kuo, Yu-Lun; Lee, Pei-Ying; Liu, Yu-Wen; Yen, Chueh-Chuan; Hsiao, Michael; Lu, Pei-Jung; Lai, Jin-Mei; Wang, Liang-Shun; Wu, Chih-Hsiung; Chiou, Jeng-Fong; Yang, Pan-Chyr; Huang, Chi-Ying F.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1180-1188</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Cancer stem cell (CSC) theory has drawn much attention, with evidence supporting the contribution of stem cells to tumor initiation, relapse, and therapy resistance.  Objectives: To screen drugs that target CSCs to improve the current treatment outcome and overcome drug resistance in patients with lung cancer.  Methods: We used publicly available embryonic stem cell and CSC-assocd. gene signatures to query the Connectivity Map for potential drugs that can, at least in part, reverse the gene expression profile of CSCs.  High scores were noted for several phenothiazine-like antipsychotic drugs, including trifluoperazine.  We then treated lung CSCs with different EGFR mutation status with trifluoperazine to examine its anti-CSC properties.  Lung CSCs resistant to epidermal growth factor receptor-tyrosine kinase inhibitor or cisplatin were treated with trifluoperazine plus gefitinib or trifluoperazine plus cisplatin.  Animal models were used for in vivo validation of the anti-CSC effect and synergistic effect of trifluoperazine with gefitinib.  Measurements and Main Results: We demonstrated that trifluoperazine inhibited CSC tumor spheroid formation and down-regulated the expression of CSC markers (CD44/CD133).  Trifluoperazine inhibited Wnt/β-catenin signaling in gefitinib-resistant lung cancer spheroids.  The combination of trifluoperazine with either gefitinib or cisplatin overcame drug resistance in lung CSCs.  Trifluoperazine inhibited the tumor growth and enhanced the inhibitory activity of gefitinib in lung cancer metastatic and orthotopic CSC animal models.  Conclusions: Using in silico drug screening by Connectivity Map followed by empirical validations, we repurposed an existing phenothiazine-like antipsychotic drug, trifluoperazine, as a potential anti-CSC agent that could overcome epidermal growth factor receptor-tyrosine kinase inhibitor and chemotherapy resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPf24lWeMWQbVg90H21EOLACvtfcHk0lgeZQ877uksgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOjtro%253D&md5=0bc2a899c88f4f891170194d22a32de9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1164%2Frccm.201207-1180OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201207-1180OC%26sid%3Dliteratum%253Aachs%26aulast%3DYeh%26aufirst%3DC.-T.%26aulast%3DWu%26aufirst%3DA.%2BT.%2BH.%26aulast%3DChang%26aufirst%3DP.%2BM.-H.%26aulast%3DChen%26aufirst%3DK.-Y.%26aulast%3DYang%26aufirst%3DC.-N.%26aulast%3DYang%26aufirst%3DS.-C.%26aulast%3DHo%26aufirst%3DC.-C.%26aulast%3DChen%26aufirst%3DC.-C.%26aulast%3DKuo%26aufirst%3DY.-L.%26aulast%3DLee%26aufirst%3DP.-Y.%26aulast%3DLiu%26aufirst%3DY.-W.%26aulast%3DYen%26aufirst%3DC.-C.%26aulast%3DHsiao%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DP.-J.%26aulast%3DLai%26aufirst%3DJ.-M.%26aulast%3DWang%26aufirst%3DL.-S.%26aulast%3DWu%26aufirst%3DC.-H.%26aulast%3DChiou%26aufirst%3DJ.-F.%26aulast%3DYang%26aufirst%3DP.-C.%26aulast%3DHuang%26aufirst%3DC.-Y.%2BF.%26atitle%3DTrifluoperazine%252C%2520an%2520Antipsychotic%2520Agent%252C%2520Inhibits%2520Cancer%2520Stem%2520Cell%2520Growth%2520and%2520Overcomes%2520Drug%2520Resistance%2520of%2520Lung%2520Cancer%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2012%26volume%3D186%26spage%3D1180%26epage%3D1188%26doi%3D10.1164%2Frccm.201207-1180oc" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prasetyanti, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medema, J. P.</span></span> <span> </span><span class="NLM_article-title">Intra-Tumor Heterogeneity from a Cancer Stem Cell Perspective</span>. <i>Mol. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">41</span>, <span class="refDoi"> DOI: 10.1186/s12943-017-0600-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1186%2Fs12943-017-0600-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=28209166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1CrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=41&author=P.+R.+Prasetyantiauthor=J.+P.+Medema&title=Intra-Tumor+Heterogeneity+from+a+Cancer+Stem+Cell+Perspective&doi=10.1186%2Fs12943-017-0600-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Intra-tumor heterogeneity from a cancer stem cell perspective</span></div><div class="casAuthors">Prasetyanti, Pramudita R.; Medema, Jan Paul.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41/1-41/9</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Tumor heterogeneity represents an ongoing challenge in the field of cancer therapy.  Heterogeneity is evident between cancers from different patients (inter-tumor heterogeneity) and within a single tumor (intra-tumor heterogeneity).  The latter includes phenotypic diversity such as cell surface markers, (epi)genetic abnormality, growth rate, apoptosis and other hallmarks of cancer that eventually drive disease progression and treatment failure.  Cancer stem cells (CSCs) have been put forward to be one of the detg. factors that contribute to intra-tumor heterogeneity.  However, recent findings have shown that the stem-like state in a given tumor cell is a plastic quality.  A corollary to this view is that stemness traits can be acquired via (epi)genetic modification and/or interaction with the tumor microenvironment (TME).  Here we discuss factors contributing to this CSC heterogeneity and the potential implications for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUKLdoGrUZEbVg90H21EOLACvtfcHk0lgeZQ877uksgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1CrsLo%253D&md5=c407c6d6c1ecaaebaa6f4f333757dbe2</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1186%2Fs12943-017-0600-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-017-0600-4%26sid%3Dliteratum%253Aachs%26aulast%3DPrasetyanti%26aufirst%3DP.%2BR.%26aulast%3DMedema%26aufirst%3DJ.%2BP.%26atitle%3DIntra-Tumor%2520Heterogeneity%2520from%2520a%2520Cancer%2520Stem%2520Cell%2520Perspective%26jtitle%3DMol.%2520Canc.%26date%3D2017%26volume%3D16%26spage%3D41%26doi%3D10.1186%2Fs12943-017-0600-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pattabiraman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Tackling the cancer stem cells - what challenges do they pose?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1038/nrd4253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fnrd4253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=24981363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOisbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=497-512&author=D.+R.+Pattabiramanauthor=R.+A.+Weinberg&title=Tackling+the+cancer+stem+cells+-+what+challenges+do+they+pose%3F&doi=10.1038%2Fnrd4253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Tackling the cancer stem cells - what challenges do they pose?</span></div><div class="casAuthors">Pattabiraman, Diwakar R.; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">497-512</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since their identification in 1994, cancer stem cells (CSCs) have been objects of intensive study.  Their properties and mechanisms of formation have become a major focus of current cancer research, in part because of their enhanced ability to initiate and drive tumor growth and their intrinsic resistance to conventional therapeutics.  The discovery that activation of the epithelial-to-mesenchymal transition (EMT) program in carcinoma cells can give rise to cells with stem-like properties has provided one possible mechanism explaining how CSCs arise and presents a possible avenue for their therapeutic manipulation.  Here we address recent developments in CSC research, focusing on carcinomas that are able to undergo EMT.  We discuss the signalling pathways that create these cells, cell-intrinsic mechanisms that could be exploited for selective elimination or induction of their differentiation, and the role of the tumor microenvironment in sustaining them.  Finally, we propose ways to use our current knowledge of the complex biol. of CSCs to design novel therapies to eliminate them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHXcwOZJN_67Vg90H21EOLACvtfcHk0lgeZQ877uksgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOisbzI&md5=db211f41b19198981cb37487b7a9abc3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrd4253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4253%26sid%3Dliteratum%253Aachs%26aulast%3DPattabiraman%26aufirst%3DD.%2BR.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DTackling%2520the%2520cancer%2520stem%2520cells%2520-%2520what%2520challenges%2520do%2520they%2520pose%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D497%26epage%3D512%26doi%3D10.1038%2Fnrd4253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martins-Neves, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleton-Jansen, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, C. M. F.</span></span> <span> </span><span class="NLM_article-title">Therapy-Induced Enrichment of Cancer Stem-Like Cells in Solid Human Tumors: Where do We Stand?</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2018.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2Fj.phrs.2018.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=30316903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKksLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2018&pages=193-204&author=S.+R.+Martins-Nevesauthor=A.-M.+Cleton-Jansenauthor=C.+M.+F.+Gomes&title=Therapy-Induced+Enrichment+of+Cancer+Stem-Like+Cells+in+Solid+Human+Tumors%3A+Where+do+We+Stand%3F&doi=10.1016%2Fj.phrs.2018.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Therapy-induced enrichment of cancer stem-like cells in solid human tumors: Where do we stand</span></div><div class="casAuthors">Martins-Neves, Sara R.; Cleton-Jansen, Anne-Marie; Gomes, Celia M. F.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">193-204</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of local recurrence and metastatic disease, most probably attributable to the intrinsic or acquired resistance of tumor cells to std. therapy, still constitute the major clin. problem preventing the cure of cancer patients.  Despite progress in the research of new therapeutic targets and compds., resistant cells displaying stem-like properties seem to play a leading role in therapeutic failures and to be the culprit cells responsible for assocd. tumor recurrence.  A whole new plethora of research studies suggest that drug-tolerant cancer stem cells may be induced by conventional cancer chemotherapeutics such as doxorubicin, cisplatinum and ionizing radiation.  This phenotypic plasticity and transition from a differentiated to stem-like cell state assocs. with the activation of diverse stem cell self-renewal (e.g. Notch, Hedgehog, Wnt), drug efflux (e.g. ABC transporters) and survival-related pathways (e.g. TGF-β, ERK, AKT), which may confer resistance and treatment failures in solid tumors.  Therefore, combined therapeutic strategies aiming to simultaneously target drug-sensitive tumor cells and their capacity of phenotypic switching may lead to survival benefits and meaningful disease remissions.  This knowledge can be applicable to the clinic and contribute to better therapeutic outcomes and prevent tumor recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDE6ThuyN1AbVg90H21EOLACvtfcHk0lhHlnZ2uE4oFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKksLfJ&md5=f68fae306b461bdd2c3b4496dc89cfe1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2018.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2018.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DMartins-Neves%26aufirst%3DS.%2BR.%26aulast%3DCleton-Jansen%26aufirst%3DA.-M.%26aulast%3DGomes%26aufirst%3DC.%2BM.%2BF.%26atitle%3DTherapy-Induced%2520Enrichment%2520of%2520Cancer%2520Stem-Like%2520Cells%2520in%2520Solid%2520Human%2520Tumors%253A%2520Where%2520do%2520We%2520Stand%253F%26jtitle%3DPharmacol.%2520Res.%26date%3D2018%26volume%3D137%26spage%3D193%26epage%3D204%26doi%3D10.1016%2Fj.phrs.2018.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tirino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desiderio, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rosa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaccio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Noce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaccio, G.</span></span> <span> </span><span class="NLM_article-title">Cancer Stem Cells in Solid Tumors: An Overview and New Approaches for Their Isolation and Characterization</span>. <i>Faseb. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1096/fj.12-218222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1096%2Ffj.12-218222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=23024375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Gqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=13-24&author=V.+Tirinoauthor=V.+Desiderioauthor=F.+Painoauthor=A.+De+Rosaauthor=F.+Papaccioauthor=M.+La+Noceauthor=L.+Lainoauthor=F.+De+Francescoauthor=G.+Papaccio&title=Cancer+Stem+Cells+in+Solid+Tumors%3A+An+Overview+and+New+Approaches+for+Their+Isolation+and+Characterization&doi=10.1096%2Ffj.12-218222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization</span></div><div class="casAuthors">Tirino, Virginia; Desiderio, Vincenzo; Paino, Francesca; De Rosa, Alfredo; Papaccio, Federica; La Noce, Marcella; Laino, Luigi; De Francesco, Francesco; Papaccio, Gianpaolo</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-24, 10.1096/fj.12-218222</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review.  Primary tumors are responsible for 10% of cancer deaths.  In most cases, the main cause of mortality is the formation of metastases.  Accumulating evidence suggests that a subpopulation of tumor cells with distinct stem-like properties is responsible for tumor initiation, invasive growth, and metastasis formation.  This population is defined as cancer stem cells (CSCs).  Existing therapies have enhanced the length of survival after diagnosis of cancer but have completely failed in terms of recovery.  CSCs appear to be resistant to chemotherapy, may remain quiescent for extended periods, and have affinity for hypoxic environments.  The CSCs can be identified and isolated by different methodologies, including isolation by CSC-specific cell surface marker expression, detection of side population phenotype by Hoechst 33342 exclusion, assessment of their ability to grow as floating spheres, and aldehyde dehydrogenase (ALDH) activity assay.  None of the methods mentioned are exclusively used to isolate the solid tumor CSCs, highlighting the imperative to delineate more specific markers or to use combinatorial markers and methodologies.  This review provides an overview of the main characteristics and approaches used to identify, isolate, and characterize CSCs from solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKHEZT73U6-bVg90H21EOLACvtfcHk0lhHlnZ2uE4oFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Gqtw%253D%253D&md5=de33a9ff83242808595b3772fac12f5d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1096%2Ffj.12-218222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.12-218222%26sid%3Dliteratum%253Aachs%26aulast%3DTirino%26aufirst%3DV.%26aulast%3DDesiderio%26aufirst%3DV.%26aulast%3DPaino%26aufirst%3DF.%26aulast%3DDe%2BRosa%26aufirst%3DA.%26aulast%3DPapaccio%26aufirst%3DF.%26aulast%3DLa%2BNoce%26aufirst%3DM.%26aulast%3DLaino%26aufirst%3DL.%26aulast%3DDe%2BFrancesco%26aufirst%3DF.%26aulast%3DPapaccio%26aufirst%3DG.%26atitle%3DCancer%2520Stem%2520Cells%2520in%2520Solid%2520Tumors%253A%2520An%2520Overview%2520and%2520New%2520Approaches%2520for%2520Their%2520Isolation%2520and%2520Characterization%26jtitle%3DFaseb.%2520J.%26date%3D2013%26volume%3D27%26spage%3D13%26epage%3D24%26doi%3D10.1096%2Ffj.12-218222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Cellular Processing of Platinum Anticancer Drugs</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1038/nrd1691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fnrd1691" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=307-320&author=D.+Wangauthor=S.+J.+Lippard&title=Cellular+Processing+of+Platinum+Anticancer+Drugs&doi=10.1038%2Fnrd1691"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd1691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1691%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DCellular%2520Processing%2520of%2520Platinum%2520Anticancer%2520Drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D4%26spage%3D307%26epage%3D320%26doi%3D10.1038%2Fnrd1691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment</span>. <i>Dalton Trans.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2536</span>– <span class="NLM_lpage">2544</span>, <span class="refDoi"> DOI: 10.1039/c8dt03923b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1039%2FC8DT03923B" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=30633263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktF2isQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2019&pages=2536-2544&author=Z.+Wangauthor=Z.+Dengauthor=G.+Zhu&title=Emerging+platinum%28iv%29+prodrugs+to+combat+cisplatin+resistance%3A+from+isolated+cancer+cells+to+tumor+microenvironment&doi=10.1039%2Fc8dt03923b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging platinum(IV) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment</span></div><div class="casAuthors">Wang, Zhigang; Deng, Zhiqin; Zhu, Guangyu</div><div class="citationInfo"><span class="NLM_cas:title">Dalton Transactions</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2536-2544</span>CODEN:
                <span class="NLM_cas:coden">DTARAF</span>;
        ISSN:<span class="NLM_cas:issn">1477-9226</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Cisplatin plays a pivotal role in the treatment of various malignant tumors, but its therapeutic effects are hampered by drug resistance.  Pt(IV) prodrugs represent a promising class of "non-conventional" platinum-based anticancer agents to circumvent drug resistance, which can be easily functionalized with other bioactive ligands.  One strategy is to build "dual-action" and "multi-action" Pt(IV) prodrugs that not only damage DNA but also perturb other pathways related to cisplatin resistance to achieve combinatorial therapeutic effects.  Another way to overcome the shortcomings of cisplatin is to deliver Pt(IV) prodrugs via nanocarriers.  Most studies in this area have focused on designing prodrugs based on the mechanism of cisplatin resistance within isolated cancer cells.  Recent findings, however, reveal that the tumor microenvironment also plays important roles in the development of cisplatin resistance.  This perspective focuses on various types of novel cisplatin-based Pt(IV) complexes, including Pt-loaded nanostructures, to overcome cisplatin resistance.  Special attention will be devoted to complexes that target the tumor microenvironment, which is a new area for the development of effective Pt(IV) prodrugs.  Our summary and outlook may have a hope to help researchers in the field generate new ideas and strategies to develop more potent Pt(IV) prodrugs to combat cisplatin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocJ9QZUedvprVg90H21EOLACvtfcHk0lhHlnZ2uE4oFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktF2isQ%253D%253D&md5=1ce9e12e6df323a99b90cbbf951f65c3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1039%2FC8DT03923B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8DT03923B%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DDeng%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DEmerging%2520platinum%2528iv%2529%2520prodrugs%2520to%2520combat%2520cisplatin%2520resistance%253A%2520from%2520isolated%2520cancer%2520cells%2520to%2520tumor%2520microenvironment%26jtitle%3DDalton%2520Trans.%26date%3D2019%26volume%3D48%26spage%3D2536%26epage%3D2544%26doi%3D10.1039%2Fc8dt03923b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Apps, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, E. H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheate, N. J.</span></span> <span> </span><span class="NLM_article-title">The State-of-Play and Future of Platinum Drugs</span>. <i>Endocr. Relat. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1530/erc-15-0237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1530%2FERC-15-0237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvVClsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=219-233&author=M.+G.+Appsauthor=E.+H.+Y.+Choiauthor=N.+J.+Wheate&title=The+State-of-Play+and+Future+of+Platinum+Drugs&doi=10.1530%2Ferc-15-0237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The state-of-play and future of platinum drugs</span></div><div class="casAuthors">Apps, Michael G.; Choi, Eugene H. Y.; Wheate, Nial J.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">R219-R233</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">The year 2015 marks the 50th anniversary since the discovery of the anticancer potential of cisplatin and it remains just as useful now as it did back then, esp. for the treatment of some endocrine-related cancers like ovarian and testicular carcinomas.  Since its discovery, five other platin drugs have received approval in various countries.  While several new platin drugs are in preclin. development, in the last decade only two new platin drugs have entered clin. trials, LA-12 and dicycloplatin, reflecting a shift in research focus from new drug design to improved formulations of already approved platin drugs.  These formulations include their encapsulation with macrocycles to slow and prevent their degrdn. by proteins and peptides; their attachment to nanoparticles to passively target solid tumors through the enhanced permeability and retention effect and their coordination to important nutrients, proteins, antibodies and aptamers for active tumor targeting.  These formulation methods have all shown potential but none have yet yielded a new marketable medicine contg. a platin drug.  The reasons for this are problems of consistent drug loading, controlling the location and timing of drug release and the inherent toxicity of some of the drug delivery vehicles.  In addn. to drug delivery, functional genomics is now playing an increasing role in predicting patients' responses to platin chemotherapy and their likelihood of experiencing severe side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkV12nqK95QLVg90H21EOLACvtfcHk0lg3dROUGP7QpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvVClsbs%253D&md5=221eda4371079fc14147e2192b977ee8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1530%2FERC-15-0237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FERC-15-0237%26sid%3Dliteratum%253Aachs%26aulast%3DApps%26aufirst%3DM.%2BG.%26aulast%3DChoi%26aufirst%3DE.%2BH.%2BY.%26aulast%3DWheate%26aufirst%3DN.%2BJ.%26atitle%3DThe%2520State-of-Play%2520and%2520Future%2520of%2520Platinum%2520Drugs%26jtitle%3DEndocr.%2520Relat.%2520Canc.%26date%3D2015%26volume%3D22%26spage%3D219%26epage%3D233%26doi%3D10.1530%2Ferc-15-0237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galanski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakupec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, B.</span></span> <span> </span><span class="NLM_article-title">Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2075</span>– <span class="NLM_lpage">2094</span>, <span class="refDoi"> DOI: 10.2174/0929867054637626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.2174%2F0929867054637626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=16101495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFCls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=2075-2094&author=M.+Galanskiauthor=M.+Jakupecauthor=B.+Keppler&title=Update+of+the+Preclinical+Situation+of+Anticancer+Platinum+Complexes%3A+Novel+Design+Strategies+and+Innovative+Analytical+Approaches&doi=10.2174%2F0929867054637626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Update of the preclinical situation of anticancer platinum complexes: Novel design strategies and innovative analytical approaches</span></div><div class="casAuthors">Galanski, Markus; Jakupec, Michael A.; Keppler, Bernhard K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2075-2094</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Research in the field of bioinorg. chem. has been stimulated by the worldwide success of the anticancer drug cisplatin.  40 Years after the first report about its biol. activity, carboplatin and oxaliplatin are in routine clin. use today, whereas nedaplatin, lobaplatin, and heptaplatin (SKI2053R) are only approved in Japan, China, and South Korea, resp.  Up to now, about 35 platinum complexes entered clin. trials to circumvent the side-effects and the problem of tumor resistance to cisplatin.  Addnl., improvement of tumor selectivity as well as the need for a broader spectrum of indications are the motivations for tremendous efforts in the development of novel anticancer platinum-based drugs.  New synthetic strategies and innovative anal. approaches provide a basis for a deeper understanding of the pharmacol. profile of cisplatin and analogs (biodistribution, clearance, detoxification, side-effects, tumor specificity, cellular uptake, acquired or intrinsic resistance, platinum-DNA adduct removal by the cellular machinery) and give rise to a rational design of promising anticancer platinum coordination compds.  This article reviews the recent development of preclin. platinum complexes with interesting in vitro and in vivo tumor inhibiting properties.  It focuses also on innovative synthetic strategies leading to novel classes of platinum complexes.  A small part of the review is dedicated to new anal. approaches which have been supplied to or emerged in this field of research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeeK9fKeT-F7Vg90H21EOLACvtfcHk0lg3dROUGP7QpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFCls7o%253D&md5=14606280f6c1db32323926741138fb73</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F0929867054637626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867054637626%26sid%3Dliteratum%253Aachs%26aulast%3DGalanski%26aufirst%3DM.%26aulast%3DJakupec%26aufirst%3DM.%26aulast%3DKeppler%26aufirst%3DB.%26atitle%3DUpdate%2520of%2520the%2520Preclinical%2520Situation%2520of%2520Anticancer%2520Platinum%2520Complexes%253A%2520Novel%2520Design%2520Strategies%2520and%2520Innovative%2520Analytical%2520Approaches%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2005%26volume%3D12%26spage%3D2075%26epage%3D2094%26doi%3D10.2174%2F0929867054637626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayub, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zia-ur-Rehman, I.</span></span> <span> </span><span class="NLM_article-title">Photoactivated Platinum-Based Anticancer Drugs</span>. <i>Coord. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">429</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2018.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2Fj.ccr.2018.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1entbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2018&pages=405-429&author=M.+Imranauthor=W.+Ayubauthor=I.+S.+Butlerauthor=I.+Zia-ur-Rehman&title=Photoactivated+Platinum-Based+Anticancer+Drugs&doi=10.1016%2Fj.ccr.2018.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Photoactivated platinum-based anticancer drugs</span></div><div class="casAuthors">Imran, Muhammad; Ayub, Wagma; Butler, Ian S.; Zia-ur-Rehman</div><div class="citationInfo"><span class="NLM_cas:title">Coordination Chemistry Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">405-429</span>CODEN:
                <span class="NLM_cas:coden">CCHRAM</span>;
        ISSN:<span class="NLM_cas:issn">0010-8545</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Following the serendipitous discovery of the anticancer drug, cisplatin, numerous platinum(II) complexes have been synthesized and some of them, such as carboplatin, oxaliplatin, nedaplatin, heptaplatin and lobaplatin, have been clin. approved either locally or worldwide.  Since these drugs are structurally related to cisplatin, the unfortunate problems that are assocd. with cisplatin are more or less the same for them.  To overcome these problems, octahedral, low-spin d6 and coordinatively satd. Pt(IV) complexes have been examd. because of their substitution inertness towards off-target biomols.  Owing to the availability of bio-reducing agents, mainly proteins, in all cell types, Pt(IV) prodrugs can be reduced to their cytotoxic active Pt(II) analogs in both cancer and normal cells.  However, prolonged hydrolysis and less stability against bio-reducing agents are problems still to be overcome.  To address the passive activation of Pt(IV) prodrugs, the choice of photoactivated Pt(IV) prodrugs seems to be a promising chemotherapeutic strategy.  Therefore, iodo-based photolabile Pt(IV) complexes which, upon light exposure, undergo photolytic reactions to give active Pt(II) species have been developed.  Unfortunately, these complexes had to be later discarded because of their low stability in the dark.  Eventually, azido-based complexes with enhanced stability in the dark were developed.  The selective photoactivation of these photolabile azido-based Pt(IV) prodrugs has dramatically opened up new avenues of research aimed at overcoming the problems assocd. with chemotherapeutic drug delivery by incorporating different polymers, biol. target mols., permeation enhancers or nanoparticles.  These photolabile complexes are the focus of the present review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA-BWgK4qkqLVg90H21EOLACvtfcHk0lg3dROUGP7QpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1entbrN&md5=61d0e5f94e6b70aa7f3145573dd833a0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2018.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2018.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DImran%26aufirst%3DM.%26aulast%3DAyub%26aufirst%3DW.%26aulast%3DButler%26aufirst%3DI.%2BS.%26aulast%3DZia-ur-Rehman%26aufirst%3DI.%26atitle%3DPhotoactivated%2520Platinum-Based%2520Anticancer%2520Drugs%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2018%26volume%3D376%26spage%3D405%26epage%3D429%26doi%3D10.1016%2Fj.ccr.2018.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Czarnomysy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surażyński, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muszynska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gornowicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawski, K.</span></span> <span> </span><span class="NLM_article-title">A Novel Series of Pyrazole-Platinum(II) Complexes as Potential Anti-Cancer Agents that Induce Cell Cycle Arrest and Apoptosis in Breast Cancer Cells</span>. <i>J. Enzym. Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1006</span>– <span class="NLM_lpage">1023</span>, <span class="refDoi"> DOI: 10.1080/14756366.2018.1471687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1080%2F14756366.2018.1471687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=29862867" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=1006-1023&author=R.+Czarnomysyauthor=A.+Sura%C5%BCy%C5%84skiauthor=A.+Muszynskaauthor=A.+Gornowiczauthor=A.+Bielawskaauthor=K.+Bielawski&title=A+Novel+Series+of+Pyrazole-Platinum%28II%29+Complexes+as+Potential+Anti-Cancer+Agents+that+Induce+Cell+Cycle+Arrest+and+Apoptosis+in+Breast+Cancer+Cells&doi=10.1080%2F14756366.2018.1471687"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1080%2F14756366.2018.1471687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2018.1471687%26sid%3Dliteratum%253Aachs%26aulast%3DCzarnomysy%26aufirst%3DR.%26aulast%3DSura%25C5%25BCy%25C5%2584ski%26aufirst%3DA.%26aulast%3DMuszynska%26aufirst%3DA.%26aulast%3DGornowicz%26aufirst%3DA.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DBielawski%26aufirst%3DK.%26atitle%3DA%2520Novel%2520Series%2520of%2520Pyrazole-Platinum%2528II%2529%2520Complexes%2520as%2520Potential%2520Anti-Cancer%2520Agents%2520that%2520Induce%2520Cell%2520Cycle%2520Arrest%2520and%2520Apoptosis%2520in%2520Breast%2520Cancer%2520Cells%26jtitle%3DJ.%2520Enzym.%2520Inhib.%2520Med.%2520Chem.%26date%3D2018%26volume%3D33%26spage%3D1006%26epage%3D1023%26doi%3D10.1080%2F14756366.2018.1471687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senovilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kepp, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castedo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms of Cisplatin Resistance</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1869</span>– <span class="NLM_lpage">1883</span>, <span class="refDoi"> DOI: 10.1038/onc.2011.384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fonc.2011.384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=21892204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFWrsr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=1869-1883&author=L.+Galluzziauthor=L.+Senovillaauthor=I.+Vitaleauthor=J.+Michelsauthor=I.+Martinsauthor=O.+Keppauthor=M.+Castedoauthor=G.+Kroemer&title=Molecular+Mechanisms+of+Cisplatin+Resistance&doi=10.1038%2Fonc.2011.384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of cisplatin resistance</span></div><div class="casAuthors">Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1869-1883</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers.  Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent (and best understood) mode of action involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of mitochondrial apoptosis.  Despite a consistent rate of initial responses, cisplatin treatment often results in the development of chemoresistance, leading to therapeutic failure.  An intense research has been conducted during the past 30 years and several mechanisms that account for the cisplatin-resistant phenotype of tumor cells have been described.  Here, we provide a systematic discussion of these mechanism by classifying them in alterations (1) that involve steps preceding the binding of cisplatin to DNA (pre-target resistance), (2) that directly relate to DNA-cisplatin adducts (on-target resistance), (3) concerning the lethal signaling pathway(s) elicited by cisplatin-mediated DNA damage (post-target resistance) and (4) affecting mol. circuitries that do not present obvious links with cisplatin-elicited signals (off-target resistance).  As in some clin. settings cisplatin constitutes the major therapeutic option, the development of chemosensitization strategies constitute a goal with important clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxTrgUhh4V17Vg90H21EOLACvtfcHk0li3C6A8C80cHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFWrsr7E&md5=4f947e6d5b834673b819e88b06309a53</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fonc.2011.384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2011.384%26sid%3Dliteratum%253Aachs%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DSenovilla%26aufirst%3DL.%26aulast%3DVitale%26aufirst%3DI.%26aulast%3DMichels%26aufirst%3DJ.%26aulast%3DMartins%26aufirst%3DI.%26aulast%3DKepp%26aufirst%3DO.%26aulast%3DCastedo%26aufirst%3DM.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DMolecular%2520Mechanisms%2520of%2520Cisplatin%2520Resistance%26jtitle%3DOncogene%26date%3D2012%26volume%3D31%26spage%3D1869%26epage%3D1883%26doi%3D10.1038%2Fonc.2011.384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelland, L.</span></span> <span> </span><span class="NLM_article-title">The Resurgence of Platinum-Based Cancer Chemotherapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">584</span>, <span class="refDoi"> DOI: 10.1038/nrc2167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fnrc2167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=17625587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotVKru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=573-584&author=L.+Kelland&title=The+Resurgence+of+Platinum-Based+Cancer+Chemotherapy&doi=10.1038%2Fnrc2167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of platinum-based cancer chemotherapy</span></div><div class="casAuthors">Kelland, Lloyd</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">573-584</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The accidental discovery of the anticancer properties of cisplatin and its clin. introduction in the 1970s represent a major landmark in the history of successful anticancer drugs.  Although carboplatin - a second-generation analog that is safer but shows a similar spectrum of activity to cisplatin - was introduced in the 1980s, the pace of further improvements slowed for many years.  However, in the past several years interest in platinum drugs has increased.  Key developments include the elucidation of mechanisms of tumor resistance to these drugs, the introduction of new platinum-based agents (oxaliplatin, satraplatin and picoplatin), and clin. combination studies using platinum drugs with resistance modulators or new molecularly targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTEI4HRCjxQrVg90H21EOLACvtfcHk0li3C6A8C80cHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotVKru7c%253D&md5=9d55f600a83a19d7836a2524de20efbf</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrc2167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2167%26sid%3Dliteratum%253Aachs%26aulast%3DKelland%26aufirst%3DL.%26atitle%3DThe%2520Resurgence%2520of%2520Platinum-Based%2520Cancer%2520Chemotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D573%26epage%3D584%26doi%3D10.1038%2Fnrc2167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Black, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santin, A.</span></span> <span> </span><span class="NLM_article-title">Clostridium Perfringens Enterotoxin (CPE) and CPE-Binding Domain (<i>c</i>-CPE) for the Detection and Treatment of Gynecologic Cancers</span>. <i>Toxins</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1116</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.3390/toxins7041116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.3390%2Ftoxins7041116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=25835384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFKms74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=1116-1125&author=J.+Blackauthor=S.+Lopezauthor=E.+Coccoauthor=C.+Schwabauthor=D.+Englishauthor=A.+Santin&title=Clostridium+Perfringens+Enterotoxin+%28CPE%29+and+CPE-Binding+Domain+%28c-CPE%29+for+the+Detection+and+Treatment+of+Gynecologic+Cancers&doi=10.3390%2Ftoxins7041116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Clostridium Perfringens enterotoxin (CPE) and CPE-binding domain (c-CPE) for the detection and treatment of gynecologic cancers</span></div><div class="casAuthors">Black, Jonathan D.; Lopez, Salvatore; Cocco, Emiliano; Schwab, Carlton L.; English, Diana P.; Santin, Alessandro D.</div><div class="citationInfo"><span class="NLM_cas:title">Toxins</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1116-1125</span>CODEN:
                <span class="NLM_cas:coden">TOXIB7</span>;
        ISSN:<span class="NLM_cas:issn">2072-6651</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Clostridium perfringens enterotoxin (CPE) is a three-domain polypeptide, which binds to Claudin-3 and Claudin-4 with high affinity.  Because these receptors are highly differentially expressed in many human tumors, claudin-3 and claudin-4 may provide an efficient mol. tool to specifically identify and target biol. aggressive human cancer cells for CPE-specific binding and cytolysis.  In this review we will discuss these surface proteins as targets for the detection and treatment of chemotherapy-resistant gynecol. malignancies overexpressing claudin-3 and -4 using CPE-based theranostic agents.  We will also discuss the use of fluorescent c-CPE peptide in the operative setting for real time detection of micro-metastatic tumors during surgery and review the potential role of CPE in other medical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKmEaM_wWnZrVg90H21EOLACvtfcHk0li3C6A8C80cHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFKms74%253D&md5=06a1e34150b702c44466970558e00e8d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3390%2Ftoxins7041116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Ftoxins7041116%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DLopez%26aufirst%3DS.%26aulast%3DCocco%26aufirst%3DE.%26aulast%3DSchwab%26aufirst%3DC.%26aulast%3DEnglish%26aufirst%3DD.%26aulast%3DSantin%26aufirst%3DA.%26atitle%3DClostridium%2520Perfringens%2520Enterotoxin%2520%2528CPE%2529%2520and%2520CPE-Binding%2520Domain%2520%2528c-CPE%2529%2520for%2520the%2520Detection%2520and%2520Treatment%2520of%2520Gynecologic%2520Cancers%26jtitle%3DToxins%26date%3D2015%26volume%3D7%26spage%3D1116%26epage%3D1125%26doi%3D10.3390%2Ftoxins7041116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalathur, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revandkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danzer-Baltzer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guccini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alajati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Mitri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Escudero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarditi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccari, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malusa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalathur, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzzene, A. P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaleu, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catapano, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frew, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimonti, A.</span></span> <span> </span><span class="NLM_article-title">A Chemogenomic Screening Identifies CK2 as a Target for Pro-Senescence Therapy in PTEN-Deficient Tumours</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">7227</span>, <span class="refDoi"> DOI: 10.1038/ncomms8227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fncomms8227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=26085373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2kt7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=7227&author=M.+Kalathurauthor=A.+Tosoauthor=J.+Chenauthor=A.+Revandkarauthor=C.+Danzer-Baltzerauthor=I.+Gucciniauthor=A.+Alajatiauthor=M.+Sartiauthor=S.+Pintonauthor=L.+Brambillaauthor=D.+Di+Mitriauthor=G.+Carboneauthor=R.+Garcia-Escuderoauthor=A.+Padovaauthor=L.+Magnoniauthor=A.+Tarditiauthor=L.+Maccariauthor=F.+Malusaauthor=R.+K.+Kalathurauthor=L.+Cozzaauthor=A.+P.+G.+Ruzzeneauthor=M.+N.+Delaleuauthor=C.+V.+Catapanoauthor=I.+J.+Frewauthor=A.+Alimonti&title=A+Chemogenomic+Screening+Identifies+CK2+as+a+Target+for+Pro-Senescence+Therapy+in+PTEN-Deficient+Tumours&doi=10.1038%2Fncomms8227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours</span></div><div class="casAuthors">Kalathur, Madhuri; Toso, Alberto; Chen, Jingjing; Revandkar, Ajinkya; Danzer-Baltzer, Claudia; Guccini, Ilaria; Alajati, Abdullah; Sarti, Manuela; Pinton, Sandra; Brambilla, Lara; Di Mitri, Diletta; Carbone, Giuseppina; Garcia-Escudero, R.; Padova, Alessandro; Magnoni, Letizia; Tarditi, Alessia; Maccari, Laura; Malusa, Federico; Kalathur, Ravi Kiran Reddy; Pinna, Lorenzo A.; Cozza, Giorgio; Ruzzene, Maria; Delaleu, Nicolas; Catapano, Carlo V.; Frew, Ian J.; Alimonti, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7227</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Enhancement of cellular senescence in tumors triggers a stable cell growth arrest and activation of an antitumor immune response that can be exploited for cancer therapy.  Currently, there are only a limited no. of targeted therapies that act by increasing senescence in cancers, but the majority of them are not selective and also target healthy cells.  Here we developed a chemogenomic screening to identify compds. that enhance senescence in PTEN-deficient cells without affecting normal cells.  By using this approach, we identified casein kinase 2 (CK2) as a pro-senescent target.  Mechanistically, we show that Pten loss increases CK2 levels by activating STAT3.  CK2 upregulation in Pten null tumors affects the stability of Pml, an essential regulator of senescence.  However, CK2 inhibition stabilizes Pml levels enhancing senescence in Pten null tumors.  Taken together, our screening strategy has identified a novel STAT3-CK2-PML network that can be targeted for pro-senescence therapy for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpepPKZTNMFMbVg90H21EOLACvtfcHk0li3C6A8C80cHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2kt7%252FP&md5=c9407799e111aa8387b164701226ca86</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fncomms8227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms8227%26sid%3Dliteratum%253Aachs%26aulast%3DKalathur%26aufirst%3DM.%26aulast%3DToso%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DRevandkar%26aufirst%3DA.%26aulast%3DDanzer-Baltzer%26aufirst%3DC.%26aulast%3DGuccini%26aufirst%3DI.%26aulast%3DAlajati%26aufirst%3DA.%26aulast%3DSarti%26aufirst%3DM.%26aulast%3DPinton%26aufirst%3DS.%26aulast%3DBrambilla%26aufirst%3DL.%26aulast%3DDi%2BMitri%26aufirst%3DD.%26aulast%3DCarbone%26aufirst%3DG.%26aulast%3DGarcia-Escudero%26aufirst%3DR.%26aulast%3DPadova%26aufirst%3DA.%26aulast%3DMagnoni%26aufirst%3DL.%26aulast%3DTarditi%26aufirst%3DA.%26aulast%3DMaccari%26aufirst%3DL.%26aulast%3DMalusa%26aufirst%3DF.%26aulast%3DKalathur%26aufirst%3DR.%2BK.%26aulast%3DCozza%26aufirst%3DL.%26aulast%3DRuzzene%26aufirst%3DA.%2BP.%2BG.%26aulast%3DDelaleu%26aufirst%3DM.%2BN.%26aulast%3DCatapano%26aufirst%3DC.%2BV.%26aulast%3DFrew%26aufirst%3DI.%2BJ.%26aulast%3DAlimonti%26aufirst%3DA.%26atitle%3DA%2520Chemogenomic%2520Screening%2520Identifies%2520CK2%2520as%2520a%2520Target%2520for%2520Pro-Senescence%2520Therapy%2520in%2520PTEN-Deficient%2520Tumours%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D7227%26doi%3D10.1038%2Fncomms8227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purwin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández-Toribio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coderch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchuk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skorokhyd, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipiak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Pascual-Teresa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, A.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Novel Dual-Target Agents for HDAC1 and CK2 Inhibition</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">66595</span>– <span class="NLM_lpage">66608</span>, <span class="refDoi"> DOI: 10.1039/c6ra09717k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1039%2FC6RA09717K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFantbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=66595-66608&author=M.+Purwinauthor=J.+Hern%C3%A1ndez-Toribioauthor=C.+Coderchauthor=R.+Panchukauthor=N.+Skorokhydauthor=K.+Filipiakauthor=B.+de+Pascual-Teresaauthor=A.+Ramos&title=Design+and+Synthesis+of+Novel+Dual-Target+Agents+for+HDAC1+and+CK2+Inhibition&doi=10.1039%2Fc6ra09717k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel dual-target agents for HDAC1 and CK2 inhibition</span></div><div class="casAuthors">Purwin, M.; Hernandez-Toribio, J.; Coderch, C.; Panchuk, R.; Skorokhyd, N.; Filipiak, K.; de Pascual-Teresa, B.; Ramos, A.</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">71</span>),
    <span class="NLM_cas:pages">66595-66608</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Drug entities able to address multiple targets can be more effective than those directed to just one biol. target.  We disclose herein a series of novel dual inhibitors to target histone deacetylase 1 (HDAC 1) and protein kinase CK2.  Our bifunctional compds. combine two complementary chemo-active prototypical scaffolds: a hydroxamate essential for the chelation of the zinc ion present in the active site of HDAC (Zinc Binding Group), and a 4,5,6,7-tetrabromobenzotriazole (TBB) moiety introduced to interact with the ATP binding site in CK2 and to act simultaneously as the cap group in the interaction with HDAC1.  The synthesized dual-acting agents exhibited promising inhibitory activities towards HDAC1 and CK2.  The best result was obtained for 5c with an IC50 of 5 μM for both enzymes.  However, its N-2 substituted isomer 5e presented the best profile in cell-based assays, with cytotoxic activity in the low micromolar LC50 in two mammalian cancer cell lines and 4-fold less activity towards a pseudonormal mammalian cell line.  Furthermore, this hybrid mol. induced apoptosis in leukemia cells in a concn.-dependent manner.  All together this makes 5e a promising lead compd. for future in vivo assays in animal tumor models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0Ospcx3QT9bVg90H21EOLACvtfcHk0lhh06V5g6_Pkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFantbfO&md5=fbaa200377d08409ca85524df9e1686c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1039%2FC6RA09717K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6RA09717K%26sid%3Dliteratum%253Aachs%26aulast%3DPurwin%26aufirst%3DM.%26aulast%3DHern%25C3%25A1ndez-Toribio%26aufirst%3DJ.%26aulast%3DCoderch%26aufirst%3DC.%26aulast%3DPanchuk%26aufirst%3DR.%26aulast%3DSkorokhyd%26aufirst%3DN.%26aulast%3DFilipiak%26aufirst%3DK.%26aulast%3Dde%2BPascual-Teresa%26aufirst%3DB.%26aulast%3DRamos%26aufirst%3DA.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Novel%2520Dual-Target%2520Agents%2520for%2520HDAC1%2520and%2520CK2%2520Inhibition%26jtitle%3DRSC%2520Adv.%26date%3D2016%26volume%3D6%26spage%3D66595%26epage%3D66608%26doi%3D10.1039%2Fc6ra09717k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossenkov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purandare, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desilva, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jure-Kunkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrilovich, D. I.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">5644</span>– <span class="NLM_lpage">5655</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-18-1229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1158%2F0008-5472.CAN-18-1229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=30139814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlSju7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=5644-5655&author=A.+Hashimotoauthor=C.+Gaoauthor=J.+Mastioauthor=A.+Kossenkovauthor=S.+I.+Abramsauthor=A.+V.+Purandareauthor=H.+Desilvaauthor=S.+Weeauthor=J.+Huntauthor=M.+Jure-Kunkelauthor=D.+I.+Gabrilovich&title=Inhibition+of+Casein+Kinase+2+Disrupts+Differentiation+of+Myeloid+Cells+in+Cancer+and+Enhances+the+Efficacy+of+Immunotherapy+in+Mice&doi=10.1158%2F0008-5472.can-18-1229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of casein kinase 2 disrupts differentiation of myeloid cells in cancer and enhances the efficacy of immunotherapy in mice</span></div><div class="casAuthors">Hashimoto, Ayumi; Gao, Chan; Mastio, Jerome; Kossenkov, Andrew; Abrams, Scott I.; Purandare, Ashok V.; Desilva, Heshani; Wee, Susan; Hunt, John; Jure-Kunkel, Maria; Gabrilovich, Dmitry I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5644-5655</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The role of myeloid cells as regulators of tumor progression that significantly impact the efficacy of cancer immunotherapies makes them an attractive target for inhibition.  Here we explore the effect of a novel, potent, and selective inhibitor of serine/threonine protein kinase casein kinase 2 (CK2) on modulating myeloid cells in the tumor microenvironment.  Although inhibition of CK2 caused only a modest effect on dendritic cells in tumor-bearing mice, it substantially reduced the amt. of polymorphonuclear myeloid-derived suppressor cells and tumor-assocd. macrophages.  This effect was not caused by the induction of apoptosis, but rather by a block of differentiation.  Our results implicated downregulation of CCAAT-enhancer binding protein-α in this effect.  Although CK2 inhibition did not directly affect tumor cells, it dramatically enhanced the antitumor activity of immune checkpoint receptor blockade using anti-CTLA-4 antibody.  These results suggest a potential role of CK2 inhibitors in combination therapies against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBY1mwFqvLhLVg90H21EOLACvtfcHk0lhh06V5g6_Pkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlSju7rO&md5=bc9ead05597f71437fbf55e6832cc2b8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-1229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-1229%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DMastio%26aufirst%3DJ.%26aulast%3DKossenkov%26aufirst%3DA.%26aulast%3DAbrams%26aufirst%3DS.%2BI.%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26aulast%3DDesilva%26aufirst%3DH.%26aulast%3DWee%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DJ.%26aulast%3DJure-Kunkel%26aufirst%3DM.%26aulast%3DGabrilovich%26aufirst%3DD.%2BI.%26atitle%3DInhibition%2520of%2520Casein%2520Kinase%25202%2520Disrupts%2520Differentiation%2520of%2520Myeloid%2520Cells%2520in%2520Cancer%2520and%2520Enhances%2520the%2520Efficacy%2520of%2520Immunotherapy%2520in%2520Mice%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D5644%26epage%3D5655%26doi%3D10.1158%2F0008-5472.can-18-1229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nitta, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gholamin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feroze, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheshier, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span> <span> </span><span class="NLM_article-title">Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">3688</span>– <span class="NLM_lpage">3699</span>, <span class="refDoi"> DOI: 10.1038/onc.2014.299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fonc.2014.299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=25241897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyhtL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2015&pages=3688-3699&author=R.+T.+Nittaauthor=S.+Gholaminauthor=A.+H.+Ferozeauthor=M.+Agarwalauthor=S.+H.+Cheshierauthor=S.+S.+Mitraauthor=G.+Li&title=Casein+kinase+2%CE%B1+regulates+glioblastoma+brain+tumor-initiating+cell+growth+through+the+%CE%B2-catenin+pathway&doi=10.1038%2Fonc.2014.299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway</span></div><div class="casAuthors">Nitta, R. T.; Gholamin, S.; Feroze, A. H.; Agarwal, M.; Cheshier, S. H.; Mitra, S. S.; Li, G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3688-3699</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Glioblastoma (GBM) is the most common and fatal primary brain tumor in humans, and it is essential that new and better therapies are developed to treat this disease.  Previous research suggests that casein kinase 2 (CK2) may be a promising therapeutic target for GBMs.  CK2 has enhanced expression or activity in numerous cancers, including GBM, and it has been demonstrated that inhibitors of CK2 regressed tumor growth in GBM xenograft mouse models.  Our studies demonstrate that the CK2 subunit, CK2α, is overexpressed in and has an important role in regulating brain tumor-initiating cells (BTIC) in GBM.  Initial studies showed that two GBM cell lines (U87-MG and U138) transduced with CK2α had enhanced proliferation and anchorage-independent growth.  Inhibition of CKα using siRNA or small-mol. inhibitors (TBBz, CX-4945) reduced cell growth, decreased tumor size, and increased survival rates in GBM xenograft mouse models.  We also verified that inhibition of CK2α decreased the activity of a well-known GBM-initiating cell regulator, β-catenin.  Loss of CK2α decreased two β-catenin-regulated genes that are involved in GBM-initiating cell growth, OCT4 and NANOG.  To det. the importance of CK2α in GBM stem cell maintenance, we reduced CK2α activity in primary GBM samples and tumor spheres derived from GBM patients.  We discovered that loss of CK2α activity reduced the sphere-forming capacity of BTIC and decreased numerous GBM stem cell markers, including CD133, CD90, CD49f and A2B5.  Our study suggests that CK2α is involved in GBM tumorigenesis by maintaining BTIC through the regulation of β-catenin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcrw3mE50HGLVg90H21EOLACvtfcHk0lhh06V5g6_Pkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyhtL7L&md5=892bcf619d64a1a0752beb8cd720814a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fonc.2014.299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2014.299%26sid%3Dliteratum%253Aachs%26aulast%3DNitta%26aufirst%3DR.%2BT.%26aulast%3DGholamin%26aufirst%3DS.%26aulast%3DFeroze%26aufirst%3DA.%2BH.%26aulast%3DAgarwal%26aufirst%3DM.%26aulast%3DCheshier%26aufirst%3DS.%2BH.%26aulast%3DMitra%26aufirst%3DS.%2BS.%26aulast%3DLi%26aufirst%3DG.%26atitle%3DCasein%2520kinase%25202%25CE%25B1%2520regulates%2520glioblastoma%2520brain%2520tumor-initiating%2520cell%2520growth%2520through%2520the%2520%25CE%25B2-catenin%2520pathway%26jtitle%3DOncogene%26date%3D2015%26volume%3D34%26spage%3D3688%26epage%3D3699%26doi%3D10.1038%2Fonc.2014.299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui-Jain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaebe, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vialettes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darjania, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stansfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliesath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drygin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proffitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streiner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trent, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckman, D. M.</span></span> <span> </span><span class="NLM_article-title">Discovery and SAR of 5-(3-chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylic Acid (<b>CX-4945</b>), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">635</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1021/jm101251q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101251q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2kurjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=635-654&author=F.+Pierreauthor=P.+C.+Chuaauthor=S.+E.+O%E2%80%99Brienauthor=A.+Siddiqui-Jainauthor=P.+Bourbonauthor=M.+Haddachauthor=J.+Michauxauthor=J.+Nagasawaauthor=M.+K.+Schwaebeauthor=E.+Stefanauthor=A.+Vialettesauthor=J.+P.+Whittenauthor=T.+K.+Chenauthor=L.+Darjaniaauthor=R.+Stansfieldauthor=K.+Anderesauthor=J.+Bliesathauthor=D.+Dryginauthor=C.+Hoauthor=M.+Omoriauthor=C.+Proffittauthor=N.+Streinerauthor=K.+Trentauthor=W.+G.+Riceauthor=D.+M.+Ryckman&title=Discovery+and+SAR+of+5-%283-chlorophenylamino%29benzo%5Bc%5D%5B2%2C6%5Dnaphthyridine-8-carboxylic+Acid+%28CX-4945%29%2C+the+First+Clinical+Stage+Inhibitor+of+Protein+Kinase+CK2+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm101251q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer</span></div><div class="casAuthors">Pierre, Fabrice; Chua, Peter C.; O'Brien, Sean E.; Siddiqui-Jain, Adam; Bourbon, Pauline; Haddach, Mustapha; Michaux, Jerome; Nagasawa, Johnny; Schwaebe, Michael K.; Stefan, Eric; Vialettes, Anne; Whitten, Jeffrey P.; Chen, Ta Kung; Darjania, Levan; Stansfield, Ryan; Anderes, Kenna; Bliesath, Josh; Drygin, Denis; Ho, Caroline; Omori, May; Proffitt, Chris; Streiner, Nicole; Trent, Katy; Rice, William G.; Ryckman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">635-654</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein we chronicle the discovery of CX-4945 (I), a first-in-class, orally bioavailable ATP-competitive inhibitor of protein kinase CK2 in clin. trials for cancer.  CK2 has long been considered a prime cancer drug target because of the roles of deregulated and overexpressed CK2 in cancer-promoting pro-survival and antiapoptotic pathways.  These biol. properties as well as the suitability of CK2's small ATP binding site for the design of selective inhibitors, led us to fashion novel therapeutic agents for cancer.  The optimization leading to I (Ki = 0.38 nM) was guided by mol. modeling, suggesting a strong binding of I resulting from a combination of hydrophobic interactions, an ionic bridge with Lys68, and hydrogen bonding with the hinge region. I was highly selective, orally bioavailable across species (20-51%) and efficacious in xenograft models.  The discovery of I will allow the therapeutic targeting of CK2 in humans for the first time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoONQeRuenlPrVg90H21EOLACvtfcHk0lgrDoMKPh0BQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2kurjL&md5=9b0f371ee1a2182b84877743c42dfda1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm101251q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101251q%26sid%3Dliteratum%253Aachs%26aulast%3DPierre%26aufirst%3DF.%26aulast%3DChua%26aufirst%3DP.%2BC.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BE.%26aulast%3DSiddiqui-Jain%26aufirst%3DA.%26aulast%3DBourbon%26aufirst%3DP.%26aulast%3DHaddach%26aufirst%3DM.%26aulast%3DMichaux%26aufirst%3DJ.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DSchwaebe%26aufirst%3DM.%2BK.%26aulast%3DStefan%26aufirst%3DE.%26aulast%3DVialettes%26aufirst%3DA.%26aulast%3DWhitten%26aufirst%3DJ.%2BP.%26aulast%3DChen%26aufirst%3DT.%2BK.%26aulast%3DDarjania%26aufirst%3DL.%26aulast%3DStansfield%26aufirst%3DR.%26aulast%3DAnderes%26aufirst%3DK.%26aulast%3DBliesath%26aufirst%3DJ.%26aulast%3DDrygin%26aufirst%3DD.%26aulast%3DHo%26aufirst%3DC.%26aulast%3DOmori%26aufirst%3DM.%26aulast%3DProffitt%26aufirst%3DC.%26aulast%3DStreiner%26aufirst%3DN.%26aulast%3DTrent%26aufirst%3DK.%26aulast%3DRice%26aufirst%3DW.%2BG.%26aulast%3DRyckman%26aufirst%3DD.%2BM.%26atitle%3DDiscovery%2520and%2520SAR%2520of%25205-%25283-chlorophenylamino%2529benzo%255Bc%255D%255B2%252C6%255Dnaphthyridine-8-carboxylic%2520Acid%2520%2528CX-4945%2529%252C%2520the%2520First%2520Clinical%2520Stage%2520Inhibitor%2520of%2520Protein%2520Kinase%2520CK2%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D635%26epage%3D654%26doi%3D10.1021%2Fjm101251q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting Cancer with Small Molecule Kinase Inhibitors</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1038/nrc2559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fnrc2559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=19104514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1yg" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=28-39&author=J.+Zhangauthor=P.+L.+Yangauthor=N.+S.+Gray&title=Targeting+Cancer+with+Small+Molecule+Kinase+Inhibitors&doi=10.1038%2Fnrc2559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small molecule kinase inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Yang, Priscilla L.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-39</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiol. constraints on growth and survival.  To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small mol. inhibitors for a host of other kinases that are implicated in cancer and other diseases.  Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations.  This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSM3BN_uEz7Vg90H21EOLACvtfcHk0lgrDoMKPh0BQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1yg&md5=35bc38f414cd21eef5e61ce181b580fb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrc2559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2559%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Cancer%2520with%2520Small%2520Molecule%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D28%26epage%3D39%26doi%3D10.1038%2Fnrc2559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katoh, M.</span></span> <span> </span><span class="NLM_article-title">Networking of WNT, FGF, Notch, BMP, and Hedgehog Signaling Pathways During Carcinogenesis</span>. <i>Stem Cell Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1007/s12015-007-0006-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1007%2Fs12015-007-0006-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=17873379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVent7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=30-38&author=M.+Katoh&title=Networking+of+WNT%2C+FGF%2C+Notch%2C+BMP%2C+and+Hedgehog+Signaling+Pathways+During+Carcinogenesis&doi=10.1007%2Fs12015-007-0006-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis</span></div><div class="casAuthors">Katoh, Masaru</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cell Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-38</span>CODEN:
                <span class="NLM_cas:coden">SCRTCI</span>;
        ISSN:<span class="NLM_cas:issn">1550-8943</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review.  The biol. functions of some orthologs within the human genome and model-animal genomes are evolutionarily conserved, but those of others are divergent due to protein evolution and promoter evolution.  Because WNT signaling mols. play key roles during embryogenesis, tissue regeneration and carcinogenesis, the author's group has carried out a human WNT-ome project for the comprehensive characterization of human genes encoding WNT signaling mols.  From 1996 to 2002, we cloned and characterized WNT2B/WNT13, WNT3, WNT3A, WNT5B, WNT6, WNT7B, WNT8A, WNT8B, WNT9A/WNT14, WNT9B/WNT14B, WNT10A, WNT10B, WNT11, FZD1, FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, FZD10, FRAT1, FRAT2, NKD1, NKD2, VANGL1, RHOU/ARHU, RHOV/ARHV, GIPC2, GIPC3, FBXW11/βTRCP2, SOX17, TCF7L1/TCF3, and established a cDNA-PCR system for snap-shot and dynamic analyses on the WNT-transcriptome.  In 2003, we identified and characterized PRICKLE1, PRICKLE2, DACT1/DAPPER1, DACT2/DAPPER2, DAAM2, and BCL9L.  After completion of the human WNT-ome project, we have been working on the stem cell signaling network.  WNT signals are transduced to β-catenin, NLK, NFAT, PKC, JNK and RhoA signaling cascades.  FGF20, JAG1 and DKK1 are target genes of the WNT-β-catenin signaling cascade.  Cross-talk of WNT and FGF signaling pathways potentiates β-catenin and NFAT signaling cascades.  BMP signals induce IHH upregulation in co-operation with RUNX.  Hedgehog signals induce upregulation of SFRP1, JAG2 and FOXL1, and then FOXL1 induces BMP4 upregulation.  The balance between WNT-FGF-Notch and BMP-Hedgehog signaling networks is important for the maintenance of homeostasis among stem and progenitor cells.  Disruption of the stem cell signaling network results in pathol. conditions, such as congenital diseases and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov8zIO_8Bm6LVg90H21EOLACvtfcHk0livFJe7H92n5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVent7nI&md5=8a4ac4dee7c0e49ec125a717a6904eaa</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs12015-007-0006-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12015-007-0006-6%26sid%3Dliteratum%253Aachs%26aulast%3DKatoh%26aufirst%3DM.%26atitle%3DNetworking%2520of%2520WNT%252C%2520FGF%252C%2520Notch%252C%2520BMP%252C%2520and%2520Hedgehog%2520Signaling%2520Pathways%2520During%2520Carcinogenesis%26jtitle%3DStem%2520Cell%2520Rev.%26date%3D2007%26volume%3D3%26spage%3D30%26epage%3D38%26doi%3D10.1007%2Fs12015-007-0006-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwind, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schetting, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montenarh, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Protein Kinase CK2 Prevents Adipogenic Differentiation of Mesenchymal Stem Cells Like C3H/10T1/2 Cells</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">22/1</span>– <span class="NLM_lpage">22/12</span>, <span class="refDoi"> DOI: 10.3390/ph10010022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.3390%2Fph10010022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=22%2F1-22%2F12&author=L.+Schwindauthor=S.+Schettingauthor=M.+Montenarh&title=Inhibition+of+Protein+Kinase+CK2+Prevents+Adipogenic+Differentiation+of+Mesenchymal+Stem+Cells+Like+C3H%2F10T1%2F2+Cells&doi=10.3390%2Fph10010022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.3390%2Fph10010022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph10010022%26sid%3Dliteratum%253Aachs%26aulast%3DSchwind%26aufirst%3DL.%26aulast%3DSchetting%26aufirst%3DS.%26aulast%3DMontenarh%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520Protein%2520Kinase%2520CK2%2520Prevents%2520Adipogenic%2520Differentiation%2520of%2520Mesenchymal%2520Stem%2520Cells%2520Like%2520C3H%252F10T1%252F2%2520Cells%26jtitle%3DPharmaceuticals%26date%3D2017%26volume%3D10%26spage%3D22%252F1%26epage%3D22%252F12%26doi%3D10.3390%2Fph10010022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsumoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamagata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitabayashi, I.</span></span> <span> </span><span class="NLM_article-title">Dual Inhibition of Enhancer of Zeste Homolog 1/2 Overactivates WNT Signaling to Deplete Cancer Stem Cells in Multiple Myeloma</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">194</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1111/cas.13840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1111%2Fcas.13840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=30343511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1eitrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2019&pages=194-208&author=M.+Nakagawaauthor=S.+Fujitaauthor=T.+Katsumotoauthor=K.+Yamagataauthor=Y.+Ogawaraauthor=A.+Hattoriauthor=Y.+Kagiyamaauthor=D.+Honmaauthor=K.+Arakiauthor=T.+Inoueauthor=A.+Katoauthor=K.+Inakiauthor=C.+Wadaauthor=Y.+Onoauthor=M.+Yamamotoauthor=O.+Miuraauthor=Y.+Nakashimaauthor=I.+Kitabayashi&title=Dual+Inhibition+of+Enhancer+of+Zeste+Homolog+1%2F2+Overactivates+WNT+Signaling+to+Deplete+Cancer+Stem+Cells+in+Multiple+Myeloma&doi=10.1111%2Fcas.13840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma</span></div><div class="casAuthors">Nakagawa, Makoto; Fujita, Shuhei; Katsumoto, Takuo; Yamagata, Kazutsune; Ogawara, Yoko; Hattori, Ayuna; Kagiyama, Yuki; Honma, Daisuke; Araki, Kazushi; Inoue, Tatsuya; Kato, Ayako; Inaki, Koichiro; Wada, Chisa; Ono, Yoshimasa; Yamamoto, Masahide; Miura, Osamu; Nakashima, Yasuharu; Kitabayashi, Issay</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">194-208</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is an incurable hematol. malignancy caused by accumulation of abnormal clonal plasma cells.  Despite the recent development of novel therapies, relapse of MM eventually occurs as a result of a remaining population of drug-resistant myeloma stem cells.  Side population (SP) cells show cancer stem cell-like characteristics in MM; thus, targeting these cells is a promising strategy to completely cure this malignancy.  Herein, we showed that SP cells expressed higher levels of enhancer of zeste homolog (EZH) 1 and EZH2, which encode the catalytic subunits of Polycomb repressive complex 2 (PRC2), than non-SP cells, suggesting that EZH1 as well as EZH2 contributes to the stemness maintenance of the MM cells and that targeting both EZH1/2 is potentially a significant therapeutic approach for eradicating myeloma stem cells.  Moreover, long-term continuous dosing of OR-S1 completely cured mice bearing orthotopic xenografts.  Addnl., PRC2 directly regulated WNT signaling in MM, and overactivation of this signaling induced by dual inhibition of EZH1/2 eradicated myeloma stem cells and neg. affected tumorigenesis, suggesting that repression of WNT signaling by PRC2 plays an important role in stemness maintenance of MM cells.  Our results show the role of EZH1/2 in the maintenance of myeloma stem cells and provide a preclin. rationale for therapeutic application of OR-S1, leading to significant advances in the treatment of MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5tCzftcXKF7Vg90H21EOLACvtfcHk0livFJe7H92n5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1eitrbJ&md5=baa39f9d47398cc1fcfebb86821c7f04</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fcas.13840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13840%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DFujita%26aufirst%3DS.%26aulast%3DKatsumoto%26aufirst%3DT.%26aulast%3DYamagata%26aufirst%3DK.%26aulast%3DOgawara%26aufirst%3DY.%26aulast%3DHattori%26aufirst%3DA.%26aulast%3DKagiyama%26aufirst%3DY.%26aulast%3DHonma%26aufirst%3DD.%26aulast%3DAraki%26aufirst%3DK.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DA.%26aulast%3DInaki%26aufirst%3DK.%26aulast%3DWada%26aufirst%3DC.%26aulast%3DOno%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DMiura%26aufirst%3DO.%26aulast%3DNakashima%26aufirst%3DY.%26aulast%3DKitabayashi%26aufirst%3DI.%26atitle%3DDual%2520Inhibition%2520of%2520Enhancer%2520of%2520Zeste%2520Homolog%25201%252F2%2520Overactivates%2520WNT%2520Signaling%2520to%2520Deplete%2520Cancer%2520Stem%2520Cells%2520in%2520Multiple%2520Myeloma%26jtitle%3DCancer%2520Sci.%26date%3D2019%26volume%3D110%26spage%3D194%26epage%3D208%26doi%3D10.1111%2Fcas.13840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becherel, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakob, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherry, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gueven, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kijas, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katyal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinnon, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smerdon, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taucher-Scholz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavin, M. F.</span></span> <span> </span><span class="NLM_article-title">CK2 Phosphorylation-Dependent Interaction Between Aprataxin and MDC1 in the DNA Damage Response</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1489</span>– <span class="NLM_lpage">1503</span>, <span class="refDoi"> DOI: 10.1093/nar/gkp1149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1093%2Fnar%2Fgkp1149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=20008512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjt1KnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1489-1503&author=O.+J.+Becherelauthor=B.+Jakobauthor=A.+L.+Cherryauthor=N.+Guevenauthor=M.+Fusserauthor=A.+W.+Kijasauthor=C.+Pengauthor=S.+Katyalauthor=P.+J.+McKinnonauthor=J.+Chenauthor=B.+Epeauthor=S.+J.+Smerdonauthor=G.+Taucher-Scholzauthor=M.+F.+Lavin&title=CK2+Phosphorylation-Dependent+Interaction+Between+Aprataxin+and+MDC1+in+the+DNA+Damage+Response&doi=10.1093%2Fnar%2Fgkp1149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response</span></div><div class="casAuthors">Becherel, Olivier J.; Jakob, Burkhard; Cherry, Amy L.; Gueven, Nuri; Fusser, Markus; Kijas, Amanda W.; Peng, Cheng; Katyal, Sachin; McKinnon, Peter J.; Chen, Junjie; Epe, Bernd; Smerdon, Stephen J.; Taucher-Scholz, Gisela; Lavin, Martin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1489-1503</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aprataxin, defective in the neurodegenerative disorder ataxia oculomotor apraxia type 1, resolves abortive DNA ligation intermediates during DNA repair.  Here, we demonstrate that aprataxin localizes at sites of DNA damage induced by high LET radiation and binds to mediator of DNA-damage checkpoint protein 1 (MDC1/NFBD1) through a phosphorylation-dependent interaction.  This interaction is mediated via the aprataxin FHA domain and multiple casein kinase 2 di-phosphorylated S-D-T-D motifs in MDC1.  X-ray structural and mutagenic anal. of aprataxin FHA domain, combined with modeling of the pSDpTD peptide interaction suggest an unusual FHA binding mechanism mediated by a cluster of basic residues at and around the canonical pT-docking site.  Mutation of aprataxin FHA Arg29 prevented its interaction with MDC1 and recruitment to sites of DNA damage.  These results indicate that aprataxin is involved not only in single strand break repair but also in the processing of a subset of double strand breaks presumably through its interaction with MDC1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreTittaIuM9LVg90H21EOLACvtfcHk0livFJe7H92n5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjt1KnsL8%253D&md5=7399dddc6f60329d390de63075e0cea7</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkp1149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkp1149%26sid%3Dliteratum%253Aachs%26aulast%3DBecherel%26aufirst%3DO.%2BJ.%26aulast%3DJakob%26aufirst%3DB.%26aulast%3DCherry%26aufirst%3DA.%2BL.%26aulast%3DGueven%26aufirst%3DN.%26aulast%3DFusser%26aufirst%3DM.%26aulast%3DKijas%26aufirst%3DA.%2BW.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DKatyal%26aufirst%3DS.%26aulast%3DMcKinnon%26aufirst%3DP.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DEpe%26aufirst%3DB.%26aulast%3DSmerdon%26aufirst%3DS.%2BJ.%26aulast%3DTaucher-Scholz%26aufirst%3DG.%26aulast%3DLavin%26aufirst%3DM.%2BF.%26atitle%3DCK2%2520Phosphorylation-Dependent%2520Interaction%2520Between%2520Aprataxin%2520and%2520MDC1%2520in%2520the%2520DNA%2520Damage%2520Response%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2010%26volume%3D38%26spage%3D1489%26epage%3D1503%26doi%3D10.1093%2Fnar%2Fgkp1149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Maira, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brustolon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertacchini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosoni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmiroli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzzene, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Inhibition of Protein Kinase CK2 Reverts the Multidrug Resistance Phenotype of a CEM Cell Line Characterized by High CK2 Level</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">6915</span>– <span class="NLM_lpage">6926</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fsj.onc.1210495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=17486073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOksbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=6915-6926&author=G.+Di%0AMairaauthor=F.+Brustolonauthor=J.+Bertacchiniauthor=K.+Tosoniauthor=S.+Marmiroliauthor=L.+A.+Pinnaauthor=M.+Ruzzene&title=Pharmacological+Inhibition+of+Protein+Kinase+CK2+Reverts+the+Multidrug+Resistance+Phenotype+of+a+CEM+Cell+Line+Characterized+by+High+CK2+Level&doi=10.1038%2Fsj.onc.1210495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level</span></div><div class="casAuthors">Di Maira, G.; Brustolon, F.; Bertacchini, J.; Tosoni, K.; Marmiroli, S.; Pinna, L. A.; Ruzzene, M.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">6915-6926</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein kinase CK2 is an ubiquitous and constitutively active kinase, which phosphorylates many cellular proteins and is implicated in the regulation of cell survival, proliferation and transformation.  We investigated its possible involvement in the multidrug resistance phenotype (MDR) by analyzing its level in two variants of CEM cells, namely S-CEM and R-CEM, normally sensitive or resistant to chem. apoptosis, resp.  We found that, while the CK2 regulatory subunit β was equally expressed in the two cell variants, CK2α catalytic subunit was higher in R-CEM and this was accompanied by a higher phosphorylation of endogenous protein substrates.  Pharmacol. downregulation of CK2 activity by a panel of specific inhibitors, or knockdown of CK2α expression by RNA interference, were able to induce cell death in R-CEM.  CK2 inhibitors could promote an increased uptake of chemotherapeutic drugs inside the cells and sensitize them to drug-induced apoptosis in a co-operative manner.  CK2 blockade was also effective in inducing cell death of a different MDR line (U2OS).  We therefore conclude that inhibition of CK2 can be considered as a promising tool to revert the MDR phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcrgFDa7ybUrVg90H21EOLACvtfcHk0lgm7Mlu2Z2yFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOksbrL&md5=242d0abbdbcc41d818d304df8dbd5d5c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210495%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMaira%26aufirst%3DG.%26aulast%3DBrustolon%26aufirst%3DF.%26aulast%3DBertacchini%26aufirst%3DJ.%26aulast%3DTosoni%26aufirst%3DK.%26aulast%3DMarmiroli%26aufirst%3DS.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26aulast%3DRuzzene%26aufirst%3DM.%26atitle%3DPharmacological%2520Inhibition%2520of%2520Protein%2520Kinase%2520CK2%2520Reverts%2520the%2520Multidrug%2520Resistance%2520Phenotype%2520of%2520a%2520CEM%2520Cell%2520Line%2520Characterized%2520by%2520High%2520CK2%2520Level%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D6915%26epage%3D6926%26doi%3D10.1038%2Fsj.onc.1210495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritt, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. D.</span></span> <span> </span><span class="NLM_article-title">Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">17804</span>– <span class="NLM_lpage">17815</span>, <span class="refDoi"> DOI: 10.1074/jbc.m115.712885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1074%2Fjbc.M115.712885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=27226552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyjt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=17804-17815&author=B.+Zhouauthor=D.+A.+Rittauthor=D.+K.+Morrisonauthor=C.+J.+Derauthor=A.+D.+Cox&title=Protein+Kinase+CK2%CE%B1+Maintains+Extracellular+Signal-regulated+Kinase+%28ERK%29+Activity+in+a+CK2%CE%B1+Kinase-independent+Manner+to+Promote+Resistance+to+Inhibitors+of+RAF+and+MEK+but+Not+ERK+in+BRAF+Mutant+Melanoma&doi=10.1074%2Fjbc.m115.712885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma</span></div><div class="casAuthors">Zhou, Bingying; Ritt, Daniel A.; Morrison, Deborah K.; Der, Channing J.; Cox, Adrienne D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">17804-17815</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The protein kinase casein kinase 2 (CK2) is a pleiotropic and constitutively active kinase that plays crucial roles in cellular proliferation and survival.  Overexpression of CK2, particularly the α catalytic subunit (CK2α, CSNK2A1), has been implicated in a wide variety of cancers and is assocd. with poorer survival and resistance to both conventional and targeted anticancer therapies.  Here, the authors found that CK2α protein is elevated in melanoma cell lines compared with normal human melanocytes.  The authors then tested the involvement of CK2α in drug resistance to Food and Drug Administration-approved single agent targeted therapies for melanoma.  In BRAF mutant melanoma cells, ectopic CK2α decreased sensitivity to vemurafenib (BRAF inhibitor), dabrafenib (BRAF inhibitor), and trametinib (MEK inhibitor) by a mechanism distinct from that of mutant NRAS.  Conversely, knockdown of CK2α sensitized cells to inhibitor treatment.  CK2α-mediated RAF-MEK kinase inhibitor resistance was tightly linked to its maintenance of ERK phosphorylation.  The authors found that CK2α post-translationally regulates the ERK-specific phosphatase dual specificity phosphatase 6 (DUSP6) in a kinase dependent-manner, decreasing its abundance.  However, the authors unexpectedly showed, by using a kinase-inactive mutant of CK2α, that RAF-MEK inhibitor resistance did not rely on CK2α kinase catalytic function, and both wild-type and kinase-inactive CK2α maintained ERK phosphorylation upon inhibition of BRAF or MEK.  That both wild-type and kinase-inactive CK2α bound equally well to the RAF-MEK-ERK scaffold kinase suppressor of Ras 1 (KSR1) suggested that CK2α increases KSR facilitation of ERK phosphorylation.  Accordingly, CK2α did not cause resistance to direct inhibition of ERK by the ERK1/2-selective inhibitor SCH772984.  The authors' findings support a kinase-independent scaffolding function of CK2α that promotes resistance to RAF- and MEK-targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEQDy70PYNPbVg90H21EOLACvtfcHk0lgm7Mlu2Z2yFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyjt7rJ&md5=b7ec61a6e142f9480f980898de72b000</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.712885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.712885%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DRitt%26aufirst%3DD.%2BA.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26aulast%3DCox%26aufirst%3DA.%2BD.%26atitle%3DProtein%2520Kinase%2520CK2%25CE%25B1%2520Maintains%2520Extracellular%2520Signal-regulated%2520Kinase%2520%2528ERK%2529%2520Activity%2520in%2520a%2520CK2%25CE%25B1%2520Kinase-independent%2520Manner%2520to%2520Promote%2520Resistance%2520to%2520Inhibitors%2520of%2520RAF%2520and%2520MEK%2520but%2520Not%2520ERK%2520in%2520BRAF%2520Mutant%2520Melanoma%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26spage%3D17804%26epage%3D17815%26doi%3D10.1074%2Fjbc.m115.712885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loizou, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Khamisy, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlatanou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meggio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldecott, K. W.</span></span> <span> </span><span class="NLM_article-title">The Protein Kinase CK2 Facilitates Repair of Chromosomal DNA Single-Strand Breaks</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1016/s0092-8674(04)00206-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2FS0092-8674%2804%2900206-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=15066279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFWqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2004&pages=17-28&author=J.+I.+Loizouauthor=S.+F.+El-Khamisyauthor=A.+Zlatanouauthor=D.+J.+Mooreauthor=D.+W.+Chanauthor=J.+Qinauthor=S.+Sarnoauthor=F.+Meggioauthor=L.+A.+Pinnaauthor=K.+W.+Caldecott&title=The+Protein+Kinase+CK2+Facilitates+Repair+of+Chromosomal+DNA+Single-Strand+Breaks&doi=10.1016%2Fs0092-8674%2804%2900206-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks</span></div><div class="casAuthors">Loizou, Joanna I.; El-Khamisy, Sherif F.; Zlatanou, Anastasia; Moore, David J.; Chan, Douglas W.; Qin, Jun; Sarno, Stefania; Meggio, Flavio; Pinna, Lorenzo A.; Caldecott, Keith W.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-28</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">CK2 was the first protein kinase identified and is required for the proliferation and survival of mammalian cells.  Here, we have identified an unanticipated role for CK2.  We show that this essential protein kinase phosphorylates the scaffold protein XRCC1 and thereby enables the assembly and activity of DNA single-strand break repair protein complexes in vitro and at sites of chromosomal breakage.  Moreover, we show that inhibiting XRCC1 phosphorylation by mutation of the CK2 phosphorylation sites or preventing CK2 activity using a highly specific inhibitor ablates the rapid repair of cellular DNA single-strand breaks by XRCC1.  These data identify a direct role for CK2 in the repair of chromosomal DNA strand breaks and in maintaining genetic integrity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqiQqOcdOwurVg90H21EOLACvtfcHk0lgm7Mlu2Z2yFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFWqsbc%253D&md5=494c5eb7c11f74d080dc07ebc17eda77</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900206-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900206-5%26sid%3Dliteratum%253Aachs%26aulast%3DLoizou%26aufirst%3DJ.%2BI.%26aulast%3DEl-Khamisy%26aufirst%3DS.%2BF.%26aulast%3DZlatanou%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DD.%2BJ.%26aulast%3DChan%26aufirst%3DD.%2BW.%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DSarno%26aufirst%3DS.%26aulast%3DMeggio%26aufirst%3DF.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26aulast%3DCaldecott%26aufirst%3DK.%2BW.%26atitle%3DThe%2520Protein%2520Kinase%2520CK2%2520Facilitates%2520Repair%2520of%2520Chromosomal%2520DNA%2520Single-Strand%2520Breaks%26jtitle%3DCell%26date%3D2004%26volume%3D117%26spage%3D17%26epage%3D28%26doi%3D10.1016%2Fs0092-8674%2804%2900206-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Au, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoppler, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jablons, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of CK 2α down-regulates Notch1 signalling in lung cancer cells</span>. <i>J. Cell Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">854</span>– <span class="NLM_lpage">862</span>, <span class="refDoi"> DOI: 10.1111/jcmm.12068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1111%2Fjcmm.12068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=23651443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlCrt77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=854-862&author=S.+Zhangauthor=H.+Longauthor=Y.+L.+Yangauthor=Y.+Wangauthor=D.+Hsiehauthor=W.+Liauthor=A.+Auauthor=H.+J.+Stopplerauthor=Z.+Xuauthor=D.+M.+Jablonsauthor=L.+You&title=Inhibition+of+CK+2%CE%B1+down-regulates+Notch1+signalling+in+lung+cancer+cells&doi=10.1111%2Fjcmm.12068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells</span></div><div class="casAuthors">Zhang, Shulin; Long, Hao; Yang, Yi-Lin; Wang, Yucheng; Hsieh, David; Li, Weiming; Au, Alfred; Stoppler, Hubert J.; Xu, Zhidong; Jablons, David M.; You, Liang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">854-862</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Protein kinase CK2 is frequently elevated in a variety of human cancers.  The Notch1 signalling pathway has been implicated in stem cell maintenance and its aberrant activation has been shown in several types of cancer including lung cancer.  Here, we show, for the first time, that CK2α is a pos. regulator of Notch1 signalling in lung cancer cell lines A549 and H1299.  We found that Notch1 protein level was reduced after CK2α silencing.  Down-regulation of Notch1 transcriptional activity was demonstrated after the silencing of CK2α in lung cancer cells.  Furthermore, small-mol. CK2α inhibitor CX-4945 led to a dose-dependent inhibition of Notch1 transcriptional activity.  Conversely, forced overexpression of CK2α resulted in an increase in Notch1 transcriptional activity.  Finally, the inhibition of CK2α led to a reduced proportion of stem-like CD44+ /CD24- cell population.  Thus, we report that the inhibition of CK2α down-regulates Notch1 signalling and subsequently reduces a cancer stem-like cell population in human lung cancer cells.  Our data suggest that CK2α inhibitors may be beneficial to the lung cancer patients with activated Notch1 signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS2z_d0QXEmrVg90H21EOLACvtfcHk0liNVipMMqDyug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlCrt77P&md5=64b28baced76a2a254fc4d99ed30bb4d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.12068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.12068%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%2BL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHsieh%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DAu%26aufirst%3DA.%26aulast%3DStoppler%26aufirst%3DH.%2BJ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DJablons%26aufirst%3DD.%2BM.%26aulast%3DYou%26aufirst%3DL.%26atitle%3DInhibition%2520of%2520CK%25202%25CE%25B1%2520down-regulates%2520Notch1%2520signalling%2520in%2520lung%2520cancer%2520cells%26jtitle%3DJ.%2520Cell%2520Mol.%2520Med.%26date%3D2013%26volume%3D17%26spage%3D854%26epage%3D862%26doi%3D10.1111%2Fjcmm.12068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iegre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brear, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Fusco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sore, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyvönen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Second-generation CK2α inhibitors targeting the αD pocket</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3041</span>– <span class="NLM_lpage">3049</span>, <span class="refDoi"> DOI: 10.1039/c7sc05122k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1039%2FC7SC05122K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=29732088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFGls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3041-3049&author=J.+Iegreauthor=P.+Brearauthor=C.+De+Fuscoauthor=M.+Yoshidaauthor=S.+L.+Mitchellauthor=M.+Rossmannauthor=L.+Carroauthor=H.+F.+Soreauthor=M.+Hyv%C3%B6nenauthor=D.+R.+Spring&title=Second-generation+CK2%CE%B1+inhibitors+targeting+the+%CE%B1D+pocket&doi=10.1039%2Fc7sc05122k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation CK2α inhibitors targeting the αD pocket</span></div><div class="casAuthors">Iegre, Jessica; Brear, Paul; De Fusco, Claudia; Yoshida, Masao; Mitchell, Sophie L.; Rossmann, Maxim; Carro, Laura; Sore, Hannah F.; Hyvonen, Marko; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3041-3049</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">CK2 is a crit. cell cycle regulator that also promotes various anti-apoptotic mechanisms.  Development of ATP-non-competitive inhibitors of CK2 is a very attractive strategy considering that the ATP binding site is highly conserved among other kinases.  We have previously utilized a pocket outside the active site to develop a novel CK2 inhibitor, CAM4066.  While CAM4066 bound to this new pocket it was also interacting with the ATP site: herein, we describe an example of a CK2α inhibitor that binds completely outside the active site.  This second generation αD-site binding inhibitor, compd. CAM4712 (IC50 = 7μM, GI50 = 10.0 ± 3.6μM), has numerous advantages over the previously reported CAM4066, including a redn. in the no. of rotatable bonds, the absence of amide groups susceptible to the action of proteases and improved cellular permeability.  Unlike with CAM4066, there was no need to facilitate cellular uptake by making a prodrug.  Moreover, CAM4712 displayed no drop off between its ability to inhibit the kinase in vitro (IC50) and the ability to inhibit cell proliferation (GI50).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprPLu-nG6dLLVg90H21EOLACvtfcHk0liNVipMMqDyug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFGls7w%253D&md5=4d57e89546e1c7bcac4868e3a02ba2f8</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1039%2FC7SC05122K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7SC05122K%26sid%3Dliteratum%253Aachs%26aulast%3DIegre%26aufirst%3DJ.%26aulast%3DBrear%26aufirst%3DP.%26aulast%3DDe%2BFusco%26aufirst%3DC.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DMitchell%26aufirst%3DS.%2BL.%26aulast%3DRossmann%26aufirst%3DM.%26aulast%3DCarro%26aufirst%3DL.%26aulast%3DSore%26aufirst%3DH.%2BF.%26aulast%3DHyv%25C3%25B6nen%26aufirst%3DM.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DSecond-generation%2520CK2%25CE%25B1%2520inhibitors%2520targeting%2520the%2520%25CE%25B1D%2520pocket%26jtitle%3DChem.%2520Sci.%26date%3D2018%26volume%3D9%26spage%3D3041%26epage%3D3049%26doi%3D10.1039%2Fc7sc05122k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S.</span></span> <span> </span><span class="NLM_article-title">Identification of a Novel Function of <b>CX-4945</b> as a Splicing Regulator</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e94978</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0094978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1371%2Fjournal.pone.0094978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=24743259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFemurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=H.+Kimauthor=K.+Choiauthor=H.+Kangauthor=S.-Y.+Leeauthor=S.-W.+Chiauthor=M.-S.+Leeauthor=J.+Songauthor=D.+Imauthor=Y.+Choiauthor=S.+Cho&title=Identification+of+a+Novel+Function+of+CX-4945+as+a+Splicing+Regulator&doi=10.1371%2Fjournal.pone.0094978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel function of CX-4945 as a splicing regulator</span></div><div class="casAuthors">Kim, Hyeongki; Choi, Kwangman; Kang, Hyunju; Lee, So-Young; Chi, Seung-wook; Lee, Min-sung; Song, Jaehyoung; Im, Donghwa; Choi, Yura; Cho, Sungchan</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e94978/1-e94978/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Alternative splicing is a nearly ubiquitous versatile process that controls gene expression and creates numerous protein isoforms with different functions from a single gene.  The significance of alternative splicing has been confirmed by the increasing no. of human diseases that are caused by misregulation of splicing events.  Very few compds., however, have been reported to act as inhibitors of alternative splicing, and their potential clin. use needs to be evaluated.  Here, we report that CX-4945, a previously well-characterized inhibitor of casein kinase 2 (CK2) and a mol. currently in clin. trials (Phase II) for cancer treatment, regulates splicing in mammalian cells in a CK2-independent manner.  Transcriptome-wide anal. using exon array also showed a widespread alteration in alternative splicing of numerous genes.  We found that CX-4945 potently inhibits the Cdc2-like kinases (Clks) in vitro and in turn, leads to suppression of the phosphorylation of serine/arginine-rich (SR) proteins in mammalian cells.  Surprisingly, the overall efficacy of CX-4945 on Clks (IC50 = 3-90 nM) was stronger than that of TG-003, the strongest inhibitor reported to date.  Of the Clks, Clk2 was most strongly inhibited by CX-4945 in an ATP-competitive manner.  Our research revealed an unexpected activity of the drug candidate CX-4945 as a potent splicing modulator and also suggested a potential application for therapy of diseases caused by abnormal splicing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEmZdGtUZUe7Vg90H21EOLACvtfcHk0liNVipMMqDyug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFemurzL&md5=5edb2338401d950cddbcba7d35e57c04</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0094978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0094978%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%26aulast%3DChoi%26aufirst%3DK.%26aulast%3DKang%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DS.-Y.%26aulast%3DChi%26aufirst%3DS.-W.%26aulast%3DLee%26aufirst%3DM.-S.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DIm%26aufirst%3DD.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520a%2520Novel%2520Function%2520of%2520CX-4945%2520as%2520a%2520Splicing%2520Regulator%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0094978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazimierczuk, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruzzene, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Maira, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orzeszko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meggio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinna, L. A.</span></span> <span> </span><span class="NLM_article-title">The Selectivity of Inhibitors of Protein Kinase CK2: an Update</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>415</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1042/bj20080309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1042%2FBJ20080309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=18588507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1CmsrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=415&publication_year=2008&pages=353-365&author=M.+A.+Paganoauthor=J.+Bainauthor=Z.+Kazimierczukauthor=S.+Sarnoauthor=M.+Ruzzeneauthor=G.+Di+Mairaauthor=M.+Elliottauthor=A.+Orzeszkoauthor=G.+Cozzaauthor=F.+Meggioauthor=L.+A.+Pinna&title=The+Selectivity+of+Inhibitors+of+Protein+Kinase+CK2%3A+an+Update&doi=10.1042%2Fbj20080309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The selectivity of inhibitors of protein kinase CK2: an update</span></div><div class="casAuthors">Pagano, Mario A.; Bain, Jenny; Kazimierczuk, Zygmunt; Sarno, Stefania; Ruzzene, Maria; Di maira, Giovanni; Elliott, Matthew; Orzeszko, Andrzej; Cozza, Giorgio; Meggio, Flavio; Pinna, Lorenzo A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">415</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">353-365</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">CK2 (casein kinase 2) is a very pleiotropic serine/threonine protein kinase whose abnormally high constitutive activity has often been correlated to pathol. conditions with special ref. to neoplasia.  The two most widely used cell permeable CK2 inhibitors, TBB (4,5,6,7-tetrabromo-1H-benzotriazole) and DMAT (2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole), are marketed as quite specific CK2 blockers.  In the present study the authors show, by using a panel of approx. 80 protein kinases, that DMAT and its parent compd. TBI (or TBBz; 4,5,6,7-tetrabromo-1H-benzimidazole) are potent inhibitors of several other kinases, with special ref. to PIM (provirus integration site for Moloney murine leukemia virus)1, PIM2, PIM3, PKD1 (protein kinase D1), HIPK2 (homeodomain-interacting protein kinase 2) and DYRK1a (dual-specificity tyrosine-phosphorylated and -regulated kinase 1a).  In contrast, TBB is significantly more selective toward CK2, although it also inhibits PIM1 and PIM3.  To improve selectivity towards CK2 a library of 68 TBB/TBI-related compds. have been tested for their ability to discriminate between CK2, PIM1, HIPK2 and DYRK1a, ending up with seven compds. whose efficacy toward CK2 is markedly higher than that toward the second most inhibited kinase.  Two of these, K64 (3,4,5,6,7-pentabromo-1H-indazole) and K66 (1-carboxymethyl-2-dimethylamino-4,5,6,7-tetrabromo-benzimidazole), display an overall selectivity much higher than TBB and DMAT when tested on a panel of 80 kinases and display similar efficacy as inducers of apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6m0pQ0Dz7b7Vg90H21EOLACvtfcHk0lidYS-o6BlqWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1CmsrnJ&md5=2a7bee7f29c2a500458240fd92fd2e3a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1042%2FBJ20080309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20080309%26sid%3Dliteratum%253Aachs%26aulast%3DPagano%26aufirst%3DM.%2BA.%26aulast%3DBain%26aufirst%3DJ.%26aulast%3DKazimierczuk%26aufirst%3DZ.%26aulast%3DSarno%26aufirst%3DS.%26aulast%3DRuzzene%26aufirst%3DM.%26aulast%3DDi%2BMaira%26aufirst%3DG.%26aulast%3DElliott%26aufirst%3DM.%26aulast%3DOrzeszko%26aufirst%3DA.%26aulast%3DCozza%26aufirst%3DG.%26aulast%3DMeggio%26aufirst%3DF.%26aulast%3DPinna%26aufirst%3DL.%2BA.%26atitle%3DThe%2520Selectivity%2520of%2520Inhibitors%2520of%2520Protein%2520Kinase%2520CK2%253A%2520an%2520Update%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D415%26spage%3D353%26epage%3D365%26doi%3D10.1042%2Fbj20080309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span> <span> </span><span class="NLM_article-title">Potent Anticancer Activity and Possible Low Toxicity of Platinum(II) Complexes with Functionalized 1,1-Cyclobutanedicarboxylate as a Leaving Ligand</span>. <i>Chem.—Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">15216</span>– <span class="NLM_lpage">15225</span>, <span class="refDoi"> DOI: 10.1002/chem.201404090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1002%2Fchem.201404090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=25256173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVert77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=15216-15225&author=J.+Zhaoauthor=S.+Gouauthor=F.+Liu&title=Potent+Anticancer+Activity+and+Possible+Low+Toxicity+of+Platinum%28II%29+Complexes+with+Functionalized+1%2C1-Cyclobutanedicarboxylate+as+a+Leaving+Ligand&doi=10.1002%2Fchem.201404090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Potent Anticancer Activity and Possible Low Toxicity of Platinum(II) Complexes with Functionalized 1,1-Cyclobutanedicarboxylate as a Leaving Ligand</span></div><div class="casAuthors">Zhao, Jian; Gou, Shaohua; Liu, Fengfan</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">15216-15225</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Two platinum(II) complexes, DN603 and DN604, were designed and prepd. by using 3-oxocyclobutane-1,1-dicarboxylate as a ligand.  The compds. were prepd. according to the concept that incorporation of a functionalized moiety in the leaving ligand that did not affect its coordination bonding to the metal atom would play a key role in the anticancer activity of the resulting platinum complex.  The newly prepd. compds. were found to show potent in vitro anticancer activity comparable to cisplatin and oxaliplatin; esp. DN604, which exhibited low acute toxicity similar to carboplatin, and presented acceptable soly. and stability in water.  Chem. and biol. results indicated that the functionalized moiety, uncoordinated, led to potent anticancer activity and low apparent toxicity of the platinum complexes by affecting the kinetic properties of the compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFM7XdNXKbZ7Vg90H21EOLACvtfcHk0lidYS-o6BlqWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVert77I&md5=4d1e67325d2bbb37d7ec277ab7d8340f</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fchem.201404090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201404090%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DF.%26atitle%3DPotent%2520Anticancer%2520Activity%2520and%2520Possible%2520Low%2520Toxicity%2520of%2520Platinum%2528II%2529%2520Complexes%2520with%2520Functionalized%25201%252C1-Cyclobutanedicarboxylate%2520as%2520a%2520Leaving%2520Ligand%26jtitle%3DChem.%25E2%2580%2594Eur.%2520J.%26date%3D2014%26volume%3D20%26spage%3D15216%26epage%3D15225%26doi%3D10.1002%2Fchem.201404090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khoury, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ademuyiwa, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandraseekhar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabbour, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLeo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Aldehyde Dehydrogenase 1A1 Expression in Breast Cancer is Associated with Stage, Triple Negativity, and Outcome to Neoadjuvant Chemotherapy</span>. <i>Mod. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1038/modpathol.2011.172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fmodpathol.2011.172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=22080062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjt1Wqtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=388-397&author=T.+Khouryauthor=F.+O.+Ademuyiwaauthor=R.+Chandraseekharauthor=M.+Jabbourauthor=A.+DeLeoauthor=S.+Ferroneauthor=Y.+Wangauthor=X.+Wang&title=Aldehyde+Dehydrogenase+1A1+Expression+in+Breast+Cancer+is+Associated+with+Stage%2C+Triple+Negativity%2C+and+Outcome+to+Neoadjuvant+Chemotherapy&doi=10.1038%2Fmodpathol.2011.172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy</span></div><div class="casAuthors">Khoury, Thaer; Ademuyiwa, Foluso O.; Chandraseekhar, Rameela; Jabbour, Marah; DeLeo, Albert; Ferrone, Soldano; Wang, Yangyang; Wang, Xinhui</div><div class="citationInfo"><span class="NLM_cas:title">Modern Pathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">388-397</span>CODEN:
                <span class="NLM_cas:coden">MODPEO</span>;
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Studies have shown that ALDH1A1 expression in the breast is assocd. with worse clin. outcome.  ALDH1A1 inactivates cyclophosphamide, which is an integral agent in breast cancer chemotherapy regimens.  The purposes of this study were to verify these results, to correlate ALDH1A1 expression with clin. outcome in patients treated with cyclophosphamide as part of the chemotherapy (adjuvant or neoadjuvant), and to evaluate ALDH1A1 as a useful marker to predict the clin. outcome of breast cancer subsets.  A total of 513 primary breast cancers were studied.  Tissue microarrays of the studied cases were stained with ALDH1A1.  Key clinicopathol. information was obtained.  Disease-free survival and overall survival were calcd.  Patients with neoadjuvant therapy who had substantial residual cancer burden (RCB) were included in the study.  Fisher's exact test and Kaplan-Meier methods were used for statistical anal.  ALDH1A1 was expressed in 53 (10%) patients, with a higher frequency in triple neg., followed by HER2+, and finally hormonal receptor+/HER2- (P<0.0001).  Tumors with advanced stage, node-pos., or larger tumor size were correlated with ALDH1A1 expression (P=0.006, P<0.0001, and P=0.05, resp.).  ALDH1A1 expression was also correlated with worse disease-free survival (P<0.006) and overall survival (P<0.01) in patients who were treated with neoadjuvant chemotherapy.  In all, 8 of 22 (36%) received neoadjuvant chemotherapy and died of disease-expressed ALDH1A1 (P=0.008).  Similarly, 8 of 23 (35%) who received neoadjuvant chemotherapy and had tumor recurrence expressed this marker (P=0.002).  The risk of recurrence was fivefold greater than neg. ALDH1A1 tumors.  The risk of recurrence became 11-fold greater when cyclophosphamide but not trastuzumab was part of the regimen.  Our results are consistent with previous studies.  Moreover, we found that ALDH1A1 could be a useful marker to predict worse clin. outcome after chemotherapy in the neoadjuvant setting with substantial RCB.  However, a larger cohort is required to verify our results.  Modern Pathol. (2012) 25, 388-397; doi:10.1038/modpathol.2011.172; published online 11 Nov. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHXWjqIR_zu7Vg90H21EOLACvtfcHk0lidYS-o6BlqWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjt1Wqtb0%253D&md5=369209539865a6da59c38be8c54beeb5</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fmodpathol.2011.172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmodpathol.2011.172%26sid%3Dliteratum%253Aachs%26aulast%3DKhoury%26aufirst%3DT.%26aulast%3DAdemuyiwa%26aufirst%3DF.%2BO.%26aulast%3DChandraseekhar%26aufirst%3DR.%26aulast%3DJabbour%26aufirst%3DM.%26aulast%3DDeLeo%26aufirst%3DA.%26aulast%3DFerrone%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DAldehyde%2520Dehydrogenase%25201A1%2520Expression%2520in%2520Breast%2520Cancer%2520is%2520Associated%2520with%2520Stage%252C%2520Triple%2520Negativity%252C%2520and%2520Outcome%2520to%2520Neoadjuvant%2520Chemotherapy%26jtitle%3DMod.%2520Pathol.%26date%3D2012%26volume%3D25%26spage%3D388%26epage%3D397%26doi%3D10.1038%2Fmodpathol.2011.172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaipio, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roering, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huhtinen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkonen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Östling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehtinen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansuri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korpela, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potdar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hynninen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auranen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grénman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hautaniemi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpén, O.</span></span> <span> </span><span class="NLM_article-title">ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>250</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1002/path.5356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1002%2Fpath.5356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=31595974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsF2lsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=250&publication_year=2020&pages=159-169&author=K.+Kaipioauthor=P.+Chenauthor=P.+Roeringauthor=K.+Huhtinenauthor=P.+Mikkonenauthor=P.+%C3%96stlingauthor=L.+Lehtinenauthor=N.+Mansuriauthor=T.+Korpelaauthor=S.+Potdarauthor=J.+Hynninenauthor=A.+Auranenauthor=S.+Gr%C3%A9nmanauthor=K.+Wennerbergauthor=S.+Hautaniemiauthor=O.+Carp%C3%A9n&title=ALDH1A1-related+stemness+in+high-grade+serous+ovarian+cancer+is+a+negative+prognostic+indicator+but+potentially+targetable+by+EGFR%2FmTOR-PI3K%2Faurora+kinase+inhibitors&doi=10.1002%2Fpath.5356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors</span></div><div class="casAuthors">Kaipio, Katja; Chen, Ping; Roering, Pia; Huhtinen, Kaisa; Mikkonen, Piia; Oestling, Paeivi; Lehtinen, Laura; Mansuri, Naziha; Korpela, Taina; Potdar, Swapnil; Hynninen, Johanna; Auranen, Annika; Grenman, Seija; Wennerberg, Krister; Hautaniemi, Sampsa; Carpen, Olli</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">250</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-169</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Poor chemotherapy response remains a major treatment challenge for high-grade serous ovarian cancer (HGSC).  Cancer stem cells are the major contributors to relapse and treatment failure as they can survive conventional therapy.  Our objectives were to characterize stemness features in primary patient-derived cell lines, correlate stemness markers with clin. outcome and test the response of our cells to both conventional and exploratory drugs.  Tissue and ascites samples, treatment-naive and/or after neoadjuvant chemotherapy, were prospectively collected.  Primary cancer cells, cultured under conditions favoring either adherent or spheroid growth, were tested for stemness markers; the same markers were analyzed in tissue and correlated with chemotherapy response and survival.  Drug sensitivity and resistance testing was performed with 306 oncol. compds.  Spheroid growth condition HGSC cells showed increased stemness marker expression (including aldehyde dehydrogenase isoform I; ALDH1A1) as compared with adherent growth condition cells, and increased resistance to platinum and taxane.  A set of eight stemness markers sepd. treatment-naive tumors into two clusters and identified a distinct subgroup of HGSC with enriched stemness features.  Expression of ALDH1A1, but not most other stemness markers, was increased after neoadjuvant chemotherapy and its expression in treatment-naive tumors correlated with chemoresistance and reduced survival.  In drug sensitivity and resistance testing, five compds., including two PI3K-mTOR inhibitors, demonstrated significant activity in both cell culture conditions.  Thirteen compds., including EGFR, PI3K-mTOR and aurora kinase inhibitors, were more toxic to spheroid cells than adherent cells.  Our results identify stemness markers in HGSC that are assocd. with a decreased response to conventional chemotherapy and reduced survival if expressed by treatment-naive tumors.  EGFR, mTOR-PI3K and aurora kinase inhibitors are candidates for targeting this cell population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpyFDLnreWCbVg90H21EOLACvtfcHk0lgZu-mhoa7RWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsF2lsbk%253D&md5=df803ac48a19ddb99a7bbdab45c15c19</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fpath.5356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.5356%26sid%3Dliteratum%253Aachs%26aulast%3DKaipio%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DRoering%26aufirst%3DP.%26aulast%3DHuhtinen%26aufirst%3DK.%26aulast%3DMikkonen%26aufirst%3DP.%26aulast%3D%25C3%2596stling%26aufirst%3DP.%26aulast%3DLehtinen%26aufirst%3DL.%26aulast%3DMansuri%26aufirst%3DN.%26aulast%3DKorpela%26aufirst%3DT.%26aulast%3DPotdar%26aufirst%3DS.%26aulast%3DHynninen%26aufirst%3DJ.%26aulast%3DAuranen%26aufirst%3DA.%26aulast%3DGr%25C3%25A9nman%26aufirst%3DS.%26aulast%3DWennerberg%26aufirst%3DK.%26aulast%3DHautaniemi%26aufirst%3DS.%26aulast%3DCarp%25C3%25A9n%26aufirst%3DO.%26atitle%3DALDH1A1-related%2520stemness%2520in%2520high-grade%2520serous%2520ovarian%2520cancer%2520is%2520a%2520negative%2520prognostic%2520indicator%2520but%2520potentially%2520targetable%2520by%2520EGFR%252FmTOR-PI3K%252Faurora%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Pathol.%26date%3D2020%26volume%3D250%26spage%3D159%26epage%3D169%26doi%3D10.1002%2Fpath.5356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span> <span> </span><span class="NLM_article-title">Garcinol From Garcinia Indica Downregulates Cancer Stem-Like Cell Biomarker ALDH1A1 in Nonsmall Cell Lung Cancer A549 Cells through DDIT3 Activation</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">3675</span>– <span class="NLM_lpage">3683</span>, <span class="refDoi"> DOI: 10.1021/acs.jafc.7b00346</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jafc.7b00346" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFCnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2017&pages=3675-3683&author=J.+Wangauthor=L.+Wangauthor=C.-T.+Hoauthor=K.+Zhangauthor=Q.+Liuauthor=H.+Zhao&title=Garcinol+From+Garcinia+Indica+Downregulates+Cancer+Stem-Like+Cell+Biomarker+ALDH1A1+in+Nonsmall+Cell+Lung+Cancer+A549+Cells+through+DDIT3+Activation&doi=10.1021%2Facs.jafc.7b00346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Garcinol from Garcinia indica Downregulates Cancer Stem-like Cell Biomarker ALDH1A1 in Nonsmall Cell Lung Cancer A549 Cells through DDIT3 Activation</span></div><div class="casAuthors">Wang, Jinhan; Wang, Liwen; Ho, Chi-Tang; Zhang, Kunsheng; Liu, Qiang; Zhao, Hui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Agricultural and Food Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3675-3683</span>CODEN:
                <span class="NLM_cas:coden">JAFCAU</span>;
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nonsmall cell lung cancer (NSCLC) is the predominant type of lung cancer.  Patients with NSCLC show high mortality rates because of failure to clean up cancer stem cells (CSCs).  The anticancer activity of phytochem. garcinol has been identified in various cancer cell models.  However, the effect of garcinol on NSCLC cell lines is still lacking.  Of the NSCLC cell lines we tested, A549 cells were the most sensitive to garcinol.  Interestingly, Aldehyde Dehydrogenase 1 Family Member A1 (ALDH1A1) was preferentially expressed in A549 cells and downregulated by the addn. of garcinol.  We also found that garcinol enriched DNA damage-inducible transcript 3 (DDIT3) and then altered DDIT3-CCAAT-enhancer-binding proteins beta (C/EBPβ) interaction resulting in a decreased binding of C/EBPβ to the endogenous ALDH1A1 promoter.  Furthermore, garcinol's inhibition of ALDH1A1 was identified in a xenograft mice model.  Garcinol repressed ALDH1A1 transcription in A549 cells through alterations in the interaction between DDIT3 and C/EBPβ.  Garcinol could be a potential dietary phytochem. candidate for NSCLCs patients whose tumors harbored high ALDH1A1 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEfTvmCNrY67Vg90H21EOLACvtfcHk0lgZu-mhoa7RWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFCnsbs%253D&md5=d38e7b2919e0bd0c4327af678c6e1b86</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jafc.7b00346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jafc.7b00346%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHo%26aufirst%3DC.-T.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DH.%26atitle%3DGarcinol%2520From%2520Garcinia%2520Indica%2520Downregulates%2520Cancer%2520Stem-Like%2520Cell%2520Biomarker%2520ALDH1A1%2520in%2520Nonsmall%2520Cell%2520Lung%2520Cancer%2520A549%2520Cells%2520through%2520DDIT3%2520Activation%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D2017%26volume%3D65%26spage%3D3675%26epage%3D3683%26doi%3D10.1021%2Facs.jafc.7b00346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morath, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmannb, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orian-Rousseau, V.</span></span> <span> </span><span class="NLM_article-title">CD44: More than a Mere Stem Cell Marker</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">166</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2016.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2Fj.biocel.2016.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=27640754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFeqsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2016&pages=166-173&author=I.+Morathauthor=T.+N.+Hartmannbauthor=V.+Orian-Rousseau&title=CD44%3A+More+than+a+Mere+Stem+Cell+Marker&doi=10.1016%2Fj.biocel.2016.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">CD44: More than a mere stem cell marker</span></div><div class="casAuthors">Morath, I.; Hartmann, T. N.; Orian-Rousseau, V.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">Part_A</span>),
    <span class="NLM_cas:pages">166-173</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">CD44 is a cell adhesion mol. that plays an important role in tumor progression and metastasis.  The role of CD44 in tumorigenesis is due to its binding to extracellular matrix components, including hyaluronan (HA) and osteopontin (OPN), and to messenger mols., such as growth factors present in the tumor microenvironment.  HA and OPN are highly abundant in the leukemic stem cell niche and in solid tumors of various cancer types, where they contribute to the maintenance of the stemness of malignant cells.  CD44 has consequently been recognized as a cancer stem cell marker in several types of cancers, which has been a topic of much recent research.  In this review we have addressed the question of how CD44 might promote cancer cell stemness by interacting with extracellular matrix components, growth factors and cytokines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruQQatjbujhrVg90H21EOLACvtfcHk0lgZu-mhoa7RWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFeqsrzJ&md5=bf58758d3734700d35bbd6c5550bb82b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2016.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2016.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DMorath%26aufirst%3DI.%26aulast%3DHartmannb%26aufirst%3DT.%2BN.%26aulast%3DOrian-Rousseau%26aufirst%3DV.%26atitle%3DCD44%253A%2520More%2520than%2520a%2520Mere%2520Stem%2520Cell%2520Marker%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2016%26volume%3D81%26spage%3D166%26epage%3D173%26doi%3D10.1016%2Fj.biocel.2016.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogoff, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keates, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murikipudi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikule, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggett, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardee, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. J.</span></span> <span> </span><span class="NLM_article-title">Suppression of Cancer Relapse and Metastasis by Inhibiting Cancer Stemness</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">1839</span>– <span class="NLM_lpage">1844</span>, <span class="refDoi"> DOI: 10.1073/pnas.1424171112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1073%2Fpnas.1424171112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=25605917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=1839-1844&author=Y.+Liauthor=H.+A.+Rogoffauthor=S.+Keatesauthor=Y.+Gaoauthor=S.+Murikipudiauthor=K.+Mikuleauthor=D.+Leggettauthor=W.+Liauthor=A.+B.+Pardeeauthor=C.+J.+Li&title=Suppression+of+Cancer+Relapse+and+Metastasis+by+Inhibiting+Cancer+Stemness&doi=10.1073%2Fpnas.1424171112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of cancer relapse and metastasis by inhibiting cancer stemness</span></div><div class="casAuthors">Li, Youzhi; Rogoff, Harry A.; Keates, Sarah; Gao, Yuan; Murikipudi, Sylaja; Mikule, Keith; Leggett, David; Li, Wei; Pardee, Arthur B.; Li, Chiang J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1839-1844</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Partial or even complete cancer regression can be achieved in some patients with current cancer treatments.  However, such initial responses are almost always followed by relapse, with the recurrent cancer being resistant to further treatments.  The discovery of therapeutic approaches that counteract relapse is, therefore, essential for advancing cancer medicine.  Cancer cells are extremely heterogeneous, even in each individual patient, in terms of their malignant potential, drug sensitivity, and their potential to metastasize and cause relapse.  Indeed, hypermalignant cancer cells, termed cancer stem cells or stemness-high cancer cells, that are highly tumorigenic and metastatic have been isolated from cancer patients with a variety of tumor types.  Moreover, such stemness-high cancer cells are resistant to conventional chemotherapy and radiation.  Here we show that BBI608, a small mol. identified by its ability to inhibit gene transcription driven by Stat3 and cancer stemness properties, can inhibit stemness gene expression and block spherogenesis of or kill stemness-high cancer cells isolated from a variety of cancer types.  Moreover, cancer relapse and metastasis were effectively blocked by BBI608 in mice.  These data demonstrate targeting cancer stemness as a novel approach to develop the next generation of cancer therapeutics to suppress cancer relapse and metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBRIs4CUCKMrVg90H21EOLACvtfcHk0li-EM0TjF221A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKht7k%253D&md5=7f77ee7a484e6f161a0d958743a5fa12</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1424171112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1424171112%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DRogoff%26aufirst%3DH.%2BA.%26aulast%3DKeates%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DMurikipudi%26aufirst%3DS.%26aulast%3DMikule%26aufirst%3DK.%26aulast%3DLeggett%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DPardee%26aufirst%3DA.%2BB.%26aulast%3DLi%26aufirst%3DC.%2BJ.%26atitle%3DSuppression%2520of%2520Cancer%2520Relapse%2520and%2520Metastasis%2520by%2520Inhibiting%2520Cancer%2520Stemness%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2015%26volume%3D112%26spage%3D1839%26epage%3D1844%26doi%3D10.1073%2Fpnas.1424171112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, D.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span> <span> </span><span class="NLM_article-title">The Neuroleptic Drug Pimozide Inhibits Stem-Like Cell Maintenance and Tumorigenicity in Hepatocellular Carcinoma</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">17593</span>– <span class="NLM_lpage">17609</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.4307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.18632%2Foncotarget.4307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=26061710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A280%3ADC%252BC2MbitVyrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=17593-17609&author=J.-J.+Chenauthor=N.+Caiauthor=G.-Z.+Chenauthor=C.-C.+Jiaauthor=D.-B.+Qiuauthor=C.+Duauthor=W.+Liuauthor=Y.+Yangauthor=Z.-J.+Longauthor=Q.+Zhang&title=The+Neuroleptic+Drug+Pimozide+Inhibits+Stem-Like+Cell+Maintenance+and+Tumorigenicity+in+Hepatocellular+Carcinoma&doi=10.18632%2Foncotarget.4307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma</span></div><div class="casAuthors">Chen Jia-Jie; Cai Nan; Chen Guan-Zhong; Jia Chang-Chang; Liu Wei; Yang Yang; Zhang Qi; Chen Jia-Jie; Cai Nan; Jia Chang-Chang; Qiu Dong-Bo; Du Cong; Zhang Qi; Chen Jia-Jie; Long Zi-Jie; Chen Guan-Zhong; Qiu Dong-Bo; Du Cong; Liu Wei; Zhang Qi</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">17593-17609</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug repurposing is currently an important approach for accelerating drug discovery and development for clinical use.  Hepatocellular carcinoma (HCC) presents drug resistance to chemotherapy, and the prognosis is poor due to the existence of liver cancer stem-like cells.  In this study, we investigated the effect of the neuroleptic agent pimozide to inhibit stem-like cell maintenance and tumorigenicity in HCC.  Our results showed that pimozide functioned as an anti-cancer drug in HCC cells or stem-like cells.  Pimozide inhibited cell proliferation and sphere formation capacities in HCC cells by inducing G0/G1 phase cell cycle arrest, as well as inhibited HCC cell migration.  Surprisingly, pimozide inhibited the maintenance and tumorigenicity of HCC stem-like cells, particularly the side population (SP) or CD133-positive cells, as evaluated by colony formation, sphere formation and transwell migration assays.  Furthermore, pimozide was found to suppress STAT3 activity in HCC cells by attenuating STAT3-dependent luciferase activity and down-regulating the transcription levels of downstream genes of STAT3 signaling.  Moreover, pimozide reversed the stem-like cell tumorigenic phenotypes induced by IL-6 treatment in HCC cells.  Further, the antitumor effect of pimozide was also proved in the nude mice HCC xenograft model.  In short, the anti-psychotic agent pimozide may act as a novel potential anti-tumor agent in treating advanced HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJREZ8s_IGh7HHuJhbyicZfW6udTcc2eaFX9c06WTtCLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbitVyrtg%253D%253D&md5=bea228d4f6fd873b07b1a1fd6b44bd39</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4307%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.-J.%26aulast%3DCai%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DG.-Z.%26aulast%3DJia%26aufirst%3DC.-C.%26aulast%3DQiu%26aufirst%3DD.-B.%26aulast%3DDu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DZ.-J.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DThe%2520Neuroleptic%2520Drug%2520Pimozide%2520Inhibits%2520Stem-Like%2520Cell%2520Maintenance%2520and%2520Tumorigenicity%2520in%2520Hepatocellular%2520Carcinoma%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D17593%26epage%3D17609%26doi%3D10.18632%2Foncotarget.4307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hooshmand, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asoodeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behnam-Rassouli, F.</span></span> <span> </span><span class="NLM_article-title">GL-9 peptide regulates gene expression of CD44 cancer marker and pro-inflammatory cytokine TNF-α in human lung epithelial adenocarcinoma cell line (A549)</span>. <i>Mol. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>423</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1007/s11010-016-2832-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1007%2Fs11010-016-2832-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=27704464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Wnur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=423&publication_year=2016&pages=141-149&author=K.+Hooshmandauthor=A.+Asoodehauthor=F.+Behnam-Rassouli&title=GL-9+peptide+regulates+gene+expression+of+CD44+cancer+marker+and+pro-inflammatory+cytokine+TNF-%CE%B1+in+human+lung+epithelial+adenocarcinoma+cell+line+%28A549%29&doi=10.1007%2Fs11010-016-2832-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">GL-9 peptide regulates gene expression of CD44 cancer marker and pro-inflammatory cytokine TNF-α in human lung epithelial adenocarcinoma cell line (A549)</span></div><div class="casAuthors">Hooshmand, Kosar; Asoodeh, Ahmad; Behnam-Rassouli, Fatemeh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">423</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">141-149</span>CODEN:
                <span class="NLM_cas:coden">MCBIB8</span>;
        ISSN:<span class="NLM_cas:issn">0300-8177</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In this study, we examd. cytotoxic effect of GL-9 peptide on A459 cell line through studying the changes in TNF-α and CD44 gene expression and ROS prodn.  Real-time PCR anal. showed that the treated A549 cells highly over expressed TNF-α, which was assocd. with a significant redn. of CD44 gene expression levels (p < 0.05).  ROS prodn. rate was measured through the usage of DCFH-DA primer.  Results demonstrated that GL-9 peptide could also induce cell death via ROS prodn.  The effect of GL-9 peptide on human erythrocytes and leukocytes was analyzed.  GL-9 peptide showed no significant toxic effect on human blood cells.  Our results suggested that the GL-9 peptide as a potent natural agent could modulate gene expression of cancer cell markers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEkCqbhy4T9rVg90H21EOLACvtfcHk0li-EM0TjF221A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Wnur%252FJ&md5=386a059268e600bef455524dc860c308</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs11010-016-2832-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11010-016-2832-9%26sid%3Dliteratum%253Aachs%26aulast%3DHooshmand%26aufirst%3DK.%26aulast%3DAsoodeh%26aufirst%3DA.%26aulast%3DBehnam-Rassouli%26aufirst%3DF.%26atitle%3DGL-9%2520peptide%2520regulates%2520gene%2520expression%2520of%2520CD44%2520cancer%2520marker%2520and%2520pro-inflammatory%2520cytokine%2520TNF-%25CE%25B1%2520in%2520human%2520lung%2520epithelial%2520adenocarcinoma%2520cell%2520line%2520%2528A549%2529%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D2016%26volume%3D423%26spage%3D141%26epage%3D149%26doi%3D10.1007%2Fs11010-016-2832-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span> <span> </span><span class="NLM_article-title">Lead- and Drug-Like Compounds: the Rule-of-Five Revolution</span>. <i>Drug Discov. Today Technol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1016/j.ddtec.2004.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2Fj.ddtec.2004.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=24981612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=337-341&author=C.+A.+Lipinski&title=Lead-+and+Drug-Like+Compounds%3A+the+Rule-of-Five+Revolution&doi=10.1016%2Fj.ddtec.2004.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Lead- and drug-like compounds: the rule-of-five revolution</span></div><div class="casAuthors">Lipinski, Christopher A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today: Technologies</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">337-341</span>CODEN:
                <span class="NLM_cas:coden">DDTTB5</span>;
        ISSN:<span class="NLM_cas:issn">1740-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Citations in CAS SciFinder to the rule-of-five (RO5) publication will exceed 1000 by year-end 2004.  Trends in the RO5 literature explosion that can be discerned are the further definitions of drug-like.  This topic is explored in terms of drug-like physicochem. features, drug-like structural features, a comparison of drug-like and non-drug-like in drug discovery and a discussion of how drug-like features relate to clin. success.  Physicochem. features of CNS drugs and features related to CNS blood-brain transporter affinity are briefly reviewed.  Recent literature on features of non-oral drugs is reviewed and how features of lead-like compds. differ from those of drug-like compds. is discussed.  Most recently, partly driven by NIH roadmap initiatives, considerations have arisen as to what tool-like means in the search for chem. tools to probe biol. space.  All these topics frame the scope of this short review/perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnjiyP3CY7lLVg90H21EOLACvtfcHk0li-EM0TjF221A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSqsrg%253D&md5=952c29b47003b884116d790ae9e4721f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ddtec.2004.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddtec.2004.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26atitle%3DLead-%2520and%2520Drug-Like%2520Compounds%253A%2520the%2520Rule-of-Five%2520Revolution%26jtitle%3DDrug%2520Discov.%2520Today%2520Technol.%26date%3D2004%26volume%3D1%26spage%3D337%26epage%3D341%26doi%3D10.1016%2Fj.ddtec.2004.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair to Overcome Cisplatin Resistance</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">15564</span>– <span class="NLM_lpage">15568</span>, <span class="refDoi"> DOI: 10.1002/anie.201608936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1002%2Fanie.201608936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1yju7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=15564-15568&author=Z.+Wangauthor=Z.+Xuauthor=G.+Zhu&title=A+Platinum%28IV%29+Anticancer+Prodrug+Targeting+Nucleotide+Excision+Repair+to+Overcome+Cisplatin+Resistance&doi=10.1002%2Fanie.201608936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance</span></div><div class="casAuthors">Wang, Zhigang; Xu, Zoufeng; Zhu, Guangyu</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">15564-15568</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">DNA damage response plays a key role not only in maintaining genome integrity but also in mediating the antitumor efficacy of DNA-damaging antineoplastic drugs.  Herein, we report the rational design and evaluation of a PtIV anticancer prodrug inhibiting nucleotide excision repair (NER), one of the most pivotal processes after the formation of cisplatin-induced DNA damage that deactivates the drug and leads to drug resistance in the clinic.  This dual-action prodrug enters cells efficiently and causes DNA damage while simultaneously inhibiting NER to promote apoptotic response.  The prodrug is strongly active against the proliferation of cisplatin-resistant human cancer cells with an up to 88-fold increase in growth inhibition compared with cisplatin, and the prodrug is much more active than a mixt. of cisplatin and an NER inhibitor.  Our study highlights the importance of targeting downstream pathways after the formation of Pt-induced DNA damage as a novel strategy to conquer cisplatin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5lc5oE4qMXrVg90H21EOLACvtfcHk0lj_MoUdkD-y9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1yju7fK&md5=551b6004833ce071b79c923cdf9483ca</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fanie.201608936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201608936%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DA%2520Platinum%2528IV%2529%2520Anticancer%2520Prodrug%2520Targeting%2520Nucleotide%2520Excision%2520Repair%2520to%2520Overcome%2520Cisplatin%2520Resistance%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D15564%26epage%3D15568%26doi%3D10.1002%2Fanie.201608936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luczak, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhitkovich, A.</span></span> <span> </span><span class="NLM_article-title">Monoubiquitinated γ-H2AX: Abundant product and specific biomarker for non-apoptotic DNA double-strand breaks</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">238</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2018.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2Fj.taap.2018.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=30006243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlentLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2018&pages=238-246&author=M.+W.+Luczakauthor=A.+Zhitkovich&title=Monoubiquitinated+%CE%B3-H2AX%3A+Abundant+product+and+specific+biomarker+for+non-apoptotic+DNA+double-strand+breaks&doi=10.1016%2Fj.taap.2018.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Monoubiquitinated γ-H2AX: Abundant product and specific biomarker for non-apoptotic DNA double-strand breaks</span></div><div class="casAuthors">Luczak, Michal W.; Zhitkovich, Anatoly</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">238-246</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">DNA double-strand breaks (DSBs) are a highly toxic form of DNA damage produced by a no. of carcinogens, drugs, and metabolic abnormalities.  Involvement of DSBs in many pathologies has led to frequent measurements of these lesions, primarily via biodosimetry of S139-phosphorylated histone H2AX (γ-H2AX).  However, γ-H2AX is also induced by some non-DSB conditions and abundantly formed in apoptosis, raising concerns about the overestimation of potential genotoxic agents and accuracy of DSB assessments.  DSB-triggered γ-H2AX undergoes RNF168-mediated K13/K15 monoubiquitination, which is rarely analyzed in DSB/genotoxicity studies.  Here we identified crit. methodol. factors that are necessary for the efficient detection of mono- (ub1) and diubiquitinated (ub2) γ-H2AX.  Using optimized tech. conditions, we found that γ-H2AX-ub1 was a predominant form of γ-H2AX in three primary human cell lines contg. mechanistically distinct types of DSBs.  Replication stress-assocd. DSBs also triggered extensive formation of γ-H2AX-ub1.  For DSBs induced by oxidative damage or topoisomerase II, both γ-H2AX and γ-H2AX-ub1 showed dose-dependent increases whereas γ-H2AX-ub2 plateaued at low levels of breaks.  Despite abundance of γ-H2AX, γ-H2AX-ub1,2 formation was blocked in apoptosis, which was assocd. with proteolytic cleavage of RNF168.  Chromatin damage also caused only the prodn. of γ-H2AX but not its ub1,2 forms.  Our results revealed a major contribution of ubiquitinated forms to the overall γ-H2AX response and demonstrated the specificity of monoubiquitinated γ-H2AX as a biodosimeter of non-apoptotic DSBs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolMYVFTOBCn7Vg90H21EOLACvtfcHk0lj_MoUdkD-y9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlentLvM&md5=f608cd88906e963551c3952acdb7f64f</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2018.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2018.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DLuczak%26aufirst%3DM.%2BW.%26aulast%3DZhitkovich%26aufirst%3DA.%26atitle%3DMonoubiquitinated%2520%25CE%25B3-H2AX%253A%2520Abundant%2520product%2520and%2520specific%2520biomarker%2520for%2520non-apoptotic%2520DNA%2520double-strand%2520breaks%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2018%26volume%3D355%26spage%3D238%26epage%3D246%26doi%3D10.1016%2Fj.taap.2018.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redon, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickey, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedelnikova, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">γH2AX and cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">957</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.1038/nrc2523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fnrc2523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=19005492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=957-967&author=W.+M.+Bonnerauthor=C.+E.+Redonauthor=J.+S.+Dickeyauthor=A.+J.+Nakamuraauthor=O.+A.+Sedelnikovaauthor=S.+Solierauthor=Y.+Pommier&title=%CE%B3H2AX+and+cancer&doi=10.1038%2Fnrc2523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">γH2AX and cancer</span></div><div class="casAuthors">Bonner, William M.; Redon, Christophe E.; Dickey, Jennifer S.; Nakamura, Asako J.; Sedelnikova, Olga A.; Solier, Stephanie; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">957-967</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone H2AX phosphorylation on a serine four residues from the carboxyl terminus (producing γH2AX) is a sensitive marker for DNA double-strand breaks (DSBs).  DSBs may lead to cancer but, paradoxically, are also used to kill cancer cells.  Using γH2AX detection to det. the extent of DSB induction may help to detect precancerous cells, to stage cancers, to monitor the effectiveness of cancer therapies and to develop novel anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDvJ8vnkfC0bVg90H21EOLACvtfcHk0lj_MoUdkD-y9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWhu7rK&md5=b0a83efe87f2823e79146ba8a2edf808</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnrc2523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2523%26sid%3Dliteratum%253Aachs%26aulast%3DBonner%26aufirst%3DW.%2BM.%26aulast%3DRedon%26aufirst%3DC.%2BE.%26aulast%3DDickey%26aufirst%3DJ.%2BS.%26aulast%3DNakamura%26aufirst%3DA.%2BJ.%26aulast%3DSedelnikova%26aufirst%3DO.%2BA.%26aulast%3DSolier%26aufirst%3DS.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3D%25CE%25B3H2AX%2520and%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D957%26epage%3D967%26doi%3D10.1038%2Fnrc2523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. P.</span></span> <span> </span><span class="NLM_article-title">Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at sites of DNA damage</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">795</span>– <span class="NLM_lpage">801</span>, <span class="refDoi"> DOI: 10.1038/embor.2008.103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fembor.2008.103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=18583988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1Snt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=795-801&author=J.+R.+Chapmanauthor=S.+P.+Jackson&title=Phospho-dependent+interactions+between+NBS1+and+MDC1+mediate+chromatin+retention+of+the+MRN+complex+at+sites+of+DNA+damage&doi=10.1038%2Fembor.2008.103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at sites of DNA damage</span></div><div class="casAuthors">Chapman, J. Ross; Jackson, Stephen P.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">795-801</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mammalian cells respond to DNA double-strand breaks (DSBs) by recruiting DNA repair and cell-cycle checkpoint proteins to such sites.  Central to these DNA damage response (DDR) events is the DNA damage mediator protein MDC1.  MDC1 interacts with several DDR proteins, including the MRE11-RAD50-NBS1 (MRN) complex.  Here, we show that MDC1 is phosphorylated on a cluster of conserved repeat motifs by casein kinase 2 (CK2).  Moreover, we establish that this phosphorylation of MDC1 promotes direct, phosphorylation-dependent interactions with NBS1 in a manner that requires the closely apposed FHA and twin BRCT domains in the amino terminus of NBS1.  Finally, we show that these CK2-targeted motifs in MDC1 are required to mediate NBS1 assocn. with chromatin-flanking sites of unrepaired DSBs.  These findings provide a mol. explanation for the MDC1-MRN interaction and yield insights into how MDC1 coordinates the focal assembly and activation of several DDR factors in response to DNA damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfw8E0hJOLwrVg90H21EOLACvtfcHk0liUhIk-cGI9aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1Snt7s%253D&md5=a6571abbd0da104e0b88c531d2804e96</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fembor.2008.103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fembor.2008.103%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DJ.%2BR.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26atitle%3DPhospho-dependent%2520interactions%2520between%2520NBS1%2520and%2520MDC1%2520mediate%2520chromatin%2520retention%2520of%2520the%2520MRN%2520complex%2520at%2520sites%2520of%2520DNA%2520damage%26jtitle%3DEMBO%2520Rep.%26date%3D2008%26volume%3D9%26spage%3D795%26epage%3D801%26doi%3D10.1038%2Fembor.2008.103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tirino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desiderio, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rosa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaccio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Noce, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papaccio, G.</span></span> <span> </span><span class="NLM_article-title">Cancer Stem Cells in Solid Tumors: an Overview and New Approaches for Their Isolation and Characterization</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1096/fj.12-218222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1096%2Ffj.12-218222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=23024375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Gqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2013&pages=13-24&author=V.+Tirinoauthor=V.+Desiderioauthor=F.+Painoauthor=A.+De+Rosaauthor=F.+Papaccioauthor=M.+La+Noceauthor=L.+Lainoauthor=F.+De+Francescoauthor=G.+Papaccio&title=Cancer+Stem+Cells+in+Solid+Tumors%3A+an+Overview+and+New+Approaches+for+Their+Isolation+and+Characterization&doi=10.1096%2Ffj.12-218222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization</span></div><div class="casAuthors">Tirino, Virginia; Desiderio, Vincenzo; Paino, Francesca; De Rosa, Alfredo; Papaccio, Federica; La Noce, Marcella; Laino, Luigi; De Francesco, Francesco; Papaccio, Gianpaolo</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-24, 10.1096/fj.12-218222</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">0892-6638</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">A review.  Primary tumors are responsible for 10% of cancer deaths.  In most cases, the main cause of mortality is the formation of metastases.  Accumulating evidence suggests that a subpopulation of tumor cells with distinct stem-like properties is responsible for tumor initiation, invasive growth, and metastasis formation.  This population is defined as cancer stem cells (CSCs).  Existing therapies have enhanced the length of survival after diagnosis of cancer but have completely failed in terms of recovery.  CSCs appear to be resistant to chemotherapy, may remain quiescent for extended periods, and have affinity for hypoxic environments.  The CSCs can be identified and isolated by different methodologies, including isolation by CSC-specific cell surface marker expression, detection of side population phenotype by Hoechst 33342 exclusion, assessment of their ability to grow as floating spheres, and aldehyde dehydrogenase (ALDH) activity assay.  None of the methods mentioned are exclusively used to isolate the solid tumor CSCs, highlighting the imperative to delineate more specific markers or to use combinatorial markers and methodologies.  This review provides an overview of the main characteristics and approaches used to identify, isolate, and characterize CSCs from solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKHEZT73U6-bVg90H21EOLACvtfcHk0liUhIk-cGI9aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Gqtw%253D%253D&md5=de33a9ff83242808595b3772fac12f5d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1096%2Ffj.12-218222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.12-218222%26sid%3Dliteratum%253Aachs%26aulast%3DTirino%26aufirst%3DV.%26aulast%3DDesiderio%26aufirst%3DV.%26aulast%3DPaino%26aufirst%3DF.%26aulast%3DDe%2BRosa%26aufirst%3DA.%26aulast%3DPapaccio%26aufirst%3DF.%26aulast%3DLa%2BNoce%26aufirst%3DM.%26aulast%3DLaino%26aufirst%3DL.%26aulast%3DDe%2BFrancesco%26aufirst%3DF.%26aulast%3DPapaccio%26aufirst%3DG.%26atitle%3DCancer%2520Stem%2520Cells%2520in%2520Solid%2520Tumors%253A%2520an%2520Overview%2520and%2520New%2520Approaches%2520for%2520Their%2520Isolation%2520and%2520Characterization%26jtitle%3DFASEB%2520J.%26date%3D2013%26volume%3D27%26spage%3D13%26epage%3D24%26doi%3D10.1096%2Ffj.12-218222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G. D.</span></span> <span> </span><span class="NLM_article-title">The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer</span>. <i>Stem Cell. Int.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1155/2016/2087204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1155%2F2016%2F2087204" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=1-15&author=R.+Thapaauthor=G.+D.+Wilson&title=The+Importance+of+CD44+as+a+Stem+Cell+Biomarker+and+Therapeutic+Target+in+Cancer&doi=10.1155%2F2016%2F2087204"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1155%2F2016%2F2087204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F2087204%26sid%3Dliteratum%253Aachs%26aulast%3DThapa%26aufirst%3DR.%26aulast%3DWilson%26aufirst%3DG.%2BD.%26atitle%3DThe%2520Importance%2520of%2520CD44%2520as%2520a%2520Stem%2520Cell%2520Biomarker%2520and%2520Therapeutic%2520Target%2520in%2520Cancer%26jtitle%3DStem%2520Cell.%2520Int.%26date%3D2016%26volume%3D2016%26spage%3D1%26epage%3D15%26doi%3D10.1155%2F2016%2F2087204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Knockdown of Oct4 and Nanog Expression Inhibits the Stemness of Pancreatic Cancer Cells</span>. <i>Canc. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>340</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2013.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2Fj.canlet.2013.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=23872274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1WrtbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=2013&pages=113-123&author=Y.+Luauthor=H.+Zhuauthor=H.+Shanauthor=J.+Luauthor=X.+Changauthor=X.+Liauthor=J.+Luauthor=X.+Fanauthor=S.+Zhuauthor=Y.+Wangauthor=Q.+Guoauthor=L.+Wangauthor=Y.+Huangauthor=M.+Zhuauthor=Z.+Wang&title=Knockdown+of+Oct4+and+Nanog+Expression+Inhibits+the+Stemness+of+Pancreatic+Cancer+Cells&doi=10.1016%2Fj.canlet.2013.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells</span></div><div class="casAuthors">Lu, Yuhua; Zhu, Hui; Shan, Haiyan; Lu, Junjie; Chang, Xu; Li, Xiaohong; Lu, Jingjing; Fan, Xiangjun; Zhu, Shajun; Wang, Yao; Guo, Qingsong; Wang, Lei; Huang, Yan; Zhu, Mingyan; Wang, Zhiwei</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-123</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Pancreatic cancer is notorious for its difficult diagnosis at early stage and poor recurrence-free prognosis.  This study aimed to investigate the possible involvement of Oct4 and Nanog in pancreatic cancer.  The high expressions of Oct4 and Nanog in human pancreatic cancer tissues were found to indicate a worse prognostic value of patients.  The pancreatic cancer stem cells (PCSCs) that isolated from PANC-1 cell line by flow cytometry exhibited high expressions of Oct4 and Nanog.  To investigate whether Oct4 and Nanog play crucial role in maintaining the stemness of PCSCs, double knockdown of Oct4 and Nanog demonstrated that Oct4 and Nanog significantly reduced proliferation, migration, invasion, chemoresistance, and tumorigenesis of PCSCs in vitro and in vivo.  The altered expression of the genes related to pancreatic carcinogenesis, metastasis, drug resistance and epithelial-mesenchymal transdifferentiation (EMT) might affect the biol. characteristics of PCSCs.  Our results suggest that Oct4 and Nanog may serve as a potential marker of prognosis and a novel target of therapy for pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokcOYM0eHQFLVg90H21EOLACvtfcHk0liUhIk-cGI9aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1WrtbzL&md5=db8be55f62a426df2ac1d6beda29d331</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2013.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2013.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DShan%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DKnockdown%2520of%2520Oct4%2520and%2520Nanog%2520Expression%2520Inhibits%2520the%2520Stemness%2520of%2520Pancreatic%2520Cancer%2520Cells%26jtitle%3DCanc.%2520Lett.%26date%3D2013%26volume%3D340%26spage%3D113%26epage%3D123%26doi%3D10.1016%2Fj.canlet.2013.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asadzadeh, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansoori, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haji-Asgarzadeh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safarzadeh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhtarzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duijf, P. H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baradaran, B.</span></span> <span> </span><span class="NLM_article-title">microRNAs in Cancer Stem Cells: Biology, Pathways, and Therapeutic Opportunities</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">10002</span>– <span class="NLM_lpage">10017</span>, <span class="refDoi"> DOI: 10.1002/jcp.27885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1002%2Fjcp.27885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=30537109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVGmsbrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2019&pages=10002-10017&author=Z.+Asadzadehauthor=B.+Mansooriauthor=A.+Mohammadiauthor=M.+Aghajaniauthor=K.+Haji-Asgarzadehauthor=E.+Safarzadehauthor=A.+Mokhtarzadehauthor=P.+H.+G.+Duijfauthor=B.+Baradaran&title=microRNAs+in+Cancer+Stem+Cells%3A+Biology%2C+Pathways%2C+and+Therapeutic+Opportunities&doi=10.1002%2Fjcp.27885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">microRNAs in cancer stem cells: Biology, pathways, and therapeutic opportunities</span></div><div class="casAuthors">Asadzadeh, Zahra; Mansoori, Behzad; Mohammadi, Ali; Aghajani, Marjan; Haji-Asgarzadeh, Khalil; Safarzadeh, Elham; Mokhtarzadeh, Ahad; Duijf, Pascal H. G.; Baradaran, Behzad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">10002-10017</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) are a small subpopulation of tumor cells that have been identified in most types of cancer.  Features that distinguish them from the bulk of tumor cells include their pluripotency, self-renewal capacity, low proliferation rate, and tumor-initiating ability.  CSCs are highly malignant, as they confer drug resistance and facilitate tumor progression, relapse, and metastasis.  The mol. mechanisms underlying CSC biol. are now beginning to be understood.  In this context, microRNAs (miRNAs) occupy a prominent place.  These endogenous, small noncoding RNA mols. control gene expression at the posttranscriptional level.  This study reviews our current understanding of how the misexpression of tumor suppressor and oncogenic miRNAs in CSCs sustain their abundance and malignant properties.  We discuss how they partly do so by acting on major CSC signaling pathways, including the Wnt, Notch, Hedgehog, and BMI-1 pathways.  Our current knowledge of miRNA functions in CSCs may now be used for cancer diagnostic and prognostic purposes.  In addn., when combined with recent tech. advances in the in vivo delivery of miRNAs, we are now in an excellent position to develop strategies that harness miRNA interference and replacement technologies for the therapeutic targeting of CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsTNiKoa2uTrVg90H21EOLACvtfcHk0ljGtLCMe3Ar-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVGmsbrL&md5=efbc05e5989b766a310155f1d39cc763</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1002%2Fjcp.27885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.27885%26sid%3Dliteratum%253Aachs%26aulast%3DAsadzadeh%26aufirst%3DZ.%26aulast%3DMansoori%26aufirst%3DB.%26aulast%3DMohammadi%26aufirst%3DA.%26aulast%3DAghajani%26aufirst%3DM.%26aulast%3DHaji-Asgarzadeh%26aufirst%3DK.%26aulast%3DSafarzadeh%26aufirst%3DE.%26aulast%3DMokhtarzadeh%26aufirst%3DA.%26aulast%3DDuijf%26aufirst%3DP.%2BH.%2BG.%26aulast%3DBaradaran%26aufirst%3DB.%26atitle%3DmicroRNAs%2520in%2520Cancer%2520Stem%2520Cells%253A%2520Biology%252C%2520Pathways%252C%2520and%2520Therapeutic%2520Opportunities%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D234%26spage%3D10002%26epage%3D10017%26doi%3D10.1002%2Fjcp.27885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, B.</span></span> <span> </span><span class="NLM_article-title">NOR1 Suppresses Cancer Stem-Like Cells Properties of Tumor Cells via the Inhibition of the AKT-GSK-3β-Wnt/β-catenin-ALDH1A1 Signal Circuit</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>232</i></span>,  <span class="NLM_fpage">2829</span>– <span class="NLM_lpage">2840</span>, <span class="refDoi"> DOI: 10.1002/jcp.25706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1002%2Fjcp.25706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=27891591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFahsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2017&pages=2829-2840&author=W.+Wangauthor=M.+Yiauthor=S.+Chenauthor=J.+Liauthor=H.+Zhangauthor=W.+Xiongauthor=G.+Liauthor=X.+Liauthor=B.+Xiang&title=NOR1+Suppresses+Cancer+Stem-Like+Cells+Properties+of+Tumor+Cells+via+the+Inhibition+of+the+AKT-GSK-3%CE%B2-Wnt%2F%CE%B2-catenin-ALDH1A1+Signal+Circuit&doi=10.1002%2Fjcp.25706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">NOR1 Suppresses Cancer Stem-Like Cells Properties of Tumor Cells via the Inhibition of the AKT-GSK-3β-Wnt/β-catenin-ALDH1A1 Signal Circuit</span></div><div class="casAuthors">Wang, Wei; Yi, Mei; Chen, Shengnan; Li, Junjun; Zhang, Haijing; Xiong, Wei; Li, Guiyuan; Li, Xiaoling; Xiang, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2829-2840</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) play a key role in tumor radiotherapy and chemotherapy resistance, relapse, and metastasis, and are primarily maintained in a resting state in vivo.  The failure of conventional therapies to target CSCs is the main cause of treatment failure.  The discovery of CSCs in nasopharyngeal carcinoma (NPC) tumors is becoming more prevalent; however, the understanding of the mechanisms underlying the maintenance of tumor stemness is still limited.  We previously cloned NOR1, a tumor suppressor gene downregulated in NPC cell lines and tissues.  In this study, we demonstrate that Wnt/β-catenin and ALDH1A1 form a signal circuit and that NOR1 antagonizes the tumor stem cell-like phenotype in NPC cell lines: the ectopic overexpression of NOR1 reduced β-catenin and ALDH1A1 expression; β-catenin/TCF4 targeted the regulation of ALDH1A1 transcription in NPC cells; silencing ALDH1A1 reduced AKT (total and phosphorylated) and GSK-3β (phosphorylated) expression; and eventually feedback decreased β-catenin expression levels.  We also found that NOR1 expression decreased cancer stem-like cell properties of NPC cells, reduced their ability to form tumor spheroids in vitro, reduced tumorigenicity in nude mice in vivo, and increased sensitivity to chemotherapy agents.  Taken together, our findings illustrated a new function of NOR1 that suppresses cancer stem-like cell properties in tumor cells by inhibiting the AKT-GSK-3β-Wnt/β-catenin-ALDH1A1 signal circuit.  The study suggests that NOR1 deletion expression in NPC cells may be a potential mol. target for cancer stem cell therapy.  J. Cell. Physiol. 9999: 1-12, 2016. © 2016 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjQREwi8U08bVg90H21EOLACvtfcHk0ljGtLCMe3Ar-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFahsr0%253D&md5=49109830d2714cadee604a7fff74c3a3</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fjcp.25706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.25706%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYi%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DB.%26atitle%3DNOR1%2520Suppresses%2520Cancer%2520Stem-Like%2520Cells%2520Properties%2520of%2520Tumor%2520Cells%2520via%2520the%2520Inhibition%2520of%2520the%2520AKT-GSK-3%25CE%25B2-Wnt%252F%25CE%25B2-catenin-ALDH1A1%2520Signal%2520Circuit%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2017%26volume%3D232%26spage%3D2829%26epage%3D2840%26doi%3D10.1002%2Fjcp.25706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedert, M.</span></span> <span> </span><span class="NLM_article-title">GSK3 Inhibitors: Development and Therapeutic Potential</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">479</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1038/nrd1415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1038%2Fnrd1415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=15173837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVaqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=479-487&author=P.+Cohenauthor=M.+Goedert&title=GSK3+Inhibitors%3A+Development+and+Therapeutic+Potential&doi=10.1038%2Fnrd1415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">GSK3 inhibitors: development and therapeutic potential</span></div><div class="casAuthors">Cohen, Philip; Goedert, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">479-487</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metab.  In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics.  Here, we describe the biol. of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL3ua5xi0_qrVg90H21EOLACvtfcHk0ljGtLCMe3Ar-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVaqsrs%253D&md5=165d1354bf11faa6021ac4dba797fda2</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnrd1415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1415%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DGoedert%26aufirst%3DM.%26atitle%3DGSK3%2520Inhibitors%253A%2520Development%2520and%2520Therapeutic%2520Potential%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D479%26epage%3D487%26doi%3D10.1038%2Fnrd1415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mills, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowsheen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. S.</span></span> <span> </span><span class="NLM_article-title">Emerging Roles of Glycogen Synthase Kinase 3 in the Treatment of Brain Tumors</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">47</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2011.00047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.3389%2Ffnmol.2011.00047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=22275880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC38XovV2j" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2011&pages=47&author=C.+N.+Millsauthor=S.+Nowsheenauthor=J.+A.+Bonnerauthor=E.+S.+Yang&title=Emerging+Roles+of+Glycogen+Synthase+Kinase+3+in+the+Treatment+of+Brain+Tumors&doi=10.3389%2Ffnmol.2011.00047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors</span></div><div class="casAuthors">Mills, Caroline N.; Nowsheen, Somaira; Bonner, James A.; Yang, Eddy S.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Nov.</span>),
    <span class="NLM_cas:pages">47</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The constitutively active protein glycogen synthase kinase 3 (GSK3), a serine/threonine kinase, acts paradoxically as a tumor suppressor in some cancers while potentiates growth in others.  Deciphering what governs its actions is vital for understanding many pathol. conditions, including brain cancer.  What are seemingly disparate roles of GSK3 stems from the complex regulation of many cellular functions by GSK3.  This review focuses on the regulation of GSK3, its role in survival, apoptosis and DNA damage, and finally its potential therapeutic impact in brain cancer.  A thorough understanding of this versatile protein is crit. for improving the outcome of various diseases, esp. cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDHgnEU2CYbVg90H21EOLACvtfcHk0lg9wndcZcq0qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovV2j&md5=a91f52a6292ec3ed914020d19393a989</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2011.00047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2011.00047%26sid%3Dliteratum%253Aachs%26aulast%3DMills%26aufirst%3DC.%2BN.%26aulast%3DNowsheen%26aufirst%3DS.%26aulast%3DBonner%26aufirst%3DJ.%2BA.%26aulast%3DYang%26aufirst%3DE.%2BS.%26atitle%3DEmerging%2520Roles%2520of%2520Glycogen%2520Synthase%2520Kinase%25203%2520in%2520the%2520Treatment%2520of%2520Brain%2520Tumors%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2011%26volume%3D4%26spage%3D47%26doi%3D10.3389%2Ffnmol.2011.00047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Combretastatin A-4 analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2132</span>– <span class="NLM_lpage">2148</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.6b00353</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.6b00353" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1yrsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=2132-2148&author=X.+Huangauthor=R.+Huangauthor=S.+Gouauthor=Z.+Wangauthor=Z.+Liaoauthor=H.+Wang&title=Combretastatin+A-4+analogue%3A+A+Dual-Targeting+and+Tubulin+Inhibitor+Containing+Antitumor+Pt%28IV%29+Moiety+with+a+Unique+Mode+of+Action&doi=10.1021%2Facs.bioconjchem.6b00353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action</span></div><div class="casAuthors">Huang, Xiaochao; Huang, Rizhen; Gou, Shaohua; Wang, Zhimei; Liao, Zhixin; Wang, Hengshan</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2132-2148</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abstr.: Three new Pt(IV) complexes comprising a combretastatin A-4 analog were designed and synthesized.  The resulting antitumor Pt(IV) complexes could significantly improve the antiproliferative activity and overcome the drug resistance of cisplatin in vitro.  Interestingly, these novel compds. can not only carry the DNA binding Pt(II) warhead into the cancer cells but also have a small mol. fragment that can inhibit tubulin polymn.  Among them, complex 13, which was attached to an inhibitor of tubulin at one axial position of Pt(IV) octahedral coordination sphere, could effectively enter cancer cells, arrest the cell cycle in HepG-2 cancer cells at G2/M phases, and induce activation of caspases triggering apoptotic signaling via the mitochondrial-dependent apoptosis pathways.  Moreover, complex 13 has the ability of effectively inhibiting the tumor growth in the HepG-2 xenograft model without causing significant loss of animal body wt. in comparison with cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_P-MRBiNaU7Vg90H21EOLACvtfcHk0lg9wndcZcq0qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1yrsbfO&md5=a86ac2b4f6898e01dc0910d4112ddf03</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.6b00353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.6b00353%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DGou%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DCombretastatin%2520A-4%2520analogue%253A%2520A%2520Dual-Targeting%2520and%2520Tubulin%2520Inhibitor%2520Containing%2520Antitumor%2520Pt%2528IV%2529%2520Moiety%2520with%2520a%2520Unique%2520Mode%2520of%2520Action%26jtitle%3DBioconjugate%2520Chem.%26date%3D2016%26volume%3D27%26spage%3D2132%26epage%3D2148%26doi%3D10.1021%2Facs.bioconjchem.6b00353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breckenridge, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, D.</span></span> <span> </span><span class="NLM_article-title">Regulation of Mitochondrial Membrane Permeabilization by BCL-2 Family Proteins and Caspases</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">652</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2004.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2Fj.ceb.2004.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=15530776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVOrtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2004&pages=647-652&author=D.+G.+Breckenridgeauthor=D.+Xue&title=Regulation+of+Mitochondrial+Membrane+Permeabilization+by+BCL-2+Family+Proteins+and+Caspases&doi=10.1016%2Fj.ceb.2004.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases</span></div><div class="casAuthors">Breckenridge, David G.; Xue, Ding</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">647-652</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Mitochondria play an important role in the integration and transmission of cell death signals, activating caspases and other cell death execution events by releasing apoptogenic proteins from the intermembrane space.  The BCL-2 family of proteins localize (or can be targeted) to mitochondria and regulate the permeability of the mitochondrial outer membrane to these apoptotic factors.  Recent evidence suggests that multiple mechanisms may regulate the release of mitochondrial factors, some of which depend on the action of caspases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgc06hGcSXVbVg90H21EOLACvtfcHk0lg9wndcZcq0qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVOrtbs%253D&md5=9e6fd14a4644e232f99dfc8183eab331</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2004.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2004.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DBreckenridge%26aufirst%3DD.%2BG.%26aulast%3DXue%26aufirst%3DD.%26atitle%3DRegulation%2520of%2520Mitochondrial%2520Membrane%2520Permeabilization%2520by%2520BCL-2%2520Family%2520Proteins%2520and%2520Caspases%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2004%26volume%3D16%26spage%3D647%26epage%3D652%26doi%3D10.1016%2Fj.ceb.2004.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6507</span>– <span class="NLM_lpage">6516</span>, <span class="refDoi"> DOI: 10.1021/acs.inorgchem.9b00708</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.inorgchem.9b00708" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFSju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=6507-6516&author=S.+Jinauthor=Y.+Guoauthor=D.+Songauthor=Z.+Zhuauthor=Z.+Zhangauthor=Y.+Sunauthor=T.+Yangauthor=Z.+Guoauthor=X.+Wang&title=Targeting+Energy+Metabolism+by+a+Platinum%28IV%29+Prodrug+as+an+Alternative+Pathway+for+Cancer+Suppression&doi=10.1021%2Facs.inorgchem.9b00708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression</span></div><div class="casAuthors">Jin, Suxing; Guo, Yan; Song, Dongfan; Zhu, Zhenzhu; Zhang, Zhenqin; Sun, Yuewen; Yang, Tao; Guo, Zijian; Wang, Xiaoyong</div><div class="citationInfo"><span class="NLM_cas:title">Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">6507-6516</span>CODEN:
                <span class="NLM_cas:coden">INOCAJ</span>;
        ISSN:<span class="NLM_cas:issn">0020-1669</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer is characterized by abnormal cellular energy metab., which preferentially switches to aerobic glycolysis rather than oxidative phosphorylation as a means of glucose metab.  Many key enzymes involved in the abnormal glycolysis are potential targets of anticancer drugs.  Platinum(IV) complexes are potential anticancer prodrugs and kinetically more inert than the platinum(II) counterparts, which offer an opportunity to be modified by functional ligands for activation or targeted delivery.  A novel platinum(IV) complex, c,c,t-[Pt(NH3)2Cl2(C10H15N2O3S)(C2HO2Cl2)] (DPB), was designed to explore the effects of axial ligands on the reactivity and bioactivity of the complex as well as on tumor energy metab.  The complex was characterized by electrospray ionization mass spectrometry and multinuclear (1H, 13C, and 195Pt) NMR spectroscopy.  The introduction of dichloroacetate (DCA) markedly increases the lipophilicity, reactivity, and cytotoxicity of the complex and blocks the growth of cancer cells having active glycolysis, and the introduction of biotin (C10H16N2O3S) enhances the tumor-targeting potential of the complex.  The cytotoxicity of DPB is increased dramatically in a variety of cancer cell lines as compared with the platinum(IV) complex PB without the DCA group.  DPB alters the mitochondrial membrane potential and disrupts the mitochondrial morphol.  The levels of mitochondrial and cellular reactive oxygen species are also decreased.  Furthermore, the mitochondrial function of tumor cells was impaired by DPB, leading to the inhibition of both glycolysis and glucose oxidn. and finally to the death of cancer cells via a mitochondria-mediated apoptotic pathway.  These findings demonstrate that DPB suppresses cancer cells mainly through altering metabolic pathways and highlight the importance of dual-targeting for the efficacy of anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVgfN85UEHMbVg90H21EOLACvtfcHk0lg9wndcZcq0qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFSju78%253D&md5=e9c4433bd6e253f5be6e3e672c5276ea</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.inorgchem.9b00708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.inorgchem.9b00708%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DTargeting%2520Energy%2520Metabolism%2520by%2520a%2520Platinum%2528IV%2529%2520Prodrug%2520as%2520an%2520Alternative%2520Pathway%2520for%2520Cancer%2520Suppression%26jtitle%3DInorg.%2520Chem.%26date%3D2019%26volume%3D58%26spage%3D6507%26epage%3D6516%26doi%3D10.1021%2Facs.inorgchem.9b00708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ike, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitomi, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of Cisplatin in Analbuminemic Rats</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">428</span>, <span class="refDoi"> DOI: 10.1002/1099-081x(199912)20:9<421::aid-bdd206>3.0.co;2-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1002%2F1099-081X%28199912%2920%3A9%3C421%3A%3AAID-BDD206%3E3.0.CO%3B2-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10951431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1ymsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=421-428&author=K.+Takadaauthor=T.+Kawamuraauthor=M.+Inaiauthor=S.+Masudaauthor=T.+Okaauthor=Y.+Yoshikawaauthor=N.+Shibataauthor=H.+Yoshikawaauthor=O.+Ikeauthor=H.+Wadaauthor=S.+Hitomi&title=Pharmacokinetics+of+Cisplatin+in+Analbuminemic+Rats&doi=10.1002%2F1099-081x%28199912%2920%3A9%3C421%3A%3Aaid-bdd206%3E3.0.co%3B2-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of cisplatin in analbuminemic rats</span></div><div class="casAuthors">Takada, Kanji; Kawamura, Tomonori; Inai, Maya; Masuda, Satoru; Oka, Takashi; Yoshikawa, Yukako; Shibata, Nobuhito; Yoshikawa, Hiroshi; Ike, Osamu; Wada, Hiromi; Hitomi, Shigeki</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">421-428</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The effect of protein binding on the pharmacokinetics of cisplatin (cis-diamminedichloro-platinum (II); CDDP) has been studied in analbuminemic rats, which genetically lack albumins, in comparison with normal rats.  CDDP was reported to highly bind to serum components, and the major binder was thought to be an albumin.  However, there were no significant differences in the serum disappearance profiles of platinum after i.v. bolus injection of CDDP to analbuminemic rats as compared with normal rats.  The total body clearance, Cltot, of platinum in normal rats was 48.7±22.0 mL h-1 (5 mg kg-1), 55.9±4.04 mL h-1 (10 mg kg-1) and 49.0±3.57 mL h-1 (20 mg kg-1), whereas Cltot in analbuminemic rats was 52.0±8.48 mL h-1 (5 mg kg-1), 62.9±10.8 mL h-1 (10 mg kg-1) and 62.8±6.81 mL h-1 (20 mg kg-1).  The serum blood urea nitrogen (BUN) and creatinine levels at 6 h after iv injection were higher in both groups of rats who received CDDP than those of pre-dose level.  However, there were no significant differences in the renal function tests between analbuminemic rats and normal rats.  The binding of CDDP to the serum samples obtained from analbuminemic rats and normal rats was measured by a centrifuging filtration method.  The binding percentages were 68.0±5.9% (2.0 μg mL-1), 56.8±4.1% (5.0 μg mL-1) and 64.6±4.4% (10.0 μg mL-1) in analbuminemic rats and 52.9±3.5% (2.0 μg mL-1), 52.2±3.4% (5.0 μg mL-1), 56.9±1.9% (10.0 μg mL-1) in normal rats.  Higher binding percentages were obtained in analbuminemic rats than in normal rats.  In vitro binding studies under the two incubation conditions (5 min and 2 h) showed that the binding percentages of CDDP to serum proteins were 59.2±3.2% (5 min) and 72.3±6.5% (2 h) for albumin, 42.3±1.9% (5 min) and 39.5±2.5% (2 h) for α1-acid glycoprotein (AAG) and 51.7±5.3% (5 min) and 49.2±1.9% (2 h) for γ-globulin.  From these studies, it was elucidated that albumin is not the major ligand in the rat serum and that other proteins also have important roles in the pharmacokinetics of CDDP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkhfZ_S9M0nLVg90H21EOLACvtfcHk0li4x4JZLBPfag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1ymsrY%253D&md5=0d512a6919d4959230e7667b9e529aea</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1002%2F1099-081X%28199912%2920%3A9%3C421%3A%3AAID-BDD206%3E3.0.CO%3B2-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1099-081X%2528199912%252920%253A9%253C421%253A%253AAID-BDD206%253E3.0.CO%253B2-9%26sid%3Dliteratum%253Aachs%26aulast%3DTakada%26aufirst%3DK.%26aulast%3DKawamura%26aufirst%3DT.%26aulast%3DInai%26aufirst%3DM.%26aulast%3DMasuda%26aufirst%3DS.%26aulast%3DOka%26aufirst%3DT.%26aulast%3DYoshikawa%26aufirst%3DY.%26aulast%3DShibata%26aufirst%3DN.%26aulast%3DYoshikawa%26aufirst%3DH.%26aulast%3DIke%26aufirst%3DO.%26aulast%3DWada%26aufirst%3DH.%26aulast%3DHitomi%26aufirst%3DS.%26atitle%3DPharmacokinetics%2520of%2520Cisplatin%2520in%2520Analbuminemic%2520Rats%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D1999%26volume%3D20%26spage%3D421%26epage%3D428%26doi%3D10.1002%2F1099-081x%28199912%2920%3A9%3C421%3A%3Aaid-bdd206%3E3.0.co%3B2-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Activity of BBI608 Derivatives Targeting on Stem Cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1016%2Fj.ejmech.2018.03.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=29604543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmslKgtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=39-50&author=Q.+Zhouauthor=C.+Pengauthor=F.+Duauthor=L.+Zhouauthor=Y.+Shiauthor=Y.+Duauthor=D.+Liuauthor=W.+Sunauthor=M.+Zhangauthor=G.+Chen&title=Design%2C+Synthesis+and+Activity+of+BBI608+Derivatives+Targeting+on+Stem+Cells&doi=10.1016%2Fj.ejmech.2018.03.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and activity of BBI608 derivatives targeting on stem cells</span></div><div class="casAuthors">Zhou, Qifan; Peng, Chen; Du, Fangyu; Zhou, Linbo; Shi, Yajie; Du, Yang; Liu, Dongdong; Sun, Wenjiao; Zhang, Meixia; Chen, Guoliang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">39-50</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">STAT3 plays a vital role in maintaining the self-renewal of tumor stem cells.  BBI608, a small mol. identified by its ability to inhibit gene transcription driven by STAT3 and cancer stemness properties, can inhibit stemness gene expression and kill stemness-high cancer cells isolated from a variety of cancer types.  In order to improve the pharmacokinetic properties of BBI608 and the antitumor activity, a series of BBI608 derivs. were designed and synthesized here.  Most of these compds. were more potent than BBI608 on HepG2 cells, compd. I had the most potent inhibitory activity among them and was 5.4-fold more potent than BBI608 (IC50=11.2μM), but had considerable activity on normal liver cells L-02.  Compds. II (IC50=3.5μM) and III (IC50=2.9μM) were found to possess significant inhibitory activities and good selectivity.  The results showed that compd. LD-19 was worthy to investigate further as a lead compd. according to its potent inhibitory activity, ideal ClogP value and better water soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlEGtqRVLqrVg90H21EOLACvtfcHk0li4x4JZLBPfag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmslKgtbc%253D&md5=3bd9949d032ee24e433b2e34b3ca9369</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.054%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DG.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Activity%2520of%2520BBI608%2520Derivatives%2520Targeting%2520on%2520Stem%2520Cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D39%26epage%3D50%26doi%3D10.1016%2Fj.ejmech.2018.03.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Livak, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmittgen, T. D.</span></span> <span> </span><span class="NLM_article-title">Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method</span>. <i>Methods</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1006/meth.2001.1262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1006%2Fmeth.2001.1262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=11846609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtFelt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2001&pages=402-408&author=K.+J.+Livakauthor=T.+D.+Schmittgen&title=Analysis+of+Relative+Gene+Expression+Data+Using+Real-Time+Quantitative+PCR+and+the+2%E2%88%92%CE%94%CE%94CT+Method&doi=10.1006%2Fmeth.2001.1262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method</span></div><div class="casAuthors">Livak, Kenneth J.; Schmittgen, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Methods (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">402-408</span>CODEN:
                <span class="NLM_cas:coden">MTHDE9</span>;
        ISSN:<span class="NLM_cas:issn">1046-2023</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The two most commonly used methods to analyze data from real-time, quant. PCR expts. are abs. quantification and relative quantification.  Abs. quantification dets. the input copy no., usually by relating the PCR signal to a std. curve.  Relative quantification relates the PCR signal of the target transcript in a treatment group to that of another sample such as an untreated control.  The 2-ΔΔCT method is a convenient way to analyze the relative changes in gene expression from real-time quant. PCR expts.  The purpose of this report is to present the derivation, assumptions, and applications of the 2-ΔΔCT method.  In addn., we present the derivation and applications of two variations of the 2-ΔΔCT method that may be useful in the anal. of real-time, quant. PCR data.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXNe1s-mDpprVg90H21EOLACvtfcHk0li4x4JZLBPfag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtFelt7s%253D&md5=f849383250ea43f7380ed540db8a64b1</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1006%2Fmeth.2001.1262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fmeth.2001.1262%26sid%3Dliteratum%253Aachs%26aulast%3DLivak%26aufirst%3DK.%2BJ.%26aulast%3DSchmittgen%26aufirst%3DT.%2BD.%26atitle%3DAnalysis%2520of%2520Relative%2520Gene%2520Expression%2520Data%2520Using%2520Real-Time%2520Quantitative%2520PCR%2520and%2520the%25202%25E2%2588%2592%25CE%2594%25CE%2594CT%2520Method%26jtitle%3DMethods%26date%3D2001%26volume%3D25%26spage%3D402%26epage%3D408%26doi%3D10.1006%2Fmeth.2001.1262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trott, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span> <span> </span><span class="NLM_article-title">AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/jcc.21334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=10.1002%2Fjcc.21334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=19499576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=455-61&author=O.+Trottauthor=A.+J.+Olson&title=AutoDock+Vina%3A+Improving+the+Speed+and+Accuracy+of+Docking+with+a+New+Scoring+Function%2C+Efficient+Optimization%2C+and+Multithreading&doi=10.1002%2Fjcc.21334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span></div><div class="casAuthors">Trott, Oleg; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">455-461</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">AutoDock Vina, a new program for mol. docking and virtual screening, is presented.  AutoDock Vina achieves an approx. 2 orders of magnitude speed-up compared with the mol. docking software previously developed in the authors' lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by the authors' tests on the training set used in AutoDock 4 development.  Further speed-up is achieved from parallelism, by using multithreading on multicore machines.  AutoDock Vina automatically calcs. the grid maps and clusters the results in a way transparent to the user.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLecOIkUxIlrVg90H21EOLACvtfcHk0lj_osLx_olf8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O&md5=c6974af8a1235f7aa09918d3e6f70dc4</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21334%26sid%3Dliteratum%253Aachs%26aulast%3DTrott%26aufirst%3DO.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock%2520Vina%253A%2520Improving%2520the%2520Speed%2520and%2520Accuracy%2520of%2520Docking%2520with%2520a%2520New%2520Scoring%2520Function%252C%2520Efficient%2520Optimization%252C%2520and%2520Multithreading%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D455%26epage%3D61%26doi%3D10.1002%2Fjcc.21334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6isj" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6isj','PDB','6isj'); return false;">PDB: 6isj</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i53"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00079">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_43216"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00079?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00079</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">The synthetic route of <b>CX-4945</b>; the proportion of CD44<sup>+</sup> subsets induced by <b>CX-4945</b>, <b>BBI608,</b> and <b>HY1</b>; RP-HPLC analysis on the stability of <b>HY1-Pt</b>; flow cytometry analysis on the cell cycles, apoptosis, and the expression of γH2AX in A549 and A549/cDDP cells induced by <b>HY1-Pt</b> and related sample; the inhibitory rate curves of <b>HY1-Pt</b> on CK2 enzyme activity; flow cytometry analysis on the expression of CD133<sup>+</sup> in A549/cDDP and A549/cDDP<sup>CD44bright</sup> cells induced by cisplatin and <b>HY1-Pt</b>; the production of ROS, changes of JC-1 and MMP in A549 and A549/cDDP cells induced by the <b>HY1-Pt</b> and related sample were detected by the flow cytometer and confocal laser scanning microscope; H.E. staining of tissues in the nude mice xenograft model of A549 and A549/cDDP; tables of the stability of <b>HY1</b> in incubation with human, rat, and mouse liver microsomes; tables of the data of the plasma concentrations at different time points after intravenous injection of <b>HY1-Pt</b> in rats; tables of the inhibitory effects of measured samples on the A549 cancer cell xenograft mice model; tables of the inhibitory effects of measured samples on the A549/cDDP cancer cell xenograft mice model; and figures of <sup>1</sup>H NMR, <sup>13</sup>C NMR, HR-MS spectra, and RP-HPLC chromatograms (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_002.csv">CSV</a>)</p></li><li><p class="inline">Atomic coordinates of <b>HY1-Pt</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_003.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_001.pdf">jm1c00079_si_001.pdf (2.38 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_002.csv">jm1c00079_si_002.csv (0.9 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00079/suppl_file/jm1c00079_si_003.pdb">jm1c00079_si_003.pdb (429.22 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00079&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00079%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-7%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00079" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e100746806d1cf","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
